[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYMa-0zoMCJixIHJWU90PdmjR5bIaaGy0hGtuRbAQMK4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Northwestern University",[4],1391,false,284,51,624714,125,870,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Pain",46,{"name":18,"count":19},"Depression",43,{"name":21,"count":22},"Breast Cancer",35,{"name":24,"count":25},"Lymphoma",29,{"name":27,"count":28},"Obesity",27,{"name":30,"count":31},"Pregnancy",23,{"name":33,"count":31},"Anxiety",{"name":35,"count":36},"Cancer",19,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT01361711","Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia","2015-08-17","alemtuzumab",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03213041","Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer","2022-06-01","Carboplatin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03016741","Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","2023-01-04","GnRH agonist\u002Fantagonist",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05325073","Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients","2023-05-23","Erythropoietin",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05620784","Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP","2023-06-06","Furosemide",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03012321","Abiraterone\u002FPrednisone, Olaparib, or Abiraterone\u002FPrednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects","2023-10-21","Olaparib",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT03513484","Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","2023-12-11","Azacitidine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03831334","Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia","2024-01-24","oral minoxidil",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06123026","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","2024-06-30","Cabergoline",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05744739","Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)","2024-08-20","Tomivosertib",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,272,295,326,373,417,580,635,665,699,717,735,761,786,811,836,859,885,952,1002,1028,1056,1081,1108,1134,1163,1192,1227,1410,1481,1573,1609,1731,1805,1948,2035,2134,2182,2248,2298,2342,2375,2403,2430,2452,2477,2495,2525,2543,2567,2585,2612,2630,2674,2692,2710,2728,2746,2773,2796,2814,2840,2865,2890,2917,2942,2960,2978,3005,3033,3051,3080,3098,3116,3142,3160,3186,3213,3231,3249,3267,3302,3421,3462,3605,3674,3712,3730,3748,3766,3784,3809,3829,3847,3865,3883,3901,3926,3944,3976,3999,4022,4040,4062,4086,4111,4136,4159,4177,4201,4224,4245,4272,4296,4323,4348,4378,4396,4423,4441,4459,4481,4503,4528,4546,4572,4645,4726,4781,4817,4858,4880,4902,4934,4957,4984,5002,5026,5051,5069,5094,5119,5137,5165,5183,5201,5219,5247,5265,5283,5301,5328,5346,5364,5388,5414,5438,5460,5483,5501,5528,5546,5573,5591,5614,5637,5655,5680,5698,5716,5734,5758,5785,5803,5828,5846,5870,5888,5918,5936,5954,5972,5990,6008,6026,6044,6067,6090,6112,6135,6153,6178,6204,6230,6252,6277,6295,6321,6345,6369,6387,6414,6432,6454,6481,6499,6524,6542,6560,6584,6602,6620,6642,6668,6686,6704,6728,6887,7078,7175,7229,7279,7317,7355,7381,7407,7433,7462,7497,7519,7542,7564,7582,7600,7618,7636,7654,7679,7697,7715,7741,7759,7783,7807,7831,7849,7871,7894,7919,7937,7960,7985,8008,8030,8048,8098,8140,8190,8232,8291,8344,8378,8419,8455,8489,8532,8565,8599,8625,8651,8677,8709,8735,8774,8800,8833,8855,8877,8899,8930,8966,8988,9010,9032,9060,9097,9133,9155,9189,9223,9251,9273,9295,9321,9356,9384,9402,9420,9442,9469,9487,9505,9528,9546,9571,9589,9612,9630,9652,9670,9697,9715,9733,9751,9774,9792,9813,9831,9855,9873,9895,9919,9937,9958,9991,10013,10035,10053,10071,10095,10113,10131,10156,10178,10196,10214,10241,10259,10277,10295,10318,10336,10354,10372,10394,10420,10438,10460,10481,10505,10527,10545,10563,10586,10604,10622,10640,10665,10683,10709,10734,10752,10774,10796,10814,10832,10856,10879,10897,10915,10938,10956,10974,10992,11014,11036,11063,11081,11104,11129,11147,11165,11186,11204,11222,11240,11258,11281,11299,11317,11340,11367,11385,11403,11421,11444,11462,11484,11502,11520,11538,11562,11587,11611,11629,11647,11669,11687,11705,11731,11763,11785,11810,11833,11851,11869,11887,11910,11931,11954,11972,12003,12021,12039,12057,12075,12096,12114,12132,12150,12173,12191,12209,12227,12245,12263,12289,12307,12325,12343,12366,12384,12402,12423,12441,12459,12482,12508,12526,12544,12568,12586,12604,12622,12640,12663,12681,12699,12721,12739,12762,12783,12808,12826,12844,12868,12892,12913,12931,12949,12973,12996,13014,13042,13067,13091,13113,13138,13160,13223,13266,13318,13360,13398,13428,13466,13492,13516,13544,13569,13601,13631,13657,13693,13716,13738,13760,13778,13803,13821,13845,13868,13891,13915,13933,13951,13972,13990,14011,14034,14059,14077,14095,14113,14134,14157,14179,14203,14221,14239,14257,14280,14298,14322,14340,14363,14381,14399,14422,14440,14464,14488,14513,14531,14549,14574,14601,14622,14644,14668,14686,14708,14734,14752,14770,14788,14811,14833,14851,14876,14898,14920,14942,14965,14983,15005,15027,15048,15066,15089,15107,15130,15155,15173,15194,15219,15237,15255,15276,15300,15318,15342,15360,15381,15404,15427,15448,15470,15488,15509,15531,15549,15576,15594,15612,15633,15655,15673,15698,15721,15743,15765,15786,15811,15829,15847,15865,15887,15911,15929],{"intervention":97,"totalTrials":98,"cells":99},"Prednisone",10,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":146,"PHASE3":230,"PHASE4":232,"NA":270},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105,124],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"conditions":112,"interventions":119},"NCT00004232","Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","COMPLETED",[90],"2002-10","1999-10",[113,114,115,24,116,117,118],"Chronic Myeloproliferative Disorders","Graft Versus Host Disease","Leukemia","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Precancerous\u002FNonmalignant Condition",[120,121,122,123],"filgrastim","cyclosporine","methylprednisolone","prednisone",{"nctId":125,"briefTitle":126,"status":108,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":140},"NCT03742258","Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma",[90],"2021-03-12","2024-02-08","2019-03-13",12,[133,134,135,136,137,138,139],"Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma",[141,142,97,143,144,145],"Cyclophosphamide","Doxorubicin Hydrochloride","Rituximab","Spleen Tyrosine Kinase Inhibitor TAK-659","Vincristine Sulfate",{"trials":147,"activeCount":229,"soonestReadout":66},[148,167,184,197,217],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":165},"NCT03704714","Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma","SUSPENDED",[90,91],"2024-12-11","2025-06-11","2018-11-20",30,[158,159,160,161,162,163,139,164],"Aggressive Non-Hodgkin Lymphoma","B-Cell Non-Hodgkin Lymphoma","CD20 Positive","Diffuse Large B-Cell Lymphoma Unclassifiable","Intravascular Large B-Cell Lymphoma","Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[141,142,166,97,143,145],"Nivolumab",{"nctId":168,"briefTitle":169,"status":108,"phases":170,"primaryCompletion":171,"completion":171,"start":111,"conditions":172,"interventions":173},"NCT00004231","Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and\u002For Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma",[91],"2006-08",[24],[174,120,175,176,177,178,179,180,181,123,182,183],"aldesleukin","recombinant interferon alfa","busulfan","cyclophosphamide","cytarabine","doxorubicin hydrochloride","leucovorin calcium","methotrexate","teniposide","vincristine sulfate",{"nctId":64,"briefTitle":65,"status":185,"phases":186,"primaryCompletion":66,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":195},"ACTIVE_NOT_RECRUITING",[91],"2027-01-16","2017-01-12",70,[191,192,193,194],"Prostate Cancer Metastatic Castration-Resistant","Abnormal DNA Repair","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer",[67,196,97],"Abiraterone Acetate",{"nctId":198,"briefTitle":199,"status":200,"phases":201,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":211},"NCT02481310","Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","UNKNOWN",[90,91],"2020-09-26","2024-07","2015-10-28",38,[207,208,133,209,210],"Adult Burkitt Lymphoma","B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma","MYC Gene Mutation","Plasmablastic Lymphoma",[141,212,142,213,214,215,97,143,216,145],"Cytarabine","Etoposide","Ixazomib Citrate","Methotrexate","Therapeutic Hydrocortisone",{"nctId":218,"briefTitle":219,"status":108,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":228},"NCT04054375","Weekly Steroids in Muscular Dystrophy",[91],"2020-06-01","2022-03-01","2019-07-01",20,[226,227],"Limb-girdle Muscular Dystrophy","Becker Muscular Dystrophy",[97],1,{"trials":231,"activeCount":102},[],{"trials":233,"activeCount":229,"soonestReadout":51},[234,245,258],{"nctId":49,"briefTitle":50,"status":185,"phases":235,"primaryCompletion":51,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":243},[93],"2029-08","2017-03-31",100,[240,193,241,194,242],"Castration-Resistant Prostatic Cancer","Recurrent Prostate Carcinoma","Hormone-Refractory Prostate Cancer",[52,97,196,244],"Enzalutamide",{"nctId":246,"briefTitle":247,"status":248,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT01676415","Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)","TERMINATED",[93],"2016-01","2016-08","2012-08",9,[255],"Chronic Rhinosinusitis Without Nasal Polyps",[97,257],"Topical mometasone",{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":102,"conditions":265,"interventions":269},"NCT00841802","Chronic Rhinosinusitis With or Without Nasal Polyps Steroid Study","WITHDRAWN",[93],"2019-06-30","2008-07",[266,267,268],"Chronic Sinusitis","Rhinosinusitis","Nasal Polyps",[97],{"trials":271,"activeCount":102},[],{"intervention":196,"totalTrials":273,"cells":274},2,{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":285,"PHASE4":287,"NA":293},{"trials":276,"activeCount":102},[],{"trials":278,"activeCount":102},[],{"trials":280,"activeCount":229,"soonestReadout":66},[281],{"nctId":64,"briefTitle":65,"status":185,"phases":282,"primaryCompletion":66,"completion":187,"start":188,"enrollment":189,"conditions":283,"interventions":284},[91],[191,192,193,194],[67,196,97],{"trials":286,"activeCount":102},[],{"trials":288,"activeCount":229,"soonestReadout":51},[289],{"nctId":49,"briefTitle":50,"status":185,"phases":290,"primaryCompletion":51,"completion":236,"start":237,"enrollment":238,"conditions":291,"interventions":292},[93],[240,193,241,194,242],[52,97,196,244],{"trials":294,"activeCount":102},[],{"intervention":244,"totalTrials":273,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":316,"PHASE4":318,"NA":324},{"trials":298,"activeCount":102},[],{"trials":300,"activeCount":102},[],{"trials":302,"activeCount":229,"soonestReadout":308},[303],{"nctId":304,"briefTitle":305,"status":306,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT06499870","Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial","RECRUITING",[91],"2028-11-19","2032-11-19","2024-09-06",50,[313],"Prostate Adenocarcinoma",[244,315],"Relugolix",{"trials":317,"activeCount":102},[],{"trials":319,"activeCount":229,"soonestReadout":51},[320],{"nctId":49,"briefTitle":50,"status":185,"phases":321,"primaryCompletion":51,"completion":236,"start":237,"enrollment":238,"conditions":322,"interventions":323},[93],[240,193,241,194,242],[52,97,196,244],{"trials":325,"activeCount":102},[],{"intervention":327,"totalTrials":273,"cells":328},"Naproxen 500 Mg",{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":357,"PHASE4":359,"NA":371},{"trials":330,"activeCount":102},[],{"trials":332,"activeCount":102},[],{"trials":334,"activeCount":229,"soonestReadout":339},[335],{"nctId":336,"briefTitle":337,"status":185,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":354},"NCT05463367","Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure",[91],"2025-06-01","2021-01-01",60,[343,344,345,346,347,348,349,350,351,352,353],"Opioid Use","Opioid Dependence","Opioid-use Disorder","Narcotic Use","Back Pain","Back Injuries","Chronic Pain","Chronic Low-back Pain","Pain, Chronic","Pain;Back Low;Chronic","Pain, Back",[355,327,356],"Carbidopa-Levodopa 25 Mg-100 Mg Oral","Opioids",{"trials":358,"activeCount":102},[],{"trials":360,"activeCount":229,"soonestReadout":365},[361],{"nctId":362,"briefTitle":363,"status":185,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":224,"conditions":368,"interventions":370},"NCT05430230","Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis",[93],"2027-06","2027-09-01","2022-08-24",[369],"Osteoarthritis, Knee",[327],{"trials":372,"activeCount":102},[],{"intervention":374,"totalTrials":375,"cells":376},"Dupilumab",3,{"EARLY_PHASE1":377,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":407},{"trials":378,"activeCount":229,"soonestReadout":383},[379],{"nctId":380,"briefTitle":381,"status":306,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":156,"conditions":386,"interventions":388},"NCT05649098","Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders",[89],"2031-06-30","2032-06-01","2023-06-12",[387],"Skin Diseases",[374],{"trials":390,"activeCount":102},[],{"trials":392,"activeCount":102},[],{"trials":394,"activeCount":102},[],{"trials":396,"activeCount":229,"soonestReadout":365},[397],{"nctId":398,"briefTitle":399,"status":306,"phases":400,"primaryCompletion":365,"completion":365,"start":401,"enrollment":402,"conditions":403,"interventions":406},"NCT05042258","Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate\u002FSevere Atopic Dermatitis",[93],"2024-08-12",40,[404,405],"Atopic Dermatitis","Sleep Disturbance",[374],{"trials":408,"activeCount":102},[409],{"nctId":410,"briefTitle":411,"status":248,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":16,"conditions":415,"interventions":416},"NCT03411837","Dupilumab Phase 4 Study",[],"2019-08-31","2017-10-16",[404],[374],{"intervention":418,"totalTrials":419,"cells":420},"Methylprednisolone",13,{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":466,"PHASE3":504,"PHASE4":554,"NA":578},{"trials":422,"activeCount":102},[],{"trials":424,"activeCount":102},[425,429,442,454],{"nctId":106,"briefTitle":107,"status":108,"phases":426,"primaryCompletion":110,"completion":110,"start":111,"conditions":427,"interventions":428},[90],[113,114,115,24,116,117,118],[120,121,122,123],{"nctId":430,"briefTitle":431,"status":248,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":253,"conditions":435,"interventions":437},"NCT00424489","Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis",[90],"2016-06","2002-02",[436],"Myasthenia Gravis",[438,141,439,440,418,441],"Hematopoietic Stem Cell Transplantation","ATG","Mesna","G-CSF",{"nctId":443,"briefTitle":444,"status":248,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":451},"NCT00278564","Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases",[90],"2016-07","2005-09",7,[450],"MYOPATHY",[452,141,440,439,418,441,453],"Hematopoietic stem cell transplantation","Rituxan",{"nctId":455,"briefTitle":456,"status":108,"phases":457,"primaryCompletion":458,"completion":458,"start":111,"conditions":459,"interventions":461},"NCT00004904","Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[90],"2000-07",[113,114,115,24,116,117,118,460],"Small Intestine Cancer",[462,120,463,177,464,122,465],"anti-thymocyte globulin","cladribine","etoposide","tacrolimus",{"trials":467,"activeCount":102},[468,483,495],{"nctId":469,"briefTitle":470,"status":108,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":481},"NCT00004357","Absorption of Corticosteroids in Children With Juvenile Dermatomyositis",[91],"2005-12","2008-02","1997-09",6,[477,478,479,480],"Vasculitis, Hypersensitivity","Connective Tissue Diseases","Dermatomyositis","Vasculitis",[418,482],"Prednisolone",{"nctId":484,"briefTitle":485,"status":248,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":490,"interventions":492},"NCT02282514","Stem Cell Transplantation for Stiff Person Syndrome (SPS)",[90,91],"2019-08-19","2019-08-30","2014-10",[491],"Stiff-Person Syndrome",[493,141,440,494,418,441,453],"Autologous Hematopoietic Stem Cells","rATG",{"nctId":496,"briefTitle":497,"status":108,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":419,"conditions":501,"interventions":503},"NCT00787722","Hematopoietic Stem Cell Transplant in Devic's Disease",[90,91],"2018-11","2009-10-10",[502],"Devic's Disease",[141,441,494,440,143,418],{"trials":505,"activeCount":102},[506,520,530,543],{"nctId":507,"briefTitle":508,"status":248,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":513,"interventions":516},"NCT03593902","Cardiac Safe Transplants for Systemic Sclerosis",[91,92],"2019-10-03","2019-10-09","2018-05-17",[514,515],"Systemic Sclerosis","Scleroderma",[143,517,141,440,494,418,441,518,519],"Fludarabine","IVIg","Autologous Stem Cells",{"nctId":521,"briefTitle":522,"status":248,"phases":523,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":527,"interventions":529},"NCT03342638","Maximizing Outcome of Multiple Sclerosis Transplantation",[92],"2019-07-23","2017-11-08",66,[528],"Multiple Sclerosis, Relapsing-Remitting",[141,440,494,418,441,518,519],{"nctId":531,"briefTitle":532,"status":248,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT01445821","Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial",[92],"2017-01-05","2019-10-10","2011-09-15",44,[539],"Scleroderma, Systemic",[541,141,440,494,418,542,517],"Peripheral Blood Stem Cells","Filgrastim",{"nctId":544,"briefTitle":545,"status":261,"phases":546,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":550,"interventions":553},"NCT03829566","Autologous Transplant To End NMO Spectrum Disorder",[91,92],"2025-01","2025-11-28","2019-11",[551,502,552],"Neuromyelitis Optica","NMO Spectrum Disorder",[143,141,440,494,418,441,518,519],{"trials":555,"activeCount":229,"soonestReadout":560},[556,568],{"nctId":557,"briefTitle":558,"status":306,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":238,"conditions":563,"interventions":565},"NCT04826237","Oral Statins and Protection From Hearing Loss",[93],"2025-10-01","2025-12-31","2023-02-09",[564],"Sudden Sensorineural Hearing Loss",[566,122,567],"Statin","dexamethasone",{"nctId":569,"briefTitle":570,"status":261,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":102,"conditions":575,"interventions":576},"NCT03973177","Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain",[93],"2022-07","2023-03","2019-05-24",[351],[577,418],"Phenol",{"trials":579,"activeCount":102},[],{"intervention":581,"totalTrials":582,"cells":583},"Dexamethasone",4,{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":633},{"trials":585,"activeCount":102},[],{"trials":587,"activeCount":102},[],{"trials":589,"activeCount":102},[],{"trials":591,"activeCount":102},[],{"trials":593,"activeCount":229,"soonestReadout":560},[594,598,611,621],{"nctId":557,"briefTitle":558,"status":306,"phases":595,"primaryCompletion":560,"completion":561,"start":562,"enrollment":238,"conditions":596,"interventions":597},[93],[564],[566,122,567],{"nctId":599,"briefTitle":600,"status":108,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":341,"conditions":605,"interventions":608},"NCT02024724","Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain",[93],"2016-03","2017-03","2013-11",[606,607],"Typical Facial Pain","Atypical Facial Pain",[609,610,581],"Bupivacaine","Triamcinolone",{"nctId":612,"briefTitle":613,"status":261,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":102,"conditions":617,"interventions":619},"NCT02655523","A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks",[93],"2022-06","2015-12",[618],"Headache",[610,581,620,609],"Normal Saline",{"nctId":622,"briefTitle":623,"status":108,"phases":624,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT01616173","Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block",[93],"2013-02","2013-06","2012-06",80,[630],"Fracture of Ankle",[581,581,632],"Saline",{"trials":634,"activeCount":102},[],{"intervention":57,"totalTrials":273,"cells":636},{"EARLY_PHASE1":637,"PHASE1":648,"PHASE2":650,"PHASE3":652,"PHASE4":654,"NA":663},{"trials":638,"activeCount":102},[639],{"nctId":640,"briefTitle":641,"status":108,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":475,"conditions":645,"interventions":647},"NCT03842254","Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease",[89],"2021-02-18","2019-01-25",[646],"Autoimmune Hepatitis",[57],{"trials":649,"activeCount":102},[],{"trials":651,"activeCount":102},[],{"trials":653,"activeCount":102},[],{"trials":655,"activeCount":229,"soonestReadout":56},[656],{"nctId":54,"briefTitle":55,"status":185,"phases":657,"primaryCompletion":56,"completion":658,"start":659,"enrollment":253,"conditions":660,"interventions":662},[93],"2024-09-30","2022-02-18",[661],"Liver Transplant Rejection",[57],{"trials":664,"activeCount":102},[],{"intervention":82,"totalTrials":273,"cells":666},{"EARLY_PHASE1":667,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":697},{"trials":668,"activeCount":102},[669],{"nctId":670,"briefTitle":671,"status":108,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":224,"conditions":676,"interventions":679},"NCT01730729","Cabergoline in Metastatic Breast Cancer",[89],"2015-12-15","2017-10-27","2013-02-11",[677,678],"Recurrent Breast Cancer","Stage IV Breast Cancer",[680],"cabergoline",{"trials":682,"activeCount":102},[],{"trials":684,"activeCount":102},[],{"trials":686,"activeCount":102},[],{"trials":688,"activeCount":229,"soonestReadout":81},[689],{"nctId":79,"briefTitle":80,"status":306,"phases":690,"primaryCompletion":81,"completion":81,"start":691,"enrollment":692,"conditions":693,"interventions":696},[93],"2023-12-18",200,[694,695],"Lactation Suppressed","Second Trimester Abortion",[82],{"trials":698,"activeCount":102},[],{"intervention":566,"totalTrials":229,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":715},{"trials":702,"activeCount":102},[],{"trials":704,"activeCount":102},[],{"trials":706,"activeCount":102},[],{"trials":708,"activeCount":102},[],{"trials":710,"activeCount":229,"soonestReadout":560},[711],{"nctId":557,"briefTitle":558,"status":306,"phases":712,"primaryCompletion":560,"completion":561,"start":562,"enrollment":238,"conditions":713,"interventions":714},[93],[564],[566,122,567],{"trials":716,"activeCount":102},[],{"intervention":52,"totalTrials":229,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":733},{"trials":720,"activeCount":102},[],{"trials":722,"activeCount":102},[],{"trials":724,"activeCount":102},[],{"trials":726,"activeCount":102},[],{"trials":728,"activeCount":229,"soonestReadout":51},[729],{"nctId":49,"briefTitle":50,"status":185,"phases":730,"primaryCompletion":51,"completion":236,"start":237,"enrollment":238,"conditions":731,"interventions":732},[93],[240,193,241,194,242],[52,97,196,244],{"trials":734,"activeCount":102},[],{"intervention":736,"totalTrials":229,"cells":737},"Morphine Sulfate",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":759},{"trials":739,"activeCount":102},[],{"trials":741,"activeCount":102},[],{"trials":743,"activeCount":102},[],{"trials":745,"activeCount":102},[],{"trials":747,"activeCount":229,"soonestReadout":752},[748],{"nctId":749,"briefTitle":750,"status":306,"phases":751,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":758},"NCT05351229","Intrathecal Morphine for Analgesia in Video-assisted and Robotic-assisted Thoracic Surgery",[93],"2026-06-01","2026-09-01","2023-09-29",90,[757],"Pain, Postoperative",[736],{"trials":760,"activeCount":102},[],{"intervention":762,"totalTrials":229,"cells":763},"botulinum toxin A",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":784},{"trials":765,"activeCount":102},[],{"trials":767,"activeCount":102},[],{"trials":769,"activeCount":102},[],{"trials":771,"activeCount":102},[],{"trials":773,"activeCount":229,"soonestReadout":778},[774],{"nctId":775,"briefTitle":776,"status":185,"phases":777,"primaryCompletion":778,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":783},"NCT02216838","Treatment of Facial Flushing With Botulinum Toxin A Injections",[93],"2025-12","2014-08",16,[782],"Facial Flushing",[762],{"trials":785,"activeCount":102},[],{"intervention":787,"totalTrials":229,"cells":788},"Gadavist 2Ml Solution for",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":797,"NA":809},{"trials":790,"activeCount":102},[],{"trials":792,"activeCount":102},[],{"trials":794,"activeCount":102},[],{"trials":796,"activeCount":102},[],{"trials":798,"activeCount":229,"soonestReadout":803},[799],{"nctId":800,"briefTitle":801,"status":306,"phases":802,"primaryCompletion":803,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":808},"NCT05215132","Investigational MRI Clinical Software and Hardware",[93],"2028-01-31","2019-12-19",2000,[807],"Image, Body",[787],{"trials":810,"activeCount":102},[],{"intervention":812,"totalTrials":229,"cells":813},"Ublituximab",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":834},{"trials":815,"activeCount":102},[],{"trials":817,"activeCount":102},[],{"trials":819,"activeCount":102},[],{"trials":821,"activeCount":102},[],{"trials":823,"activeCount":229,"soonestReadout":828},[824],{"nctId":825,"briefTitle":826,"status":306,"phases":827,"primaryCompletion":828,"completion":829,"start":548,"enrollment":402,"conditions":830,"interventions":833},"NCT07225361","Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis",[93],"2029-03-15","2029-08-01",[831,832],"Multiple Sclerosis","Multiple Sclerosis (MS) - Relapsing-remitting",[812],{"trials":835,"activeCount":102},[],{"intervention":837,"totalTrials":229,"cells":838},"Topical EMLA cream",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":857},{"trials":840,"activeCount":102},[],{"trials":842,"activeCount":102},[],{"trials":844,"activeCount":102},[],{"trials":846,"activeCount":102},[],{"trials":848,"activeCount":229,"soonestReadout":778},[849],{"nctId":850,"briefTitle":851,"status":185,"phases":852,"primaryCompletion":778,"completion":778,"start":853,"enrollment":156,"conditions":854,"interventions":856},"NCT02318654","Ice Versus EMLA for Pain in Laser Hair Removal",[93],"2014-12-30",[855],"Hair Removal",[837],{"trials":858,"activeCount":102},[],{"intervention":860,"totalTrials":229,"cells":861},"Misoprostol Tabets",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":883},{"trials":863,"activeCount":102},[],{"trials":865,"activeCount":102},[],{"trials":867,"activeCount":102},[],{"trials":869,"activeCount":102},[],{"trials":871,"activeCount":229,"soonestReadout":876},[872],{"nctId":873,"briefTitle":874,"status":306,"phases":875,"primaryCompletion":876,"completion":876,"start":877,"enrollment":402,"conditions":878,"interventions":882},"NCT07286188","Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy",[93],"2026-12","2025-12-16",[879,880,881],"Fibroids, Uterine","Fluid Deficit","Hysteroscopy \u002F Methods",[860],{"trials":884,"activeCount":102},[],{"intervention":886,"totalTrials":887,"cells":888},"celecoxib",5,{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":925,"PHASE4":927,"NA":941},{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":102},[895,905,916],{"nctId":896,"briefTitle":897,"status":108,"phases":898,"primaryCompletion":899,"completion":899,"start":110,"enrollment":900,"conditions":901,"interventions":903},"NCT00057980","Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma",[90,91],"2007-02",8,[902],"Liver Cancer",[886,904],"epirubicin hydrochloride",{"nctId":906,"briefTitle":907,"status":108,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"conditions":911,"interventions":913},"NCT00073866","Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer",[90,91],"2004-12","2003-06",[912],"Lung Cancer",[886,914,915],"docetaxel","irinotecan hydrochloride",{"nctId":917,"briefTitle":918,"status":108,"phases":919,"primaryCompletion":920,"completion":920,"start":921,"conditions":922,"interventions":924},"NCT00058006","Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer",[91],"2006-12","2002-09",[923,912],"Head and Neck Cancer",[886],{"trials":926,"activeCount":102},[],{"trials":928,"activeCount":229,"soonestReadout":933},[929],{"nctId":930,"briefTitle":931,"status":306,"phases":932,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":936,"interventions":938},"NCT06245109","Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis",[93],"2028-03-15","2024-02-26",180,[937],"Knee Osteoarthritis",[939,940],"Duloxetine","Celecoxib",{"trials":942,"activeCount":102},[943],{"nctId":944,"briefTitle":945,"status":108,"phases":946,"primaryCompletion":250,"completion":947,"start":252,"enrollment":948,"conditions":949,"interventions":951},"NCT02779166","Evaluation of Perioperative Celecoxib for Hip Arthroscopy",[94],"2016-05",98,[950],"Hip Labral Tears",[940],{"intervention":939,"totalTrials":582,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":990},{"trials":955,"activeCount":102},[],{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":102},[],{"trials":963,"activeCount":229,"soonestReadout":933},[964,968,980],{"nctId":930,"briefTitle":931,"status":306,"phases":965,"primaryCompletion":933,"completion":933,"start":934,"enrollment":935,"conditions":966,"interventions":967},[93],[937],[939,940],{"nctId":969,"briefTitle":970,"status":261,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":102,"conditions":974,"interventions":978},"NCT02351440","Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery",[93],"2017-08-31","2016-04",[975,976,977],"Quality of Recovery","Gynecologic Surgery","Laparoscopy",[979],"duloxetine",{"nctId":981,"briefTitle":982,"status":108,"phases":983,"primaryCompletion":984,"completion":779,"start":985,"enrollment":402,"conditions":986,"interventions":988},"NCT01558700","Duloxetine in Osteoarthritis (OA) Pain",[93],"2014-04","2012-03",[987],"Osteoarthritis",[939,989],"Sugar pill",{"trials":991,"activeCount":102},[992],{"nctId":993,"briefTitle":994,"status":108,"phases":995,"primaryCompletion":996,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1001},"NCT02903238","Brain Morphometry in OA Patients Treated With Duloxetine",[94],"2011-10","2011-12","2011-07",21,[15,987],[939],{"intervention":1003,"totalTrials":229,"cells":1004},"cocoa flavanols",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1024,"NA":1026},{"trials":1006,"activeCount":102},[],{"trials":1008,"activeCount":102},[],{"trials":1010,"activeCount":102},[],{"trials":1012,"activeCount":229,"soonestReadout":1017},[1013],{"nctId":1014,"briefTitle":1015,"status":306,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT04794530","The COCOA-PAD II Trial",[92],"2026-12-31","2027-06-01","2021-11-19",190,[1022],"Peripheral Artery Disease",[1003],{"trials":1025,"activeCount":102},[],{"trials":1027,"activeCount":102},[],{"intervention":1029,"totalTrials":229,"cells":1030},"Valproic Acid",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1052,"NA":1054},{"trials":1032,"activeCount":102},[],{"trials":1034,"activeCount":102},[],{"trials":1036,"activeCount":102},[],{"trials":1038,"activeCount":229,"soonestReadout":1044},[1039],{"nctId":1040,"briefTitle":1041,"status":1042,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1051},"NCT07166393","Valproic AcId for Traumatic BRAin INjury Trial","NOT_YET_RECRUITING",[91,92],"2030-02","2030-12","2026-05",432,[1049,1050],"Moderate Traumatic Brain Injury (TBI)","Severe Traumatic Brain Injury",[1029],{"trials":1053,"activeCount":102},[],{"trials":1055,"activeCount":102},[],{"intervention":1057,"totalTrials":229,"cells":1058},"Islet Cell Transplant",{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1065,"PHASE4":1077,"NA":1079},{"trials":1060,"activeCount":102},[],{"trials":1062,"activeCount":102},[],{"trials":1064,"activeCount":102},[],{"trials":1066,"activeCount":229,"soonestReadout":1071},[1067],{"nctId":1068,"briefTitle":1069,"status":185,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":627,"enrollment":402,"conditions":1073,"interventions":1076},"NCT01897688","A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients",[92],"2025-03","2027-03",[1074,1075],"Type 1 Diabetes","Severe Hypoglycemic Unawareness",[1057],{"trials":1078,"activeCount":102},[],{"trials":1080,"activeCount":102},[],{"intervention":1082,"totalTrials":229,"cells":1083},"OnabotulinumtoxinA",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1104,"NA":1106},{"trials":1085,"activeCount":102},[],{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":102},[],{"trials":1091,"activeCount":229,"soonestReadout":752},[1092],{"nctId":1093,"briefTitle":1094,"status":306,"phases":1095,"primaryCompletion":752,"completion":1096,"start":1097,"enrollment":526,"conditions":1098,"interventions":1103},"NCT05878951","Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms",[91,92],"2026-08-24","2023-07-13",[1099,1100,1101,1102],"Urinary Incontinence","Overactive Bladder Syndrome","Overactive Bladder","Urologic Diseases",[1082],{"trials":1105,"activeCount":102},[],{"trials":1107,"activeCount":102},[],{"intervention":1109,"totalTrials":229,"cells":1110},"Fresh Frozen Plasma",{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1115,"PHASE3":1117,"PHASE4":1130,"NA":1132},{"trials":1112,"activeCount":102},[],{"trials":1114,"activeCount":102},[],{"trials":1116,"activeCount":102},[],{"trials":1118,"activeCount":229,"soonestReadout":1123},[1119],{"nctId":1120,"briefTitle":1121,"status":306,"phases":1122,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1129},"NCT06062888","FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial",[91,92],"2028-08","2029-06","2026-02-01",357,[1128],"Moderate to Severe Traumatic Brain Injury",[1109],{"trials":1131,"activeCount":102},[],{"trials":1133,"activeCount":102},[],{"intervention":1135,"totalTrials":229,"cells":1136},"Dronabinol",{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1159,"NA":1161},{"trials":1138,"activeCount":102},[],{"trials":1140,"activeCount":102},[],{"trials":1142,"activeCount":102},[],{"trials":1144,"activeCount":229,"soonestReadout":876},[1145],{"nctId":1146,"briefTitle":1147,"status":185,"phases":1148,"primaryCompletion":876,"completion":365,"start":1149,"enrollment":156,"conditions":1150,"interventions":1158},"NCT05335252","Dronabinol After Arthroscopic Surgery",[92],"2022-06-28",[937,1151,1152,1153,1154,1155,1156,1157],"Knee Injuries","Meniscus Tear","Synovitis of Knee","Knee Ligament Injury","Chondral Injury of Left Knee","Chondral Injury of Right Knee","Loose Body Knee",[1135],{"trials":1160,"activeCount":102},[],{"trials":1162,"activeCount":102},[],{"intervention":1164,"totalTrials":229,"cells":1165},"Nitrate Rich Beetroot Juice",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1188,"NA":1190},{"trials":1167,"activeCount":102},[],{"trials":1169,"activeCount":102},[],{"trials":1171,"activeCount":102},[],{"trials":1173,"activeCount":229,"soonestReadout":1178},[1174],{"nctId":1175,"briefTitle":1176,"status":306,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1187},"NCT06686121","Improving Mobility After Revascularization in Peripheral Artery Disease",[92],"2032-02-01","2032-08-01","2025-08-04",386,[1022,1183,1184,1185,1186],"Intermittent Claudication","Peripheral Vascular Disease","Mobility Limitation","Revascularization",[1164],{"trials":1189,"activeCount":102},[],{"trials":1191,"activeCount":102},[],{"intervention":62,"totalTrials":273,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1213,"NA":1215},{"trials":1195,"activeCount":102},[],{"trials":1197,"activeCount":102},[],{"trials":1199,"activeCount":102},[],{"trials":1201,"activeCount":229,"soonestReadout":61},[1202],{"nctId":59,"briefTitle":60,"status":306,"phases":1203,"primaryCompletion":61,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1212},[92],"2024-08-01","2023-03-01",138,[1208,1209,1210,1211],"BPH With Urinary Obstruction","BPH","Hematuria","Same Day Discharge",[62],{"trials":1214,"activeCount":102},[],{"trials":1216,"activeCount":102},[1217],{"nctId":1218,"briefTitle":1219,"status":248,"phases":1220,"primaryCompletion":985,"completion":985,"start":1221,"enrollment":31,"conditions":1222,"interventions":1226},"NCT01054404","Furosemide vs Placebo for Brain Relaxation",[94],"2010-02",[1223,1224,1225],"Brain Swelling","Brain Edema","Dehydration",[62],{"intervention":1228,"totalTrials":131,"cells":1229},"Pembrolizumab",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1271,"PHASE3":1404,"PHASE4":1406,"NA":1408},{"trials":1231,"activeCount":102},[],{"trials":1233,"activeCount":102},[1234,1246,1257],{"nctId":1235,"briefTitle":1236,"status":261,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1238,"enrollment":102,"conditions":1239,"interventions":1244},"NCT05093387","SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer",[90],"2022-11-10",[1240,1241,1242,1243],"Anatomic Stage IV Breast Cancer AJCC v8","Breast Inflammatory Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8",[47,1228,1245],"Transferrin Receptor-Targeted Liposomal p53 cDNA",{"nctId":1247,"briefTitle":1248,"status":248,"phases":1249,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":582,"conditions":1253,"interventions":1255},"NCT02530502","Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma",[90],"2016-05-10","2020-02-12","2015-09-30",[1254],"Adult Glioblastoma",[1228,1256],"Temozolomide",{"nctId":1258,"briefTitle":1259,"status":108,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":253,"conditions":1264,"interventions":1269},"NCT02808143","Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer",[90],"2020-05-15","2022-08-05","2017-02-10",[1265,1266,1267,1268],"Recurrent Bladder Carcinoma","Stage 0a Bladder Urothelial Carcinoma","Stage 0is Bladder Urothelial Carcinoma","Stage I Bladder Cancer",[1270,1228],"BCG Solution",{"trials":1272,"activeCount":375,"soonestReadout":46},[1273,1285,1309,1323,1333,1349,1365,1378,1392],{"nctId":44,"briefTitle":45,"status":306,"phases":1274,"primaryCompletion":46,"completion":1275,"start":1276,"enrollment":238,"conditions":1277,"interventions":1284},[91],"2023-07","2017-09-14",[1278,1279,1280,1281,1282,678,1283],"Estrogen Receptor Negative","Estrogen Receptor Positive","HER2\u002FNeu Negative","Progesterone Receptor Negative","Recurrent Breast Carcinoma","Triple-Negative Breast Carcinoma",[47,1228],{"nctId":1286,"briefTitle":1287,"status":261,"phases":1288,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":102,"conditions":1292,"interventions":1307},"NCT04795869","Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma",[91],"2026-03-15","2029-03","2020-03-01",[1293,1294,1295,1296,1297,1298,1299,1300,1301,1302,1303,1304,1305,1306],"Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Enteropathy-Associated T-Cell Lymphoma","Recurrent Follicular T-Cell Lymphoma","Recurrent Hepatosplenic T-Cell Lymphoma","Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified","Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Enteropathy-Associated T-Cell Lymphoma","Refractory Follicular T-Cell Lymphoma","Refractory Hepatosplenic T-Cell Lymphoma","Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma",[1308,1228],"Brentuximab Vedotin",{"nctId":1310,"briefTitle":1311,"status":108,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1321},"NCT02901899","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[91],"2020-04-01","2023-03-31","2016-11-11",45,[1318,1319,1320],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[1322,1228],"Guadecitabine",{"nctId":1324,"briefTitle":1325,"status":185,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":658,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT06242834","Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma",[91],"2027-04-24","2028-11-24",32,[159],[1228,1332],"Tazemetostat",{"nctId":1334,"briefTitle":1335,"status":200,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":156,"conditions":1340,"interventions":1346},"NCT03226249","PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma",[91],"2019-05-17","2024-10","2017-11-09",[1341,1342,1343,1344,1345],"Classical Hodgkin Lymphoma","Lymphocyte-Depleted Classical Hodgkin Lymphoma","Lymphocyte-Rich Classical Hodgkin Lymphoma","Mixed Cellularity Classical Hodgkin Lymphoma","Nodular Sclerosis Classical Hodgkin Lymphoma",[1347,142,1228,1348],"Dacarbazine","Vinblastine Sulfate",{"nctId":1350,"briefTitle":1351,"status":200,"phases":1352,"primaryCompletion":1353,"completion":1354,"start":1355,"enrollment":19,"conditions":1356,"interventions":1363},"NCT03077828","Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[91],"2020-12-30","2024-12","2017-04-21",[1343,1357,1358,1359,1360,1361,1362],"Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma","Recurrent Mixed Cellularity Classical Hodgkin Lymphoma","Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma","Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma","Refractory Mixed Cellularity Classical Hodgkin Lymphoma","Refractory Nodular Sclerosis Classical Hodgkin Lymphoma",[47,213,1364,1228],"Ifosfamide",{"nctId":1366,"briefTitle":1367,"status":248,"phases":1368,"primaryCompletion":804,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1376},"NCT03723915","Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer",[91],"2021-04-24","2018-11-14",17,[1373,1374,1375],"Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8",[1228,1377],"Wild-type Reovirus",{"nctId":1379,"briefTitle":1380,"status":200,"phases":1381,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":156,"conditions":1385,"interventions":1390},"NCT03044730","Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery",[91],"2019-04-24","2021-05","2017-05-25",[1278,1280,1281,1282,1386,1387,1388,1389,678,1283],"Stage III Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[1391,1228],"Capecitabine",{"nctId":1393,"briefTitle":1394,"status":185,"phases":1395,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":156,"conditions":1399,"interventions":1401},"NCT06164275","Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma",[91],"2029-12-31","2031-12-31","2024-02-06",[1400],"Classic Hodgkin Lymphoma",[1347,1402,1228,1403],"Doxorubicin","Vinblastine",{"trials":1405,"activeCount":102},[],{"trials":1407,"activeCount":102},[],{"trials":1409,"activeCount":102},[],{"intervention":1411,"totalTrials":375,"cells":1412},"Zanzalintinib",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1414,"activeCount":102},[],{"trials":1416,"activeCount":102},[],{"trials":1418,"activeCount":375,"soonestReadout":1468},[1419,1433,1464],{"nctId":1420,"briefTitle":1421,"status":1042,"phases":1422,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1432},"NCT07042919","Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer",[90,91],"2029-03-04","2031-03-04","2026-03-04",53,[1428,1429,1430,1431],"Advanced Hepatocellular Carcinoma","Cirrhosis","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8",[1411],{"nctId":1434,"briefTitle":1435,"status":306,"phases":1436,"primaryCompletion":1437,"completion":1438,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1463},"NCT06959641","XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer",[91],"2028-09-11","2030-09-11","2025-06-06",33,[1442,1443,1444,1445,1446,1447,1448,1449,1450,1451,1452,1453,1454,1455,1456,1457,1458,1459,1460,1461,1462],"Locally Advanced Differentiated Thyroid Gland Carcinoma","Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma","Locally Advanced Thyroid Gland Follicular Carcinoma","Locally Advanced Thyroid Gland Oncocytic Carcinoma","Locally Advanced Thyroid Gland Papillary Carcinoma","Metastatic Differentiated Thyroid Gland Carcinoma","Metastatic Poorly Differentiated Thyroid Gland Carcinoma","Metastatic Thyroid Gland Follicular Carcinoma","Metastatic Thyroid Gland Oncocytic Carcinoma","Metastatic Thyroid Gland Papillary Carcinoma","Refractory Differentiated Thyroid Gland Carcinoma","Refractory Poorly Differentiated Thyroid Gland Carcinoma","Refractory Thyroid Gland Follicular Carcinoma","Refractory Thyroid Gland Oncocytic Carcinoma","Refractory Thyroid Gland Papillary Carcinoma","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","Stage III Thyroid Gland Follicular Carcinoma AJCC v8","Stage III Thyroid Gland Papillary Carcinoma AJCC v8","Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8","Stage IV Thyroid Gland Follicular Carcinoma AJCC v8","Stage IV Thyroid Gland Papillary Carcinoma AJCC v8",[1411],{"nctId":1465,"briefTitle":1466,"status":306,"phases":1467,"primaryCompletion":1468,"completion":1469,"start":1470,"enrollment":25,"conditions":1471,"interventions":1474},"NCT06571734","XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma",[91],"2028-07-01","2029-07-01","2024-09-19",[1472,1473],"Metastatic Leiomyosarcoma","Unresectable Leiomyosarcoma",[1411],{"trials":1476,"activeCount":102},[],{"trials":1478,"activeCount":102},[],{"trials":1480,"activeCount":102},[],{"intervention":1482,"totalTrials":475,"cells":1483},"Pemetrexed",{"EARLY_PHASE1":1484,"PHASE1":1502,"PHASE2":1515,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1485,"activeCount":102},[1486],{"nctId":1487,"briefTitle":1488,"status":108,"phases":1489,"primaryCompletion":1490,"completion":1491,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1501},"NCT00424242","Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases",[89],"2010-01","2011-09","2007-01",15,[1495,113,115,24,1496,1497,116,117,1498,1499,1500],"Brain and Central Nervous System Tumors","Lymphoproliferative Disorder","Metastatic Cancer","Precancerous Condition","Secondary Myelofibrosis","Unspecified Adult Solid Tumor, Protocol Specific",[1482],{"trials":1503,"activeCount":102},[1504],{"nctId":1505,"briefTitle":1506,"status":248,"phases":1507,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":1511,"conditions":1512,"interventions":1513},"NCT00369629","Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome",[90],"2012-07-16","2013-06-04","2006-08-28",14,[24],[1514,1482],"Gemcitabine",{"trials":1516,"activeCount":273,"soonestReadout":1521},[1517,1530,1542,1551],{"nctId":1518,"briefTitle":1519,"status":306,"phases":1520,"primaryCompletion":1521,"completion":1522,"start":1523,"enrollment":1524,"conditions":1525,"interventions":1529},"NCT06630416","Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors",[91],"2029-05-10","2030-05-10","2024-11-27",64,[1526,1527,1528],"Metastatic Bladder Urothelial Carcinoma","Metastatic Malignant Solid Neoplasm","Stage IV Bladder Cancer AJCC v8",[1482],{"nctId":1531,"briefTitle":1532,"status":108,"phases":1533,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":9,"conditions":1537,"interventions":1538},"NCT00234052","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[91],"2011-03-01","2011-11-28","2005-07-28",[912],[1539,1540,1541],"bevacizumab","carboplatin","pemetrexed",{"nctId":1543,"briefTitle":1544,"status":200,"phases":1545,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1550},"NCT00276783","Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases",[91],"2022-12","2005-11",31,[1495,24,1497],[1541],{"nctId":1552,"briefTitle":1553,"status":1042,"phases":1554,"primaryCompletion":1555,"completion":1555,"start":1556,"enrollment":1557,"conditions":1558,"interventions":1565},"NCT07594626","BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion",[90,91],"2030-12-09","2027-12-09",72,[1559,1560,1561,1562,1527,1563,1564,1375],"Metastatic Biliary Tract Carcinoma","Metastatic Colon Carcinoma","Metastatic Esophageal Carcinoma","Metastatic Malignant Digestive System Neoplasm","Metastatic Pancreatic Carcinoma","Stage IV Colon Cancer AJCC v8",[1482,1566],"PRMT5 Inhibitor BMS-986504",{"trials":1568,"activeCount":102},[],{"trials":1570,"activeCount":102},[],{"trials":1572,"activeCount":102},[],{"intervention":1574,"totalTrials":273,"cells":1575},"Extended Release Metformin Hydrochloride",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1577,"activeCount":102},[],{"trials":1579,"activeCount":102},[],{"trials":1581,"activeCount":273,"soonestReadout":1595},[1582,1591],{"nctId":1583,"briefTitle":1584,"status":185,"phases":1585,"primaryCompletion":1017,"completion":1586,"start":1587,"enrollment":311,"conditions":1588,"interventions":1590},"NCT04931017","Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer",[91],"2027-06-30","2022-09-09",[1589],"Lung Carcinoma",[1574],{"nctId":1592,"briefTitle":1593,"status":185,"phases":1594,"primaryCompletion":1595,"completion":1596,"start":1597,"enrollment":9,"conditions":1598,"interventions":1601},"NCT04576104","Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer",[91],"2025-08-28","2026-06-30","2021-11-29",[1599,1600],"Endometrial Atypical Hyperplasia\u002FEndometrioid Intraepithelial Neoplasia","Endometrial Carcinoma",[1574,1602],"Megestrol Acetate",{"trials":1604,"activeCount":102},[],{"trials":1606,"activeCount":102},[],{"trials":1608,"activeCount":102},[],{"intervention":632,"totalTrials":1610,"cells":1611},11,{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1625,"PHASE3":1676,"PHASE4":1678,"NA":1707},{"trials":1613,"activeCount":102},[],{"trials":1615,"activeCount":229,"soonestReadout":1621},[1616],{"nctId":1617,"briefTitle":1618,"status":1619,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":76,"enrollment":238,"conditions":1622,"interventions":1623},"NCT04260854","Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery","ENROLLING_BY_INVITATION",[90],"2025-06",[757],[1624,632],"Bupivacaine Hydrochloride",{"trials":1626,"activeCount":229,"soonestReadout":778},[1627,1639,1649,1659,1667],{"nctId":1628,"briefTitle":1629,"status":261,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":102,"conditions":1633,"interventions":1637},"NCT02907983","Stellate Ganglion Blockade in Post-Menopausal Women",[91],"2023-08-24","2018-07-10",[1634,1635,1636],"Hot Flashes","Hot Flushes","Vasomotor Symptoms",[1638,632],"Stellate Ganglion Block Injection with Bupivicaine",{"nctId":1640,"briefTitle":1641,"status":108,"phases":1642,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1647},"NCT02513329","Stellate Ganglion Block (SGB) For Women for Breast Cancer",[91],"2020-01","2015-07",37,[1635,1634],[1648,632],"Bupivicaine",{"nctId":1650,"briefTitle":1651,"status":108,"phases":1652,"primaryCompletion":1653,"completion":603,"start":1654,"enrollment":1655,"conditions":1656,"interventions":1657},"NCT02525718","Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction",[91],"2016-11","2015-08",47,[21],[632,1658],"0.25 % bupivacaine (2.5 mg\u002Fml) w\u002F 1:100,000 epinephrine & 4 mg dexamethasone",{"nctId":1660,"briefTitle":1661,"status":185,"phases":1662,"primaryCompletion":778,"completion":778,"start":1663,"enrollment":1610,"conditions":1664,"interventions":1666},"NCT04018859","Platelet-rich Plasma for Eyebrows",[91],"2019-09-25",[1665],"Eyebrow Hypotrichosis",[632],{"nctId":1668,"briefTitle":1669,"status":248,"phases":1670,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":273,"conditions":1673,"interventions":1674},"NCT03122301","Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer",[91],"2020-07-01","2017-06-01",[1634,1635,1636],[1675,632],"Stellate Ganglion Block injection with bupivicaine",{"trials":1677,"activeCount":102},[],{"trials":1679,"activeCount":102},[1680,1690,1703],{"nctId":1681,"briefTitle":1682,"status":261,"phases":1683,"primaryCompletion":1684,"completion":1684,"start":1684,"enrollment":102,"conditions":1685,"interventions":1688},"NCT02378740","Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion",[93],"2015-04",[1686,15,1687],"Anesthesia","Surgery",[632,1689],"Ketamine",{"nctId":1691,"briefTitle":1692,"status":248,"phases":1693,"primaryCompletion":1694,"completion":1694,"start":1695,"enrollment":273,"conditions":1696,"interventions":1700},"NCT03316118","US Guided GNB vs Saline Injection for TKA",[93],"2021-06-21","2017-10-05",[1697,1698,1699],"Postoperative Pain","Total Knee Arthroplasty","Nerve Block",[1701,1702],"bupivacaine","saline",{"nctId":622,"briefTitle":623,"status":108,"phases":1704,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":1705,"interventions":1706},[93],[630],[581,581,632],{"trials":1708,"activeCount":102},[1709,1718],{"nctId":1710,"briefTitle":1711,"status":261,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":102,"conditions":1715,"interventions":1716},"NCT01125059","Methadone Versus Placebo in Spine Fusion",[94],"2014-01","2010-05",[1697],[1717,632],"Methadone",{"nctId":1719,"briefTitle":1720,"status":108,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1729},"NCT01977898","Incidence of Headache Following an Unintentional Dural Puncture",[94],"2019-03-01","2011-11",68,[1726,1727,1728],"Postdural Puncture Headache","Post-Lumbar Puncture Headache","Cerebrospinal Fluid Leaks",[1730,632],"Morphine",{"intervention":1732,"totalTrials":475,"cells":1733},"Alemtuzumab",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1778,"PHASE4":1780,"NA":1803},{"trials":1735,"activeCount":102},[],{"trials":1737,"activeCount":102},[],{"trials":1739,"activeCount":229,"soonestReadout":41},[1740,1750,1761,1769],{"nctId":1741,"briefTitle":1742,"status":261,"phases":1743,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":1745,"interventions":1747},"NCT04154735","Autologous Transplant Targeted Against Crohn's",[91],"2024-03",[1746],"Crohn's Disease",[517,141,440,1732,441,1748,1749],"Rifaximin","Tacrolimus",{"nctId":39,"briefTitle":40,"status":185,"phases":1751,"primaryCompletion":41,"completion":1752,"start":1753,"enrollment":1426,"conditions":1754,"interventions":1759},[91],"2027-05","2011-06",[1755,1756,1757,1758],"Stage I Chronic Lymphocytic Leukemia","Stage II Chronic Lymphocytic Leukemia","Stage III Chronic Lymphocytic Leukemia","Stage IV Chronic Lymphocytic Leukemia",[42,1760],"ofatumumab",{"nctId":1762,"briefTitle":1763,"status":108,"phases":1764,"primaryCompletion":1765,"completion":1766,"start":458,"enrollment":1645,"conditions":1767,"interventions":1768},"NCT00057967","Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome",[91],"2007-06-26","2010-07-26",[24],[42],{"nctId":1770,"briefTitle":1771,"status":108,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":156,"conditions":1776,"interventions":1777},"NCT00858117","A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL",[91],"2010-03-17","2013-01-24","2005-09-26",[115],[1732,143],{"trials":1779,"activeCount":102},[],{"trials":1781,"activeCount":102},[1782,1792],{"nctId":1783,"briefTitle":1784,"status":248,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT01213329","Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab",[93],"2009-04","2006-02",52,[1790],"Kidney Transplant",[1732],{"nctId":1793,"briefTitle":1794,"status":248,"phases":1795,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":402,"conditions":1798,"interventions":1800},"NCT00166712","A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression",[93],"2010-04","2005-04",[1799],"Kidney Transplant Failure and Rejection",[1749,1801,1732,1802],"Sirolimus","Mycophenolate mofetil",{"trials":1804,"activeCount":102},[],{"intervention":1539,"totalTrials":1610,"cells":1806},{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1808,"activeCount":102},[],{"trials":1810,"activeCount":102},[],{"trials":1812,"activeCount":229,"soonestReadout":1856},[1813,1830,1841,1852,1866,1877,1881,1891,1900,1919,1929],{"nctId":1814,"briefTitle":1815,"status":108,"phases":1816,"primaryCompletion":1817,"completion":1818,"start":1819,"enrollment":375,"conditions":1820,"interventions":1827},"NCT04753216","Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],"2021-08-31","2021-10-25","2021-03-16",[1821,1822,1823,1318,1319,1320,1824,1825,1826],"Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Refractory Fallopian Tube Carcinoma","Refractory Ovarian Carcinoma","Refractory Primary Peritoneal Carcinoma",[1828,1829],"Bevacizumab","Irinotecan Sucrosofate",{"nctId":1831,"briefTitle":1832,"status":108,"phases":1833,"primaryCompletion":1834,"completion":1835,"start":1836,"enrollment":1837,"conditions":1838,"interventions":1839},"NCT00720356","Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",[91],"2014-06-24","2018-07-05","2009-07-07",115,[1495],[1539,1840],"erlotinib hydrochloride",{"nctId":1842,"briefTitle":1843,"status":248,"phases":1844,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1329,"conditions":1848,"interventions":1849},"NCT00334763","Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer",[91],"2007-05","2007-11","2006-05",[912],[1539,1540,1850,1851],"chemoprotection","paclitaxel",{"nctId":1853,"briefTitle":1854,"status":306,"phases":1855,"primaryCompletion":1856,"completion":876,"start":1857,"enrollment":28,"conditions":1858,"interventions":1865},"NCT02847559","Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma",[91],"2026-09","2016-08-01",[1859,1860,1861,1862,1863,1864],"Anaplastic (Malignant) Meningioma","Atypical Meningioma","Grade II Meningioma","Grade III Meningioma","Recurrent Meningioma","Supratentorial Meningioma",[1828],{"nctId":1867,"briefTitle":1868,"status":108,"phases":1869,"primaryCompletion":1870,"completion":1871,"start":1872,"enrollment":1548,"conditions":1873,"interventions":1875},"NCT00460174","Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer",[91],"2007-12-17","2010-07-16","2005-10-10",[1874],"Pancreatic Cancer",[1539,1876],"gemcitabine",{"nctId":1531,"briefTitle":1532,"status":108,"phases":1878,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":9,"conditions":1879,"interventions":1880},[91],[912],[1539,1540,1541],{"nctId":1882,"briefTitle":1883,"status":108,"phases":1884,"primaryCompletion":1885,"completion":1886,"start":1887,"enrollment":1888,"conditions":1889,"interventions":1890},"NCT00337207","Bevacizumab in Treating Patients With Recurrent or Progressive Glioma",[91],"2008-11","2009-05","2006-03",55,[1495],[1539],{"nctId":1892,"briefTitle":1893,"status":108,"phases":1894,"primaryCompletion":1895,"completion":1896,"start":1897,"enrollment":28,"conditions":1898,"interventions":1899},"NCT01898130","Bevacizumab in Pats w\u002F Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy",[91],"2017-03-23","2018-09-05","2013-11-27",[1497,1500],[1539],{"nctId":1901,"briefTitle":1902,"status":108,"phases":1903,"primaryCompletion":1904,"completion":1905,"start":1906,"enrollment":311,"conditions":1907,"interventions":1918},"NCT01125046","Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas",[91],"2014-03-10","2018-12-31","2010-06-17",[1908,1909,1910,1911,1912,1913,1914,1915,1916,1917],"Acoustic Schwannoma","Adult Anaplastic Meningioma","Adult Ependymoma","Adult Grade I Meningioma","Adult Grade II Meningioma","Adult Meningeal Hemangiopericytoma","Adult Papillary Meningioma","Neurofibromatosis Type 1","Neurofibromatosis Type 2","Recurrent Adult Brain Tumor",[1539],{"nctId":1920,"briefTitle":1921,"status":108,"phases":1922,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1329,"conditions":1926,"interventions":1928},"NCT00288015","Bevacizumab in Treating Patients With Angiosarcoma",[91],"2013-06-06","2016-11-10","2005-10",[1927],"Sarcoma",[1828],{"nctId":1930,"briefTitle":1931,"status":248,"phases":1932,"primaryCompletion":1933,"completion":1933,"start":1934,"enrollment":1935,"conditions":1936,"interventions":1941},"NCT01478321","Efficacy of Hypofractionated XRT w\u002FBev. + Temozolomide for Recurrent Gliomas",[91],"2018-09-12","2011-12-14",54,[1937,1938,1939,1940,1254],"Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma",[1256,1539],{"trials":1943,"activeCount":102},[],{"trials":1945,"activeCount":102},[],{"trials":1947,"activeCount":102},[],{"intervention":1540,"totalTrials":98,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1958,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":1951,"activeCount":102},[],{"trials":1953,"activeCount":102},[1954],{"nctId":1235,"briefTitle":1236,"status":261,"phases":1955,"primaryCompletion":1238,"completion":1238,"start":1238,"enrollment":102,"conditions":1956,"interventions":1957},[90],[1240,1241,1242,1243],[47,1228,1245],{"trials":1959,"activeCount":229,"soonestReadout":46},[1960,1964,1968,1980,1987,1996,2014,2018,2022],{"nctId":44,"briefTitle":45,"status":306,"phases":1961,"primaryCompletion":46,"completion":1275,"start":1276,"enrollment":238,"conditions":1962,"interventions":1963},[91],[1278,1279,1280,1281,1282,678,1283],[47,1228],{"nctId":1842,"briefTitle":1843,"status":248,"phases":1965,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1329,"conditions":1966,"interventions":1967},[91],[912],[1539,1540,1850,1851],{"nctId":1969,"briefTitle":1970,"status":248,"phases":1971,"primaryCompletion":434,"completion":1972,"start":1973,"enrollment":1974,"conditions":1975,"interventions":1976},"NCT00004093","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer",[90,91],"2002-03","1999-08",36,[912],[1540,1514,1851,1977,1978,1979],"vinorelbine","Navelbine","Taxol",{"nctId":1981,"briefTitle":1982,"status":108,"phases":1983,"primaryCompletion":1972,"completion":1972,"start":1973,"conditions":1984,"interventions":1985},"NCT00004096","Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[90,91],[912],[1540,1986],"vinorelbine ditartrate",{"nctId":1988,"briefTitle":1989,"status":108,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":111,"conditions":1992,"interventions":1993},"NCT00004172","Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer",[91],"2003-10",[21],[120,1540,177,1994,1995],"ifosfamide","thiotepa",{"nctId":1997,"briefTitle":1998,"status":200,"phases":1999,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":156,"conditions":2003,"interventions":2012},"NCT01372579","Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients",[91],"2020-06","2021-06","2011-08",[2004,2005,2006,2007,2008,2009,2010,1387,1388,1389,2011],"Estrogen Receptor-negative Breast Cancer","HER2-negative Breast Cancer","Male Breast Cancer","Progesterone Receptor-negative Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage II Breast Cancer","Triple-negative Breast Cancer",[2013,1540],"eribulin mesylate",{"nctId":1531,"briefTitle":1532,"status":108,"phases":2015,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":9,"conditions":2016,"interventions":2017},[91],[912],[1539,1540,1541],{"nctId":1350,"briefTitle":1351,"status":200,"phases":2019,"primaryCompletion":1353,"completion":1354,"start":1355,"enrollment":19,"conditions":2020,"interventions":2021},[91],[1343,1357,1358,1359,1360,1361,1362],[47,213,1364,1228],{"nctId":2023,"briefTitle":2024,"status":108,"phases":2025,"primaryCompletion":1492,"completion":1492,"start":2026,"conditions":2027,"interventions":2028},"NCT00004169","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease",[91],"1993-11",[24],[1540,177,464],{"trials":2030,"activeCount":102},[],{"trials":2032,"activeCount":102},[],{"trials":2034,"activeCount":102},[],{"intervention":2036,"totalTrials":887,"cells":2037},"gemcitabine hydrochloride",{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2074,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2039,"activeCount":102},[],{"trials":2041,"activeCount":102},[2042,2052,2066],{"nctId":2043,"briefTitle":2044,"status":108,"phases":2045,"primaryCompletion":2046,"completion":2046,"start":1973,"enrollment":205,"conditions":2047,"interventions":2051},"NCT00004095","Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors",[90],"2008-10",[2048,21,2049,2050,912,1874],"Bladder Cancer","Colorectal Cancer","Kidney Cancer",[2036,915],{"nctId":2053,"briefTitle":2054,"status":108,"phases":2055,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":999,"conditions":2059,"interventions":2064},"NCT01473940","Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery",[90],"2014-10-16","2018-05-06","2012-06-11",[2060,2061,2062,2063],"Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer",[2065,2036],"ipilimumab",{"nctId":2067,"briefTitle":2068,"status":108,"phases":2069,"primaryCompletion":2070,"completion":2070,"start":1973,"conditions":2071,"interventions":2072},"NCT00004090","Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors",[90],"2002-08",[1500],[2073,2036],"cisplatin",{"trials":2075,"activeCount":229,"soonestReadout":2090},[2076,2086],{"nctId":2077,"briefTitle":2078,"status":248,"phases":2079,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":1329,"conditions":2083,"interventions":2084},"NCT00290706","A Phase I\u002FII Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma",[90,91],"2011-02-11","2012-09-05","2006-04-07",[24],[2085,2036],"bortezomib",{"nctId":2087,"briefTitle":2088,"status":306,"phases":2089,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":2093,"conditions":2094,"interventions":2123},"NCT05733000","CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors",[91],"2028-01-04","2030-03-04","2023-03-08",94,[2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,1559,2105,2106,2107,2108,1563,2109,2110,2111,2112,2113,1825,2114,2115,2116,2117,2118,2119,1374,2120,2121,2122,1375],"Advanced Biliary Tract Carcinoma","Advanced Colorectal Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Lung Adenocarcinoma","Advanced Malignant Solid Neoplasm","Advanced Ovarian Carcinoma","Advanced Pancreatic Carcinoma","Advanced Urothelial Carcinoma","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Metastatic Colorectal Carcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Lung Adenocarcinoma","Metastatic Ovarian Carcinoma","Metastatic Urothelial Carcinoma","Refractory Biliary Tract Carcinoma","Refractory Colorectal Carcinoma","Refractory Gastroesophageal Junction Adenocarcinoma","Refractory Lung Adenocarcinoma","Refractory Pancreatic Carcinoma","Refractory Urothelial Carcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8",[2124,2125,2126,2127],"Devimistat","Fluorouracil","Gemcitabine Hydrochloride","Hydroxychloroquine",{"trials":2129,"activeCount":102},[],{"trials":2131,"activeCount":102},[],{"trials":2133,"activeCount":102},[],{"intervention":2135,"totalTrials":582,"cells":2136},"fluorouracil",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2149,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2138,"activeCount":102},[],{"trials":2140,"activeCount":102},[2141],{"nctId":2142,"briefTitle":2143,"status":108,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":2146,"conditions":2147,"interventions":2148},"NCT00004913","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors",[90],"2002-05","2000-01",[1500],[2073,914,2135,180],{"trials":2150,"activeCount":229,"soonestReadout":2090},[2151,2155,2164],{"nctId":2087,"briefTitle":2088,"status":306,"phases":2152,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":2093,"conditions":2153,"interventions":2154},[91],[2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,1559,2105,2106,2107,2108,1563,2109,2110,2111,2112,2113,1825,2114,2115,2116,2117,2118,2119,1374,2120,2121,2122,1375],[2124,2125,2126,2127],{"nctId":2156,"briefTitle":2157,"status":248,"phases":2158,"primaryCompletion":2159,"completion":1846,"start":111,"conditions":2160,"interventions":2162},"NCT00004897","Combination Chemotherapy and Interferon Alfa Followed by Surgery and\u002For Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer",[91],"2007-07",[2161],"Esophageal Cancer",[175,2073,2135,2163,180],"hydroxyurea",{"nctId":2165,"briefTitle":2166,"status":108,"phases":2167,"primaryCompletion":2168,"completion":2169,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2174},"NCT00711243","Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor",[90,91],"2008-12-15","2011-02-25","2005-04-20",59,[2173,1500],"Gastric Cancer",[914,2135,2175],"oxaliplatin",{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":102},[],{"trials":2181,"activeCount":102},[],{"intervention":2183,"totalTrials":375,"cells":2184},"lenalidomide",{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2186,"activeCount":102},[],{"trials":2188,"activeCount":102},[],{"trials":2190,"activeCount":229,"soonestReadout":2195},[2191,2206,2233],{"nctId":2192,"briefTitle":2193,"status":185,"phases":2194,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":2198,"conditions":2199,"interventions":2203},"NCT06723457","Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma",[91],"2027-02-18","2029-02-18","2025-07-25",34,[2200,2201,2202],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder","Refractory B-Cell Non-Hodgkin Lymphoma",[2204,2205],"Epcoritamab","Lenalidomide",{"nctId":2207,"briefTitle":2208,"status":200,"phases":2209,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":156,"conditions":2213,"interventions":2231},"NCT02232516","Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma",[91],"2020-08-11","2024-08","2015-06-11",[2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230],"Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic T-cell Lymphoma","Peripheral T-cell Lymphoma","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IA Mycosis Fungoides\u002FSezary Syndrome","Stage IB Mycosis Fungoides\u002FSezary Syndrome","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIB Mycosis Fungoides\u002FSezary Syndrome","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IIIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIIB Mycosis Fungoides\u002FSezary Syndrome","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IVA Mycosis Fungoides\u002FSezary Syndrome","Stage IVB Mycosis Fungoides\u002FSezary Syndrome",[2232,2183],"romidepsin",{"nctId":2234,"briefTitle":2235,"status":108,"phases":2236,"primaryCompletion":2237,"completion":2238,"start":2239,"enrollment":1440,"conditions":2240,"interventions":2241},"NCT00466921","Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides\u002FSezary Syndrome",[91],"2010-04-05","2013-05-17","2005-04-19",[24],[2183],{"trials":2243,"activeCount":102},[],{"trials":2245,"activeCount":102},[],{"trials":2247,"activeCount":102},[],{"intervention":2249,"totalTrials":375,"cells":2250},"Afimoxifene",{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2255,"PHASE3":2292,"PHASE4":2294,"NA":2296},{"trials":2252,"activeCount":102},[],{"trials":2254,"activeCount":102},[],{"trials":2256,"activeCount":229,"soonestReadout":2261},[2257,2270,2282],{"nctId":2258,"briefTitle":2259,"status":185,"phases":2260,"primaryCompletion":2261,"completion":2262,"start":2263,"enrollment":2264,"conditions":2265,"interventions":2269},"NCT04009044","Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast",[91],"2026-01-31","2026-06-25","2020-02-17",156,[2266,2267,2268],"Cancer Survivor","Ductal Breast Carcinoma In Situ","Invasive Breast Carcinoma",[2249],{"nctId":2271,"briefTitle":2272,"status":108,"phases":2273,"primaryCompletion":1491,"start":2274,"enrollment":28,"conditions":2275,"interventions":2278},"NCT00952731","4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ",[91],"2009-12",[2276,2277],"Ductal Breast Carcinoma in Situ","Estrogen Receptor-positive Breast Cancer",[2279,2280,2281],"oral placebo","afimoxifene","tamoxifen citrate",{"nctId":2283,"briefTitle":2284,"status":108,"phases":2285,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":238,"conditions":2289,"interventions":2290},"NCT02993159","Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast",[91],"2021-03-30","2022-01-24","2017-05-31",[2267,1279],[2249,2291],"Tamoxifen Citrate",{"trials":2293,"activeCount":102},[],{"trials":2295,"activeCount":102},[],{"trials":2297,"activeCount":102},[],{"intervention":1347,"totalTrials":375,"cells":2299},{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2336,"PHASE4":2338,"NA":2340},{"trials":2301,"activeCount":102},[],{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":229,"soonestReadout":1396},[2306,2310,2314],{"nctId":1334,"briefTitle":1335,"status":200,"phases":2307,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":156,"conditions":2308,"interventions":2309},[91],[1341,1342,1343,1344,1345],[1347,142,1228,1348],{"nctId":1393,"briefTitle":1394,"status":185,"phases":2311,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":156,"conditions":2312,"interventions":2313},[91],[1400],[1347,1402,1228,1403],{"nctId":2315,"briefTitle":2316,"status":108,"phases":2317,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":2321,"interventions":2329},"NCT01476410","Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma",[91],"2017-04-06","2020-05-26",49,[2322,2323,2324,2325,2326,2327,2328],"Adult Lymphocyte Depletion Hodgkin Lymphoma","Adult Lymphocyte Predominant Hodgkin Lymphoma","Adult Mixed Cellularity Hodgkin Lymphoma","Adult Nodular Sclerosis Hodgkin Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage IV Adult Hodgkin Lymphoma",[2330,179,2331,2332,2333,2334,2335],"brentuximab vedotin","vinblastine","dacarbazine","DNA analysis","RNA analysis","polymorphism analysis",{"trials":2337,"activeCount":102},[],{"trials":2339,"activeCount":102},[],{"trials":2341,"activeCount":102},[],{"intervention":2343,"totalTrials":273,"cells":2344},"Erlotinib",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2346,"activeCount":102},[],{"trials":2348,"activeCount":102},[],{"trials":2350,"activeCount":229,"soonestReadout":383},[2351,2361],{"nctId":2352,"briefTitle":2353,"status":1042,"phases":2354,"primaryCompletion":383,"completion":383,"start":2355,"enrollment":537,"conditions":2356,"interventions":2360},"NCT06545695","Epidermal Growth Factor Receptor Inhibition for Keratinopathies",[90,91],"2027-07-01",[2357,2358,2359],"Epidermolytic Ichthyosis","Palmoplantar Keratoderma","Pachyonychia Congenita",[2343],{"nctId":2362,"briefTitle":2363,"status":261,"phases":2364,"enrollment":102,"conditions":2365,"interventions":2367},"NCT01006096","Erlotinib for Treatment of Psoriasis",[91],[2366],"Psoriasis",[2368],"erlotinib",{"trials":2370,"activeCount":102},[],{"trials":2372,"activeCount":102},[],{"trials":2374,"activeCount":102},[],{"intervention":1602,"totalTrials":273,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2378,"activeCount":102},[],{"trials":2380,"activeCount":102},[],{"trials":2382,"activeCount":229,"soonestReadout":1595},[2383,2387],{"nctId":1592,"briefTitle":1593,"status":185,"phases":2384,"primaryCompletion":1595,"completion":1596,"start":1597,"enrollment":9,"conditions":2385,"interventions":2386},[91],[1599,1600],[1574,1602],{"nctId":2388,"briefTitle":2389,"status":108,"phases":2390,"primaryCompletion":2391,"completion":2391,"start":2146,"conditions":2392,"interventions":2395},"NCT00004912","Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss",[91],"2003-11",[2393,2394,1500],"Cachexia","Fatigue",[2396],"megestrol acetate",{"trials":2398,"activeCount":102},[],{"trials":2400,"activeCount":102},[],{"trials":2402,"activeCount":102},[],{"intervention":1402,"totalTrials":273,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2424,"PHASE4":2426,"NA":2428},{"trials":2406,"activeCount":102},[],{"trials":2408,"activeCount":102},[],{"trials":2410,"activeCount":229,"soonestReadout":1396},[2411,2420],{"nctId":2412,"briefTitle":2413,"status":108,"phases":2414,"primaryCompletion":2415,"completion":2416,"start":2417,"enrollment":1316,"conditions":2418,"interventions":2419},"NCT00956930","Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery",[91],"2016-06-02","2016-07-15","2009-08",[902],[1402],{"nctId":1393,"briefTitle":1394,"status":185,"phases":2421,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":156,"conditions":2422,"interventions":2423},[91],[1400],[1347,1402,1228,1403],{"trials":2425,"activeCount":102},[],{"trials":2427,"activeCount":102},[],{"trials":2429,"activeCount":102},[],{"intervention":1403,"totalTrials":273,"cells":2431},{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2433,"activeCount":102},[],{"trials":2435,"activeCount":102},[],{"trials":2437,"activeCount":229,"soonestReadout":1396},[2438,2442],{"nctId":1393,"briefTitle":1394,"status":185,"phases":2439,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":156,"conditions":2440,"interventions":2441},[91],[1400],[1347,1402,1228,1403],{"nctId":2315,"briefTitle":2316,"status":108,"phases":2443,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":2444,"interventions":2445},[91],[2322,2323,2324,2325,2326,2327,2328],[2330,179,2331,2332,2333,2334,2335],{"trials":2447,"activeCount":102},[],{"trials":2449,"activeCount":102},[],{"trials":2451,"activeCount":102},[],{"intervention":2453,"totalTrials":229,"cells":2454},"Y90 + Atezolizumab and Bevacizumab",{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2471,"PHASE4":2473,"NA":2475},{"trials":2456,"activeCount":102},[],{"trials":2458,"activeCount":102},[],{"trials":2460,"activeCount":229,"soonestReadout":2465},[2461],{"nctId":2462,"briefTitle":2463,"status":306,"phases":2464,"primaryCompletion":2465,"completion":2465,"start":2466,"enrollment":692,"conditions":2467,"interventions":2469},"NCT05620771","Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk",[91],"2040-07-01","2022-11-30",[2468],"Hepatocellular Carcinoma",[2453,2470],"Y90 + TKI",{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[],{"trials":2476,"activeCount":102},[],{"intervention":2470,"totalTrials":229,"cells":2478},{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2489,"PHASE4":2491,"NA":2493},{"trials":2480,"activeCount":102},[],{"trials":2482,"activeCount":102},[],{"trials":2484,"activeCount":229,"soonestReadout":2465},[2485],{"nctId":2462,"briefTitle":2463,"status":306,"phases":2486,"primaryCompletion":2465,"completion":2465,"start":2466,"enrollment":692,"conditions":2487,"interventions":2488},[91],[2468],[2453,2470],{"trials":2490,"activeCount":102},[],{"trials":2492,"activeCount":102},[],{"trials":2494,"activeCount":102},[],{"intervention":2496,"totalTrials":229,"cells":2497},"Chemotherapy, albumin-bound paclitaxel",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2499,"activeCount":102},[],{"trials":2501,"activeCount":102},[],{"trials":2503,"activeCount":229,"soonestReadout":1017},[2504],{"nctId":2505,"briefTitle":2506,"status":185,"phases":2507,"primaryCompletion":1017,"completion":1017,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2517},"NCT04528680","Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma",[90,91],"2020-10-29",57,[2511,2512,2513,2514,2515,2516],"Glioblastoma","Gliosarcoma","GBM","Glioblastoma Multiforme","Glioblastoma, IDH-wildtype","Recurrent Glioblastoma",[2496,2518],"Chemotherapy, carboplatin",{"trials":2520,"activeCount":102},[],{"trials":2522,"activeCount":102},[],{"trials":2524,"activeCount":102},[],{"intervention":2518,"totalTrials":229,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2528,"activeCount":102},[],{"trials":2530,"activeCount":102},[],{"trials":2532,"activeCount":229,"soonestReadout":1017},[2533],{"nctId":2505,"briefTitle":2506,"status":185,"phases":2534,"primaryCompletion":1017,"completion":1017,"start":2508,"enrollment":2509,"conditions":2535,"interventions":2536},[90,91],[2511,2512,2513,2514,2515,2516],[2496,2518],{"trials":2538,"activeCount":102},[],{"trials":2540,"activeCount":102},[],{"trials":2542,"activeCount":102},[],{"intervention":2544,"totalTrials":229,"cells":2545},"Selenium supplementation",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2561,"PHASE4":2563,"NA":2565},{"trials":2547,"activeCount":102},[],{"trials":2549,"activeCount":102},[],{"trials":2551,"activeCount":229,"soonestReadout":2556},[2552],{"nctId":2553,"briefTitle":2554,"status":306,"phases":2555,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":935,"conditions":2558,"interventions":2560},"NCT07427017","Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies",[91],"2028-12","2026-04-29",[2559],"Ulcerative Colitis (UC)",[2544],{"trials":2562,"activeCount":102},[],{"trials":2564,"activeCount":102},[],{"trials":2566,"activeCount":102},[],{"intervention":2204,"totalTrials":229,"cells":2568},{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2570,"activeCount":102},[],{"trials":2572,"activeCount":102},[],{"trials":2574,"activeCount":229,"soonestReadout":2195},[2575],{"nctId":2192,"briefTitle":2193,"status":185,"phases":2576,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":2198,"conditions":2577,"interventions":2578},[91],[2200,2201,2202],[2204,2205],{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[],{"intervention":2586,"totalTrials":229,"cells":2587},"STAT3 Inhibitor WP1066",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2589,"activeCount":102},[],{"trials":2591,"activeCount":102},[],{"trials":2593,"activeCount":229,"soonestReadout":2598},[2594],{"nctId":2595,"briefTitle":2596,"status":306,"phases":2597,"primaryCompletion":2598,"completion":2599,"start":2600,"enrollment":2601,"conditions":2602,"interventions":2605},"NCT05879250","WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",[91],"2027-12-27","2028-12-27","2024-05-22",39,[2603,2604],"Glioblastoma, IDH-Wildtype","MGMT-Unmethylated Glioblastoma",[2586],{"trials":2607,"activeCount":102},[],{"trials":2609,"activeCount":102},[],{"trials":2611,"activeCount":102},[],{"intervention":1760,"totalTrials":229,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2624,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":102},[],{"trials":2617,"activeCount":102},[],{"trials":2619,"activeCount":229,"soonestReadout":41},[2620],{"nctId":39,"briefTitle":40,"status":185,"phases":2621,"primaryCompletion":41,"completion":1752,"start":1753,"enrollment":1426,"conditions":2622,"interventions":2623},[91],[1755,1756,1757,1758],[42,1760],{"trials":2625,"activeCount":102},[],{"trials":2627,"activeCount":102},[],{"trials":2629,"activeCount":102},[],{"intervention":2631,"totalTrials":229,"cells":2632},"Chimeric Antigen Receptor T-Cell Therapy",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2668,"PHASE4":2670,"NA":2672},{"trials":2634,"activeCount":102},[],{"trials":2636,"activeCount":102},[],{"trials":2638,"activeCount":229,"soonestReadout":2643},[2639],{"nctId":2640,"briefTitle":2641,"status":185,"phases":2642,"primaryCompletion":2643,"completion":2644,"start":2645,"enrollment":2646,"conditions":2647,"interventions":2666},"NCT05202782","Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma",[91],"2026-10-09","2029-10-09","2022-03-21",24,[2648,2649,138,2650,2651,2652,2653,2654,2655,2656,2657,2658,2659,2660,2661,2662,2663,2664,2665],"Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Large B-Cell Lymphoma With IRF4 Rearrangement","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent Intravascular Large B-Cell Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma","Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory Intravascular Large B-Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Refractory T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Refractory Transformed B-Cell Non-Hodgkin Lymphoma",[2631,2667],"Zanubrutinib",{"trials":2669,"activeCount":102},[],{"trials":2671,"activeCount":102},[],{"trials":2673,"activeCount":102},[],{"intervention":2667,"totalTrials":229,"cells":2675},{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2686,"PHASE4":2688,"NA":2690},{"trials":2677,"activeCount":102},[],{"trials":2679,"activeCount":102},[],{"trials":2681,"activeCount":229,"soonestReadout":2643},[2682],{"nctId":2640,"briefTitle":2641,"status":185,"phases":2683,"primaryCompletion":2643,"completion":2644,"start":2645,"enrollment":2646,"conditions":2684,"interventions":2685},[91],[2648,2649,138,2650,2651,2652,2653,2654,2655,2656,2657,2658,2659,2660,2661,2662,2663,2664,2665],[2631,2667],{"trials":2687,"activeCount":102},[],{"trials":2689,"activeCount":102},[],{"trials":2691,"activeCount":102},[],{"intervention":2124,"totalTrials":229,"cells":2693},{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2704,"PHASE4":2706,"NA":2708},{"trials":2695,"activeCount":102},[],{"trials":2697,"activeCount":102},[],{"trials":2699,"activeCount":229,"soonestReadout":2090},[2700],{"nctId":2087,"briefTitle":2088,"status":306,"phases":2701,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":2093,"conditions":2702,"interventions":2703},[91],[2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,1559,2105,2106,2107,2108,1563,2109,2110,2111,2112,2113,1825,2114,2115,2116,2117,2118,2119,1374,2120,2121,2122,1375],[2124,2125,2126,2127],{"trials":2705,"activeCount":102},[],{"trials":2707,"activeCount":102},[],{"trials":2709,"activeCount":102},[],{"intervention":2127,"totalTrials":229,"cells":2711},{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":229,"soonestReadout":2090},[2718],{"nctId":2087,"briefTitle":2088,"status":306,"phases":2719,"primaryCompletion":2090,"completion":2091,"start":2092,"enrollment":2093,"conditions":2720,"interventions":2721},[91],[2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,1559,2105,2106,2107,2108,1563,2109,2110,2111,2112,2113,1825,2114,2115,2116,2117,2118,2119,1374,2120,2121,2122,1375],[2124,2125,2126,2127],{"trials":2723,"activeCount":102},[],{"trials":2725,"activeCount":102},[],{"trials":2727,"activeCount":102},[],{"intervention":1332,"totalTrials":229,"cells":2729},{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2731,"activeCount":102},[],{"trials":2733,"activeCount":102},[],{"trials":2735,"activeCount":229,"soonestReadout":1327},[2736],{"nctId":1324,"briefTitle":1325,"status":185,"phases":2737,"primaryCompletion":1327,"completion":1328,"start":658,"enrollment":1329,"conditions":2738,"interventions":2739},[91],[159],[1228,1332],{"trials":2741,"activeCount":102},[],{"trials":2743,"activeCount":102},[],{"trials":2745,"activeCount":102},[],{"intervention":2747,"totalTrials":229,"cells":2748},"Atorvastatin Calcium",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2753,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2750,"activeCount":102},[],{"trials":2752,"activeCount":102},[],{"trials":2754,"activeCount":229,"soonestReadout":2759},[2755],{"nctId":2756,"briefTitle":2757,"status":185,"phases":2758,"primaryCompletion":2759,"completion":2760,"start":2761,"enrollment":2762,"conditions":2763,"interventions":2766},"NCT04767984","Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis",[91],"2025-12-04","2026-11-30","2021-09-24",42,[2764,2765],"Colorectal Carcinoma","Ulcerative Colitis",[2747],{"trials":2768,"activeCount":102},[],{"trials":2770,"activeCount":102},[],{"trials":2772,"activeCount":102},[],{"intervention":2774,"totalTrials":229,"cells":2775},"Chemical Peels",{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2790,"PHASE4":2792,"NA":2794},{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":229,"soonestReadout":876},[2782],{"nctId":2783,"briefTitle":2784,"status":1042,"phases":2785,"primaryCompletion":876,"completion":876,"start":2786,"enrollment":341,"conditions":2787,"interventions":2789},"NCT04429308","PDT vs Peels for Treatment of Actinic Keratoses",[91],"2025-08",[2788],"Actinic Keratoses",[2774],{"trials":2791,"activeCount":102},[],{"trials":2793,"activeCount":102},[],{"trials":2795,"activeCount":102},[],{"intervention":67,"totalTrials":229,"cells":2797},{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2799,"activeCount":102},[],{"trials":2801,"activeCount":102},[],{"trials":2803,"activeCount":229,"soonestReadout":66},[2804],{"nctId":64,"briefTitle":65,"status":185,"phases":2805,"primaryCompletion":66,"completion":187,"start":188,"enrollment":189,"conditions":2806,"interventions":2807},[91],[191,192,193,194],[67,196,97],{"trials":2809,"activeCount":102},[],{"trials":2811,"activeCount":102},[],{"trials":2813,"activeCount":102},[],{"intervention":2815,"totalTrials":229,"cells":2816},"Cemiplimab",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2834,"PHASE4":2836,"NA":2838},{"trials":2818,"activeCount":102},[],{"trials":2820,"activeCount":102},[],{"trials":2822,"activeCount":229,"soonestReadout":2827},[2823],{"nctId":2824,"briefTitle":2825,"status":306,"phases":2826,"primaryCompletion":2827,"completion":2828,"start":2829,"enrollment":1493,"conditions":2830,"interventions":2833},"NCT07050186","Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma",[91],"2030-11-20","2035-11-20","2025-08-15",[2831,2832],"Metastatic NUT Carcinoma","Unresectable NUT Carcinoma",[2815],{"trials":2835,"activeCount":102},[],{"trials":2837,"activeCount":102},[],{"trials":2839,"activeCount":102},[],{"intervention":2841,"totalTrials":229,"cells":2842},"Nitrate-Rich Beetroot Juice + supervised exercise therapy",{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2859,"PHASE4":2861,"NA":2863},{"trials":2844,"activeCount":102},[],{"trials":2846,"activeCount":102},[],{"trials":2848,"activeCount":229,"soonestReadout":1469},[2849],{"nctId":2850,"briefTitle":2851,"status":306,"phases":2852,"primaryCompletion":1469,"completion":2853,"start":2854,"enrollment":692,"conditions":2855,"interventions":2858},"NCT06657976","Response to Exercise and Nitric Oxide in PAD",[91],"2029-10-01","2025-01-23",[1022,2856,1183,2857],"Exercise","Nitric Oxide",[2841],{"trials":2860,"activeCount":102},[],{"trials":2862,"activeCount":102},[],{"trials":2864,"activeCount":102},[],{"intervention":2866,"totalTrials":229,"cells":2867},"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2884,"PHASE4":2886,"NA":2888},{"trials":2869,"activeCount":102},[],{"trials":2871,"activeCount":102},[],{"trials":2873,"activeCount":229,"soonestReadout":1468},[2874],{"nctId":2875,"briefTitle":2876,"status":306,"phases":2877,"primaryCompletion":1468,"completion":2878,"start":2879,"enrollment":19,"conditions":2880,"interventions":2883},"NCT05576896","Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory",[91],"2030-07-01","2022-10-10",[2881,2049,2882],"Stage IV Colorectal Cancer Positive for BRAF V600E Mutation","Colorectal Cancer Stage IV",[2866],{"trials":2885,"activeCount":102},[],{"trials":2887,"activeCount":102},[],{"trials":2889,"activeCount":102},[],{"intervention":2891,"totalTrials":229,"cells":2892},"elacestrant, palbociclib, abemaciclib, ribociclib",{"EARLY_PHASE1":2893,"PHASE1":2895,"PHASE2":2897,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2894,"activeCount":102},[],{"trials":2896,"activeCount":102},[],{"trials":2898,"activeCount":229,"soonestReadout":2903},[2899],{"nctId":2900,"briefTitle":2901,"status":306,"phases":2902,"primaryCompletion":2903,"completion":2355,"start":754,"enrollment":2904,"conditions":2905,"interventions":2910},"NCT06062498","Elacestrant vs Elacestrant Plus a CDK4\u002F6 Inhibitor in Patients With ERpositive\u002FHER2-negative Advanced or Metastatic Breast Cancer",[91],"2026-07-01",174,[2906,2907,2908,2909],"Estrogen-receptor-positive Breast Cancer","HER2\u002FNeu-Negative Breast Cancer","Advanced Breast Cancerv","Metastatic Breast Cancer",[2891],{"trials":2912,"activeCount":102},[],{"trials":2914,"activeCount":102},[],{"trials":2916,"activeCount":102},[],{"intervention":2918,"totalTrials":229,"cells":2919},"IncobotulinumtoxinA",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2936,"PHASE4":2938,"NA":2940},{"trials":2921,"activeCount":102},[],{"trials":2923,"activeCount":102},[],{"trials":2925,"activeCount":229,"soonestReadout":2930},[2926],{"nctId":2927,"briefTitle":2928,"status":1042,"phases":2929,"primaryCompletion":2930,"completion":2930,"start":2931,"enrollment":156,"conditions":2932,"interventions":2934},"NCT07537855","Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction",[91],"2028-06","2026-06",[2933],"Erectile Dysfunction",[2918,2935],"Tadalafil 20 MG",{"trials":2937,"activeCount":102},[],{"trials":2939,"activeCount":102},[],{"trials":2941,"activeCount":102},[],{"intervention":2935,"totalTrials":229,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2954,"PHASE4":2956,"NA":2958},{"trials":2945,"activeCount":102},[],{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":229,"soonestReadout":2930},[2950],{"nctId":2927,"briefTitle":2928,"status":1042,"phases":2951,"primaryCompletion":2930,"completion":2930,"start":2931,"enrollment":156,"conditions":2952,"interventions":2953},[91],[2933],[2918,2935],{"trials":2955,"activeCount":102},[],{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":102},[],{"intervention":1566,"totalTrials":229,"cells":2961},{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2972,"PHASE4":2974,"NA":2976},{"trials":2963,"activeCount":102},[],{"trials":2965,"activeCount":102},[],{"trials":2967,"activeCount":229,"soonestReadout":1555},[2968],{"nctId":1552,"briefTitle":1553,"status":1042,"phases":2969,"primaryCompletion":1555,"completion":1555,"start":1556,"enrollment":1557,"conditions":2970,"interventions":2971},[90,91],[1559,1560,1561,1562,1527,1563,1564,1375],[1482,1566],{"trials":2973,"activeCount":102},[],{"trials":2975,"activeCount":102},[],{"trials":2977,"activeCount":102},[],{"intervention":2979,"totalTrials":229,"cells":2980},"Dapagliflozin 10 MG [Farxiga]",{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[],{"trials":2986,"activeCount":229,"soonestReadout":2991},[2987],{"nctId":2988,"briefTitle":2989,"status":306,"phases":2990,"primaryCompletion":2991,"completion":2991,"start":2992,"enrollment":341,"conditions":2993,"interventions":2998},"NCT05719714","Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease",[90,91],"2026-09-30","2024-01-16",[2994,2995,2996,2997],"Chronic Kidney Diseases","Heart Failure With Preserved Ejection Fraction","Kidney Diseases","Heart Failure",[2979],{"trials":3000,"activeCount":102},[],{"trials":3002,"activeCount":102},[],{"trials":3004,"activeCount":102},[],{"intervention":3006,"totalTrials":229,"cells":3007},"Group B active comparator",{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":3009,"activeCount":102},[],{"trials":3011,"activeCount":102},[],{"trials":3013,"activeCount":229,"soonestReadout":3018},[3014],{"nctId":3015,"briefTitle":3016,"status":306,"phases":3017,"primaryCompletion":3018,"completion":3019,"start":3020,"enrollment":3021,"conditions":3022,"interventions":3025},"NCT06608277","Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD",[91],"2027-12-30","2028-04-30","2025-07-02",175,[3023,3024],"Posttraumatic Headache","Posttraumatic Stress Disorder",[3006,3026],"Group C Experimental",{"trials":3028,"activeCount":102},[],{"trials":3030,"activeCount":102},[],{"trials":3032,"activeCount":102},[],{"intervention":3026,"totalTrials":229,"cells":3034},{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3045,"PHASE4":3047,"NA":3049},{"trials":3036,"activeCount":102},[],{"trials":3038,"activeCount":102},[],{"trials":3040,"activeCount":229,"soonestReadout":3018},[3041],{"nctId":3015,"briefTitle":3016,"status":306,"phases":3042,"primaryCompletion":3018,"completion":3019,"start":3020,"enrollment":3021,"conditions":3043,"interventions":3044},[91],[3023,3024],[3006,3026],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":102},[],{"trials":3050,"activeCount":102},[],{"intervention":3052,"totalTrials":229,"cells":3053},"Balstilimab",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3058,"PHASE3":3074,"PHASE4":3076,"NA":3078},{"trials":3055,"activeCount":102},[],{"trials":3057,"activeCount":102},[],{"trials":3059,"activeCount":229,"soonestReadout":3064},[3060],{"nctId":3061,"briefTitle":3062,"status":306,"phases":3063,"primaryCompletion":3064,"completion":3065,"start":3066,"enrollment":3067,"conditions":3068,"interventions":3071},"NCT05864534","Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma",[91],"2031-07-31","2031-08-31","2024-01-19",25,[3069,3070,2512,2514],"Newly Diagnosed Glioblastoma","Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype",[3052,3072,3073],"Botensilimab","Liposomal Doxorubicin",{"trials":3075,"activeCount":102},[],{"trials":3077,"activeCount":102},[],{"trials":3079,"activeCount":102},[],{"intervention":3072,"totalTrials":229,"cells":3081},{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3086,"PHASE3":3092,"PHASE4":3094,"NA":3096},{"trials":3083,"activeCount":102},[],{"trials":3085,"activeCount":102},[],{"trials":3087,"activeCount":229,"soonestReadout":3064},[3088],{"nctId":3061,"briefTitle":3062,"status":306,"phases":3089,"primaryCompletion":3064,"completion":3065,"start":3066,"enrollment":3067,"conditions":3090,"interventions":3091},[91],[3069,3070,2512,2514],[3052,3072,3073],{"trials":3093,"activeCount":102},[],{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":102},[],{"intervention":3073,"totalTrials":229,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3101,"activeCount":102},[],{"trials":3103,"activeCount":102},[],{"trials":3105,"activeCount":229,"soonestReadout":3064},[3106],{"nctId":3061,"briefTitle":3062,"status":306,"phases":3107,"primaryCompletion":3064,"completion":3065,"start":3066,"enrollment":3067,"conditions":3108,"interventions":3109},[91],[3069,3070,2512,2514],[3052,3072,3073],{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[],{"trials":3115,"activeCount":102},[],{"intervention":3117,"totalTrials":229,"cells":3118},"Antiandrogen Therapy",{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3136,"PHASE4":3138,"NA":3140},{"trials":3120,"activeCount":102},[],{"trials":3122,"activeCount":102},[],{"trials":3124,"activeCount":229,"soonestReadout":2195},[3125],{"nctId":3126,"briefTitle":3127,"status":306,"phases":3128,"primaryCompletion":2195,"completion":3129,"start":3130,"enrollment":11,"conditions":3131,"interventions":3134},"NCT06244004","FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial",[91],"2028-02-18","2024-02-18",[3132,193,3133],"Castration-Sensitive Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8",[3117,3135],"Cytotoxic Chemotherapy",{"trials":3137,"activeCount":102},[],{"trials":3139,"activeCount":102},[],{"trials":3141,"activeCount":102},[],{"intervention":3135,"totalTrials":229,"cells":3143},{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3154,"PHASE4":3156,"NA":3158},{"trials":3145,"activeCount":102},[],{"trials":3147,"activeCount":102},[],{"trials":3149,"activeCount":229,"soonestReadout":2195},[3150],{"nctId":3126,"briefTitle":3127,"status":306,"phases":3151,"primaryCompletion":2195,"completion":3129,"start":3130,"enrollment":11,"conditions":3152,"interventions":3153},[91],[3132,193,3133],[3117,3135],{"trials":3155,"activeCount":102},[],{"trials":3157,"activeCount":102},[],{"trials":3159,"activeCount":102},[],{"intervention":3161,"totalTrials":229,"cells":3162},"Vudalimab",{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3164,"activeCount":102},[],{"trials":3166,"activeCount":102},[],{"trials":3168,"activeCount":229,"soonestReadout":3173},[3169],{"nctId":3170,"briefTitle":3171,"status":185,"phases":3172,"primaryCompletion":3173,"completion":3174,"start":3175,"enrollment":1935,"conditions":3176,"interventions":3179},"NCT05453799","Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer",[91],"2026-07-15","2027-07-15","2022-07-21",[3177,3178,1450],"Locally Advanced Thyroid Gland Anaplastic Carcinoma","Metastatic Thyroid Gland Anaplastic Carcinoma",[3161],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[],{"trials":3185,"activeCount":102},[],{"intervention":3187,"totalTrials":229,"cells":3188},"Fisetin",{"EARLY_PHASE1":3189,"PHASE1":3191,"PHASE2":3193,"PHASE3":3207,"PHASE4":3209,"NA":3211},{"trials":3190,"activeCount":102},[],{"trials":3192,"activeCount":102},[],{"trials":3194,"activeCount":229,"soonestReadout":3199},[3195],{"nctId":3196,"briefTitle":3197,"status":306,"phases":3198,"primaryCompletion":3199,"completion":365,"start":658,"enrollment":2198,"conditions":3200,"interventions":3206},"NCT06399809","Fisetin to Reduce Senescence and Mobility Impairment in PAD",[91],"2026-11",[3201,3202,3203,3204,3205],"Peripheral Arterial Disease","Aging","Peripheral Vascular Diseases","Walking, Difficulty","Claudication",[3187],{"trials":3208,"activeCount":102},[],{"trials":3210,"activeCount":102},[],{"trials":3212,"activeCount":102},[],{"intervention":355,"totalTrials":229,"cells":3214},{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3216,"activeCount":102},[],{"trials":3218,"activeCount":102},[],{"trials":3220,"activeCount":229,"soonestReadout":339},[3221],{"nctId":336,"briefTitle":337,"status":185,"phases":3222,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":3223,"interventions":3224},[91],[343,344,345,346,347,348,349,350,351,352,353],[355,327,356],{"trials":3226,"activeCount":102},[],{"trials":3228,"activeCount":102},[],{"trials":3230,"activeCount":102},[],{"intervention":356,"totalTrials":229,"cells":3232},{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3234,"activeCount":102},[],{"trials":3236,"activeCount":102},[],{"trials":3238,"activeCount":229,"soonestReadout":339},[3239],{"nctId":336,"briefTitle":337,"status":185,"phases":3240,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":3241,"interventions":3242},[91],[343,344,345,346,347,348,349,350,351,352,353],[355,327,356],{"trials":3244,"activeCount":102},[],{"trials":3246,"activeCount":102},[],{"trials":3248,"activeCount":102},[],{"intervention":315,"totalTrials":229,"cells":3250},{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3255,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3252,"activeCount":102},[],{"trials":3254,"activeCount":102},[],{"trials":3256,"activeCount":229,"soonestReadout":308},[3257],{"nctId":304,"briefTitle":305,"status":306,"phases":3258,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":3259,"interventions":3260},[91],[313],[244,315],{"trials":3262,"activeCount":102},[],{"trials":3264,"activeCount":102},[],{"trials":3266,"activeCount":102},[],{"intervention":3268,"totalTrials":273,"cells":3269},"Lisinopril",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3271,"activeCount":102},[],{"trials":3273,"activeCount":102},[],{"trials":3275,"activeCount":229,"soonestReadout":3280},[3276],{"nctId":3277,"briefTitle":3278,"status":185,"phases":3279,"primaryCompletion":3280,"completion":2991,"start":3281,"enrollment":1316,"conditions":3282,"interventions":3284},"NCT04550481","Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study",[91],"2025-08-08","2021-05-11",[2468,3283],"Nonalcoholic Steatohepatitis",[3268],{"trials":3286,"activeCount":102},[],{"trials":3288,"activeCount":102},[],{"trials":3290,"activeCount":102},[3291],{"nctId":3292,"briefTitle":3293,"status":248,"phases":3294,"primaryCompletion":1714,"completion":1714,"start":3295,"enrollment":375,"conditions":3296,"interventions":3298},"NCT00743197","Women With Chest Pain and Normal Coronary Arteries Study",[94],"2008-05",[3297],"Chest Pain",[3299,3268,3300,3301],"Aspirin","Simvastatin","Lovaza",{"intervention":1256,"totalTrials":1610,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3359,"PHASE3":3415,"PHASE4":3417,"NA":3419},{"trials":3305,"activeCount":102},[],{"trials":3307,"activeCount":375,"soonestReadout":3342},[3308,3320,3334,3338,3349],{"nctId":3309,"briefTitle":3310,"status":185,"phases":3311,"primaryCompletion":3312,"completion":1018,"start":3313,"enrollment":3314,"conditions":3315,"interventions":3316},"NCT04047706","Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma",[90],"2027-02-15","2019-08-13",18,[2511],[3317,166,1256,3318,3319],"IDO1 Inhibitor BMS-986205 25mg","IDO1 Inhibitor BMS-986205 50 mg","IDO1 Inhibitor BMS-986205 100 mg",{"nctId":3321,"briefTitle":3322,"status":306,"phases":3323,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":156,"conditions":3327,"interventions":3332},"NCT06410248","Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma",[90],"2029-05-12","2030-05-12","2024-07-23",[3328,3329,3330,3331],"Recurrent Glioblastoma, IDH-Wildtype","Recurrent WHO Grade 2 Glioma","Recurrent WHO Grade 3 Glioma","Recurrent WHO Grade 4 Glioma",[1256,3333],"Triapine",{"nctId":1247,"briefTitle":1248,"status":248,"phases":3335,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":582,"conditions":3336,"interventions":3337},[90],[1254],[1228,1256],{"nctId":3339,"briefTitle":3340,"status":185,"phases":3341,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":341,"conditions":3345,"interventions":3347},"NCT05236036","Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma",[90],"2026-01-12","2029-01-03","2022-08-08",[3346,2511,2603,2604,2516],"Astrocytoma",[3348,1256],"Mycophenolate Mofetil",{"nctId":3350,"briefTitle":3351,"status":248,"phases":3352,"primaryCompletion":3353,"completion":3353,"start":3354,"enrollment":1511,"conditions":3355,"interventions":3356},"NCT00516282","VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma",[90],"2009-10","2007-08",[1495],[3357,3358],"CLORETAZINE","temozolomide",{"trials":3360,"activeCount":102},[3361,3376,3385,3393,3403,3411],{"nctId":3362,"briefTitle":3363,"status":108,"phases":3364,"primaryCompletion":3365,"completion":3366,"start":3367,"enrollment":25,"conditions":3368,"interventions":3374},"NCT01465659","Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery",[90,91],"2018-07-30","2021-01-27","2011-12-12",[3369,3370,3371,3372,3373],"Pancreatic Alpha Cell Carcinoma","Pancreatic Beta Islet Cell Carcinoma","Pancreatic Delta Cell Carcinoma","Pancreatic G-cell Carcinoma","Recurrent Islet Cell Carcinoma",[3358,3375],"pazopanib hydrochloride",{"nctId":3377,"briefTitle":3378,"status":108,"phases":3379,"primaryCompletion":3380,"completion":3381,"start":1886,"enrollment":98,"conditions":3382,"interventions":3383},"NCT00990652","Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide",[91],"2011-04","2012-10",[1495],[3384,1256],"Bortezomib",{"nctId":3386,"briefTitle":3387,"status":200,"phases":3388,"primaryCompletion":1383,"completion":1383,"start":3389,"enrollment":311,"conditions":3390,"interventions":3391},"NCT00275067","Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery",[90,91],"2005-05",[1495],[3392,3358],"arsenic trioxide",{"nctId":3394,"briefTitle":3395,"status":108,"phases":3396,"primaryCompletion":3397,"completion":3398,"start":3399,"enrollment":224,"conditions":3400,"interventions":3402},"NCT00301067","Phase I\u002FII Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma",[90,91],"2012-04-05","2012-07-09","2005-01-30",[3401],"Metastatic Melanoma",[1256],{"nctId":3404,"briefTitle":3405,"status":248,"phases":3406,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":25,"conditions":3409,"interventions":3410},"NCT00004106","Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome",[91],"2006-04","1998-05",[24],[3358],{"nctId":1930,"briefTitle":1931,"status":248,"phases":3412,"primaryCompletion":1933,"completion":1933,"start":1934,"enrollment":1935,"conditions":3413,"interventions":3414},[91],[1937,1938,1939,1940,1254],[1256,1539],{"trials":3416,"activeCount":102},[],{"trials":3418,"activeCount":102},[],{"trials":3420,"activeCount":102},[],{"intervention":1802,"totalTrials":582,"cells":3422},{"EARLY_PHASE1":3423,"PHASE1":3425,"PHASE2":3441,"PHASE3":3452,"PHASE4":3454,"NA":3460},{"trials":3424,"activeCount":102},[],{"trials":3426,"activeCount":229,"soonestReadout":3342},[3427,3431],{"nctId":3339,"briefTitle":3340,"status":185,"phases":3428,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":341,"conditions":3429,"interventions":3430},[90],[3346,2511,2603,2604,2516],[3348,1256],{"nctId":3432,"briefTitle":3433,"status":248,"phases":3434,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":3435,"interventions":3437},"NCT00282412","Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism",[90],[3436],"Rheumatoid Arthritis",[438,517,141,3438,3439,3440,3348],"Campath 1H","GCSF","Cyclosporins",{"trials":3442,"activeCount":102},[3443],{"nctId":3444,"briefTitle":3445,"status":108,"phases":3446,"primaryCompletion":3447,"completion":3448,"start":602,"enrollment":253,"conditions":3449,"interventions":3451},"NCT02370693","Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis",[91],"2019-12-16","2020-01-01",[3450,514,515],"Lung Diseases, Interstitial",[3384,1802],{"trials":3453,"activeCount":102},[],{"trials":3455,"activeCount":102},[3456],{"nctId":1793,"briefTitle":1794,"status":248,"phases":3457,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":402,"conditions":3458,"interventions":3459},[93],[1799],[1749,1801,1732,1802],{"trials":3461,"activeCount":102},[],{"intervention":166,"totalTrials":1610,"cells":3463},{"EARLY_PHASE1":3464,"PHASE1":3474,"PHASE2":3523,"PHASE3":3599,"PHASE4":3601,"NA":3603},{"trials":3465,"activeCount":102},[3466],{"nctId":3467,"briefTitle":3468,"status":248,"phases":3469,"primaryCompletion":3470,"completion":3470,"start":3471,"enrollment":273,"conditions":3472,"interventions":3473},"NCT03812562","Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection",[89],"2023-10-19","2019-02-07",[2468],[166],{"trials":3475,"activeCount":229,"soonestReadout":3312},[3476,3480,3493,3508],{"nctId":3309,"briefTitle":3310,"status":185,"phases":3477,"primaryCompletion":3312,"completion":1018,"start":3313,"enrollment":3314,"conditions":3478,"interventions":3479},[90],[2511],[3317,166,1256,3318,3319],{"nctId":3481,"briefTitle":3482,"status":108,"phases":3483,"primaryCompletion":3484,"completion":3485,"start":446,"enrollment":28,"conditions":3486,"interventions":3492},"NCT02837029","Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer",[90],"2019-07-17","2020-11-01",[3487,3488,3489,3490,3491],"Stage IIIA Hepatocellular Carcinoma","Stage IIIB Hepatocellular Carcinoma","Stage IIIC Hepatocellular Carcinoma","Stage IVA Hepatocellular Carcinoma","Stage IVB Hepatocellular Carcinoma",[166],{"nctId":3494,"briefTitle":3495,"status":108,"phases":3496,"primaryCompletion":3497,"completion":3498,"start":3499,"enrollment":1493,"conditions":3500,"interventions":3506},"NCT03061188","Phase I\u002FIb Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma",[90],"2018-03-11","2020-08-04","2017-05-23",[3501,158,3502,3503,3504,3505],"Advanced Solid Neoplasm","Recurrent Solid Neoplasm","Refractory Mantle Cell Lymphoma","T-Cell Non-Hodgkin Lymphoma","Unresectable Solid Neoplasm",[166,3507],"Veliparib",{"nctId":3509,"briefTitle":3510,"status":248,"phases":3511,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":229,"conditions":3515,"interventions":3521},"NCT02819804","Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[90],"2017-08-27","2018-08-30","2017-08-17",[3516,3517,3518,3519,3520],"B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Refractory Adult Acute Lymphoblastic Leukemia","Refractory Childhood Acute Lymphoblastic Leukemia",[3522,166],"Dasatinib",{"trials":3524,"activeCount":102},[3525,3529,3544,3561,3574,3589],{"nctId":149,"briefTitle":150,"status":151,"phases":3526,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":3527,"interventions":3528},[90,91],[158,159,160,161,162,163,139,164],[141,142,166,97,143,145],{"nctId":3530,"briefTitle":3531,"status":261,"phases":3532,"primaryCompletion":3533,"completion":3534,"start":3535,"enrollment":102,"conditions":3536,"interventions":3542},"NCT06247540","Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[91],"2029-12-29","2031-12-29","2024-03-29",[3537,3538,3539,3540,3541],"Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Transformed Chronic Lymphocytic Leukemia","Richter Syndrome","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma",[166,143,3543],"Venetoclax",{"nctId":3545,"briefTitle":3546,"status":200,"phases":3547,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":3067,"conditions":3551,"interventions":3559},"NCT03146650","Nivolumab and Ipilimumab in Treating Patients With Metastatic\u002FRecurrent ACC of All Sites and Non-ACC Salivary Gland Cancer",[91],"2021-02-24","2025-08-11","2017-05-19",[3552,3553,3554,3555,3556,3557,3558],"Major Salivary Gland Carcinoma","Minor Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Stage IV Major Salivary Gland Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVC Major Salivary Gland Carcinoma",[3560,166],"Ipilimumab",{"nctId":3562,"briefTitle":3563,"status":248,"phases":3564,"primaryCompletion":3565,"completion":3566,"start":3567,"enrollment":98,"conditions":3568,"interventions":3573},"NCT02720484","Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer",[91],"2017-04-17","2018-11-02","2016-03-30",[3569,3570,3571,3572],"Metastatic Carcinoma in the Adrenal Cortex","Recurrent Adrenal Cortex Carcinoma","Stage III Adrenal Cortex Carcinoma","Stage IV Adrenal Cortex Carcinoma",[166],{"nctId":3575,"briefTitle":3576,"status":200,"phases":3577,"primaryCompletion":3578,"completion":3579,"start":3580,"enrollment":1371,"conditions":3581,"interventions":3587},"NCT03048500","Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",[91],"2019-09-19","2021-09","2017-07-12",[3582,3583,3584,3585,3586],"Recurrent Non-Small Cell Lung Carcinoma","Stage III Non-Small Cell Lung Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[3588,166],"Metformin Hydrochloride",{"nctId":3590,"briefTitle":3591,"status":248,"phases":3592,"primaryCompletion":3593,"completion":3593,"start":3594,"enrollment":375,"conditions":3595,"interventions":3598},"NCT02892734","Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer",[91],"2019-02-04","2017-09-18",[1280,3596,678,3597],"Recurrent Inflammatory Breast Carcinoma","Stage IV Inflammatory Breast Carcinoma",[3560,166],{"trials":3600,"activeCount":102},[],{"trials":3602,"activeCount":102},[],{"trials":3604,"activeCount":102},[],{"intervention":1851,"totalTrials":475,"cells":3606},{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3642,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3608,"activeCount":102},[],{"trials":3610,"activeCount":229,"soonestReadout":3621},[3611,3617],{"nctId":3612,"briefTitle":3613,"status":108,"phases":3614,"primaryCompletion":3295,"completion":3295,"start":111,"enrollment":156,"conditions":3615,"interventions":3616},"NCT00004174","Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer",[90],[21],[120,177,1851,1995],{"nctId":3618,"briefTitle":3619,"status":1042,"phases":3620,"primaryCompletion":3621,"completion":3622,"start":3623,"enrollment":3314,"conditions":3624,"interventions":3638},"NCT07594548","Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",[90],"2030-09-09","2031-09-09","2027-09-09",[3625,3626,3627,2103,3628,3629,2104,3630,3631,3632,3633,3634,2106,3635,3636,3637],"Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Locally Advanced Esophageal Adenocarcinoma","Locally Advanced Gastric Adenocarcinoma","Locally Advanced Gastroesophageal Junction Adenocarcinoma","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Unresectable Esophageal Adenocarcinoma","Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Carcinoma",[3639,3640,3641],"Futibatinib","Paclitaxel","Ramucirumab",{"trials":3643,"activeCount":102},[3644,3651,3655,3659],{"nctId":3645,"briefTitle":3646,"status":108,"phases":3647,"primaryCompletion":110,"completion":110,"start":3648,"conditions":3649,"interventions":3650},"NCT00004916","Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",[90,91],"1999-02",[24],[1994,1851,182],{"nctId":1842,"briefTitle":1843,"status":248,"phases":3652,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1329,"conditions":3653,"interventions":3654},[91],[912],[1539,1540,1850,1851],{"nctId":1969,"briefTitle":1970,"status":248,"phases":3656,"primaryCompletion":434,"completion":1972,"start":1973,"enrollment":1974,"conditions":3657,"interventions":3658},[90,91],[912],[1540,1514,1851,1977,1978,1979],{"nctId":3660,"briefTitle":3661,"status":200,"phases":3662,"primaryCompletion":3663,"completion":1546,"start":3664,"enrollment":935,"conditions":3665,"interventions":3666},"NCT00499525","Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer",[91],"2020-12","2007-06",[21],[1851,3667],"sorafenib tosylate",{"trials":3669,"activeCount":102},[],{"trials":3671,"activeCount":102},[],{"trials":3673,"activeCount":102},[],{"intervention":3675,"totalTrials":273,"cells":3676},"Letrozole",{"EARLY_PHASE1":3677,"PHASE1":3690,"PHASE2":3704,"PHASE3":3706,"PHASE4":3708,"NA":3710},{"trials":3678,"activeCount":102},[3679],{"nctId":3680,"briefTitle":3681,"status":108,"phases":3682,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":28,"conditions":3686,"interventions":3688},"NCT04049227","Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer",[89],"2023-04-01","2023-05-15","2019-08-12",[3687],"Endometrial Endometrioid Adenocarcinoma",[3689,3675],"Abemaciclib",{"trials":3691,"activeCount":229,"soonestReadout":2930},[3692],{"nctId":3693,"briefTitle":3694,"status":1042,"phases":3695,"primaryCompletion":2930,"completion":2930,"start":752,"enrollment":3696,"conditions":3697,"interventions":3702},"NCT07604272","Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males",[90],75,[3698,3699,3700,3701],"Inguinal Hernia Unilateral","Inguinal Hernia Bilateral","Inguinal Hernia Without Obstruction or Gangrene","Inguinal Hernia, Without Mention of Obstruction or Gangrene",[3703,3703,3675],"Fulvestrant",{"trials":3705,"activeCount":102},[],{"trials":3707,"activeCount":102},[],{"trials":3709,"activeCount":102},[],{"trials":3711,"activeCount":102},[],{"intervention":3317,"totalTrials":229,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3715,"activeCount":102},[],{"trials":3717,"activeCount":229,"soonestReadout":3312},[3718],{"nctId":3309,"briefTitle":3310,"status":185,"phases":3719,"primaryCompletion":3312,"completion":1018,"start":3313,"enrollment":3314,"conditions":3720,"interventions":3721},[90],[2511],[3317,166,1256,3318,3319],{"trials":3723,"activeCount":102},[],{"trials":3725,"activeCount":102},[],{"trials":3727,"activeCount":102},[],{"trials":3729,"activeCount":102},[],{"intervention":3318,"totalTrials":229,"cells":3731},{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3740,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3733,"activeCount":102},[],{"trials":3735,"activeCount":229,"soonestReadout":3312},[3736],{"nctId":3309,"briefTitle":3310,"status":185,"phases":3737,"primaryCompletion":3312,"completion":1018,"start":3313,"enrollment":3314,"conditions":3738,"interventions":3739},[90],[2511],[3317,166,1256,3318,3319],{"trials":3741,"activeCount":102},[],{"trials":3743,"activeCount":102},[],{"trials":3745,"activeCount":102},[],{"trials":3747,"activeCount":102},[],{"intervention":3319,"totalTrials":229,"cells":3749},{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3758,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3751,"activeCount":102},[],{"trials":3753,"activeCount":229,"soonestReadout":3312},[3754],{"nctId":3309,"briefTitle":3310,"status":185,"phases":3755,"primaryCompletion":3312,"completion":1018,"start":3313,"enrollment":3314,"conditions":3756,"interventions":3757},[90],[2511],[3317,166,1256,3318,3319],{"trials":3759,"activeCount":102},[],{"trials":3761,"activeCount":102},[],{"trials":3763,"activeCount":102},[],{"trials":3765,"activeCount":102},[],{"intervention":3333,"totalTrials":229,"cells":3767},{"EARLY_PHASE1":3768,"PHASE1":3770,"PHASE2":3776,"PHASE3":3778,"PHASE4":3780,"NA":3782},{"trials":3769,"activeCount":102},[],{"trials":3771,"activeCount":229,"soonestReadout":3324},[3772],{"nctId":3321,"briefTitle":3322,"status":306,"phases":3773,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":156,"conditions":3774,"interventions":3775},[90],[3328,3329,3330,3331],[1256,3333],{"trials":3777,"activeCount":102},[],{"trials":3779,"activeCount":102},[],{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":102},[],{"intervention":3785,"totalTrials":229,"cells":3786},"NSC-CRAd-S-pk7",{"EARLY_PHASE1":3787,"PHASE1":3789,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3788,"activeCount":102},[],{"trials":3790,"activeCount":229,"soonestReadout":1396},[3791],{"nctId":3792,"briefTitle":3793,"status":306,"phases":3794,"primaryCompletion":1396,"completion":3795,"start":3796,"enrollment":224,"conditions":3797,"interventions":3800},"NCT06169280","Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma",[90],"2030-12-31","2025-06-27",[3798,3799],"Glioma, Malignant","New Diagnosis Tumor",[3785],{"trials":3802,"activeCount":102},[],{"trials":3804,"activeCount":102},[],{"trials":3806,"activeCount":102},[],{"trials":3808,"activeCount":102},[],{"intervention":87,"totalTrials":229,"cells":3810},{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3812,"activeCount":102},[],{"trials":3814,"activeCount":229,"soonestReadout":86},[3815],{"nctId":84,"briefTitle":85,"status":185,"phases":3816,"primaryCompletion":86,"completion":3817,"start":754,"enrollment":1493,"conditions":3818,"interventions":3820},[90],"2030-04-23",[3819],"Acute Myeloid Leukemia",[87],{"trials":3822,"activeCount":102},[],{"trials":3824,"activeCount":102},[],{"trials":3826,"activeCount":102},[],{"trials":3828,"activeCount":102},[],{"intervention":3703,"totalTrials":229,"cells":3830},{"EARLY_PHASE1":3831,"PHASE1":3833,"PHASE2":3839,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3832,"activeCount":102},[],{"trials":3834,"activeCount":229,"soonestReadout":2930},[3835],{"nctId":3693,"briefTitle":3694,"status":1042,"phases":3836,"primaryCompletion":2930,"completion":2930,"start":752,"enrollment":3696,"conditions":3837,"interventions":3838},[90],[3698,3699,3700,3701],[3703,3703,3675],{"trials":3840,"activeCount":102},[],{"trials":3842,"activeCount":102},[],{"trials":3844,"activeCount":102},[],{"trials":3846,"activeCount":102},[],{"intervention":3639,"totalTrials":229,"cells":3848},{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3857,"PHASE3":3859,"PHASE4":3861,"NA":3863},{"trials":3850,"activeCount":102},[],{"trials":3852,"activeCount":229,"soonestReadout":3621},[3853],{"nctId":3618,"briefTitle":3619,"status":1042,"phases":3854,"primaryCompletion":3621,"completion":3622,"start":3623,"enrollment":3314,"conditions":3855,"interventions":3856},[90],[3625,3626,3627,2103,3628,3629,2104,3630,3631,3632,3633,3634,2106,3635,3636,3637],[3639,3640,3641],{"trials":3858,"activeCount":102},[],{"trials":3860,"activeCount":102},[],{"trials":3862,"activeCount":102},[],{"trials":3864,"activeCount":102},[],{"intervention":3641,"totalTrials":229,"cells":3866},{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3875,"PHASE3":3877,"PHASE4":3879,"NA":3881},{"trials":3868,"activeCount":102},[],{"trials":3870,"activeCount":229,"soonestReadout":3621},[3871],{"nctId":3618,"briefTitle":3619,"status":1042,"phases":3872,"primaryCompletion":3621,"completion":3622,"start":3623,"enrollment":3314,"conditions":3873,"interventions":3874},[90],[3625,3626,3627,2103,3628,3629,2104,3630,3631,3632,3633,3634,2106,3635,3636,3637],[3639,3640,3641],{"trials":3876,"activeCount":102},[],{"trials":3878,"activeCount":102},[],{"trials":3880,"activeCount":102},[],{"trials":3882,"activeCount":102},[],{"intervention":1624,"totalTrials":229,"cells":3884},{"EARLY_PHASE1":3885,"PHASE1":3887,"PHASE2":3893,"PHASE3":3895,"PHASE4":3897,"NA":3899},{"trials":3886,"activeCount":102},[],{"trials":3888,"activeCount":229,"soonestReadout":1621},[3889],{"nctId":1617,"briefTitle":1618,"status":1619,"phases":3890,"primaryCompletion":1621,"completion":1621,"start":76,"enrollment":238,"conditions":3891,"interventions":3892},[90],[757],[1624,632],{"trials":3894,"activeCount":102},[],{"trials":3896,"activeCount":102},[],{"trials":3898,"activeCount":102},[],{"trials":3900,"activeCount":102},[],{"intervention":72,"totalTrials":229,"cells":3902},{"EARLY_PHASE1":3903,"PHASE1":3905,"PHASE2":3918,"PHASE3":3920,"PHASE4":3922,"NA":3924},{"trials":3904,"activeCount":102},[],{"trials":3906,"activeCount":229,"soonestReadout":71},[3907],{"nctId":69,"briefTitle":70,"status":185,"phases":3908,"primaryCompletion":71,"completion":3909,"start":1370,"enrollment":537,"conditions":3910,"interventions":3916},[90],"2027-01",[3911,3912,3913,3914,3915],"Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Fibroblast Growth Factor Basic Form Measurement","FLT3 Internal Tandem Duplication","Recurrent Adult Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[72,3917],"Nintedanib",{"trials":3919,"activeCount":102},[],{"trials":3921,"activeCount":102},[],{"trials":3923,"activeCount":102},[],{"trials":3925,"activeCount":102},[],{"intervention":3917,"totalTrials":229,"cells":3927},{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3936,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3929,"activeCount":102},[],{"trials":3931,"activeCount":229,"soonestReadout":71},[3932],{"nctId":69,"briefTitle":70,"status":185,"phases":3933,"primaryCompletion":71,"completion":3909,"start":1370,"enrollment":537,"conditions":3934,"interventions":3935},[90],[3911,3912,3913,3914,3915],[72,3917],{"trials":3937,"activeCount":102},[],{"trials":3939,"activeCount":102},[],{"trials":3941,"activeCount":102},[],{"trials":3943,"activeCount":102},[],{"intervention":3945,"totalTrials":273,"cells":3946},"APR-TD011",{"EARLY_PHASE1":3947,"PHASE1":3966,"PHASE2":3968,"PHASE3":3970,"PHASE4":3972,"NA":3974},{"trials":3948,"activeCount":229,"soonestReadout":2556},[3949,3956],{"nctId":3950,"briefTitle":3951,"status":1042,"phases":3952,"primaryCompletion":2556,"completion":2556,"start":3909,"enrollment":156,"conditions":3953,"interventions":3955},"NCT05728879","Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution",[89],[3954],"Cutaneous T Cell Lymphoma",[3945],{"nctId":3957,"briefTitle":3958,"status":108,"phases":3959,"primaryCompletion":3960,"completion":3961,"start":3962,"enrollment":1493,"conditions":3963,"interventions":3965},"NCT05533866","Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution",[89],"2024-09-24","2025-03-31","2023-02-06",[3964],"Epidermolysis Bullosa",[3945],{"trials":3967,"activeCount":102},[],{"trials":3969,"activeCount":102},[],{"trials":3971,"activeCount":102},[],{"trials":3973,"activeCount":102},[],{"trials":3975,"activeCount":102},[],{"intervention":3977,"totalTrials":229,"cells":3978},"Upadacitinib 15 MG",{"EARLY_PHASE1":3979,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3995,"NA":3997},{"trials":3980,"activeCount":229,"soonestReadout":365},[3981],{"nctId":3982,"briefTitle":3983,"status":306,"phases":3984,"primaryCompletion":365,"completion":365,"start":3985,"enrollment":98,"conditions":3986,"interventions":3988},"NCT06684522","Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis",[89],"2025-12-18",[3987],"Eyelid Dermatitis",[3977],{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":102},[],{"trials":3996,"activeCount":102},[],{"trials":3998,"activeCount":102},[],{"intervention":4000,"totalTrials":229,"cells":4001},"Onabotulinum Toxin A",{"EARLY_PHASE1":4002,"PHASE1":4012,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4003,"activeCount":229,"soonestReadout":778},[4004],{"nctId":4005,"briefTitle":4006,"status":185,"phases":4007,"primaryCompletion":778,"completion":778,"start":604,"enrollment":224,"conditions":4008,"interventions":4010},"NCT02019004","A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles",[89],[4009],"Wrinkles",[4000,4011],"Incobotulinum Toxin A",{"trials":4013,"activeCount":102},[],{"trials":4015,"activeCount":102},[],{"trials":4017,"activeCount":102},[],{"trials":4019,"activeCount":102},[],{"trials":4021,"activeCount":102},[],{"intervention":4011,"totalTrials":229,"cells":4023},{"EARLY_PHASE1":4024,"PHASE1":4030,"PHASE2":4032,"PHASE3":4034,"PHASE4":4036,"NA":4038},{"trials":4025,"activeCount":229,"soonestReadout":778},[4026],{"nctId":4005,"briefTitle":4006,"status":185,"phases":4027,"primaryCompletion":778,"completion":778,"start":604,"enrollment":224,"conditions":4028,"interventions":4029},[89],[4009],[4000,4011],{"trials":4031,"activeCount":102},[],{"trials":4033,"activeCount":102},[],{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":102},[],{"intervention":4041,"totalTrials":229,"cells":4042},"Hyaluronidase",{"EARLY_PHASE1":4043,"PHASE1":4052,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4044,"activeCount":229,"soonestReadout":778},[4045],{"nctId":4046,"briefTitle":4047,"status":185,"phases":4048,"primaryCompletion":778,"completion":778,"start":3381,"enrollment":887,"conditions":4049,"interventions":4051},"NCT01722916","Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase",[89],[4050],"Drug Safety",[4041],{"trials":4053,"activeCount":102},[],{"trials":4055,"activeCount":102},[],{"trials":4057,"activeCount":102},[],{"trials":4059,"activeCount":102},[],{"trials":4061,"activeCount":102},[],{"intervention":4063,"totalTrials":229,"cells":4064},"Tapinarof",{"EARLY_PHASE1":4065,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4082,"NA":4084},{"trials":4066,"activeCount":229,"soonestReadout":4071},[4067],{"nctId":4068,"briefTitle":4069,"status":1619,"phases":4070,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":98,"conditions":4073,"interventions":4075},"NCT06661213","Tapinarof for Cutaneous Lupus Erythematosus",[89],"2027-11","2025-04-03",[4074],"Cutaneous Lupus Erythematosus",[4063],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[],{"trials":4083,"activeCount":102},[],{"trials":4085,"activeCount":102},[],{"intervention":4087,"totalTrials":229,"cells":4088},"Tizanidine",{"EARLY_PHASE1":4089,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4107,"NA":4109},{"trials":4090,"activeCount":229,"soonestReadout":4095},[4091],{"nctId":4092,"briefTitle":4093,"status":306,"phases":4094,"primaryCompletion":4095,"completion":4096,"start":4097,"enrollment":1524,"conditions":4098,"interventions":4100},"NCT06666673","Effect of Neural Constraints on Movement in Stroke",[89],"2029-06-30","2029-07-31","2024-08-23",[4099],"Stroke",[4087],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":102},[],{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":102},[],{"trials":4110,"activeCount":102},[],{"intervention":4112,"totalTrials":229,"cells":4113},"18F-DCFPyL",{"EARLY_PHASE1":4114,"PHASE1":4126,"PHASE2":4128,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4115,"activeCount":229,"soonestReadout":4120},[4116],{"nctId":4117,"briefTitle":4118,"status":185,"phases":4119,"primaryCompletion":4120,"completion":752,"start":4121,"enrollment":4122,"conditions":4123,"interventions":4125},"NCT03392181","PET\u002FMRI for the Staging of Newly Diagnosed Prostate Cancer",[89],"2026-05-01","2018-06-08",48,[4124],"Prostate Cancer",[4112],{"trials":4127,"activeCount":102},[],{"trials":4129,"activeCount":102},[],{"trials":4131,"activeCount":102},[],{"trials":4133,"activeCount":102},[],{"trials":4135,"activeCount":102},[],{"intervention":4137,"totalTrials":229,"cells":4138},"lidocaine 2.5%\u002Fprilocaine 2.5% topical anesthetic",{"EARLY_PHASE1":4139,"PHASE1":4149,"PHASE2":4151,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4140,"activeCount":229,"soonestReadout":778},[4141],{"nctId":4142,"briefTitle":4143,"status":185,"phases":4144,"primaryCompletion":778,"completion":778,"start":1684,"enrollment":4122,"conditions":4145,"interventions":4147},"NCT02427724","The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser",[89],[4146],"Lentigo",[4137,4148],"lidocaine 7%\u002Ftetracaine 7% topical anesthetic",{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":102},[],{"trials":4154,"activeCount":102},[],{"trials":4156,"activeCount":102},[],{"trials":4158,"activeCount":102},[],{"intervention":4148,"totalTrials":229,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4167,"PHASE2":4169,"PHASE3":4171,"PHASE4":4173,"NA":4175},{"trials":4162,"activeCount":229,"soonestReadout":778},[4163],{"nctId":4142,"briefTitle":4143,"status":185,"phases":4164,"primaryCompletion":778,"completion":778,"start":1684,"enrollment":4122,"conditions":4165,"interventions":4166},[89],[4146],[4137,4148],{"trials":4168,"activeCount":102},[],{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[],{"trials":4174,"activeCount":102},[],{"trials":4176,"activeCount":102},[],{"intervention":4178,"totalTrials":229,"cells":4179},"Anakinra",{"EARLY_PHASE1":4180,"PHASE1":4191,"PHASE2":4193,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4181,"activeCount":229,"soonestReadout":4186},[4182],{"nctId":4183,"briefTitle":4184,"status":1042,"phases":4185,"primaryCompletion":4186,"completion":4187,"start":1125,"enrollment":224,"conditions":4188,"interventions":4190},"NCT07410312","BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction",[89],"2027-08","2027-12",[4189],"Lung Transplant Recipient",[4178],{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":102},[],{"trials":4196,"activeCount":102},[],{"trials":4198,"activeCount":102},[],{"trials":4200,"activeCount":102},[],{"intervention":4202,"totalTrials":229,"cells":4203},"Etanercept Injection [Enbrel]",{"EARLY_PHASE1":4204,"PHASE1":4214,"PHASE2":4216,"PHASE3":4218,"PHASE4":4220,"NA":4222},{"trials":4205,"activeCount":229,"soonestReadout":876},[4206],{"nctId":4207,"briefTitle":4208,"status":1619,"phases":4209,"primaryCompletion":876,"completion":4187,"start":4210,"enrollment":224,"conditions":4211,"interventions":4213},"NCT05950724","RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant",[89],"2023-09-17",[4212],"Lung Transplant; Complications",[4202],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[],{"trials":4221,"activeCount":102},[],{"trials":4223,"activeCount":102},[],{"intervention":77,"totalTrials":229,"cells":4225},{"EARLY_PHASE1":4226,"PHASE1":4235,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4243},{"trials":4227,"activeCount":229,"soonestReadout":76},[4228],{"nctId":74,"briefTitle":75,"status":185,"phases":4229,"primaryCompletion":76,"completion":4230,"start":4231,"enrollment":1511,"conditions":4232,"interventions":4234},[89],"2026-08","2019-04-09",[4233],"Permanent Chemotherapy-induced Alopecia",[77],{"trials":4236,"activeCount":102},[],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[],{"intervention":4246,"totalTrials":229,"cells":4247},"Nogapendekin Alfa Inbakicept",{"EARLY_PHASE1":4248,"PHASE1":4262,"PHASE2":4264,"PHASE3":4266,"PHASE4":4268,"NA":4270},{"trials":4249,"activeCount":229,"soonestReadout":4254},[4250],{"nctId":4251,"briefTitle":4252,"status":306,"phases":4253,"primaryCompletion":4254,"completion":4255,"start":4256,"enrollment":900,"conditions":4257,"interventions":4261},"NCT07261657","N-803 in Patients With Progressive Synovial Sarcoma and Myxoid\u002FRound Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy",[89],"2030-09-02","2032-09-02","2026-04-13",[4258,4259,4260],"Myxoid Liposarcoma","Round Cell Liposarcoma","Synovial Sarcoma",[4246],{"trials":4263,"activeCount":102},[],{"trials":4265,"activeCount":102},[],{"trials":4267,"activeCount":102},[],{"trials":4269,"activeCount":102},[],{"trials":4271,"activeCount":102},[],{"intervention":4273,"totalTrials":229,"cells":4274},"Imiquimod",{"EARLY_PHASE1":4275,"PHASE1":4286,"PHASE2":4288,"PHASE3":4290,"PHASE4":4292,"NA":4294},{"trials":4276,"activeCount":229,"soonestReadout":1018},[4277],{"nctId":4278,"briefTitle":4279,"status":306,"phases":4280,"primaryCompletion":1018,"completion":4281,"start":4282,"enrollment":3067,"conditions":4283,"interventions":4285},"NCT05838599","Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides",[89],"2027-12-01","2023-07-24",[4284],"Mycosis Fungoides",[4273],{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":102},[],{"trials":4291,"activeCount":102},[],{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[],{"intervention":4297,"totalTrials":229,"cells":4298},"Decipher Prostate Cancer Test",{"EARLY_PHASE1":4299,"PHASE1":4313,"PHASE2":4315,"PHASE3":4317,"PHASE4":4319,"NA":4321},{"trials":4300,"activeCount":229,"soonestReadout":4305},[4301],{"nctId":4302,"briefTitle":4303,"status":306,"phases":4304,"primaryCompletion":4305,"completion":4306,"start":4307,"enrollment":402,"conditions":4308,"interventions":4312},"NCT05852041","rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance",[89],"2027-06-07","2035-06-07","2023-06-07",[313,4309,4310,4311],"Stage I Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8",[4297],{"trials":4314,"activeCount":102},[],{"trials":4316,"activeCount":102},[],{"trials":4318,"activeCount":102},[],{"trials":4320,"activeCount":102},[],{"trials":4322,"activeCount":102},[],{"intervention":4324,"totalTrials":229,"cells":4325},"Light and Citalopram",{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4332,"PHASE4":4334,"NA":4336},{"trials":4327,"activeCount":102},[],{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":102},[],{"trials":4335,"activeCount":102},[],{"trials":4337,"activeCount":229,"soonestReadout":4342},[4338],{"nctId":4339,"briefTitle":4340,"status":306,"phases":4341,"primaryCompletion":4342,"completion":4096,"start":4343,"enrollment":4344,"conditions":4345,"interventions":4347},"NCT06949644","Pupillometry in Delayed Sleep Wake Phase Disorder",[94],"2029-02-28","2025-09-01",220,[4346],"Delayed Sleep-Wake Phase Disorder",[4324],{"intervention":4349,"totalTrials":229,"cells":4350},"Methocarbamol",{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4357,"PHASE4":4359,"NA":4361},{"trials":4352,"activeCount":102},[],{"trials":4354,"activeCount":102},[],{"trials":4356,"activeCount":102},[],{"trials":4358,"activeCount":102},[],{"trials":4360,"activeCount":102},[],{"trials":4362,"activeCount":229,"soonestReadout":4367},[4363],{"nctId":4364,"briefTitle":4365,"status":185,"phases":4366,"primaryCompletion":4367,"completion":876,"start":4368,"enrollment":4369,"conditions":4370,"interventions":4376},"NCT05100017","Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S\u002FP Ureteroscopy Procedure",[94],"2025-06-30","2021-09-30",126,[4371,2996,4372,4373,4374,4375],"Kidney Calculi","Nephrolithiasis","Urolithiasis","Ureteral Diseases","Ureteral Calculi",[4349,4377],"Oxybutynin",{"intervention":4377,"totalTrials":229,"cells":4379},{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4384,"PHASE3":4386,"PHASE4":4388,"NA":4390},{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[],{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":102},[],{"trials":4389,"activeCount":102},[],{"trials":4391,"activeCount":229,"soonestReadout":4367},[4392],{"nctId":4364,"briefTitle":4365,"status":185,"phases":4393,"primaryCompletion":4367,"completion":876,"start":4368,"enrollment":4369,"conditions":4394,"interventions":4395},[94],[4371,2996,4372,4373,4374,4375],[4349,4377],{"intervention":4397,"totalTrials":229,"cells":4398},"Potassium citrate",{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4405,"PHASE4":4407,"NA":4409},{"trials":4400,"activeCount":102},[],{"trials":4402,"activeCount":102},[],{"trials":4404,"activeCount":102},[],{"trials":4406,"activeCount":102},[],{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":229,"soonestReadout":4415},[4411],{"nctId":4412,"briefTitle":4413,"status":185,"phases":4414,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":98,"conditions":4418,"interventions":4420},"NCT05389995","Potassium Citrate and Crystal Light Lemonade",[94],"2025-04-01","2027-01-31","2022-08-01",[4419],"Kidney Stone",[4397,4421,4422],"Crystal light","Potassium citrate + crystal light",{"intervention":4421,"totalTrials":229,"cells":4424},{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4426,"activeCount":102},[],{"trials":4428,"activeCount":102},[],{"trials":4430,"activeCount":102},[],{"trials":4432,"activeCount":102},[],{"trials":4434,"activeCount":102},[],{"trials":4436,"activeCount":229,"soonestReadout":4415},[4437],{"nctId":4412,"briefTitle":4413,"status":185,"phases":4438,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":98,"conditions":4439,"interventions":4440},[94],[4419],[4397,4421,4422],{"intervention":4422,"totalTrials":229,"cells":4442},{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4444,"activeCount":102},[],{"trials":4446,"activeCount":102},[],{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[],{"trials":4452,"activeCount":102},[],{"trials":4454,"activeCount":229,"soonestReadout":4415},[4455],{"nctId":4412,"briefTitle":4413,"status":185,"phases":4456,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":98,"conditions":4457,"interventions":4458},[94],[4419],[4397,4421,4422],{"intervention":4460,"totalTrials":229,"cells":4461},"ALA",{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4463,"activeCount":102},[],{"trials":4465,"activeCount":102},[],{"trials":4467,"activeCount":102},[],{"trials":4469,"activeCount":102},[],{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":229,"soonestReadout":778},[4474],{"nctId":4475,"briefTitle":4476,"status":185,"phases":4477,"primaryCompletion":778,"completion":778,"start":4478,"enrollment":341,"conditions":4479,"interventions":4480},"NCT03066843","Photodynamic Therapy Incubation Times for Actinic Keratosis",[94],"2017-03-01",[2788],[4460],{"intervention":4482,"totalTrials":229,"cells":4483},"Empatica Smartwatch",{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4488,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4485,"activeCount":102},[],{"trials":4487,"activeCount":102},[],{"trials":4489,"activeCount":102},[],{"trials":4491,"activeCount":102},[],{"trials":4493,"activeCount":102},[],{"trials":4495,"activeCount":229,"soonestReadout":4500},[4496],{"nctId":4497,"briefTitle":4498,"status":1042,"phases":4499,"primaryCompletion":4500,"completion":4500,"start":4120,"enrollment":1837,"conditions":4501,"interventions":4502},"NCT06994988","ARPA-H Smart Band-Aid to Measure Chronic Pain in Women",[],"2027-04-23",[349],[4482],{"intervention":4504,"totalTrials":229,"cells":4505},"GLP-1",{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4510,"PHASE3":4512,"PHASE4":4514,"NA":4516},{"trials":4507,"activeCount":102},[],{"trials":4509,"activeCount":102},[],{"trials":4511,"activeCount":102},[],{"trials":4513,"activeCount":102},[],{"trials":4515,"activeCount":102},[],{"trials":4517,"activeCount":229,"soonestReadout":4522},[4518],{"nctId":4519,"briefTitle":4520,"status":306,"phases":4521,"primaryCompletion":4522,"completion":4523,"start":4524,"enrollment":238,"conditions":4525,"interventions":4526},"NCT07207148","People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists",[],"2028-04-01","2028-08-31","2025-11-15",[831],[4504,4527],"Ocrelizumab",{"intervention":4527,"totalTrials":229,"cells":4529},{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4536,"PHASE4":4538,"NA":4540},{"trials":4531,"activeCount":102},[],{"trials":4533,"activeCount":102},[],{"trials":4535,"activeCount":102},[],{"trials":4537,"activeCount":102},[],{"trials":4539,"activeCount":102},[],{"trials":4541,"activeCount":229,"soonestReadout":4522},[4542],{"nctId":4519,"briefTitle":4520,"status":306,"phases":4543,"primaryCompletion":4522,"completion":4523,"start":4524,"enrollment":238,"conditions":4544,"interventions":4545},[],[831],[4504,4527],{"intervention":4547,"totalTrials":229,"cells":4548},"Dupilumab - Standard Dose",{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4553,"PHASE3":4555,"PHASE4":4557,"NA":4559},{"trials":4550,"activeCount":102},[],{"trials":4552,"activeCount":102},[],{"trials":4554,"activeCount":102},[],{"trials":4556,"activeCount":102},[],{"trials":4558,"activeCount":102},[],{"trials":4560,"activeCount":229,"soonestReadout":4565},[4561],{"nctId":4562,"briefTitle":4563,"status":306,"phases":4564,"primaryCompletion":4565,"completion":4566,"start":4567,"enrollment":156,"conditions":4568,"interventions":4571},"NCT06892704","Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.",[],"2027-04-30","2027-12-31","2025-05-01",[4569,4570],"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","Smell Loss",[4547],{"intervention":609,"totalTrials":900,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4580,"PHASE4":4592,"NA":4643},{"trials":4575,"activeCount":102},[],{"trials":4577,"activeCount":102},[],{"trials":4579,"activeCount":102},[],{"trials":4581,"activeCount":102},[4582],{"nctId":4583,"briefTitle":4584,"status":108,"phases":4585,"primaryCompletion":4567,"completion":4586,"start":4587,"enrollment":341,"conditions":4588,"interventions":4590},"NCT05171179","The Use of Pecs Blocks in Combination With Exparel in Breast Reconstruction Surgery",[92],"2025-07-01","2021-10-22",[4589],"Mammaplasty",[4591,609],"Exparel",{"trials":4593,"activeCount":102},[4594,4604,4608,4617,4626,4630,4634],{"nctId":4595,"briefTitle":4596,"status":248,"phases":4597,"primaryCompletion":4598,"completion":616,"start":4599,"enrollment":3314,"conditions":4600,"interventions":4602},"NCT02008617","Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction",[93],"2015-11","2013-12",[4601],"Rupture of Anterior Cruciate Ligament",[609,4603],"Preservative free normal saline",{"nctId":599,"briefTitle":600,"status":108,"phases":4605,"primaryCompletion":602,"completion":603,"start":604,"enrollment":341,"conditions":4606,"interventions":4607},[93],[606,607],[609,610,581],{"nctId":4609,"briefTitle":4610,"status":248,"phases":4611,"primaryCompletion":4612,"completion":4612,"start":627,"enrollment":1371,"conditions":4613,"interventions":4615},"NCT01615939","A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block",[93],"2015-01",[4614],"Fracture of Foot",[609,4616],"Ropivacaine",{"nctId":4618,"briefTitle":4619,"status":108,"phases":4620,"primaryCompletion":4621,"completion":616,"start":4622,"enrollment":402,"conditions":4623,"interventions":4625},"NCT02100579","Ultrasound-guided Adductor Canal Block for Total Knee Replacement",[93],"2015-10","2014-03",[4624,1151],"Complications; Arthroplasty",[609,4603],{"nctId":1691,"briefTitle":1692,"status":248,"phases":4627,"primaryCompletion":1694,"completion":1694,"start":1695,"enrollment":273,"conditions":4628,"interventions":4629},[93],[1697,1698,1699],[1701,1702],{"nctId":612,"briefTitle":613,"status":261,"phases":4631,"primaryCompletion":615,"completion":615,"start":616,"enrollment":102,"conditions":4632,"interventions":4633},[93],[618],[610,581,620,609],{"nctId":4635,"briefTitle":4636,"status":108,"phases":4637,"primaryCompletion":252,"start":4638,"enrollment":4639,"conditions":4640,"interventions":4642},"NCT01272921","The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block",[93],"2010-11",142,[4641],"The Duration of Motor Block May Vary Between 12-36 Hrs",[609,4616],{"trials":4644,"activeCount":102},[],{"intervention":4646,"totalTrials":475,"cells":4647},"Tranexamic acid",{"EARLY_PHASE1":4648,"PHASE1":4662,"PHASE2":4664,"PHASE3":4686,"PHASE4":4711,"NA":4724},{"trials":4649,"activeCount":102},[4650],{"nctId":4651,"briefTitle":4652,"status":108,"phases":4653,"primaryCompletion":4654,"completion":4654,"start":1653,"enrollment":4655,"conditions":4656,"interventions":4659},"NCT02911831","IV Tranexamic Acid Prior to Hysterectomy",[89],"2022-04",71,[4657,4658],"Hysterectomy","Blood Loss, Surgical",[4660,4661],"Tranexamic Acid","Sodium Chloride",{"trials":4663,"activeCount":102},[],{"trials":4665,"activeCount":102},[4666,4676],{"nctId":4667,"briefTitle":4668,"status":108,"phases":4669,"primaryCompletion":4670,"completion":4670,"start":4671,"enrollment":4672,"conditions":4673,"interventions":4675},"NCT01728636","The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery",[91],"2017-12-30","2013-01-15",61,[4674],"Curvature of Spine",[4660],{"nctId":4677,"briefTitle":4678,"status":261,"phases":4679,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":102,"conditions":4682,"interventions":4684},"NCT05554211","Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage",[91],"2024-07-01","2022-07-12",[21,4683],"BRCA Mutation",[4646,4685],"Normal saline",{"trials":4687,"activeCount":102},[4688,4701],{"nctId":4689,"briefTitle":4690,"status":261,"phases":4691,"primaryCompletion":1744,"completion":4692,"start":4693,"enrollment":102,"conditions":4694,"interventions":4700},"NCT05710146","Tranexamic Acid (TXA) in Hip Arthroscopy",[92],"2024-09","2023-12",[4695,4696,4697,4698,4699],"Hip Pain Chronic","Hip Impingement Syndrome","Hip Injuries","Blood Loss","Femoro Acetabular Impingement",[4646],{"nctId":4702,"briefTitle":4703,"status":261,"phases":4704,"primaryCompletion":4705,"completion":4706,"start":4707,"enrollment":102,"conditions":4708,"interventions":4710},"NCT04724772","Use of Tranexamic Acid in Blepharoplasties",[92],"2023-07-20","2023-09-20","2020-02-20",[757,4709],"Bruising",[4646],{"trials":4712,"activeCount":102},[4713],{"nctId":4714,"briefTitle":4715,"status":108,"phases":4716,"primaryCompletion":4717,"completion":4718,"start":4719,"enrollment":4720,"conditions":4721,"interventions":4723},"NCT05082142","Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)",[93],"2022-06-15","2022-12-14","2021-09-17",110,[4371,1102,4722],"Benign Prostatic Hypertrophy",[4646],{"trials":4725,"activeCount":102},[],{"intervention":4727,"totalTrials":582,"cells":4728},"Naproxen",{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4733,"PHASE3":4756,"PHASE4":4758,"NA":4779},{"trials":4730,"activeCount":102},[],{"trials":4732,"activeCount":102},[],{"trials":4734,"activeCount":102},[4735,4744],{"nctId":4736,"briefTitle":4737,"status":261,"phases":4738,"primaryCompletion":4612,"completion":4612,"start":4739,"enrollment":102,"conditions":4740,"interventions":4742},"NCT02116790","Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects",[91],"2014-05",[4741],"Acute Pain",[4727,4743,4743],"Sinemet",{"nctId":4745,"briefTitle":4746,"status":261,"phases":4747,"primaryCompletion":4748,"completion":4749,"start":4750,"enrollment":102,"conditions":4751,"interventions":4754},"NCT05087914","Novel Non-opioid Post-surgical Pain Treatment in Females",[91],"2023-12-30","2024-01-30","2021-11-01",[4741,4752,4753],"Bunionectomy","Toe Fusion",[4755,4727],"Carbidopa-Levodopa (100mg\u002F25mg):",{"trials":4757,"activeCount":102},[],{"trials":4759,"activeCount":102},[4760,4769],{"nctId":4761,"briefTitle":4762,"status":108,"phases":4763,"primaryCompletion":947,"completion":947,"start":489,"enrollment":4764,"conditions":4765,"interventions":4767},"NCT02013427","Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial",[93],82,[4766],"Chronic Low Back Pain",[4727,4768],"Omeprazole",{"nctId":4770,"briefTitle":4771,"status":108,"phases":4772,"primaryCompletion":4773,"completion":4773,"start":4774,"enrollment":1557,"conditions":4775,"interventions":4777},"NCT01951105","Effect of L-dopa In Subacute Back Pain Population",[93],"2017-09-25","2015-02-24",[4776],"Sub-acute Back Pain",[4727,4778],"Carbidopa\u002FLevodopa",{"trials":4780,"activeCount":102},[],{"intervention":1749,"totalTrials":582,"cells":4782},{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4801,"PHASE3":4807,"PHASE4":4809,"NA":4815},{"trials":4784,"activeCount":102},[],{"trials":4786,"activeCount":102},[4787,4797],{"nctId":4788,"briefTitle":4789,"status":248,"phases":4790,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":4792,"interventions":4793},"NCT00278512","Hematopoietic Stem Cell Support in Vasculitis",[90],"2003-08",[480],[4794,4795,141,439,441,4796,517,1749,440],"Autologous Stem Cell Transplant","Allogeneic Stem Cell Transplant","Campath-1h",{"nctId":455,"briefTitle":456,"status":108,"phases":4798,"primaryCompletion":458,"completion":458,"start":111,"conditions":4799,"interventions":4800},[90],[113,114,115,24,116,117,118,460],[462,120,463,177,464,122,465],{"trials":4802,"activeCount":102},[4803],{"nctId":1741,"briefTitle":1742,"status":261,"phases":4804,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":4805,"interventions":4806},[91],[1746],[517,141,440,1732,441,1748,1749],{"trials":4808,"activeCount":102},[],{"trials":4810,"activeCount":102},[4811],{"nctId":1793,"briefTitle":1794,"status":248,"phases":4812,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":402,"conditions":4813,"interventions":4814},[93],[1799],[1749,1801,1732,1802],{"trials":4816,"activeCount":102},[],{"intervention":4818,"totalTrials":375,"cells":4819},"D-cycloserine",{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4824,"PHASE3":4836,"PHASE4":4845,"NA":4856},{"trials":4821,"activeCount":102},[],{"trials":4823,"activeCount":102},[],{"trials":4825,"activeCount":102},[4826],{"nctId":4827,"briefTitle":4828,"status":248,"phases":4829,"primaryCompletion":4830,"completion":4830,"start":4831,"enrollment":4832,"conditions":4833,"interventions":4835},"NCT03535688","D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain",[91],"2024-02-07","2018-03-30",203,[4834,15],"Low Back Pain",[4818],{"trials":4837,"activeCount":102},[4838],{"nctId":4839,"briefTitle":4840,"status":248,"phases":4841,"primaryCompletion":899,"completion":3295,"start":1787,"enrollment":448,"conditions":4842,"interventions":4844},"NCT00301080","D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain",[92],[4843,15,21],"Neurotoxicity",[4818],{"trials":4846,"activeCount":102},[4847],{"nctId":4848,"briefTitle":4849,"status":248,"phases":4850,"primaryCompletion":947,"completion":433,"start":4851,"enrollment":2646,"conditions":4852,"interventions":4854},"NCT02385266","Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain",[93],"2013-09",[4853],"Chronic Prostatitis With Chronic Pelvic Pain Syndrome",[4855],"D-Cycloserine",{"trials":4857,"activeCount":102},[],{"intervention":4603,"totalTrials":273,"cells":4859},{"EARLY_PHASE1":4860,"PHASE1":4862,"PHASE2":4864,"PHASE3":4866,"PHASE4":4868,"NA":4878},{"trials":4861,"activeCount":102},[],{"trials":4863,"activeCount":102},[],{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":102},[],{"trials":4869,"activeCount":102},[4870,4874],{"nctId":4595,"briefTitle":4596,"status":248,"phases":4871,"primaryCompletion":4598,"completion":616,"start":4599,"enrollment":3314,"conditions":4872,"interventions":4873},[93],[4601],[609,4603],{"nctId":4618,"briefTitle":4619,"status":108,"phases":4875,"primaryCompletion":4621,"completion":616,"start":4622,"enrollment":402,"conditions":4876,"interventions":4877},[93],[4624,1151],[609,4603],{"trials":4879,"activeCount":102},[],{"intervention":4616,"totalTrials":273,"cells":4881},{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4888,"PHASE4":4890,"NA":4900},{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"trials":4887,"activeCount":102},[],{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[4892,4896],{"nctId":4609,"briefTitle":4610,"status":248,"phases":4893,"primaryCompletion":4612,"completion":4612,"start":627,"enrollment":1371,"conditions":4894,"interventions":4895},[93],[4614],[609,4616],{"nctId":4635,"briefTitle":4636,"status":108,"phases":4897,"primaryCompletion":252,"start":4638,"enrollment":4639,"conditions":4898,"interventions":4899},[93],[4641],[609,4616],{"trials":4901,"activeCount":102},[],{"intervention":989,"totalTrials":273,"cells":4903},{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4932},{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[],{"trials":4911,"activeCount":102},[],{"trials":4913,"activeCount":102},[4914,4918],{"nctId":981,"briefTitle":982,"status":108,"phases":4915,"primaryCompletion":984,"completion":779,"start":985,"enrollment":402,"conditions":4916,"interventions":4917},[93],[987],[939,989],{"nctId":4919,"briefTitle":4920,"status":108,"phases":4921,"primaryCompletion":4922,"completion":4923,"start":1886,"enrollment":2601,"conditions":4924,"interventions":4929},"NCT00908375","Efficacy of Pregabalin in Patients With Radicular Pain",[93],"2012-09","2012-12",[4925,4926,4927,4928],"Neuropathy; Radicular, Lumbar, Lumbosacral","Failed Back Surgery Syndrome","Spinal Stenosis","Herniated Disc",[4930,4931],"Pregabalin","Sugar Pill",{"trials":4933,"activeCount":102},[],{"intervention":4935,"totalTrials":229,"cells":4936},"Feraheme",{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4943,"PHASE4":4945,"NA":4955},{"trials":4938,"activeCount":102},[],{"trials":4940,"activeCount":102},[],{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[],{"trials":4946,"activeCount":102},[4947],{"nctId":4948,"briefTitle":4949,"status":108,"phases":4950,"primaryCompletion":4367,"completion":4367,"start":4951,"enrollment":1440,"conditions":4952,"interventions":4954},"NCT05515874","Predicting Stroke Risk in ICAD With Novel MRI",[93],"2020-09-01",[4953],"Intracranial Atherosclerosis",[4935],{"trials":4956,"activeCount":102},[],{"intervention":4958,"totalTrials":229,"cells":4959},"Amlodipine Besylate",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4966,"PHASE4":4968,"NA":4982},{"trials":4961,"activeCount":102},[],{"trials":4963,"activeCount":102},[],{"trials":4965,"activeCount":102},[],{"trials":4967,"activeCount":102},[],{"trials":4969,"activeCount":102},[4970],{"nctId":4971,"briefTitle":4972,"status":261,"phases":4973,"primaryCompletion":4974,"completion":4975,"start":4681,"enrollment":102,"conditions":4976,"interventions":4980},"NCT05275907","Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)",[93],"2023-10-02","2023-10-04",[4977,4978,4979],"High Blood Pressure","Liver Transplant","Renal Function Abnormal",[4958,4981],"Chlorthalidone",{"trials":4983,"activeCount":102},[],{"intervention":4981,"totalTrials":229,"cells":4985},{"EARLY_PHASE1":4986,"PHASE1":4988,"PHASE2":4990,"PHASE3":4992,"PHASE4":4994,"NA":5000},{"trials":4987,"activeCount":102},[],{"trials":4989,"activeCount":102},[],{"trials":4991,"activeCount":102},[],{"trials":4993,"activeCount":102},[],{"trials":4995,"activeCount":102},[4996],{"nctId":4971,"briefTitle":4972,"status":261,"phases":4997,"primaryCompletion":4974,"completion":4975,"start":4681,"enrollment":102,"conditions":4998,"interventions":4999},[93],[4977,4978,4979],[4958,4981],{"trials":5001,"activeCount":102},[],{"intervention":5003,"totalTrials":229,"cells":5004},"Ulipristal",{"EARLY_PHASE1":5005,"PHASE1":5007,"PHASE2":5009,"PHASE3":5011,"PHASE4":5013,"NA":5024},{"trials":5006,"activeCount":102},[],{"trials":5008,"activeCount":102},[],{"trials":5010,"activeCount":102},[],{"trials":5012,"activeCount":102},[],{"trials":5014,"activeCount":102},[5015],{"nctId":5016,"briefTitle":5017,"status":108,"phases":5018,"primaryCompletion":1653,"completion":5019,"start":5020,"enrollment":229,"conditions":5021,"interventions":5023},"NCT02213081","Ulipristal for Endometriosis-related Pelvic Pain",[93],"2016-12","2015-02",[5022],"Endometriosis",[5003],{"trials":5025,"activeCount":102},[],{"intervention":5027,"totalTrials":229,"cells":5028},"Study drug metoclopramide",{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5037,"NA":5049},{"trials":5030,"activeCount":102},[],{"trials":5032,"activeCount":102},[],{"trials":5034,"activeCount":102},[],{"trials":5036,"activeCount":102},[],{"trials":5038,"activeCount":102},[5039],{"nctId":5040,"briefTitle":5041,"status":108,"phases":5042,"primaryCompletion":4749,"completion":129,"start":5043,"enrollment":1557,"conditions":5044,"interventions":5047},"NCT05033041","Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide",[93],"2021-10-20",[30,5045,5046],"Cesarean Section","Aspiration",[5027,5048],"Study drug placebo administration",{"trials":5050,"activeCount":102},[],{"intervention":5048,"totalTrials":229,"cells":5052},{"EARLY_PHASE1":5053,"PHASE1":5055,"PHASE2":5057,"PHASE3":5059,"PHASE4":5061,"NA":5067},{"trials":5054,"activeCount":102},[],{"trials":5056,"activeCount":102},[],{"trials":5058,"activeCount":102},[],{"trials":5060,"activeCount":102},[],{"trials":5062,"activeCount":102},[5063],{"nctId":5040,"briefTitle":5041,"status":108,"phases":5064,"primaryCompletion":4749,"completion":129,"start":5043,"enrollment":1557,"conditions":5065,"interventions":5066},[93],[30,5045,5046],[5027,5048],{"trials":5068,"activeCount":102},[],{"intervention":5070,"totalTrials":229,"cells":5071},"Depot-Medroxyprogestereone Acetate",{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5092},{"trials":5073,"activeCount":102},[],{"trials":5075,"activeCount":102},[],{"trials":5077,"activeCount":102},[],{"trials":5079,"activeCount":102},[],{"trials":5081,"activeCount":102},[5082],{"nctId":5083,"briefTitle":5084,"status":108,"phases":5085,"primaryCompletion":5086,"completion":5087,"start":4417,"enrollment":5088,"conditions":5089,"interventions":5091},"NCT05505435","Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients",[93],"2023-09-30","2024-03-30",263,[5090],"Contraception",[5070,5070],{"trials":5093,"activeCount":102},[],{"intervention":5095,"totalTrials":229,"cells":5096},"10 mL 2% lidocaine",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5101,"PHASE3":5103,"PHASE4":5105,"NA":5117},{"trials":5098,"activeCount":102},[],{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[],{"trials":5106,"activeCount":102},[5107],{"nctId":5108,"briefTitle":5109,"status":248,"phases":5110,"primaryCompletion":5111,"completion":5111,"start":5112,"enrollment":229,"conditions":5113,"interventions":5115},"NCT05046639","Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain",[93],"2023-07-26","2021-09-01",[15,5114],"Amputation",[5095,5116],"10 mL preservative free saline",{"trials":5118,"activeCount":102},[],{"intervention":5116,"totalTrials":229,"cells":5120},{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5127,"PHASE4":5129,"NA":5135},{"trials":5122,"activeCount":102},[],{"trials":5124,"activeCount":102},[],{"trials":5126,"activeCount":102},[],{"trials":5128,"activeCount":102},[],{"trials":5130,"activeCount":102},[5131],{"nctId":5108,"briefTitle":5109,"status":248,"phases":5132,"primaryCompletion":5111,"completion":5111,"start":5112,"enrollment":229,"conditions":5133,"interventions":5134},[93],[15,5114],[5095,5116],{"trials":5136,"activeCount":102},[],{"intervention":5138,"totalTrials":229,"cells":5139},"Epidural saline + IV saline",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5146,"PHASE4":5148,"NA":5163},{"trials":5141,"activeCount":102},[],{"trials":5143,"activeCount":102},[],{"trials":5145,"activeCount":102},[],{"trials":5147,"activeCount":102},[],{"trials":5149,"activeCount":102},[5150],{"nctId":5151,"briefTitle":5152,"status":108,"phases":5153,"primaryCompletion":5154,"completion":5155,"start":5156,"enrollment":5157,"conditions":5158,"interventions":5160},"NCT03470675","Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries",[93],"2024-05-20","2024-06-20","2018-06-27",67,[15,5159],"Postpartum Depression",[5138,5161,5162],"Epidural morphine 3 mg + IV saline","Epidural morphine 3 mg + IV ketamine 0.3 mg\u002Fkg",{"trials":5164,"activeCount":102},[],{"intervention":5161,"totalTrials":229,"cells":5166},{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5171,"PHASE3":5173,"PHASE4":5175,"NA":5181},{"trials":5168,"activeCount":102},[],{"trials":5170,"activeCount":102},[],{"trials":5172,"activeCount":102},[],{"trials":5174,"activeCount":102},[],{"trials":5176,"activeCount":102},[5177],{"nctId":5151,"briefTitle":5152,"status":108,"phases":5178,"primaryCompletion":5154,"completion":5155,"start":5156,"enrollment":5157,"conditions":5179,"interventions":5180},[93],[15,5159],[5138,5161,5162],{"trials":5182,"activeCount":102},[],{"intervention":5162,"totalTrials":229,"cells":5184},{"EARLY_PHASE1":5185,"PHASE1":5187,"PHASE2":5189,"PHASE3":5191,"PHASE4":5193,"NA":5199},{"trials":5186,"activeCount":102},[],{"trials":5188,"activeCount":102},[],{"trials":5190,"activeCount":102},[],{"trials":5192,"activeCount":102},[],{"trials":5194,"activeCount":102},[5195],{"nctId":5151,"briefTitle":5152,"status":108,"phases":5196,"primaryCompletion":5154,"completion":5155,"start":5156,"enrollment":5157,"conditions":5197,"interventions":5198},[93],[15,5159],[5138,5161,5162],{"trials":5200,"activeCount":102},[],{"intervention":577,"totalTrials":229,"cells":5202},{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5209,"PHASE4":5211,"NA":5217},{"trials":5204,"activeCount":102},[],{"trials":5206,"activeCount":102},[],{"trials":5208,"activeCount":102},[],{"trials":5210,"activeCount":102},[],{"trials":5212,"activeCount":102},[5213],{"nctId":569,"briefTitle":570,"status":261,"phases":5214,"primaryCompletion":572,"completion":573,"start":574,"enrollment":102,"conditions":5215,"interventions":5216},[93],[351],[577,418],{"trials":5218,"activeCount":102},[],{"intervention":5220,"totalTrials":229,"cells":5221},"long-acting injectable risperidone",{"EARLY_PHASE1":5222,"PHASE1":5224,"PHASE2":5226,"PHASE3":5228,"PHASE4":5230,"NA":5245},{"trials":5223,"activeCount":102},[],{"trials":5225,"activeCount":102},[],{"trials":5227,"activeCount":102},[],{"trials":5229,"activeCount":102},[],{"trials":5231,"activeCount":102},[5232],{"nctId":5233,"briefTitle":5234,"status":108,"phases":5235,"primaryCompletion":5236,"completion":5236,"start":5237,"enrollment":5238,"conditions":5239,"interventions":5242},"NCT00539071","High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone",[93],"2012-05","2008-03",160,[5240,5241],"Schizophrenia","Schizoaffective Disorder",[5220,5243,5244],"long acting injectable risperidone, Conventional Dose Group","long acting injectable risperidone, High Dose Group",{"trials":5246,"activeCount":102},[],{"intervention":5243,"totalTrials":229,"cells":5248},{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5255,"PHASE4":5257,"NA":5263},{"trials":5250,"activeCount":102},[],{"trials":5252,"activeCount":102},[],{"trials":5254,"activeCount":102},[],{"trials":5256,"activeCount":102},[],{"trials":5258,"activeCount":102},[5259],{"nctId":5233,"briefTitle":5234,"status":108,"phases":5260,"primaryCompletion":5236,"completion":5236,"start":5237,"enrollment":5238,"conditions":5261,"interventions":5262},[93],[5240,5241],[5220,5243,5244],{"trials":5264,"activeCount":102},[],{"intervention":5244,"totalTrials":229,"cells":5266},{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5275,"NA":5281},{"trials":5268,"activeCount":102},[],{"trials":5270,"activeCount":102},[],{"trials":5272,"activeCount":102},[],{"trials":5274,"activeCount":102},[],{"trials":5276,"activeCount":102},[5277],{"nctId":5233,"briefTitle":5234,"status":108,"phases":5278,"primaryCompletion":5236,"completion":5236,"start":5237,"enrollment":5238,"conditions":5279,"interventions":5280},[93],[5240,5241],[5220,5243,5244],{"trials":5282,"activeCount":102},[],{"intervention":257,"totalTrials":229,"cells":5284},{"EARLY_PHASE1":5285,"PHASE1":5287,"PHASE2":5289,"PHASE3":5291,"PHASE4":5293,"NA":5299},{"trials":5286,"activeCount":102},[],{"trials":5288,"activeCount":102},[],{"trials":5290,"activeCount":102},[],{"trials":5292,"activeCount":102},[],{"trials":5294,"activeCount":102},[5295],{"nctId":246,"briefTitle":247,"status":248,"phases":5296,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":5297,"interventions":5298},[93],[255],[97,257],{"trials":5300,"activeCount":102},[],{"intervention":5302,"totalTrials":229,"cells":5303},"NPH Insulin",{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5308,"PHASE3":5310,"PHASE4":5312,"NA":5326},{"trials":5305,"activeCount":102},[],{"trials":5307,"activeCount":102},[],{"trials":5309,"activeCount":102},[],{"trials":5311,"activeCount":102},[],{"trials":5313,"activeCount":102},[5314],{"nctId":5315,"briefTitle":5316,"status":248,"phases":5317,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":375,"conditions":5320,"interventions":5323},"NCT03511521","Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia",[93],"2019-08-15","2018-03-27",[5321,5322],"Hyperglycemia Steroid-induced","Insulin Resistance, Diabetes",[5302,5324,5325],"glargine","Insulin Aspart",{"trials":5327,"activeCount":102},[],{"intervention":5324,"totalTrials":229,"cells":5329},{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5336,"PHASE4":5338,"NA":5344},{"trials":5331,"activeCount":102},[],{"trials":5333,"activeCount":102},[],{"trials":5335,"activeCount":102},[],{"trials":5337,"activeCount":102},[],{"trials":5339,"activeCount":102},[5340],{"nctId":5315,"briefTitle":5316,"status":248,"phases":5341,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":375,"conditions":5342,"interventions":5343},[93],[5321,5322],[5302,5324,5325],{"trials":5345,"activeCount":102},[],{"intervention":5325,"totalTrials":229,"cells":5347},{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5354,"PHASE4":5356,"NA":5362},{"trials":5349,"activeCount":102},[],{"trials":5351,"activeCount":102},[],{"trials":5353,"activeCount":102},[],{"trials":5355,"activeCount":102},[],{"trials":5357,"activeCount":102},[5358],{"nctId":5315,"briefTitle":5316,"status":248,"phases":5359,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":375,"conditions":5360,"interventions":5361},[93],[5321,5322],[5302,5324,5325],{"trials":5363,"activeCount":102},[],{"intervention":5365,"totalTrials":229,"cells":5366},"Gabapentin",{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5371,"PHASE3":5373,"PHASE4":5375,"NA":5386},{"trials":5368,"activeCount":102},[],{"trials":5370,"activeCount":102},[],{"trials":5372,"activeCount":102},[],{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[5377],{"nctId":5378,"briefTitle":5379,"status":248,"phases":5380,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":224,"conditions":5383,"interventions":5385},"NCT03151746","Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion",[93],"2021-12-02","2018-01-14",[1686,5384],"Urethral Obstruction",[5365],{"trials":5387,"activeCount":102},[],{"intervention":5389,"totalTrials":229,"cells":5390},"Indocyanine green",{"EARLY_PHASE1":5391,"PHASE1":5393,"PHASE2":5395,"PHASE3":5397,"PHASE4":5399,"NA":5412},{"trials":5392,"activeCount":102},[],{"trials":5394,"activeCount":102},[],{"trials":5396,"activeCount":102},[],{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[5401],{"nctId":5402,"briefTitle":5403,"status":261,"phases":5404,"primaryCompletion":5405,"completion":5405,"start":5405,"enrollment":102,"conditions":5406,"interventions":5411},"NCT06164392","Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography",[93],"2024-12-28",[5407,5408,5409,5410],"Neuroma","Neuroma Amputation","Neuroma of Upper Limb","Neuroma of Lower Limb",[5389],{"trials":5413,"activeCount":102},[],{"intervention":5415,"totalTrials":229,"cells":5416},"Somatropin",{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5421,"PHASE3":5423,"PHASE4":5425,"NA":5436},{"trials":5418,"activeCount":102},[],{"trials":5420,"activeCount":102},[],{"trials":5422,"activeCount":102},[],{"trials":5424,"activeCount":102},[],{"trials":5426,"activeCount":102},[5427],{"nctId":5428,"briefTitle":5429,"status":108,"phases":5430,"primaryCompletion":5431,"completion":5020,"start":5432,"enrollment":1493,"conditions":5433,"interventions":5435},"NCT01380366","rHGH and Intestinal Permeability in Intestinal Failure",[93],"2011-02","2006-10",[5434],"Short Bowel Syndrome",[5415],{"trials":5437,"activeCount":102},[],{"intervention":5439,"totalTrials":229,"cells":5440},"Divalproex Sodium Extended-Release",{"EARLY_PHASE1":5441,"PHASE1":5443,"PHASE2":5445,"PHASE3":5447,"PHASE4":5449,"NA":5458},{"trials":5442,"activeCount":102},[],{"trials":5444,"activeCount":102},[],{"trials":5446,"activeCount":102},[],{"trials":5448,"activeCount":102},[],{"trials":5450,"activeCount":102},[5451],{"nctId":5452,"briefTitle":5453,"status":108,"phases":5454,"primaryCompletion":5455,"completion":5455,"start":1887,"enrollment":341,"conditions":5456,"interventions":5457},"NCT00306475","Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?",[93],"2008-04",[5240,5241],[5439],{"trials":5459,"activeCount":102},[],{"intervention":5461,"totalTrials":229,"cells":5462},"Tolvaptan",{"EARLY_PHASE1":5463,"PHASE1":5465,"PHASE2":5467,"PHASE3":5469,"PHASE4":5471,"NA":5481},{"trials":5464,"activeCount":102},[],{"trials":5466,"activeCount":102},[],{"trials":5468,"activeCount":102},[],{"trials":5470,"activeCount":102},[],{"trials":5472,"activeCount":102},[5473],{"nctId":5474,"briefTitle":5475,"status":108,"phases":5476,"primaryCompletion":616,"completion":602,"start":604,"enrollment":1371,"conditions":5477,"interventions":5479},"NCT01973140","Effects of Tolvaptan in Healthy Adults",[93],[5478],"Healthy",[5461,5480],"Hypertonic saline",{"trials":5482,"activeCount":102},[],{"intervention":5480,"totalTrials":229,"cells":5484},{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5489,"PHASE3":5491,"PHASE4":5493,"NA":5499},{"trials":5486,"activeCount":102},[],{"trials":5488,"activeCount":102},[],{"trials":5490,"activeCount":102},[],{"trials":5492,"activeCount":102},[],{"trials":5494,"activeCount":102},[5495],{"nctId":5474,"briefTitle":5475,"status":108,"phases":5496,"primaryCompletion":616,"completion":602,"start":604,"enrollment":1371,"conditions":5497,"interventions":5498},[93],[5478],[5461,5480],{"trials":5500,"activeCount":102},[],{"intervention":5502,"totalTrials":229,"cells":5503},"Povidone-Iodine",{"EARLY_PHASE1":5504,"PHASE1":5506,"PHASE2":5508,"PHASE3":5510,"PHASE4":5512,"NA":5526},{"trials":5505,"activeCount":102},[],{"trials":5507,"activeCount":102},[],{"trials":5509,"activeCount":102},[],{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[5514],{"nctId":5515,"briefTitle":5516,"status":108,"phases":5517,"primaryCompletion":5518,"completion":5519,"start":5520,"enrollment":5521,"conditions":5522,"interventions":5524},"NCT03305159","Tolerance of Chlorhexidine Gluconate Vaginal Cleansing Solution",[93],"2018-04-01","2018-04-15","2017-08-01",134,[5523],"Surgical Preparation of the Vagina",[5502,5525],"4% Chlorhexidine Gluconate",{"trials":5527,"activeCount":102},[],{"intervention":5525,"totalTrials":229,"cells":5529},{"EARLY_PHASE1":5530,"PHASE1":5532,"PHASE2":5534,"PHASE3":5536,"PHASE4":5538,"NA":5544},{"trials":5531,"activeCount":102},[],{"trials":5533,"activeCount":102},[],{"trials":5535,"activeCount":102},[],{"trials":5537,"activeCount":102},[],{"trials":5539,"activeCount":102},[5540],{"nctId":5515,"briefTitle":5516,"status":108,"phases":5541,"primaryCompletion":5518,"completion":5519,"start":5520,"enrollment":5521,"conditions":5542,"interventions":5543},[93],[5523],[5502,5525],{"trials":5545,"activeCount":102},[],{"intervention":5547,"totalTrials":229,"cells":5548},"transdermal estradiol patch",{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5553,"PHASE3":5555,"PHASE4":5557,"NA":5571},{"trials":5550,"activeCount":102},[],{"trials":5552,"activeCount":102},[],{"trials":5554,"activeCount":102},[],{"trials":5556,"activeCount":102},[],{"trials":5558,"activeCount":102},[5559],{"nctId":5560,"briefTitle":5561,"status":108,"phases":5562,"completion":3389,"start":5563,"enrollment":5564,"conditions":5565,"interventions":5570},"NCT00361075","Midlife Cholesterol Study",[93],"1998-07",120,[5566,5567,5568,5569],"Menopause","Postmenopause","Premenopause","Cardiovascular Disease",[5547],{"trials":5572,"activeCount":102},[],{"intervention":4768,"totalTrials":229,"cells":5574},{"EARLY_PHASE1":5575,"PHASE1":5577,"PHASE2":5579,"PHASE3":5581,"PHASE4":5583,"NA":5589},{"trials":5576,"activeCount":102},[],{"trials":5578,"activeCount":102},[],{"trials":5580,"activeCount":102},[],{"trials":5582,"activeCount":102},[],{"trials":5584,"activeCount":102},[5585],{"nctId":4761,"briefTitle":4762,"status":108,"phases":5586,"primaryCompletion":947,"completion":947,"start":489,"enrollment":4764,"conditions":5587,"interventions":5588},[93],[4766],[4727,4768],{"trials":5590,"activeCount":102},[],{"intervention":5592,"totalTrials":229,"cells":5593},"Iloperidone",{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5598,"PHASE3":5600,"PHASE4":5602,"NA":5612},{"trials":5595,"activeCount":102},[],{"trials":5597,"activeCount":102},[],{"trials":5599,"activeCount":102},[],{"trials":5601,"activeCount":102},[],{"trials":5603,"activeCount":102},[5604],{"nctId":5605,"briefTitle":5606,"status":248,"phases":5607,"primaryCompletion":5608,"completion":489,"start":5609,"enrollment":36,"conditions":5610,"interventions":5611},"NCT01929889","Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia",[93],"2014-02","2012-04",[5240,5241],[5592],{"trials":5613,"activeCount":102},[],{"intervention":5615,"totalTrials":229,"cells":5616},"Sevoflurane",{"EARLY_PHASE1":5617,"PHASE1":5619,"PHASE2":5621,"PHASE3":5623,"PHASE4":5625,"NA":5635},{"trials":5618,"activeCount":102},[],{"trials":5620,"activeCount":102},[],{"trials":5622,"activeCount":102},[],{"trials":5624,"activeCount":102},[],{"trials":5626,"activeCount":102},[5627],{"nctId":5628,"briefTitle":5629,"status":108,"phases":5630,"primaryCompletion":984,"completion":984,"start":5631,"enrollment":755,"conditions":5632,"interventions":5633},"NCT01755234","Propofol Versus Sevoflurane Recovery After Gynecological Surgery",[93],"2012-11",[1687,1686],[5615,5634],"Propofol",{"trials":5636,"activeCount":102},[],{"intervention":5634,"totalTrials":229,"cells":5638},{"EARLY_PHASE1":5639,"PHASE1":5641,"PHASE2":5643,"PHASE3":5645,"PHASE4":5647,"NA":5653},{"trials":5640,"activeCount":102},[],{"trials":5642,"activeCount":102},[],{"trials":5644,"activeCount":102},[],{"trials":5646,"activeCount":102},[],{"trials":5648,"activeCount":102},[5649],{"nctId":5628,"briefTitle":5629,"status":108,"phases":5650,"primaryCompletion":984,"completion":984,"start":5631,"enrollment":755,"conditions":5651,"interventions":5652},[93],[1687,1686],[5615,5634],{"trials":5654,"activeCount":102},[],{"intervention":5656,"totalTrials":229,"cells":5657},"Sodium hypochlorite (bleach) baths",{"EARLY_PHASE1":5658,"PHASE1":5660,"PHASE2":5662,"PHASE3":5664,"PHASE4":5666,"NA":5678},{"trials":5659,"activeCount":102},[],{"trials":5661,"activeCount":102},[],{"trials":5663,"activeCount":102},[],{"trials":5665,"activeCount":102},[],{"trials":5667,"activeCount":102},[5668],{"nctId":5669,"briefTitle":5670,"status":108,"phases":5671,"primaryCompletion":5672,"completion":5672,"start":447,"enrollment":1548,"conditions":5673,"interventions":5674},"NCT00179959","The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis",[93],"2011-03",[404],[5656,5675,5676,5677],"Mupirocin ointment","Water","Petrolatum Ointment",{"trials":5679,"activeCount":102},[],{"intervention":5675,"totalTrials":229,"cells":5681},{"EARLY_PHASE1":5682,"PHASE1":5684,"PHASE2":5686,"PHASE3":5688,"PHASE4":5690,"NA":5696},{"trials":5683,"activeCount":102},[],{"trials":5685,"activeCount":102},[],{"trials":5687,"activeCount":102},[],{"trials":5689,"activeCount":102},[],{"trials":5691,"activeCount":102},[5692],{"nctId":5669,"briefTitle":5670,"status":108,"phases":5693,"primaryCompletion":5672,"completion":5672,"start":447,"enrollment":1548,"conditions":5694,"interventions":5695},[93],[404],[5656,5675,5676,5677],{"trials":5697,"activeCount":102},[],{"intervention":5676,"totalTrials":229,"cells":5699},{"EARLY_PHASE1":5700,"PHASE1":5702,"PHASE2":5704,"PHASE3":5706,"PHASE4":5708,"NA":5714},{"trials":5701,"activeCount":102},[],{"trials":5703,"activeCount":102},[],{"trials":5705,"activeCount":102},[],{"trials":5707,"activeCount":102},[],{"trials":5709,"activeCount":102},[5710],{"nctId":5669,"briefTitle":5670,"status":108,"phases":5711,"primaryCompletion":5672,"completion":5672,"start":447,"enrollment":1548,"conditions":5712,"interventions":5713},[93],[404],[5656,5675,5676,5677],{"trials":5715,"activeCount":102},[],{"intervention":5677,"totalTrials":229,"cells":5717},{"EARLY_PHASE1":5718,"PHASE1":5720,"PHASE2":5722,"PHASE3":5724,"PHASE4":5726,"NA":5732},{"trials":5719,"activeCount":102},[],{"trials":5721,"activeCount":102},[],{"trials":5723,"activeCount":102},[],{"trials":5725,"activeCount":102},[],{"trials":5727,"activeCount":102},[5728],{"nctId":5669,"briefTitle":5670,"status":108,"phases":5729,"primaryCompletion":5672,"completion":5672,"start":447,"enrollment":1548,"conditions":5730,"interventions":5731},[93],[404],[5656,5675,5676,5677],{"trials":5733,"activeCount":102},[],{"intervention":5735,"totalTrials":229,"cells":5736},"0.25% Bupivacaine",{"EARLY_PHASE1":5737,"PHASE1":5739,"PHASE2":5741,"PHASE3":5743,"PHASE4":5745,"NA":5756},{"trials":5738,"activeCount":102},[],{"trials":5740,"activeCount":102},[],{"trials":5742,"activeCount":102},[],{"trials":5744,"activeCount":102},[],{"trials":5746,"activeCount":102},[5747],{"nctId":5748,"briefTitle":5749,"status":108,"phases":5750,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":1724,"conditions":5753,"interventions":5755},"NCT01279447","Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control",[93],"2013-08","2011-01",[5754],"Internal Derangement of Knee",[5735,620],{"trials":5757,"activeCount":102},[],{"intervention":5759,"totalTrials":229,"cells":5760},"Low volume bolus",{"EARLY_PHASE1":5761,"PHASE1":5763,"PHASE2":5765,"PHASE3":5767,"PHASE4":5769,"NA":5783},{"trials":5762,"activeCount":102},[],{"trials":5764,"activeCount":102},[],{"trials":5766,"activeCount":102},[],{"trials":5768,"activeCount":102},[],{"trials":5770,"activeCount":102},[5771],{"nctId":5772,"briefTitle":5773,"status":248,"phases":5774,"primaryCompletion":5775,"completion":5776,"start":5777,"enrollment":5778,"conditions":5779,"interventions":5781},"NCT03553576","Drug Concentration and Volume on Adequate Labor Analgesia With PIEB",[93],"2023-05-31","2023-06-01","2020-01-21",146,[15,1686,5780],"Labor Pain",[5759,5782],"High volume bolus",{"trials":5784,"activeCount":102},[],{"intervention":5782,"totalTrials":229,"cells":5786},{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5795,"NA":5801},{"trials":5788,"activeCount":102},[],{"trials":5790,"activeCount":102},[],{"trials":5792,"activeCount":102},[],{"trials":5794,"activeCount":102},[],{"trials":5796,"activeCount":102},[5797],{"nctId":5772,"briefTitle":5773,"status":248,"phases":5798,"primaryCompletion":5775,"completion":5776,"start":5777,"enrollment":5778,"conditions":5799,"interventions":5800},[93],[15,1686,5780],[5759,5782],{"trials":5802,"activeCount":102},[],{"intervention":5804,"totalTrials":229,"cells":5805},"Intrathecal Morphine",{"EARLY_PHASE1":5806,"PHASE1":5808,"PHASE2":5810,"PHASE3":5812,"PHASE4":5814,"NA":5826},{"trials":5807,"activeCount":102},[],{"trials":5809,"activeCount":102},[],{"trials":5811,"activeCount":102},[],{"trials":5813,"activeCount":102},[],{"trials":5815,"activeCount":102},[5816],{"nctId":5817,"briefTitle":5818,"status":261,"phases":5819,"primaryCompletion":5820,"completion":5820,"start":5821,"enrollment":102,"conditions":5822,"interventions":5824},"NCT03282669","TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia",[93],"2021-12","2019-08",[757,27,5823],"Respiratory Insufficiency",[5804,5825],"Intravenous hydromorphone",{"trials":5827,"activeCount":102},[],{"intervention":5825,"totalTrials":229,"cells":5829},{"EARLY_PHASE1":5830,"PHASE1":5832,"PHASE2":5834,"PHASE3":5836,"PHASE4":5838,"NA":5844},{"trials":5831,"activeCount":102},[],{"trials":5833,"activeCount":102},[],{"trials":5835,"activeCount":102},[],{"trials":5837,"activeCount":102},[],{"trials":5839,"activeCount":102},[5840],{"nctId":5817,"briefTitle":5818,"status":261,"phases":5841,"primaryCompletion":5820,"completion":5820,"start":5821,"enrollment":102,"conditions":5842,"interventions":5843},[93],[757,27,5823],[5804,5825],{"trials":5845,"activeCount":102},[],{"intervention":5847,"totalTrials":229,"cells":5848},"Dexamethasone 0.05mg\u002Fkr administration",{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5855,"PHASE4":5857,"NA":5868},{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":102},[],{"trials":5854,"activeCount":102},[],{"trials":5856,"activeCount":102},[],{"trials":5858,"activeCount":102},[5859],{"nctId":5860,"briefTitle":5861,"status":108,"phases":5862,"primaryCompletion":5863,"completion":5863,"start":1490,"enrollment":5564,"conditions":5864,"interventions":5866},"NCT01052038","Post Operative Sore Throat and Dexamethasone",[93],"2010-09",[5865,15],"Sore Throat",[5847,5867],"Dexamethasone 0.1mg\u002Fkg",{"trials":5869,"activeCount":102},[],{"intervention":5867,"totalTrials":229,"cells":5871},{"EARLY_PHASE1":5872,"PHASE1":5874,"PHASE2":5876,"PHASE3":5878,"PHASE4":5880,"NA":5886},{"trials":5873,"activeCount":102},[],{"trials":5875,"activeCount":102},[],{"trials":5877,"activeCount":102},[],{"trials":5879,"activeCount":102},[],{"trials":5881,"activeCount":102},[5882],{"nctId":5860,"briefTitle":5861,"status":108,"phases":5883,"primaryCompletion":5863,"completion":5863,"start":1490,"enrollment":5564,"conditions":5884,"interventions":5885},[93],[5865,15],[5847,5867],{"trials":5887,"activeCount":102},[],{"intervention":5889,"totalTrials":229,"cells":5890},"Ciprofloxacin",{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5895,"PHASE3":5897,"PHASE4":5899,"NA":5916},{"trials":5892,"activeCount":102},[],{"trials":5894,"activeCount":102},[],{"trials":5896,"activeCount":102},[],{"trials":5898,"activeCount":102},[],{"trials":5900,"activeCount":102},[5901],{"nctId":5902,"briefTitle":5903,"status":108,"phases":5904,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":5906,"interventions":5908},"NCT01659866","Antibiotic Prophylaxis for Transrectal Prostate Biopsy",[93],563,[5907],"Infection",[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],"trimethoprim-sulfamethoxazole","cefuroxime","ceftriaxone","gentamicin","amikacin","aztreonam","imipenem",{"trials":5917,"activeCount":102},[],{"intervention":5909,"totalTrials":229,"cells":5919},{"EARLY_PHASE1":5920,"PHASE1":5922,"PHASE2":5924,"PHASE3":5926,"PHASE4":5928,"NA":5934},{"trials":5921,"activeCount":102},[],{"trials":5923,"activeCount":102},[],{"trials":5925,"activeCount":102},[],{"trials":5927,"activeCount":102},[],{"trials":5929,"activeCount":102},[5930],{"nctId":5902,"briefTitle":5903,"status":108,"phases":5931,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":5932,"interventions":5933},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":5935,"activeCount":102},[],{"intervention":5910,"totalTrials":229,"cells":5937},{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5942,"PHASE3":5944,"PHASE4":5946,"NA":5952},{"trials":5939,"activeCount":102},[],{"trials":5941,"activeCount":102},[],{"trials":5943,"activeCount":102},[],{"trials":5945,"activeCount":102},[],{"trials":5947,"activeCount":102},[5948],{"nctId":5902,"briefTitle":5903,"status":108,"phases":5949,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":5950,"interventions":5951},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":5953,"activeCount":102},[],{"intervention":5911,"totalTrials":229,"cells":5955},{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5970},{"trials":5957,"activeCount":102},[],{"trials":5959,"activeCount":102},[],{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[5966],{"nctId":5902,"briefTitle":5903,"status":108,"phases":5967,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":5968,"interventions":5969},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":5971,"activeCount":102},[],{"intervention":5912,"totalTrials":229,"cells":5973},{"EARLY_PHASE1":5974,"PHASE1":5976,"PHASE2":5978,"PHASE3":5980,"PHASE4":5982,"NA":5988},{"trials":5975,"activeCount":102},[],{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":102},[],{"trials":5981,"activeCount":102},[],{"trials":5983,"activeCount":102},[5984],{"nctId":5902,"briefTitle":5903,"status":108,"phases":5985,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":5986,"interventions":5987},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":5989,"activeCount":102},[],{"intervention":5913,"totalTrials":229,"cells":5991},{"EARLY_PHASE1":5992,"PHASE1":5994,"PHASE2":5996,"PHASE3":5998,"PHASE4":6000,"NA":6006},{"trials":5993,"activeCount":102},[],{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":102},[],{"trials":5999,"activeCount":102},[],{"trials":6001,"activeCount":102},[6002],{"nctId":5902,"briefTitle":5903,"status":108,"phases":6003,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":6004,"interventions":6005},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":6007,"activeCount":102},[],{"intervention":5914,"totalTrials":229,"cells":6009},{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6014,"PHASE3":6016,"PHASE4":6018,"NA":6024},{"trials":6011,"activeCount":102},[],{"trials":6013,"activeCount":102},[],{"trials":6015,"activeCount":102},[],{"trials":6017,"activeCount":102},[],{"trials":6019,"activeCount":102},[6020],{"nctId":5902,"briefTitle":5903,"status":108,"phases":6021,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":6022,"interventions":6023},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":6025,"activeCount":102},[],{"intervention":5915,"totalTrials":229,"cells":6027},{"EARLY_PHASE1":6028,"PHASE1":6030,"PHASE2":6032,"PHASE3":6034,"PHASE4":6036,"NA":6042},{"trials":6029,"activeCount":102},[],{"trials":6031,"activeCount":102},[],{"trials":6033,"activeCount":102},[],{"trials":6035,"activeCount":102},[],{"trials":6037,"activeCount":102},[6038],{"nctId":5902,"briefTitle":5903,"status":108,"phases":6039,"primaryCompletion":1654,"completion":251,"start":252,"enrollment":5905,"conditions":6040,"interventions":6041},[93],[5907],[5889,5909,5910,5911,5912,5913,5914,5915,5911,5912,5913,5914,5915],{"trials":6043,"activeCount":102},[],{"intervention":6045,"totalTrials":229,"cells":6046},".5% Bupivacaine",{"EARLY_PHASE1":6047,"PHASE1":6049,"PHASE2":6051,"PHASE3":6053,"PHASE4":6055,"NA":6065},{"trials":6048,"activeCount":102},[],{"trials":6050,"activeCount":102},[],{"trials":6052,"activeCount":102},[],{"trials":6054,"activeCount":102},[],{"trials":6056,"activeCount":102},[6057],{"nctId":6058,"briefTitle":6059,"status":248,"phases":6060,"primaryCompletion":6061,"completion":6061,"start":6062,"enrollment":229,"conditions":6063,"interventions":6064},"NCT03796195","(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes",[93],"2021-07-16","2019-11-13",[4124,1634],[6045],{"trials":6066,"activeCount":102},[],{"intervention":6068,"totalTrials":229,"cells":6069},"Angiotensin II",{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6074,"PHASE3":6076,"PHASE4":6078,"NA":6088},{"trials":6071,"activeCount":102},[],{"trials":6073,"activeCount":102},[],{"trials":6075,"activeCount":102},[],{"trials":6077,"activeCount":102},[],{"trials":6079,"activeCount":102},[6080],{"nctId":6081,"briefTitle":6082,"status":248,"phases":6083,"primaryCompletion":6084,"completion":4680,"start":46,"enrollment":273,"conditions":6085,"interventions":6087},"NCT04904562","Angiotensin II for Distributive Shock",[93],"2024-05-01",[6086],"Distributive Shock",[6068],{"trials":6089,"activeCount":102},[],{"intervention":6091,"totalTrials":229,"cells":6092},"Non-coumadin Oral Anticoagulant",{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6099,"PHASE4":6101,"NA":6110},{"trials":6094,"activeCount":102},[],{"trials":6096,"activeCount":102},[],{"trials":6098,"activeCount":102},[],{"trials":6100,"activeCount":102},[],{"trials":6102,"activeCount":102},[6103],{"nctId":6104,"briefTitle":6105,"status":108,"phases":6106,"primaryCompletion":5020,"completion":5020,"start":3381,"enrollment":2171,"conditions":6107,"interventions":6109},"NCT01706146","Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring",[93],[6108],"Atrial Fibrillation",[6091],{"trials":6111,"activeCount":102},[],{"intervention":6113,"totalTrials":229,"cells":6114},"Morphine with clonidine",{"EARLY_PHASE1":6115,"PHASE1":6117,"PHASE2":6119,"PHASE3":6121,"PHASE4":6123,"NA":6133},{"trials":6116,"activeCount":102},[],{"trials":6118,"activeCount":102},[],{"trials":6120,"activeCount":102},[],{"trials":6122,"activeCount":102},[],{"trials":6124,"activeCount":102},[6125],{"nctId":6126,"briefTitle":6127,"status":108,"phases":6128,"primaryCompletion":6129,"completion":6129,"start":4598,"enrollment":189,"conditions":6130,"interventions":6132},"NCT02530151","Intra-articular Morphine and Clonidine Injections for Pain Management in Hip Arthroscopy",[93],"2017-05",[6131,757],"Femoracetabular Impingement",[6113],{"trials":6134,"activeCount":102},[],{"intervention":4778,"totalTrials":229,"cells":6136},{"EARLY_PHASE1":6137,"PHASE1":6139,"PHASE2":6141,"PHASE3":6143,"PHASE4":6145,"NA":6151},{"trials":6138,"activeCount":102},[],{"trials":6140,"activeCount":102},[],{"trials":6142,"activeCount":102},[],{"trials":6144,"activeCount":102},[],{"trials":6146,"activeCount":102},[6147],{"nctId":4770,"briefTitle":4771,"status":108,"phases":6148,"primaryCompletion":4773,"completion":4773,"start":4774,"enrollment":1557,"conditions":6149,"interventions":6150},[93],[4776],[4727,4778],{"trials":6152,"activeCount":102},[],{"intervention":6154,"totalTrials":229,"cells":6155},"Midazolam",{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6162,"PHASE4":6164,"NA":6176},{"trials":6157,"activeCount":102},[],{"trials":6159,"activeCount":102},[],{"trials":6161,"activeCount":102},[],{"trials":6163,"activeCount":102},[],{"trials":6165,"activeCount":102},[6166],{"nctId":6167,"briefTitle":6168,"status":261,"phases":6169,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":102,"conditions":6172,"interventions":6174},"NCT04220125","Preoperative Ketamine and Perioperative Depression",[93],"2023-02-02","2022-09-01",[6173],"Depressive Disorder",[6175,6154],"Ketamine Group",{"trials":6177,"activeCount":102},[],{"intervention":6179,"totalTrials":229,"cells":6180},"Augmentin\u002FFlagyl or Augmentin\u002FClindamycin",{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6185,"PHASE3":6187,"PHASE4":6189,"NA":6202},{"trials":6182,"activeCount":102},[],{"trials":6184,"activeCount":102},[],{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[],{"trials":6190,"activeCount":102},[6191],{"nctId":6192,"briefTitle":6193,"status":200,"phases":6194,"primaryCompletion":6195,"completion":6196,"start":6197,"enrollment":6198,"conditions":6199,"interventions":6201},"NCT04573504","Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair",[93],"2024-09-23","2024-12-31","2020-09-23",274,[6200],"Vaginal Laceration During Delivery",[6179],{"trials":6203,"activeCount":102},[],{"intervention":6205,"totalTrials":229,"cells":6206},"Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg",{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6213,"PHASE4":6215,"NA":6228},{"trials":6208,"activeCount":102},[],{"trials":6210,"activeCount":102},[],{"trials":6212,"activeCount":102},[],{"trials":6214,"activeCount":102},[],{"trials":6216,"activeCount":102},[6217],{"nctId":6218,"briefTitle":6219,"status":261,"phases":6220,"primaryCompletion":6221,"completion":6222,"start":6223,"enrollment":102,"conditions":6224,"interventions":6227},"NCT04697485","Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus",[93],"2022-01-01","2022-03-30","2021-01-08",[6225,6226],"HF - Heart Failure","Diabetes Mellitus",[6205],{"trials":6229,"activeCount":102},[],{"intervention":6231,"totalTrials":229,"cells":6232},"Lurasidone",{"EARLY_PHASE1":6233,"PHASE1":6235,"PHASE2":6237,"PHASE3":6239,"PHASE4":6241,"NA":6250},{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[],{"trials":6238,"activeCount":102},[],{"trials":6240,"activeCount":102},[],{"trials":6242,"activeCount":102},[6243],{"nctId":6244,"briefTitle":6245,"status":108,"phases":6246,"primaryCompletion":1644,"completion":1644,"start":996,"enrollment":6247,"conditions":6248,"interventions":6249},"NCT01569659","High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia",[93],101,[5240],[6231,6231],{"trials":6251,"activeCount":102},[],{"intervention":6253,"totalTrials":229,"cells":6254},"Ondansetron 4 MG",{"EARLY_PHASE1":6255,"PHASE1":6257,"PHASE2":6259,"PHASE3":6261,"PHASE4":6263,"NA":6275},{"trials":6256,"activeCount":102},[],{"trials":6258,"activeCount":102},[],{"trials":6260,"activeCount":102},[],{"trials":6262,"activeCount":102},[],{"trials":6264,"activeCount":102},[6265],{"nctId":6266,"briefTitle":6267,"status":261,"phases":6268,"primaryCompletion":6269,"completion":6221,"start":5112,"enrollment":102,"conditions":6270,"interventions":6273},"NCT04983498","Enhanced Recovery Pathway for Endoscopy",[93],"2021-12-01",[6271,6272],"Enhanced Recovery Pathway","Endoscopy",[6253,6274],"Lactated Ringers, Intravenous",{"trials":6276,"activeCount":102},[],{"intervention":6274,"totalTrials":229,"cells":6278},{"EARLY_PHASE1":6279,"PHASE1":6281,"PHASE2":6283,"PHASE3":6285,"PHASE4":6287,"NA":6293},{"trials":6280,"activeCount":102},[],{"trials":6282,"activeCount":102},[],{"trials":6284,"activeCount":102},[],{"trials":6286,"activeCount":102},[],{"trials":6288,"activeCount":102},[6289],{"nctId":6266,"briefTitle":6267,"status":261,"phases":6290,"primaryCompletion":6269,"completion":6221,"start":5112,"enrollment":102,"conditions":6291,"interventions":6292},[93],[6271,6272],[6253,6274],{"trials":6294,"activeCount":102},[],{"intervention":6296,"totalTrials":229,"cells":6297},"Varenicline",{"EARLY_PHASE1":6298,"PHASE1":6300,"PHASE2":6302,"PHASE3":6304,"PHASE4":6306,"NA":6319},{"trials":6299,"activeCount":102},[],{"trials":6301,"activeCount":102},[],{"trials":6303,"activeCount":102},[],{"trials":6305,"activeCount":102},[],{"trials":6307,"activeCount":102},[6308],{"nctId":6309,"briefTitle":6310,"status":108,"phases":6311,"primaryCompletion":6312,"completion":6312,"start":6313,"enrollment":6314,"conditions":6315,"interventions":6318},"NCT02378714","Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers",[93],"2020-03-13","2015-07-24",300,[6316,6317],"Nicotine Dependence","Major Depressive Disorder",[6296],{"trials":6320,"activeCount":102},[],{"intervention":6322,"totalTrials":229,"cells":6323},"insulin glargine",{"EARLY_PHASE1":6324,"PHASE1":6326,"PHASE2":6328,"PHASE3":6330,"PHASE4":6332,"NA":6343},{"trials":6325,"activeCount":102},[],{"trials":6327,"activeCount":102},[],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[6334],{"nctId":6335,"briefTitle":6336,"status":108,"phases":6337,"primaryCompletion":3389,"completion":3389,"start":6338,"enrollment":3696,"conditions":6339,"interventions":6342},"NCT00338104","Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin",[93],"2004-07",[6340,6341],"Hyperglycemia","Diabetes",[6322,6322,6322],{"trials":6344,"activeCount":102},[],{"intervention":6346,"totalTrials":229,"cells":6347},"Transdermal Estradiol",{"EARLY_PHASE1":6348,"PHASE1":6350,"PHASE2":6352,"PHASE3":6354,"PHASE4":6356,"NA":6367},{"trials":6349,"activeCount":102},[],{"trials":6351,"activeCount":102},[],{"trials":6353,"activeCount":102},[],{"trials":6355,"activeCount":102},[],{"trials":6357,"activeCount":102},[6358],{"nctId":6359,"briefTitle":6360,"status":248,"phases":6361,"primaryCompletion":4851,"completion":4851,"start":6362,"enrollment":6363,"conditions":6364,"interventions":6365},"NCT00744328","Postpartum Depression: Transdermal Estradiol Versus Sertraline",[93],"2008-08",85,[5159],[6346,6366],"Sertraline",{"trials":6368,"activeCount":102},[],{"intervention":6366,"totalTrials":229,"cells":6370},{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6375,"PHASE3":6377,"PHASE4":6379,"NA":6385},{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[],{"trials":6376,"activeCount":102},[],{"trials":6378,"activeCount":102},[],{"trials":6380,"activeCount":102},[6381],{"nctId":6359,"briefTitle":6360,"status":248,"phases":6382,"primaryCompletion":4851,"completion":4851,"start":6362,"enrollment":6363,"conditions":6383,"interventions":6384},[93],[5159],[6346,6366],{"trials":6386,"activeCount":102},[],{"intervention":6388,"totalTrials":229,"cells":6389},"OnabotulinumtoxinA (Botox ®) Injections",{"EARLY_PHASE1":6390,"PHASE1":6392,"PHASE2":6394,"PHASE3":6396,"PHASE4":6398,"NA":6412},{"trials":6391,"activeCount":102},[],{"trials":6393,"activeCount":102},[],{"trials":6395,"activeCount":102},[],{"trials":6397,"activeCount":102},[],{"trials":6399,"activeCount":102},[6400],{"nctId":6401,"briefTitle":6402,"status":108,"phases":6403,"primaryCompletion":6404,"completion":6404,"start":6405,"enrollment":238,"conditions":6406,"interventions":6410},"NCT02678377","The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence",[93],"2021-07-26","2016-02",[6407,6408,6409],"Mixed Urinary Incontinence","Stress Urinary Incontinence","Urgency Incontinence",[6388,6411],"Saline Injections",{"trials":6413,"activeCount":102},[],{"intervention":6411,"totalTrials":229,"cells":6415},{"EARLY_PHASE1":6416,"PHASE1":6418,"PHASE2":6420,"PHASE3":6422,"PHASE4":6424,"NA":6430},{"trials":6417,"activeCount":102},[],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"trials":6423,"activeCount":102},[],{"trials":6425,"activeCount":102},[6426],{"nctId":6401,"briefTitle":6402,"status":108,"phases":6427,"primaryCompletion":6404,"completion":6404,"start":6405,"enrollment":238,"conditions":6428,"interventions":6429},[93],[6407,6408,6409],[6388,6411],{"trials":6431,"activeCount":102},[],{"intervention":6433,"totalTrials":229,"cells":6434},"Conivaptan",{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6439,"PHASE3":6441,"PHASE4":6443,"NA":6452},{"trials":6436,"activeCount":102},[],{"trials":6438,"activeCount":102},[],{"trials":6440,"activeCount":102},[],{"trials":6442,"activeCount":102},[],{"trials":6444,"activeCount":102},[6445],{"nctId":6446,"briefTitle":6447,"status":248,"phases":6448,"primaryCompletion":1490,"completion":1221,"start":6362,"enrollment":475,"conditions":6449,"interventions":6451},"NCT00727090","Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients",[93],[6450],"Hyponatremia",[6433],{"trials":6453,"activeCount":102},[],{"intervention":6455,"totalTrials":229,"cells":6456},"Experimental Group 1 triamcinolone and lidocaine",{"EARLY_PHASE1":6457,"PHASE1":6459,"PHASE2":6461,"PHASE3":6463,"PHASE4":6465,"NA":6479},{"trials":6458,"activeCount":102},[],{"trials":6460,"activeCount":102},[],{"trials":6462,"activeCount":102},[],{"trials":6464,"activeCount":102},[],{"trials":6466,"activeCount":102},[6467],{"nctId":6468,"briefTitle":6469,"status":108,"phases":6470,"primaryCompletion":6471,"completion":6472,"start":6473,"enrollment":6474,"conditions":6475,"interventions":6477},"NCT03127137","CESI With Low Dose Lidocaine and Transient Weakness",[93],"2019-06-06","2019-06-15","2018-08-01",123,[6476,15],"Cervical Radiculitis",[6455,6478],"Experimental Group 2 triamcinolone and saline",{"trials":6480,"activeCount":102},[],{"intervention":6478,"totalTrials":229,"cells":6482},{"EARLY_PHASE1":6483,"PHASE1":6485,"PHASE2":6487,"PHASE3":6489,"PHASE4":6491,"NA":6497},{"trials":6484,"activeCount":102},[],{"trials":6486,"activeCount":102},[],{"trials":6488,"activeCount":102},[],{"trials":6490,"activeCount":102},[],{"trials":6492,"activeCount":102},[6493],{"nctId":6468,"briefTitle":6469,"status":108,"phases":6494,"primaryCompletion":6471,"completion":6472,"start":6473,"enrollment":6474,"conditions":6495,"interventions":6496},[93],[6476,15],[6455,6478],{"trials":6498,"activeCount":102},[],{"intervention":6500,"totalTrials":229,"cells":6501},"0.2% Ropivacaine",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6508,"PHASE4":6510,"NA":6522},{"trials":6503,"activeCount":102},[],{"trials":6505,"activeCount":102},[],{"trials":6507,"activeCount":102},[],{"trials":6509,"activeCount":102},[],{"trials":6511,"activeCount":102},[6512],{"nctId":6513,"briefTitle":6514,"status":108,"phases":6515,"primaryCompletion":6516,"completion":6516,"start":1490,"enrollment":5564,"conditions":6517,"interventions":6518},"NCT01170702","Transverse Abdominis Plane (TAP) Block After Cesarean Delivery",[93],"2017-01",[1697,30,27],[6519,6500,6520,6521],"0.9% Normal Saline","0.5% Ropivacaine","0.75% Ropivacaine",{"trials":6523,"activeCount":102},[],{"intervention":6520,"totalTrials":229,"cells":6525},{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6532,"PHASE4":6534,"NA":6540},{"trials":6527,"activeCount":102},[],{"trials":6529,"activeCount":102},[],{"trials":6531,"activeCount":102},[],{"trials":6533,"activeCount":102},[],{"trials":6535,"activeCount":102},[6536],{"nctId":6513,"briefTitle":6514,"status":108,"phases":6537,"primaryCompletion":6516,"completion":6516,"start":1490,"enrollment":5564,"conditions":6538,"interventions":6539},[93],[1697,30,27],[6519,6500,6520,6521],{"trials":6541,"activeCount":102},[],{"intervention":6521,"totalTrials":229,"cells":6543},{"EARLY_PHASE1":6544,"PHASE1":6546,"PHASE2":6548,"PHASE3":6550,"PHASE4":6552,"NA":6558},{"trials":6545,"activeCount":102},[],{"trials":6547,"activeCount":102},[],{"trials":6549,"activeCount":102},[],{"trials":6551,"activeCount":102},[],{"trials":6553,"activeCount":102},[6554],{"nctId":6513,"briefTitle":6514,"status":108,"phases":6555,"primaryCompletion":6516,"completion":6516,"start":1490,"enrollment":5564,"conditions":6556,"interventions":6557},[93],[1697,30,27],[6519,6500,6520,6521],{"trials":6559,"activeCount":102},[],{"intervention":6561,"totalTrials":229,"cells":6562},"Geologie Acne Regimen - one side of face",{"EARLY_PHASE1":6563,"PHASE1":6565,"PHASE2":6567,"PHASE3":6569,"PHASE4":6571,"NA":6582},{"trials":6564,"activeCount":102},[],{"trials":6566,"activeCount":102},[],{"trials":6568,"activeCount":102},[],{"trials":6570,"activeCount":102},[],{"trials":6572,"activeCount":102},[6573],{"nctId":6574,"briefTitle":6575,"status":108,"phases":6576,"primaryCompletion":5775,"completion":6577,"start":4717,"enrollment":25,"conditions":6578,"interventions":6580},"NCT05446402","Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne",[93],"2023-12-31",[6579],"Acne",[6561,6581],"Proactive Acne Regimen - other side of face",{"trials":6583,"activeCount":102},[],{"intervention":6581,"totalTrials":229,"cells":6585},{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6590,"PHASE3":6592,"PHASE4":6594,"NA":6600},{"trials":6587,"activeCount":102},[],{"trials":6589,"activeCount":102},[],{"trials":6591,"activeCount":102},[],{"trials":6593,"activeCount":102},[],{"trials":6595,"activeCount":102},[6596],{"nctId":6574,"briefTitle":6575,"status":108,"phases":6597,"primaryCompletion":5775,"completion":6577,"start":4717,"enrollment":25,"conditions":6598,"interventions":6599},[93],[6579],[6561,6581],{"trials":6601,"activeCount":102},[],{"intervention":4930,"totalTrials":229,"cells":6603},{"EARLY_PHASE1":6604,"PHASE1":6606,"PHASE2":6608,"PHASE3":6610,"PHASE4":6612,"NA":6618},{"trials":6605,"activeCount":102},[],{"trials":6607,"activeCount":102},[],{"trials":6609,"activeCount":102},[],{"trials":6611,"activeCount":102},[],{"trials":6613,"activeCount":102},[6614],{"nctId":4919,"briefTitle":4920,"status":108,"phases":6615,"primaryCompletion":4922,"completion":4923,"start":1886,"enrollment":2601,"conditions":6616,"interventions":6617},[93],[4925,4926,4927,4928],[4930,4931],{"trials":6619,"activeCount":102},[],{"intervention":6621,"totalTrials":229,"cells":6622},"armodafinil",{"EARLY_PHASE1":6623,"PHASE1":6625,"PHASE2":6627,"PHASE3":6629,"PHASE4":6631,"NA":6640},{"trials":6624,"activeCount":102},[],{"trials":6626,"activeCount":102},[],{"trials":6628,"activeCount":102},[],{"trials":6630,"activeCount":102},[],{"trials":6632,"activeCount":102},[6633],{"nctId":6634,"briefTitle":6635,"status":108,"phases":6636,"primaryCompletion":1490,"completion":1490,"start":171,"enrollment":6637,"conditions":6638,"interventions":6639},"NCT00373672","Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder",[93],58,[5240,5241],[6621],{"trials":6641,"activeCount":102},[],{"intervention":6643,"totalTrials":229,"cells":6644},"pregabalin\u002Fcelecoxib",{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6649,"PHASE3":6651,"PHASE4":6653,"NA":6666},{"trials":6646,"activeCount":102},[],{"trials":6648,"activeCount":102},[],{"trials":6650,"activeCount":102},[],{"trials":6652,"activeCount":102},[],{"trials":6654,"activeCount":102},[6655],{"nctId":6656,"briefTitle":6657,"status":248,"phases":6658,"primaryCompletion":5751,"completion":6659,"start":996,"enrollment":31,"conditions":6660,"interventions":6663},"NCT01555073","Preemptive Analgesia Following Uterine Artery Embolization",[93],"2013-10",[6661,6662],"Uterine Fibroids","Uterine Artery Embolization",[6643,6664,6665],"pregabalin\u002Fplacebo","celecoxib\u002Fplacebo",{"trials":6667,"activeCount":102},[],{"intervention":6664,"totalTrials":229,"cells":6669},{"EARLY_PHASE1":6670,"PHASE1":6672,"PHASE2":6674,"PHASE3":6676,"PHASE4":6678,"NA":6684},{"trials":6671,"activeCount":102},[],{"trials":6673,"activeCount":102},[],{"trials":6675,"activeCount":102},[],{"trials":6677,"activeCount":102},[],{"trials":6679,"activeCount":102},[6680],{"nctId":6656,"briefTitle":6657,"status":248,"phases":6681,"primaryCompletion":5751,"completion":6659,"start":996,"enrollment":31,"conditions":6682,"interventions":6683},[93],[6661,6662],[6643,6664,6665],{"trials":6685,"activeCount":102},[],{"intervention":6665,"totalTrials":229,"cells":6687},{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6692,"PHASE3":6694,"PHASE4":6696,"NA":6702},{"trials":6689,"activeCount":102},[],{"trials":6691,"activeCount":102},[],{"trials":6693,"activeCount":102},[],{"trials":6695,"activeCount":102},[],{"trials":6697,"activeCount":102},[6698],{"nctId":6656,"briefTitle":6657,"status":248,"phases":6699,"primaryCompletion":5751,"completion":6659,"start":996,"enrollment":31,"conditions":6700,"interventions":6701},[93],[6661,6662],[6643,6664,6665],{"trials":6703,"activeCount":102},[],{"intervention":6705,"totalTrials":229,"cells":6706},"Triamcinolone 80mg",{"EARLY_PHASE1":6707,"PHASE1":6709,"PHASE2":6711,"PHASE3":6713,"PHASE4":6715,"NA":6726},{"trials":6708,"activeCount":102},[],{"trials":6710,"activeCount":102},[],{"trials":6712,"activeCount":102},[],{"trials":6714,"activeCount":102},[],{"trials":6716,"activeCount":102},[6717],{"nctId":6718,"briefTitle":6719,"status":108,"phases":6720,"primaryCompletion":446,"completion":446,"start":4622,"enrollment":6721,"conditions":6722,"interventions":6725},"NCT02095197","C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain",[93],79,[6723,6724],"Radicular; Neuropathic, Cervical","Neck Pain",[6705],{"trials":6727,"activeCount":102},[],{"intervention":141,"totalTrials":6729,"cells":6730},28,{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6774,"PHASE3":6858,"PHASE4":6883,"NA":6885},{"trials":6732,"activeCount":102},[],{"trials":6734,"activeCount":102},[6735,6739,6750,6754,6758,6762,6766,6770],{"nctId":125,"briefTitle":126,"status":108,"phases":6736,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":6737,"interventions":6738},[90],[133,134,135,136,137,138,139],[141,142,97,143,144,145],{"nctId":6740,"briefTitle":6741,"status":261,"phases":6742,"primaryCompletion":6743,"completion":6743,"start":6744,"enrollment":102,"conditions":6745,"interventions":6748},"NCT00006126","Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",[90],"2001-04","1999-09",[21,2050,912,6746,6747],"Melanoma (Skin)","Testicular Germ Cell Tumor",[176,177,464,6749],"fludarabine phosphate",{"nctId":430,"briefTitle":431,"status":248,"phases":6751,"primaryCompletion":433,"completion":433,"start":434,"enrollment":253,"conditions":6752,"interventions":6753},[90],[436],[438,141,439,440,418,441],{"nctId":443,"briefTitle":444,"status":248,"phases":6755,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":6756,"interventions":6757},[90],[450],[452,141,440,439,418,441,453],{"nctId":3612,"briefTitle":3613,"status":108,"phases":6759,"primaryCompletion":3295,"completion":3295,"start":111,"enrollment":156,"conditions":6760,"interventions":6761},[90],[21],[120,177,1851,1995],{"nctId":4788,"briefTitle":4789,"status":248,"phases":6763,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":6764,"interventions":6765},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"nctId":455,"briefTitle":456,"status":108,"phases":6767,"primaryCompletion":458,"completion":458,"start":111,"conditions":6768,"interventions":6769},[90],[113,114,115,24,116,117,118,460],[462,120,463,177,464,122,465],{"nctId":3432,"briefTitle":3433,"status":248,"phases":6771,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":6772,"interventions":6773},[90],[3436],[438,517,141,3438,3439,3440,3348],{"trials":6775,"activeCount":102},[6776,6780,6788,6792,6796,6802,6806,6810,6814,6821,6828,6834,6843,6850,6854],{"nctId":149,"briefTitle":150,"status":151,"phases":6777,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":6778,"interventions":6779},[90,91],[158,159,160,161,162,163,139,164],[141,142,166,97,143,145],{"nctId":6781,"briefTitle":6782,"status":108,"phases":6783,"primaryCompletion":6784,"completion":6784,"start":6785,"conditions":6786,"interventions":6787},"NCT00004908","Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma",[91],"2002-06","1999-11",[24],[177],{"nctId":1741,"briefTitle":1742,"status":261,"phases":6789,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":6790,"interventions":6791},[91],[1746],[517,141,440,1732,441,1748,1749],{"nctId":168,"briefTitle":169,"status":108,"phases":6793,"primaryCompletion":171,"completion":171,"start":111,"conditions":6794,"interventions":6795},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":6797,"briefTitle":6798,"status":108,"phases":6799,"primaryCompletion":6784,"completion":6784,"start":111,"conditions":6800,"interventions":6801},"NCT00004171","Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma",[91],[24],[176,177],{"nctId":484,"briefTitle":485,"status":248,"phases":6803,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":6804,"interventions":6805},[90,91],[491],[493,141,440,494,418,441,453],{"nctId":1988,"briefTitle":1989,"status":108,"phases":6807,"primaryCompletion":1991,"completion":1991,"start":111,"conditions":6808,"interventions":6809},[91],[21],[120,1540,177,1994,1995],{"nctId":198,"briefTitle":199,"status":200,"phases":6811,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":6812,"interventions":6813},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"nctId":6815,"briefTitle":6816,"status":108,"phases":6817,"primaryCompletion":6818,"completion":6818,"start":111,"enrollment":475,"conditions":6819,"interventions":6820},"NCT00004898","Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia",[90,91],"2003-07",[115,24],[120,177,464],{"nctId":6822,"briefTitle":6823,"status":108,"phases":6824,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":6826,"interventions":6827},"NCT00004181","Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia",[91],"2004-08",[113,115,116],[176,177],{"nctId":6829,"briefTitle":6830,"status":108,"phases":6831,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":6832,"interventions":6833},"NCT00004907","Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma",[90,91],[24],[176,177,464],{"nctId":6835,"briefTitle":6836,"status":108,"phases":6837,"primaryCompletion":6838,"completion":6839,"start":6840,"conditions":6841,"interventions":6842},"NCT00004175","Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer",[91],"2004-09","2005-06","1998-11",[21],[177,914,179],{"nctId":6844,"briefTitle":6845,"status":108,"phases":6846,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":6847,"interventions":6849},"NCT00004896","Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",[91],[115,117,6848],"Myelodysplastic\u002FMyeloproliferative Diseases",[176,177],{"nctId":2023,"briefTitle":2024,"status":108,"phases":6851,"primaryCompletion":1492,"completion":1492,"start":2026,"conditions":6852,"interventions":6853},[91],[24],[1540,177,464],{"nctId":496,"briefTitle":497,"status":108,"phases":6855,"primaryCompletion":499,"completion":499,"start":500,"enrollment":419,"conditions":6856,"interventions":6857},[90,91],[502],[141,441,494,440,143,418],{"trials":6859,"activeCount":102},[6860,6864,6871,6875,6879],{"nctId":507,"briefTitle":508,"status":248,"phases":6861,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":6862,"interventions":6863},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":6865,"briefTitle":6866,"status":108,"phases":6867,"primaryCompletion":1972,"completion":1972,"start":111,"enrollment":22,"conditions":6868,"interventions":6869},"NCT00004230","Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation",[92],[35],[6870,177],"captopril",{"nctId":521,"briefTitle":522,"status":248,"phases":6872,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":6873,"interventions":6874},[92],[528],[141,440,494,418,441,518,519],{"nctId":531,"briefTitle":532,"status":248,"phases":6876,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":6877,"interventions":6878},[92],[539],[541,141,440,494,418,542,517],{"nctId":544,"briefTitle":545,"status":261,"phases":6880,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":6881,"interventions":6882},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":6884,"activeCount":102},[],{"trials":6886,"activeCount":102},[],{"intervention":143,"totalTrials":419,"cells":6888},{"EARLY_PHASE1":6889,"PHASE1":6900,"PHASE2":6918,"PHASE3":7064,"PHASE4":7074,"NA":7076},{"trials":6890,"activeCount":102},[6891],{"nctId":6892,"briefTitle":6893,"status":261,"phases":6894,"start":1885,"enrollment":102,"conditions":6895,"interventions":6896},"NCT00734773","Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL",[89],[1495,24,4843],[143,212,215,6897,6898,6899],"Motexafin gadolinium","Procarbazine hydrochloride","Vincristine sulfate",{"trials":6901,"activeCount":102},[6902,6906],{"nctId":125,"briefTitle":126,"status":108,"phases":6903,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":6904,"interventions":6905},[90],[133,134,135,136,137,138,139],[141,142,97,143,144,145],{"nctId":6907,"briefTitle":6908,"status":108,"phases":6909,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":537,"conditions":6913,"interventions":6914},"NCT00058292","Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2006-06","2009-03","2000-04",[24],[120,6915,6916,178,464,6917],"rituximab","Carmustine","melphalan",{"trials":6919,"activeCount":102},[6920,6924,6928,6938,6942,6946,6950,6960],{"nctId":149,"briefTitle":150,"status":151,"phases":6921,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":6922,"interventions":6923},[90,91],[158,159,160,161,162,163,139,164],[141,142,166,97,143,145],{"nctId":3530,"briefTitle":3531,"status":261,"phases":6925,"primaryCompletion":3533,"completion":3534,"start":3535,"enrollment":102,"conditions":6926,"interventions":6927},[91],[3537,3538,3539,3540,3541],[166,143,3543],{"nctId":6929,"briefTitle":6930,"status":248,"phases":6931,"primaryCompletion":6932,"completion":6933,"start":6934,"enrollment":3314,"conditions":6935,"interventions":6936},"NCT00372905","Phase I\u002FII Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma",[90,91],"2010-06-22","2013-07-08","2007-07-24",[24],[6915,2085,6937],"Ibritumomab tiuxetan",{"nctId":198,"briefTitle":199,"status":200,"phases":6939,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":6940,"interventions":6941},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"nctId":1770,"briefTitle":1771,"status":108,"phases":6943,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":156,"conditions":6944,"interventions":6945},[91],[115],[1732,143],{"nctId":496,"briefTitle":497,"status":108,"phases":6947,"primaryCompletion":499,"completion":499,"start":500,"enrollment":419,"conditions":6948,"interventions":6949},[90,91],[502],[141,441,494,440,143,418],{"nctId":6951,"briefTitle":6952,"status":108,"phases":6953,"primaryCompletion":6954,"completion":6955,"start":6956,"enrollment":2762,"conditions":6957,"interventions":6959},"NCT00369707","Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL",[91],"2012-05-22","2014-10-10","2006-08-09",[6958],"Non-Hodgkin's Lymphoma",[143,2085],{"nctId":6961,"briefTitle":6962,"status":248,"phases":6963,"primaryCompletion":3594,"completion":1905,"start":6964,"enrollment":224,"conditions":6965,"interventions":7063},"NCT01805037","Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w\u002F CD30+ and\u002For EBV+ Lymphomas",[90,91],"2013-03-05",[6966,2214,2215,2216,6967,6968,6969,6970,6971,6972,6973,6974,6975,6976,6977,6978,6979,6980,6981,2217,6982,6983,6984,6985,6986,6987,6988,6989,6990,6991,6992,6993,6994,6995,6996,2218,6997,6998,6999,7000,7001,7002,7003,7004,7005,7006,7007,7008,7009,7010,7011,7012,7013,7014,7015,7016,7017,7018,7019,7020,7021,7022,7023,7024,7025,2219,7026,7027,7028,7029,7030,7031,2220,2221,2326,7032,2222,2223,2224,7033,7034,7035,7036,2327,7037,7038,7039,2225,7040,7041,7042,7043,7044,7045,2226,2227,7046,7047,7048,7049,2328,7050,7051,7052,2228,7053,7054,7055,7056,7057,7058,2229,2230,7059,7060,7061,7062],"Adult Grade III Lymphomatoid Granulomatosis","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Epstein-Barr Virus Infection","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Noncutaneous Extranodal Lymphoma","Post-transplant Lymphoproliferative Disorder","Progressive Hairy Cell Leukemia, Initial Treatment","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Adult T-cell Leukemia\u002FLymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Small Lymphocytic Lymphoma","Stage II Adult T-cell Leukemia\u002FLymphoma","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Small Lymphocytic Lymphoma","T-cell Large Granular Lymphocyte Leukemia","Testicular Lymphoma","Untreated Hairy Cell Leukemia","Waldenström Macroglobulinemia",[2330,6915],{"trials":7065,"activeCount":102},[7066,7070],{"nctId":507,"briefTitle":508,"status":248,"phases":7067,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7068,"interventions":7069},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":544,"briefTitle":545,"status":261,"phases":7071,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":7072,"interventions":7073},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":7075,"activeCount":102},[],{"trials":7077,"activeCount":102},[],{"intervention":120,"totalTrials":419,"cells":7079},{"EARLY_PHASE1":7080,"PHASE1":7082,"PHASE2":7131,"PHASE3":7159,"PHASE4":7171,"NA":7173},{"trials":7081,"activeCount":102},[],{"trials":7083,"activeCount":102},[7084,7088,7107,7111,7115,7127],{"nctId":106,"briefTitle":107,"status":108,"phases":7085,"primaryCompletion":110,"completion":110,"start":111,"conditions":7086,"interventions":7087},[90],[113,114,115,24,116,117,118],[120,121,122,123],{"nctId":7089,"briefTitle":7090,"status":248,"phases":7091,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":273,"conditions":7095,"interventions":7103},"NCT04250051","Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia",[90],"2022-01-16","2022-12-20","2020-12-21",[7096,7097,7098,3915,7099,7100,7101,7102],"Recurrent Acute Myeloid Leukemia","Recurrent Myelodysplastic Syndrome","Recurrent Myeloproliferative Neoplasm","Refractory Myelodysplastic Syndrome","Newly Diagnosed Acute Myeloid Leukemia (AML)","IDH1 Mutation Myeloid Neoplasms","Acute Myeloid Leukemia (AML)",[212,542,517,7104,7105,7106],"Fludarabine Phosphate","Ivosidenib","Idarubicin",{"nctId":3612,"briefTitle":3613,"status":108,"phases":7108,"primaryCompletion":3295,"completion":3295,"start":111,"enrollment":156,"conditions":7109,"interventions":7110},[90],[21],[120,177,1851,1995],{"nctId":455,"briefTitle":456,"status":108,"phases":7112,"primaryCompletion":458,"completion":458,"start":111,"conditions":7113,"interventions":7114},[90],[113,114,115,24,116,117,118,460],[462,120,463,177,464,122,465],{"nctId":7116,"briefTitle":7117,"status":248,"phases":7118,"primaryCompletion":7119,"completion":7119,"start":6744,"enrollment":375,"conditions":7120,"interventions":7122},"NCT00005787","Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2002-01",[24,7121],"Neutropenia",[7123,120,7124,7125,7126],"epoetin alfa","recombinant flt3 ligand","recombinant interleukin-3","sargramostim",{"nctId":6907,"briefTitle":6908,"status":108,"phases":7128,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":537,"conditions":7129,"interventions":7130},[90],[24],[120,6915,6916,178,464,6917],{"trials":7132,"activeCount":102},[7133,7137,7141,7145,7153],{"nctId":168,"briefTitle":169,"status":108,"phases":7134,"primaryCompletion":171,"completion":171,"start":111,"conditions":7135,"interventions":7136},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":1988,"briefTitle":1989,"status":108,"phases":7138,"primaryCompletion":1991,"completion":1991,"start":111,"conditions":7139,"interventions":7140},[91],[21],[120,1540,177,1994,1995],{"nctId":6815,"briefTitle":6816,"status":108,"phases":7142,"primaryCompletion":6818,"completion":6818,"start":111,"enrollment":475,"conditions":7143,"interventions":7144},[90,91],[115,24],[120,177,464],{"nctId":7146,"briefTitle":7147,"status":108,"phases":7148,"primaryCompletion":7149,"completion":7149,"start":6785,"conditions":7150,"interventions":7151},"NCT00006225","Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer",[90,91],"2004-01",[21,115,24,116,6848],[120,7124,7152,7125],"recombinant human thrombopoietin",{"nctId":7154,"briefTitle":7155,"status":108,"phases":7156,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":7157,"interventions":7158},"NCT00004899","Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",[91],[115,117,6848],[120,176,464],{"trials":7160,"activeCount":102},[7161,7167],{"nctId":7162,"briefTitle":7163,"status":108,"phases":7164,"primaryCompletion":4791,"completion":4791,"start":111,"conditions":7165,"interventions":7166},"NCT00004165","Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[92],[116],[120,6917],{"nctId":531,"briefTitle":532,"status":248,"phases":7168,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":7169,"interventions":7170},[92],[539],[541,141,440,494,418,542,517],{"trials":7172,"activeCount":102},[],{"trials":7174,"activeCount":102},[],{"intervention":440,"totalTrials":98,"cells":7176},{"EARLY_PHASE1":7177,"PHASE1":7179,"PHASE2":7193,"PHASE3":7207,"PHASE4":7225,"NA":7227},{"trials":7178,"activeCount":102},[],{"trials":7180,"activeCount":102},[7181,7185,7189],{"nctId":430,"briefTitle":431,"status":248,"phases":7182,"primaryCompletion":433,"completion":433,"start":434,"enrollment":253,"conditions":7183,"interventions":7184},[90],[436],[438,141,439,440,418,441],{"nctId":443,"briefTitle":444,"status":248,"phases":7186,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":7187,"interventions":7188},[90],[450],[452,141,440,439,418,441,453],{"nctId":4788,"briefTitle":4789,"status":248,"phases":7190,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":7191,"interventions":7192},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"trials":7194,"activeCount":102},[7195,7199,7203],{"nctId":1741,"briefTitle":1742,"status":261,"phases":7196,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":7197,"interventions":7198},[91],[1746],[517,141,440,1732,441,1748,1749],{"nctId":484,"briefTitle":485,"status":248,"phases":7200,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":7201,"interventions":7202},[90,91],[491],[493,141,440,494,418,441,453],{"nctId":496,"briefTitle":497,"status":108,"phases":7204,"primaryCompletion":499,"completion":499,"start":500,"enrollment":419,"conditions":7205,"interventions":7206},[90,91],[502],[141,441,494,440,143,418],{"trials":7208,"activeCount":102},[7209,7213,7217,7221],{"nctId":507,"briefTitle":508,"status":248,"phases":7210,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7211,"interventions":7212},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":521,"briefTitle":522,"status":248,"phases":7214,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":7215,"interventions":7216},[92],[528],[141,440,494,418,441,518,519],{"nctId":531,"briefTitle":532,"status":248,"phases":7218,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":7219,"interventions":7220},[92],[539],[541,141,440,494,418,542,517],{"nctId":544,"briefTitle":545,"status":261,"phases":7222,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":7223,"interventions":7224},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":7226,"activeCount":102},[],{"trials":7228,"activeCount":102},[],{"intervention":441,"totalTrials":253,"cells":7230},{"EARLY_PHASE1":7231,"PHASE1":7233,"PHASE2":7247,"PHASE3":7261,"PHASE4":7275,"NA":7277},{"trials":7232,"activeCount":102},[],{"trials":7234,"activeCount":102},[7235,7239,7243],{"nctId":430,"briefTitle":431,"status":248,"phases":7236,"primaryCompletion":433,"completion":433,"start":434,"enrollment":253,"conditions":7237,"interventions":7238},[90],[436],[438,141,439,440,418,441],{"nctId":443,"briefTitle":444,"status":248,"phases":7240,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":7241,"interventions":7242},[90],[450],[452,141,440,439,418,441,453],{"nctId":4788,"briefTitle":4789,"status":248,"phases":7244,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":7245,"interventions":7246},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"trials":7248,"activeCount":102},[7249,7253,7257],{"nctId":1741,"briefTitle":1742,"status":261,"phases":7250,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":7251,"interventions":7252},[91],[1746],[517,141,440,1732,441,1748,1749],{"nctId":484,"briefTitle":485,"status":248,"phases":7254,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":7255,"interventions":7256},[90,91],[491],[493,141,440,494,418,441,453],{"nctId":496,"briefTitle":497,"status":108,"phases":7258,"primaryCompletion":499,"completion":499,"start":500,"enrollment":419,"conditions":7259,"interventions":7260},[90,91],[502],[141,441,494,440,143,418],{"trials":7262,"activeCount":102},[7263,7267,7271],{"nctId":507,"briefTitle":508,"status":248,"phases":7264,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7265,"interventions":7266},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":521,"briefTitle":522,"status":248,"phases":7268,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":7269,"interventions":7270},[92],[528],[141,440,494,418,441,518,519],{"nctId":544,"briefTitle":545,"status":261,"phases":7272,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":7273,"interventions":7274},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":7276,"activeCount":102},[],{"trials":7278,"activeCount":102},[],{"intervention":517,"totalTrials":475,"cells":7280},{"EARLY_PHASE1":7281,"PHASE1":7283,"PHASE2":7297,"PHASE3":7303,"PHASE4":7313,"NA":7315},{"trials":7282,"activeCount":102},[],{"trials":7284,"activeCount":102},[7285,7289,7293],{"nctId":7089,"briefTitle":7090,"status":248,"phases":7286,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":273,"conditions":7287,"interventions":7288},[90],[7096,7097,7098,3915,7099,7100,7101,7102],[212,542,517,7104,7105,7106],{"nctId":4788,"briefTitle":4789,"status":248,"phases":7290,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":7291,"interventions":7292},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"nctId":3432,"briefTitle":3433,"status":248,"phases":7294,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":7295,"interventions":7296},[90],[3436],[438,517,141,3438,3439,3440,3348],{"trials":7298,"activeCount":102},[7299],{"nctId":1741,"briefTitle":1742,"status":261,"phases":7300,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":7301,"interventions":7302},[91],[1746],[517,141,440,1732,441,1748,1749],{"trials":7304,"activeCount":102},[7305,7309],{"nctId":507,"briefTitle":508,"status":248,"phases":7306,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7307,"interventions":7308},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":531,"briefTitle":532,"status":248,"phases":7310,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":7311,"interventions":7312},[92],[539],[541,141,440,494,418,542,517],{"trials":7314,"activeCount":102},[],{"trials":7316,"activeCount":102},[],{"intervention":494,"totalTrials":475,"cells":7318},{"EARLY_PHASE1":7319,"PHASE1":7321,"PHASE2":7323,"PHASE3":7333,"PHASE4":7351,"NA":7353},{"trials":7320,"activeCount":102},[],{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":102},[7325,7329],{"nctId":484,"briefTitle":485,"status":248,"phases":7326,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":7327,"interventions":7328},[90,91],[491],[493,141,440,494,418,441,453],{"nctId":496,"briefTitle":497,"status":108,"phases":7330,"primaryCompletion":499,"completion":499,"start":500,"enrollment":419,"conditions":7331,"interventions":7332},[90,91],[502],[141,441,494,440,143,418],{"trials":7334,"activeCount":102},[7335,7339,7343,7347],{"nctId":507,"briefTitle":508,"status":248,"phases":7336,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7337,"interventions":7338},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":521,"briefTitle":522,"status":248,"phases":7340,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":7341,"interventions":7342},[92],[528],[141,440,494,418,441,518,519],{"nctId":531,"briefTitle":532,"status":248,"phases":7344,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":7345,"interventions":7346},[92],[539],[541,141,440,494,418,542,517],{"nctId":544,"briefTitle":545,"status":261,"phases":7348,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":7349,"interventions":7350},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":7352,"activeCount":102},[],{"trials":7354,"activeCount":102},[],{"intervention":518,"totalTrials":375,"cells":7356},{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7361,"PHASE3":7363,"PHASE4":7377,"NA":7379},{"trials":7358,"activeCount":102},[],{"trials":7360,"activeCount":102},[],{"trials":7362,"activeCount":102},[],{"trials":7364,"activeCount":102},[7365,7369,7373],{"nctId":507,"briefTitle":508,"status":248,"phases":7366,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7367,"interventions":7368},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":521,"briefTitle":522,"status":248,"phases":7370,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":7371,"interventions":7372},[92],[528],[141,440,494,418,441,518,519],{"nctId":544,"briefTitle":545,"status":261,"phases":7374,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":7375,"interventions":7376},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":7378,"activeCount":102},[],{"trials":7380,"activeCount":102},[],{"intervention":519,"totalTrials":375,"cells":7382},{"EARLY_PHASE1":7383,"PHASE1":7385,"PHASE2":7387,"PHASE3":7389,"PHASE4":7403,"NA":7405},{"trials":7384,"activeCount":102},[],{"trials":7386,"activeCount":102},[],{"trials":7388,"activeCount":102},[],{"trials":7390,"activeCount":102},[7391,7395,7399],{"nctId":507,"briefTitle":508,"status":248,"phases":7392,"primaryCompletion":510,"completion":511,"start":512,"enrollment":253,"conditions":7393,"interventions":7394},[91,92],[514,515],[143,517,141,440,494,418,441,518,519],{"nctId":521,"briefTitle":522,"status":248,"phases":7396,"primaryCompletion":524,"completion":511,"start":525,"enrollment":526,"conditions":7397,"interventions":7398},[92],[528],[141,440,494,418,441,518,519],{"nctId":544,"briefTitle":545,"status":261,"phases":7400,"primaryCompletion":547,"completion":548,"start":549,"enrollment":102,"conditions":7401,"interventions":7402},[91,92],[551,502,552],[143,141,440,494,418,441,518,519],{"trials":7404,"activeCount":102},[],{"trials":7406,"activeCount":102},[],{"intervention":6870,"totalTrials":273,"cells":7408},{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7413,"PHASE3":7423,"PHASE4":7429,"NA":7431},{"trials":7410,"activeCount":102},[],{"trials":7412,"activeCount":102},[],{"trials":7414,"activeCount":102},[7415],{"nctId":7416,"briefTitle":7417,"status":108,"phases":7418,"primaryCompletion":7419,"completion":7419,"start":6818,"conditions":7420,"interventions":7421},"NCT00086723","In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer",[90,91],"2006-01",[1500],[7422,6870],"recombinant tissue plasminogen activator",{"trials":7424,"activeCount":102},[7425],{"nctId":6865,"briefTitle":6866,"status":108,"phases":7426,"primaryCompletion":1972,"completion":1972,"start":111,"enrollment":22,"conditions":7427,"interventions":7428},[92],[35],[6870,177],{"trials":7430,"activeCount":102},[],{"trials":7432,"activeCount":102},[],{"intervention":7434,"totalTrials":273,"cells":7435},"Hydroxyurea",{"EARLY_PHASE1":7436,"PHASE1":7438,"PHASE2":7440,"PHASE3":7446,"PHASE4":7458,"NA":7460},{"trials":7437,"activeCount":102},[],{"trials":7439,"activeCount":102},[],{"trials":7441,"activeCount":102},[7442],{"nctId":2156,"briefTitle":2157,"status":248,"phases":7443,"primaryCompletion":2159,"completion":1846,"start":111,"conditions":7444,"interventions":7445},[91],[2161],[175,2073,2135,2163,180],{"trials":7447,"activeCount":102},[7448],{"nctId":7449,"briefTitle":7450,"status":108,"phases":7451,"enrollment":238,"conditions":7452,"interventions":7454},"NCT00002230","A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients",[92],[7453],"HIV Infections",[7434,7455,7456,7457],"Efavirenz","Stavudine","Didanosine",{"trials":7459,"activeCount":102},[],{"trials":7461,"activeCount":102},[],{"intervention":7463,"totalTrials":273,"cells":7464},"zoledronic acid",{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7483,"PHASE4":7493,"NA":7495},{"trials":7466,"activeCount":102},[],{"trials":7468,"activeCount":102},[],{"trials":7470,"activeCount":102},[7471],{"nctId":7472,"briefTitle":7473,"status":108,"phases":7474,"primaryCompletion":7475,"completion":7475,"start":5020,"enrollment":341,"conditions":7476,"interventions":7481},"NCT02325414","Prevention of Bone Loss After Acute SCI by Zoledronic Acid",[91],"2020-08-25",[7477,7478,7479,7480],"Spinal Cord Injury","Acute Spinal Cord Injury","Bone Loss","Osteoporosis",[7482],"Zoledronic acid",{"trials":7484,"activeCount":102},[7485],{"nctId":7486,"briefTitle":7487,"status":248,"phases":7488,"primaryCompletion":1885,"completion":1885,"start":7489,"enrollment":1426,"conditions":7490,"interventions":7491},"NCT00058188","Zolendronate for the Prevention of Bone Loss in Men w\u002F Prostate CA on Long-Term Androgen Deprivation",[92],"2003-03",[7480,4124],[7492,7463],"calcium gluconate",{"trials":7494,"activeCount":102},[],{"trials":7496,"activeCount":102},[],{"intervention":6917,"totalTrials":273,"cells":7498},{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7507,"PHASE3":7509,"PHASE4":7515,"NA":7517},{"trials":7500,"activeCount":102},[],{"trials":7502,"activeCount":102},[7503],{"nctId":6907,"briefTitle":6908,"status":108,"phases":7504,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":537,"conditions":7505,"interventions":7506},[90],[24],[120,6915,6916,178,464,6917],{"trials":7508,"activeCount":102},[],{"trials":7510,"activeCount":102},[7511],{"nctId":7162,"briefTitle":7163,"status":108,"phases":7512,"primaryCompletion":4791,"completion":4791,"start":111,"conditions":7513,"interventions":7514},[92],[116],[120,6917],{"trials":7516,"activeCount":102},[],{"trials":7518,"activeCount":102},[],{"intervention":7520,"totalTrials":229,"cells":7521},"Nicotinamide riboside",{"EARLY_PHASE1":7522,"PHASE1":7524,"PHASE2":7526,"PHASE3":7528,"PHASE4":7538,"NA":7540},{"trials":7523,"activeCount":102},[],{"trials":7525,"activeCount":102},[],{"trials":7527,"activeCount":102},[],{"trials":7529,"activeCount":102},[7530],{"nctId":7531,"briefTitle":7532,"status":108,"phases":7533,"primaryCompletion":56,"completion":56,"start":7534,"enrollment":755,"conditions":7535,"interventions":7536},"NCT03743636","Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease",[92],"2018-10-01",[1022],[7520,7537],"Resveratrol",{"trials":7539,"activeCount":102},[],{"trials":7541,"activeCount":102},[],{"intervention":7543,"totalTrials":229,"cells":7544},"Dutasteride",{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7549,"PHASE3":7551,"PHASE4":7560,"NA":7562},{"trials":7546,"activeCount":102},[],{"trials":7548,"activeCount":102},[],{"trials":7550,"activeCount":102},[],{"trials":7552,"activeCount":102},[7553],{"nctId":7554,"briefTitle":7555,"status":248,"phases":7556,"primaryCompletion":1786,"completion":1786,"start":5432,"enrollment":582,"conditions":7557,"interventions":7559},"NCT00431626","A Clinical Trial Comparing Laser TURP With and Without Dutasteride.",[92],[7558],"Benign Prostatic Hyperplasia",[7543],{"trials":7561,"activeCount":102},[],{"trials":7563,"activeCount":102},[],{"intervention":7455,"totalTrials":229,"cells":7565},{"EARLY_PHASE1":7566,"PHASE1":7568,"PHASE2":7570,"PHASE3":7572,"PHASE4":7578,"NA":7580},{"trials":7567,"activeCount":102},[],{"trials":7569,"activeCount":102},[],{"trials":7571,"activeCount":102},[],{"trials":7573,"activeCount":102},[7574],{"nctId":7449,"briefTitle":7450,"status":108,"phases":7575,"enrollment":238,"conditions":7576,"interventions":7577},[92],[7453],[7434,7455,7456,7457],{"trials":7579,"activeCount":102},[],{"trials":7581,"activeCount":102},[],{"intervention":7456,"totalTrials":229,"cells":7583},{"EARLY_PHASE1":7584,"PHASE1":7586,"PHASE2":7588,"PHASE3":7590,"PHASE4":7596,"NA":7598},{"trials":7585,"activeCount":102},[],{"trials":7587,"activeCount":102},[],{"trials":7589,"activeCount":102},[],{"trials":7591,"activeCount":102},[7592],{"nctId":7449,"briefTitle":7450,"status":108,"phases":7593,"enrollment":238,"conditions":7594,"interventions":7595},[92],[7453],[7434,7455,7456,7457],{"trials":7597,"activeCount":102},[],{"trials":7599,"activeCount":102},[],{"intervention":7457,"totalTrials":229,"cells":7601},{"EARLY_PHASE1":7602,"PHASE1":7604,"PHASE2":7606,"PHASE3":7608,"PHASE4":7614,"NA":7616},{"trials":7603,"activeCount":102},[],{"trials":7605,"activeCount":102},[],{"trials":7607,"activeCount":102},[],{"trials":7609,"activeCount":102},[7610],{"nctId":7449,"briefTitle":7450,"status":108,"phases":7611,"enrollment":238,"conditions":7612,"interventions":7613},[92],[7453],[7434,7455,7456,7457],{"trials":7615,"activeCount":102},[],{"trials":7617,"activeCount":102},[],{"intervention":4591,"totalTrials":229,"cells":7619},{"EARLY_PHASE1":7620,"PHASE1":7622,"PHASE2":7624,"PHASE3":7626,"PHASE4":7632,"NA":7634},{"trials":7621,"activeCount":102},[],{"trials":7623,"activeCount":102},[],{"trials":7625,"activeCount":102},[],{"trials":7627,"activeCount":102},[7628],{"nctId":4583,"briefTitle":4584,"status":108,"phases":7629,"primaryCompletion":4567,"completion":4586,"start":4587,"enrollment":341,"conditions":7630,"interventions":7631},[92],[4589],[4591,609],{"trials":7633,"activeCount":102},[],{"trials":7635,"activeCount":102},[],{"intervention":7492,"totalTrials":229,"cells":7637},{"EARLY_PHASE1":7638,"PHASE1":7640,"PHASE2":7642,"PHASE3":7644,"PHASE4":7650,"NA":7652},{"trials":7639,"activeCount":102},[],{"trials":7641,"activeCount":102},[],{"trials":7643,"activeCount":102},[],{"trials":7645,"activeCount":102},[7646],{"nctId":7486,"briefTitle":7487,"status":248,"phases":7647,"primaryCompletion":1885,"completion":1885,"start":7489,"enrollment":1426,"conditions":7648,"interventions":7649},[92],[7480,4124],[7492,7463],{"trials":7651,"activeCount":102},[],{"trials":7653,"activeCount":102},[],{"intervention":7655,"totalTrials":229,"cells":7656},"Clopidogrel",{"EARLY_PHASE1":7657,"PHASE1":7659,"PHASE2":7661,"PHASE3":7663,"PHASE4":7675,"NA":7677},{"trials":7658,"activeCount":102},[],{"trials":7660,"activeCount":102},[],{"trials":7662,"activeCount":102},[],{"trials":7664,"activeCount":102},[7665],{"nctId":7666,"briefTitle":7667,"status":108,"phases":7668,"primaryCompletion":1796,"completion":997,"start":2159,"enrollment":7669,"conditions":7670,"interventions":7672},"NCT01586975","Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events",[91,92],93,[4099,7671],"Myocardial Infarctions",[7655,7673,7674],"Aspirin 81 mg","Aspirin >300 mg",{"trials":7676,"activeCount":102},[],{"trials":7678,"activeCount":102},[],{"intervention":7673,"totalTrials":229,"cells":7680},{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7685,"PHASE3":7687,"PHASE4":7693,"NA":7695},{"trials":7682,"activeCount":102},[],{"trials":7684,"activeCount":102},[],{"trials":7686,"activeCount":102},[],{"trials":7688,"activeCount":102},[7689],{"nctId":7666,"briefTitle":7667,"status":108,"phases":7690,"primaryCompletion":1796,"completion":997,"start":2159,"enrollment":7669,"conditions":7691,"interventions":7692},[91,92],[4099,7671],[7655,7673,7674],{"trials":7694,"activeCount":102},[],{"trials":7696,"activeCount":102},[],{"intervention":7674,"totalTrials":229,"cells":7698},{"EARLY_PHASE1":7699,"PHASE1":7701,"PHASE2":7703,"PHASE3":7705,"PHASE4":7711,"NA":7713},{"trials":7700,"activeCount":102},[],{"trials":7702,"activeCount":102},[],{"trials":7704,"activeCount":102},[],{"trials":7706,"activeCount":102},[7707],{"nctId":7666,"briefTitle":7667,"status":108,"phases":7708,"primaryCompletion":1796,"completion":997,"start":2159,"enrollment":7669,"conditions":7709,"interventions":7710},[91,92],[4099,7671],[7655,7673,7674],{"trials":7712,"activeCount":102},[],{"trials":7714,"activeCount":102},[],{"intervention":7716,"totalTrials":229,"cells":7717},"Gadolinium",{"EARLY_PHASE1":7718,"PHASE1":7720,"PHASE2":7722,"PHASE3":7724,"PHASE4":7737,"NA":7739},{"trials":7719,"activeCount":102},[],{"trials":7721,"activeCount":102},[],{"trials":7723,"activeCount":102},[],{"trials":7725,"activeCount":102},[7726],{"nctId":7727,"briefTitle":7728,"status":108,"phases":7729,"primaryCompletion":7730,"completion":7730,"start":7731,"enrollment":402,"conditions":7732,"interventions":7735},"NCT01234870","Comprehensive Evaluation of Ischemic Heart Disease Using MRI",[91,92],"2012-01","2010-06",[7733,7734],"Heart Disease, Ischemic","Atherosclerosis, Coronary",[7716,7736],"Adenosine",{"trials":7738,"activeCount":102},[],{"trials":7740,"activeCount":102},[],{"intervention":7736,"totalTrials":229,"cells":7742},{"EARLY_PHASE1":7743,"PHASE1":7745,"PHASE2":7747,"PHASE3":7749,"PHASE4":7755,"NA":7757},{"trials":7744,"activeCount":102},[],{"trials":7746,"activeCount":102},[],{"trials":7748,"activeCount":102},[],{"trials":7750,"activeCount":102},[7751],{"nctId":7727,"briefTitle":7728,"status":108,"phases":7752,"primaryCompletion":7730,"completion":7730,"start":7731,"enrollment":402,"conditions":7753,"interventions":7754},[91,92],[7733,7734],[7716,7736],{"trials":7756,"activeCount":102},[],{"trials":7758,"activeCount":102},[],{"intervention":7760,"totalTrials":229,"cells":7761},"Ramelteon",{"EARLY_PHASE1":7762,"PHASE1":7764,"PHASE2":7766,"PHASE3":7768,"PHASE4":7779,"NA":7781},{"trials":7763,"activeCount":102},[],{"trials":7765,"activeCount":102},[],{"trials":7767,"activeCount":102},[],{"trials":7769,"activeCount":102},[7770],{"nctId":7771,"briefTitle":7772,"status":248,"phases":7773,"primaryCompletion":7774,"completion":7774,"start":5237,"enrollment":273,"conditions":7775,"interventions":7778},"NCT00869167","Ramelteon for Insomnia Comorbid With Asthma",[92],"2009-06",[7776,7777],"Insomnia","Asthma",[7760],{"trials":7780,"activeCount":102},[],{"trials":7782,"activeCount":102},[],{"intervention":7784,"totalTrials":229,"cells":7785},"amifostine trihydrate",{"EARLY_PHASE1":7786,"PHASE1":7788,"PHASE2":7790,"PHASE3":7792,"PHASE4":7803,"NA":7805},{"trials":7787,"activeCount":102},[],{"trials":7789,"activeCount":102},[],{"trials":7791,"activeCount":102},[],{"trials":7793,"activeCount":102},[7794],{"nctId":7795,"briefTitle":7796,"status":108,"phases":7797,"primaryCompletion":7798,"completion":7798,"start":111,"conditions":7799,"interventions":7802},"NCT00004166","Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy",[92],"2003-01",[7800,7801],"Ovarian Cancer","Quality of Life",[7784],{"trials":7804,"activeCount":102},[],{"trials":7806,"activeCount":102},[],{"intervention":7808,"totalTrials":229,"cells":7809},"aripiprazole",{"EARLY_PHASE1":7810,"PHASE1":7812,"PHASE2":7814,"PHASE3":7816,"PHASE4":7827,"NA":7829},{"trials":7811,"activeCount":102},[],{"trials":7813,"activeCount":102},[],{"trials":7815,"activeCount":102},[],{"trials":7817,"activeCount":102},[7818],{"nctId":7819,"briefTitle":7820,"status":248,"phases":7821,"primaryCompletion":7822,"completion":7822,"start":7419,"enrollment":4122,"conditions":7823,"interventions":7825},"NCT00288353","Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes",[92],"2008-12",[5240,5241,7824],"Bipolar Disorder",[7808,7826],"ziprasidone",{"trials":7828,"activeCount":102},[],{"trials":7830,"activeCount":102},[],{"intervention":7826,"totalTrials":229,"cells":7832},{"EARLY_PHASE1":7833,"PHASE1":7835,"PHASE2":7837,"PHASE3":7839,"PHASE4":7845,"NA":7847},{"trials":7834,"activeCount":102},[],{"trials":7836,"activeCount":102},[],{"trials":7838,"activeCount":102},[],{"trials":7840,"activeCount":102},[7841],{"nctId":7819,"briefTitle":7820,"status":248,"phases":7842,"primaryCompletion":7822,"completion":7822,"start":7419,"enrollment":4122,"conditions":7843,"interventions":7844},[92],[5240,5241,7824],[7808,7826],{"trials":7846,"activeCount":102},[],{"trials":7848,"activeCount":102},[],{"intervention":7850,"totalTrials":229,"cells":7851},"Ramipril",{"EARLY_PHASE1":7852,"PHASE1":7854,"PHASE2":7856,"PHASE3":7858,"PHASE4":7867,"NA":7869},{"trials":7853,"activeCount":102},[],{"trials":7855,"activeCount":102},[],{"trials":7857,"activeCount":102},[],{"trials":7859,"activeCount":102},[7860],{"nctId":7861,"briefTitle":7862,"status":248,"phases":7863,"primaryCompletion":7731,"completion":7731,"start":264,"enrollment":7864,"conditions":7865,"interventions":7866},"NCT00729365","PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)",[92],65,[1074],[7850],{"trials":7868,"activeCount":102},[],{"trials":7870,"activeCount":102},[],{"intervention":7872,"totalTrials":229,"cells":7873},"Metformin",{"EARLY_PHASE1":7874,"PHASE1":7876,"PHASE2":7878,"PHASE3":7880,"PHASE4":7890,"NA":7892},{"trials":7875,"activeCount":102},[],{"trials":7877,"activeCount":102},[],{"trials":7879,"activeCount":102},[],{"trials":7881,"activeCount":102},[7882],{"nctId":7883,"briefTitle":7884,"status":108,"phases":7885,"primaryCompletion":7886,"completion":7887,"start":3499,"enrollment":4832,"conditions":7888,"interventions":7889},"NCT03054519","Improve PAD PERformance With METformin",[92],"2025-08-20","2025-11-01",[1022],[7872],{"trials":7891,"activeCount":102},[],{"trials":7893,"activeCount":102},[],{"intervention":7895,"totalTrials":229,"cells":7896},"Atazanavir",{"EARLY_PHASE1":7897,"PHASE1":7899,"PHASE2":7901,"PHASE3":7903,"PHASE4":7915,"NA":7917},{"trials":7898,"activeCount":102},[],{"trials":7900,"activeCount":102},[],{"trials":7902,"activeCount":102},[],{"trials":7904,"activeCount":102},[7905],{"nctId":7906,"briefTitle":7907,"status":108,"phases":7908,"primaryCompletion":7909,"completion":7909,"start":6839,"enrollment":311,"conditions":7910,"interventions":7913},"NCT00225017","Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study",[92],"2008-06",[7911,7912],"HIV Infection","Hyperlipidemia",[7895,7914],"current antiretroviral regimen",{"trials":7916,"activeCount":102},[],{"trials":7918,"activeCount":102},[],{"intervention":7914,"totalTrials":229,"cells":7920},{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7927,"PHASE4":7933,"NA":7935},{"trials":7922,"activeCount":102},[],{"trials":7924,"activeCount":102},[],{"trials":7926,"activeCount":102},[],{"trials":7928,"activeCount":102},[7929],{"nctId":7906,"briefTitle":7907,"status":108,"phases":7930,"primaryCompletion":7909,"completion":7909,"start":6839,"enrollment":311,"conditions":7931,"interventions":7932},[92],[7911,7912],[7895,7914],{"trials":7934,"activeCount":102},[],{"trials":7936,"activeCount":102},[],{"intervention":7938,"totalTrials":229,"cells":7939},"Ranolazine",{"EARLY_PHASE1":7940,"PHASE1":7942,"PHASE2":7944,"PHASE3":7946,"PHASE4":7956,"NA":7958},{"trials":7941,"activeCount":102},[],{"trials":7943,"activeCount":102},[],{"trials":7945,"activeCount":102},[],{"trials":7947,"activeCount":102},[7948],{"nctId":7949,"briefTitle":7950,"status":108,"phases":7951,"primaryCompletion":1713,"completion":489,"start":7731,"enrollment":1610,"conditions":7952,"interventions":7955},"NCT01174173","Ranolazine and Pulmonary Hypertension",[92],[7953,7954],"Angina","Pulmonary Arterial Hypertension",[7938],{"trials":7957,"activeCount":102},[],{"trials":7959,"activeCount":102},[],{"intervention":7961,"totalTrials":229,"cells":7962},"Pentoxifylline",{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7969,"PHASE4":7981,"NA":7983},{"trials":7964,"activeCount":102},[],{"trials":7966,"activeCount":102},[],{"trials":7968,"activeCount":102},[],{"trials":7970,"activeCount":102},[7971],{"nctId":7972,"briefTitle":7973,"status":108,"phases":7974,"primaryCompletion":7975,"completion":7975,"start":7976,"enrollment":7977,"conditions":7978,"interventions":7980},"NCT00267670","Pentoxifylline\u002FNonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH",[91,92],"2009-09","2005-03",26,[3283,7979],"Liver Diseases",[7961],{"trials":7982,"activeCount":102},[],{"trials":7984,"activeCount":102},[],{"intervention":7986,"totalTrials":229,"cells":7987},"Amantadine",{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":7992,"PHASE3":7994,"PHASE4":8004,"NA":8006},{"trials":7989,"activeCount":102},[],{"trials":7991,"activeCount":102},[],{"trials":7993,"activeCount":102},[],{"trials":7995,"activeCount":102},[7996],{"nctId":7997,"briefTitle":7998,"status":248,"phases":7999,"primaryCompletion":8000,"completion":1654,"start":1753,"enrollment":375,"conditions":8001,"interventions":8003},"NCT01652534","Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease",[92],"2015-05",[8002],"Parkinson's Disease",[7986],{"trials":8005,"activeCount":102},[],{"trials":8007,"activeCount":102},[],{"intervention":8009,"totalTrials":229,"cells":8010},"adjunctive treatment with buspirone",{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8015,"PHASE3":8017,"PHASE4":8026,"NA":8028},{"trials":8012,"activeCount":102},[],{"trials":8014,"activeCount":102},[],{"trials":8016,"activeCount":102},[],{"trials":8018,"activeCount":102},[8019],{"nctId":8020,"briefTitle":8021,"status":108,"phases":8022,"primaryCompletion":8023,"completion":8023,"start":7798,"enrollment":341,"conditions":8024,"interventions":8025},"NCT00178971","Serotonin 1A Agonists and Cognition in Schizophrenia",[92],"2004-10",[5240,5241],[8009],{"trials":8027,"activeCount":102},[],{"trials":8029,"activeCount":102},[],{"intervention":541,"totalTrials":229,"cells":8031},{"EARLY_PHASE1":8032,"PHASE1":8034,"PHASE2":8036,"PHASE3":8038,"PHASE4":8044,"NA":8046},{"trials":8033,"activeCount":102},[],{"trials":8035,"activeCount":102},[],{"trials":8037,"activeCount":102},[],{"trials":8039,"activeCount":102},[8040],{"nctId":531,"briefTitle":532,"status":248,"phases":8041,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":8042,"interventions":8043},[92],[539],[541,141,440,494,418,542,517],{"trials":8045,"activeCount":102},[],{"trials":8047,"activeCount":102},[],{"intervention":464,"totalTrials":253,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8066,"PHASE3":8092,"PHASE4":8094,"NA":8096},{"trials":8051,"activeCount":102},[],{"trials":8053,"activeCount":102},[8054,8058,8062],{"nctId":6740,"briefTitle":6741,"status":261,"phases":8055,"primaryCompletion":6743,"completion":6743,"start":6744,"enrollment":102,"conditions":8056,"interventions":8057},[90],[21,2050,912,6746,6747],[176,177,464,6749],{"nctId":455,"briefTitle":456,"status":108,"phases":8059,"primaryCompletion":458,"completion":458,"start":111,"conditions":8060,"interventions":8061},[90],[113,114,115,24,116,117,118,460],[462,120,463,177,464,122,465],{"nctId":6907,"briefTitle":6908,"status":108,"phases":8063,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":537,"conditions":8064,"interventions":8065},[90],[24],[120,6915,6916,178,464,6917],{"trials":8067,"activeCount":102},[8068,8072,8076,8080,8084,8088],{"nctId":198,"briefTitle":199,"status":200,"phases":8069,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":8070,"interventions":8071},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"nctId":6815,"briefTitle":6816,"status":108,"phases":8073,"primaryCompletion":6818,"completion":6818,"start":111,"enrollment":475,"conditions":8074,"interventions":8075},[90,91],[115,24],[120,177,464],{"nctId":1350,"briefTitle":1351,"status":200,"phases":8077,"primaryCompletion":1353,"completion":1354,"start":1355,"enrollment":19,"conditions":8078,"interventions":8079},[91],[1343,1357,1358,1359,1360,1361,1362],[47,213,1364,1228],{"nctId":7154,"briefTitle":7155,"status":108,"phases":8081,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":8082,"interventions":8083},[91],[115,117,6848],[120,176,464],{"nctId":6829,"briefTitle":6830,"status":108,"phases":8085,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":8086,"interventions":8087},[90,91],[24],[176,177,464],{"nctId":2023,"briefTitle":2024,"status":108,"phases":8089,"primaryCompletion":1492,"completion":1492,"start":2026,"conditions":8090,"interventions":8091},[91],[24],[1540,177,464],{"trials":8093,"activeCount":102},[],{"trials":8095,"activeCount":102},[],{"trials":8097,"activeCount":102},[],{"intervention":142,"totalTrials":448,"cells":8099},{"EARLY_PHASE1":8100,"PHASE1":8102,"PHASE2":8108,"PHASE3":8134,"PHASE4":8136,"NA":8138},{"trials":8101,"activeCount":102},[],{"trials":8103,"activeCount":102},[8104],{"nctId":125,"briefTitle":126,"status":108,"phases":8105,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":8106,"interventions":8107},[90],[133,134,135,136,137,138,139],[141,142,97,143,144,145],{"trials":8109,"activeCount":102},[8110,8114,8118,8122,8126,8130],{"nctId":149,"briefTitle":150,"status":151,"phases":8111,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":8112,"interventions":8113},[90,91],[158,159,160,161,162,163,139,164],[141,142,166,97,143,145],{"nctId":168,"briefTitle":169,"status":108,"phases":8115,"primaryCompletion":171,"completion":171,"start":111,"conditions":8116,"interventions":8117},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":1334,"briefTitle":1335,"status":200,"phases":8119,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":156,"conditions":8120,"interventions":8121},[91],[1341,1342,1343,1344,1345],[1347,142,1228,1348],{"nctId":198,"briefTitle":199,"status":200,"phases":8123,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":8124,"interventions":8125},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"nctId":6835,"briefTitle":6836,"status":108,"phases":8127,"primaryCompletion":6838,"completion":6839,"start":6840,"conditions":8128,"interventions":8129},[91],[21],[177,914,179],{"nctId":2315,"briefTitle":2316,"status":108,"phases":8131,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":8132,"interventions":8133},[91],[2322,2323,2324,2325,2326,2327,2328],[2330,179,2331,2332,2333,2334,2335],{"trials":8135,"activeCount":102},[],{"trials":8137,"activeCount":102},[],{"trials":8139,"activeCount":102},[],{"intervention":2085,"totalTrials":448,"cells":8141},{"EARLY_PHASE1":8142,"PHASE1":8144,"PHASE2":8146,"PHASE3":8184,"PHASE4":8186,"NA":8188},{"trials":8143,"activeCount":102},[],{"trials":8145,"activeCount":102},[],{"trials":8147,"activeCount":102},[8148,8152,8156,8160,8164,8171,8180],{"nctId":2077,"briefTitle":2078,"status":248,"phases":8149,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":1329,"conditions":8150,"interventions":8151},[90,91],[24],[2085,2036],{"nctId":3444,"briefTitle":3445,"status":108,"phases":8153,"primaryCompletion":3447,"completion":3448,"start":602,"enrollment":253,"conditions":8154,"interventions":8155},[91],[3450,514,515],[3384,1802],{"nctId":6929,"briefTitle":6930,"status":248,"phases":8157,"primaryCompletion":6932,"completion":6933,"start":6934,"enrollment":3314,"conditions":8158,"interventions":8159},[90,91],[24],[6915,2085,6937],{"nctId":3377,"briefTitle":3378,"status":108,"phases":8161,"primaryCompletion":3380,"completion":3381,"start":1886,"enrollment":98,"conditions":8162,"interventions":8163},[91],[1495],[3384,1256],{"nctId":8165,"briefTitle":8166,"status":108,"phases":8167,"primaryCompletion":2391,"completion":2391,"start":8168,"conditions":8169,"interventions":8170},"NCT00028639","PS-341 in Treating Women With Metastatic Breast Cancer",[91],"2001-08",[21],[2085],{"nctId":8172,"briefTitle":8173,"status":248,"phases":8174,"primaryCompletion":8175,"completion":8175,"start":8176,"enrollment":1371,"conditions":8177,"interventions":8179},"NCT01163786","A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD",[91],"2015-09-09","2010-10-07",[8178],"Bronchiolitis Obliterans",[3384],{"nctId":6951,"briefTitle":6952,"status":108,"phases":8181,"primaryCompletion":6954,"completion":6955,"start":6956,"enrollment":2762,"conditions":8182,"interventions":8183},[91],[6958],[143,2085],{"trials":8185,"activeCount":102},[],{"trials":8187,"activeCount":102},[],{"trials":8189,"activeCount":102},[],{"intervention":176,"totalTrials":448,"cells":8191},{"EARLY_PHASE1":8192,"PHASE1":8194,"PHASE2":8200,"PHASE3":8226,"PHASE4":8228,"NA":8230},{"trials":8193,"activeCount":102},[],{"trials":8195,"activeCount":102},[8196],{"nctId":6740,"briefTitle":6741,"status":261,"phases":8197,"primaryCompletion":6743,"completion":6743,"start":6744,"enrollment":102,"conditions":8198,"interventions":8199},[90],[21,2050,912,6746,6747],[176,177,464,6749],{"trials":8201,"activeCount":102},[8202,8206,8210,8214,8218,8222],{"nctId":168,"briefTitle":169,"status":108,"phases":8203,"primaryCompletion":171,"completion":171,"start":111,"conditions":8204,"interventions":8205},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":6797,"briefTitle":6798,"status":108,"phases":8207,"primaryCompletion":6784,"completion":6784,"start":111,"conditions":8208,"interventions":8209},[91],[24],[176,177],{"nctId":6822,"briefTitle":6823,"status":108,"phases":8211,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":8212,"interventions":8213},[91],[113,115,116],[176,177],{"nctId":7154,"briefTitle":7155,"status":108,"phases":8215,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":8216,"interventions":8217},[91],[115,117,6848],[120,176,464],{"nctId":6829,"briefTitle":6830,"status":108,"phases":8219,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":8220,"interventions":8221},[90,91],[24],[176,177,464],{"nctId":6844,"briefTitle":6845,"status":108,"phases":8223,"primaryCompletion":6825,"completion":6825,"start":111,"conditions":8224,"interventions":8225},[91],[115,117,6848],[176,177],{"trials":8227,"activeCount":102},[],{"trials":8229,"activeCount":102},[],{"trials":8231,"activeCount":102},[],{"intervention":212,"totalTrials":475,"cells":8233},{"EARLY_PHASE1":8234,"PHASE1":8240,"PHASE2":8275,"PHASE3":8285,"PHASE4":8287,"NA":8289},{"trials":8235,"activeCount":102},[8236],{"nctId":6892,"briefTitle":6893,"status":261,"phases":8237,"start":1885,"enrollment":102,"conditions":8238,"interventions":8239},[89],[1495,24,4843],[143,212,215,6897,6898,6899],{"trials":8241,"activeCount":102},[8242,8246,8271],{"nctId":7089,"briefTitle":7090,"status":248,"phases":8243,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":273,"conditions":8244,"interventions":8245},[90],[7096,7097,7098,3915,7099,7100,7101,7102],[212,542,517,7104,7105,7106],{"nctId":8247,"briefTitle":8248,"status":248,"phases":8249,"primaryCompletion":8250,"completion":8250,"start":8251,"enrollment":273,"conditions":8252,"interventions":8269},"NCT01849276","Metformin+Cytarabine for the Treatment of Relapsed\u002FRefractory AML",[90],"2016-01-21","2015-03-11",[8253,8254,8255,8256,8257,8258,8259,8260,8261,8262,8263,8264,8265,8266,8267,3914,8268],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Blastic Phase Chronic Myelogenous Leukemia","Untreated Adult Acute Myeloid Leukemia",[8270,178],"metformin hydrochloride",{"nctId":6907,"briefTitle":6908,"status":108,"phases":8272,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":537,"conditions":8273,"interventions":8274},[90],[24],[120,6915,6916,178,464,6917],{"trials":8276,"activeCount":102},[8277,8281],{"nctId":168,"briefTitle":169,"status":108,"phases":8278,"primaryCompletion":171,"completion":171,"start":111,"conditions":8279,"interventions":8280},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":198,"briefTitle":199,"status":200,"phases":8282,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":8283,"interventions":8284},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"trials":8286,"activeCount":102},[],{"trials":8288,"activeCount":102},[],{"trials":8290,"activeCount":102},[],{"intervention":452,"totalTrials":475,"cells":8292},{"EARLY_PHASE1":8293,"PHASE1":8295,"PHASE2":8309,"PHASE3":8338,"PHASE4":8340,"NA":8342},{"trials":8294,"activeCount":102},[],{"trials":8296,"activeCount":102},[8297,8301,8305],{"nctId":430,"briefTitle":431,"status":248,"phases":8298,"primaryCompletion":433,"completion":433,"start":434,"enrollment":253,"conditions":8299,"interventions":8300},[90],[436],[438,141,439,440,418,441],{"nctId":443,"briefTitle":444,"status":248,"phases":8302,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":8303,"interventions":8304},[90],[450],[452,141,440,439,418,441,453],{"nctId":3432,"briefTitle":3433,"status":248,"phases":8306,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":8307,"interventions":8308},[90],[3436],[438,517,141,3438,3439,3440,3348],{"trials":8310,"activeCount":102},[8311,8317,8327],{"nctId":8312,"briefTitle":8313,"status":248,"phases":8314,"primaryCompletion":997,"completion":5236,"start":910,"enrollment":999,"conditions":8315,"interventions":8316},"NCT00278655","Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis",[90,91],[831],[452],{"nctId":8318,"briefTitle":8319,"status":108,"phases":8320,"primaryCompletion":8321,"completion":8322,"start":8323,"enrollment":1329,"conditions":8324,"interventions":8326},"NCT00278538","Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)\u002FRituximab in Patients With Systemic Lupus Erythematosus",[91],"2018-12","2019-05","2005-09-23",[8325],"Systemic Lupus Erythematosus",[452],{"nctId":8328,"briefTitle":8329,"status":108,"phases":8330,"primaryCompletion":8331,"completion":8332,"start":8333,"enrollment":628,"conditions":8334,"interventions":8336},"NCT00278629","Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy",[91],"2017-01-14","2019-11-04","2005-02-21",[8335],"Chronic Inflammatory Demyelinating Polyneuropathy",[8337],"hematopoietic stem cell transplantation",{"trials":8339,"activeCount":102},[],{"trials":8341,"activeCount":102},[],{"trials":8343,"activeCount":102},[],{"intervention":145,"totalTrials":887,"cells":8345},{"EARLY_PHASE1":8346,"PHASE1":8352,"PHASE2":8358,"PHASE3":8372,"PHASE4":8374,"NA":8376},{"trials":8347,"activeCount":102},[8348],{"nctId":6892,"briefTitle":6893,"status":261,"phases":8349,"start":1885,"enrollment":102,"conditions":8350,"interventions":8351},[89],[1495,24,4843],[143,212,215,6897,6898,6899],{"trials":8353,"activeCount":102},[8354],{"nctId":125,"briefTitle":126,"status":108,"phases":8355,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":8356,"interventions":8357},[90],[133,134,135,136,137,138,139],[141,142,97,143,144,145],{"trials":8359,"activeCount":102},[8360,8364,8368],{"nctId":149,"briefTitle":150,"status":151,"phases":8361,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":8362,"interventions":8363},[90,91],[158,159,160,161,162,163,139,164],[141,142,166,97,143,145],{"nctId":168,"briefTitle":169,"status":108,"phases":8365,"primaryCompletion":171,"completion":171,"start":111,"conditions":8366,"interventions":8367},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":198,"briefTitle":199,"status":200,"phases":8369,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":8370,"interventions":8371},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"trials":8373,"activeCount":102},[],{"trials":8375,"activeCount":102},[],{"trials":8377,"activeCount":102},[],{"intervention":914,"totalTrials":887,"cells":8379},{"EARLY_PHASE1":8380,"PHASE1":8382,"PHASE2":8388,"PHASE3":8413,"PHASE4":8415,"NA":8417},{"trials":8381,"activeCount":102},[],{"trials":8383,"activeCount":102},[8384],{"nctId":2142,"briefTitle":2143,"status":108,"phases":8385,"primaryCompletion":2145,"completion":2145,"start":2146,"conditions":8386,"interventions":8387},[90],[1500],[2073,914,2135,180],{"trials":8389,"activeCount":102},[8390,8401,8405,8409],{"nctId":8391,"briefTitle":8392,"status":261,"phases":8393,"primaryCompletion":8394,"completion":8395,"start":3470,"enrollment":102,"conditions":8396,"interventions":8397},"NCT06060587","Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone",[91],"2024-05-03","2030-12-22",[4124],[8398,8399,8400],"Docetaxel","ADT","Abiraterone",{"nctId":906,"briefTitle":907,"status":108,"phases":8402,"primaryCompletion":909,"completion":909,"start":910,"conditions":8403,"interventions":8404},[90,91],[912],[886,914,915],{"nctId":6835,"briefTitle":6836,"status":108,"phases":8406,"primaryCompletion":6838,"completion":6839,"start":6840,"conditions":8407,"interventions":8408},[91],[21],[177,914,179],{"nctId":2165,"briefTitle":2166,"status":108,"phases":8410,"primaryCompletion":2168,"completion":2169,"start":2170,"enrollment":2171,"conditions":8411,"interventions":8412},[90,91],[2173,1500],[914,2135,2175],{"trials":8414,"activeCount":102},[],{"trials":8416,"activeCount":102},[],{"trials":8418,"activeCount":102},[],{"intervention":915,"totalTrials":582,"cells":8420},{"EARLY_PHASE1":8421,"PHASE1":8423,"PHASE2":8429,"PHASE3":8449,"PHASE4":8451,"NA":8453},{"trials":8422,"activeCount":102},[],{"trials":8424,"activeCount":102},[8425],{"nctId":2043,"briefTitle":2044,"status":108,"phases":8426,"primaryCompletion":2046,"completion":2046,"start":1973,"enrollment":205,"conditions":8427,"interventions":8428},[90],[2048,21,2049,2050,912,1874],[2036,915],{"trials":8430,"activeCount":102},[8431,8437,8441],{"nctId":8432,"briefTitle":8433,"status":108,"phases":8434,"primaryCompletion":6912,"completion":6912,"start":111,"conditions":8435,"interventions":8436},"NCT00004182","Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer",[91],[21],[915],{"nctId":906,"briefTitle":907,"status":108,"phases":8438,"primaryCompletion":909,"completion":909,"start":910,"conditions":8439,"interventions":8440},[90,91],[912],[886,914,915],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8444,"primaryCompletion":4612,"completion":4612,"start":8445,"enrollment":6729,"conditions":8446,"interventions":8447},"NCT00940316","Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",[91],"2010-01-18",[2049],[8448,1840,915],"panitumumab",{"trials":8450,"activeCount":102},[],{"trials":8452,"activeCount":102},[],{"trials":8454,"activeCount":102},[],{"intervention":180,"totalTrials":582,"cells":8456},{"EARLY_PHASE1":8457,"PHASE1":8459,"PHASE2":8465,"PHASE3":8483,"PHASE4":8485,"NA":8487},{"trials":8458,"activeCount":102},[],{"trials":8460,"activeCount":102},[8461],{"nctId":2142,"briefTitle":2143,"status":108,"phases":8462,"primaryCompletion":2145,"completion":2145,"start":2146,"conditions":8463,"interventions":8464},[90],[1500],[2073,914,2135,180],{"trials":8466,"activeCount":102},[8467,8471,8475],{"nctId":168,"briefTitle":169,"status":108,"phases":8468,"primaryCompletion":171,"completion":171,"start":111,"conditions":8469,"interventions":8470},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":2156,"briefTitle":2157,"status":248,"phases":8472,"primaryCompletion":2159,"completion":1846,"start":111,"conditions":8473,"interventions":8474},[91],[2161],[175,2073,2135,2163,180],{"nctId":8476,"briefTitle":8477,"status":248,"phases":8478,"primaryCompletion":6784,"completion":6784,"start":8479,"conditions":8480,"interventions":8481},"NCT00005608","Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer",[91],"2000-02",[21],[180,8482],"tegafur-uracil",{"trials":8484,"activeCount":102},[],{"trials":8486,"activeCount":102},[],{"trials":8488,"activeCount":102},[],{"intervention":3392,"totalTrials":582,"cells":8490},{"EARLY_PHASE1":8491,"PHASE1":8493,"PHASE2":8505,"PHASE3":8526,"PHASE4":8528,"NA":8530},{"trials":8492,"activeCount":102},[],{"trials":8494,"activeCount":102},[8495],{"nctId":8496,"briefTitle":8497,"status":248,"phases":8498,"primaryCompletion":8499,"completion":8499,"start":3353,"enrollment":582,"conditions":8500,"interventions":8502},"NCT00985530","Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia",[90],"2011-05",[8501],"Acute Promyelocytic Leukemia",[8503,8504],"Tamibarotene","Arsenic trioxide",{"trials":8506,"activeCount":102},[8507,8514,8518],{"nctId":8508,"briefTitle":8509,"status":108,"phases":8510,"primaryCompletion":8511,"completion":8511,"start":8479,"enrollment":1610,"conditions":8512,"interventions":8513},"NCT00005795","Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia",[91],"2002-07",[115],[3392],{"nctId":3386,"briefTitle":3387,"status":200,"phases":8515,"primaryCompletion":1383,"completion":1383,"start":3389,"enrollment":311,"conditions":8516,"interventions":8517},[90,91],[1495],[3392,3358],{"nctId":8519,"briefTitle":8520,"status":248,"phases":8521,"primaryCompletion":8522,"completion":8522,"start":8523,"enrollment":273,"conditions":8524,"interventions":8525},"NCT00005595","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease",[91],"2002-04","2000-06",[24],[3392],{"trials":8527,"activeCount":102},[],{"trials":8529,"activeCount":102},[],{"trials":8531,"activeCount":102},[],{"intervention":1514,"totalTrials":582,"cells":8533},{"EARLY_PHASE1":8534,"PHASE1":8536,"PHASE2":8549,"PHASE3":8559,"PHASE4":8561,"NA":8563},{"trials":8535,"activeCount":102},[],{"trials":8537,"activeCount":102},[8538,8545],{"nctId":8539,"briefTitle":8540,"status":248,"phases":8541,"primaryCompletion":2046,"completion":2046,"start":7976,"enrollment":36,"conditions":8542,"interventions":8543},"NCT00281996","Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer",[90],[1874],[1514,8544],"Imatinib mesylate",{"nctId":1505,"briefTitle":1506,"status":248,"phases":8546,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":1511,"conditions":8547,"interventions":8548},[90],[24],[1514,1482],{"trials":8550,"activeCount":102},[8551,8555],{"nctId":1969,"briefTitle":1970,"status":248,"phases":8552,"primaryCompletion":434,"completion":1972,"start":1973,"enrollment":1974,"conditions":8553,"interventions":8554},[90,91],[912],[1540,1514,1851,1977,1978,1979],{"nctId":1867,"briefTitle":1868,"status":108,"phases":8556,"primaryCompletion":1870,"completion":1871,"start":1872,"enrollment":1548,"conditions":8557,"interventions":8558},[91],[1874],[1539,1876],{"trials":8560,"activeCount":102},[],{"trials":8562,"activeCount":102},[],{"trials":8564,"activeCount":102},[],{"intervention":1840,"totalTrials":375,"cells":8566},{"EARLY_PHASE1":8567,"PHASE1":8569,"PHASE2":8571,"PHASE3":8593,"PHASE4":8595,"NA":8597},{"trials":8568,"activeCount":102},[],{"trials":8570,"activeCount":102},[],{"trials":8572,"activeCount":102},[8573,8585,8589],{"nctId":8574,"briefTitle":8575,"status":108,"phases":8576,"primaryCompletion":1509,"completion":8577,"start":8578,"enrollment":205,"conditions":8579,"interventions":8582},"NCT01259089","Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer",[90,91],"2014-09-29","2011-04-27",[8580,8581],"Adenocarcinoma of the Lung","Non-small Cell Lung Cancer",[1840,8583,8584],"Hsp90 inhibitor AUY922","mutation analysis",{"nctId":1831,"briefTitle":1832,"status":108,"phases":8586,"primaryCompletion":1834,"completion":1835,"start":1836,"enrollment":1837,"conditions":8587,"interventions":8588},[91],[1495],[1539,1840],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8590,"primaryCompletion":4612,"completion":4612,"start":8445,"enrollment":6729,"conditions":8591,"interventions":8592},[91],[2049],[8448,1840,915],{"trials":8594,"activeCount":102},[],{"trials":8596,"activeCount":102},[],{"trials":8598,"activeCount":102},[],{"intervention":1994,"totalTrials":375,"cells":8600},{"EARLY_PHASE1":8601,"PHASE1":8603,"PHASE2":8605,"PHASE3":8619,"PHASE4":8621,"NA":8623},{"trials":8602,"activeCount":102},[],{"trials":8604,"activeCount":102},[],{"trials":8606,"activeCount":102},[8607,8611,8615],{"nctId":3645,"briefTitle":3646,"status":108,"phases":8608,"primaryCompletion":110,"completion":110,"start":3648,"conditions":8609,"interventions":8610},[90,91],[24],[1994,1851,182],{"nctId":1988,"briefTitle":1989,"status":108,"phases":8612,"primaryCompletion":1991,"completion":1991,"start":111,"conditions":8613,"interventions":8614},[91],[21],[120,1540,177,1994,1995],{"nctId":1350,"briefTitle":1351,"status":200,"phases":8616,"primaryCompletion":1353,"completion":1354,"start":1355,"enrollment":19,"conditions":8617,"interventions":8618},[91],[1343,1357,1358,1359,1360,1361,1362],[47,213,1364,1228],{"trials":8620,"activeCount":102},[],{"trials":8622,"activeCount":102},[],{"trials":8624,"activeCount":102},[],{"intervention":215,"totalTrials":375,"cells":8626},{"EARLY_PHASE1":8627,"PHASE1":8633,"PHASE2":8635,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8628,"activeCount":102},[8629],{"nctId":6892,"briefTitle":6893,"status":261,"phases":8630,"start":1885,"enrollment":102,"conditions":8631,"interventions":8632},[89],[1495,24,4843],[143,212,215,6897,6898,6899],{"trials":8634,"activeCount":102},[],{"trials":8636,"activeCount":102},[8637,8641],{"nctId":168,"briefTitle":169,"status":108,"phases":8638,"primaryCompletion":171,"completion":171,"start":111,"conditions":8639,"interventions":8640},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":198,"briefTitle":199,"status":200,"phases":8642,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":8643,"interventions":8644},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"trials":8646,"activeCount":102},[],{"trials":8648,"activeCount":102},[],{"trials":8650,"activeCount":102},[],{"intervention":2073,"totalTrials":375,"cells":8652},{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8665,"PHASE3":8671,"PHASE4":8673,"NA":8675},{"trials":8654,"activeCount":102},[],{"trials":8656,"activeCount":102},[8657,8661],{"nctId":2142,"briefTitle":2143,"status":108,"phases":8658,"primaryCompletion":2145,"completion":2145,"start":2146,"conditions":8659,"interventions":8660},[90],[1500],[2073,914,2135,180],{"nctId":2067,"briefTitle":2068,"status":108,"phases":8662,"primaryCompletion":2070,"completion":2070,"start":1973,"conditions":8663,"interventions":8664},[90],[1500],[2073,2036],{"trials":8666,"activeCount":102},[8667],{"nctId":2156,"briefTitle":2157,"status":248,"phases":8668,"primaryCompletion":2159,"completion":1846,"start":111,"conditions":8669,"interventions":8670},[91],[2161],[175,2073,2135,2163,180],{"trials":8672,"activeCount":102},[],{"trials":8674,"activeCount":102},[],{"trials":8676,"activeCount":102},[],{"intervention":174,"totalTrials":375,"cells":8678},{"EARLY_PHASE1":8679,"PHASE1":8688,"PHASE2":8690,"PHASE3":8703,"PHASE4":8705,"NA":8707},{"trials":8680,"activeCount":102},[8681],{"nctId":8682,"briefTitle":8683,"status":108,"phases":8684,"primaryCompletion":7774,"completion":5863,"start":1797,"enrollment":224,"conditions":8685,"interventions":8686},"NCT00278369","Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer",[89],[2050],[174,8687],"denileukin diftitox",{"trials":8689,"activeCount":102},[],{"trials":8691,"activeCount":102},[8692,8696],{"nctId":168,"briefTitle":169,"status":108,"phases":8693,"primaryCompletion":171,"completion":171,"start":111,"conditions":8694,"interventions":8695},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":8697,"briefTitle":8698,"status":248,"phases":8699,"primaryCompletion":7119,"completion":7119,"start":8700,"conditions":8701,"interventions":8702},"NCT00005788","Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome",[91],"1997-04",[24],[174],{"trials":8704,"activeCount":102},[],{"trials":8706,"activeCount":102},[],{"trials":8708,"activeCount":102},[],{"intervention":2330,"totalTrials":375,"cells":8710},{"EARLY_PHASE1":8711,"PHASE1":8713,"PHASE2":8715,"PHASE3":8729,"PHASE4":8731,"NA":8733},{"trials":8712,"activeCount":102},[],{"trials":8714,"activeCount":102},[],{"trials":8716,"activeCount":102},[8717,8721,8725],{"nctId":1286,"briefTitle":1287,"status":261,"phases":8718,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":102,"conditions":8719,"interventions":8720},[91],[1293,1294,1295,1296,1297,1298,1299,1300,1301,1302,1303,1304,1305,1306],[1308,1228],{"nctId":2315,"briefTitle":2316,"status":108,"phases":8722,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":8723,"interventions":8724},[91],[2322,2323,2324,2325,2326,2327,2328],[2330,179,2331,2332,2333,2334,2335],{"nctId":6961,"briefTitle":6962,"status":248,"phases":8726,"primaryCompletion":3594,"completion":1905,"start":6964,"enrollment":224,"conditions":8727,"interventions":8728},[90,91],[6966,2214,2215,2216,6967,6968,6969,6970,6971,6972,6973,6974,6975,6976,6977,6978,6979,6980,6981,2217,6982,6983,6984,6985,6986,6987,6988,6989,6990,6991,6992,6993,6994,6995,6996,2218,6997,6998,6999,7000,7001,7002,7003,7004,7005,7006,7007,7008,7009,7010,7011,7012,7013,7014,7015,7016,7017,7018,7019,7020,7021,7022,7023,7024,7025,2219,7026,7027,7028,7029,7030,7031,2220,2221,2326,7032,2222,2223,2224,7033,7034,7035,7036,2327,7037,7038,7039,2225,7040,7041,7042,7043,7044,7045,2226,2227,7046,7047,7048,7049,2328,7050,7051,7052,2228,7053,7054,7055,7056,7057,7058,2229,2230,7059,7060,7061,7062],[2330,6915],{"trials":8730,"activeCount":102},[],{"trials":8732,"activeCount":102},[],{"trials":8734,"activeCount":102},[],{"intervention":8736,"totalTrials":375,"cells":8737},"Vinorelbine",{"EARLY_PHASE1":8738,"PHASE1":8740,"PHASE2":8762,"PHASE3":8768,"PHASE4":8770,"NA":8772},{"trials":8739,"activeCount":102},[],{"trials":8741,"activeCount":102},[8742,8751],{"nctId":8743,"briefTitle":8744,"status":248,"phases":8745,"primaryCompletion":8746,"completion":4851,"start":1221,"enrollment":900,"conditions":8747,"interventions":8749},"NCT01060514","Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer",[90],"2012-02",[8748,2909],"Metastatic Non Small Cell Lung Cancer",[8750,8736],"Pazopanib",{"nctId":8752,"briefTitle":8753,"status":261,"phases":8754,"primaryCompletion":8755,"completion":8755,"start":6577,"enrollment":102,"conditions":8756,"interventions":8760},"NCT06137651","Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis",[90],"2024-03-27",[8757,8758,8759],"Breast Carcinoma","Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Neoplasm in the Leptomeninges",[8761,8736],"Trotabresib",{"trials":8763,"activeCount":102},[8764],{"nctId":1969,"briefTitle":1970,"status":248,"phases":8765,"primaryCompletion":434,"completion":1972,"start":1973,"enrollment":1974,"conditions":8766,"interventions":8767},[90,91],[912],[1540,1514,1851,1977,1978,1979],{"trials":8769,"activeCount":102},[],{"trials":8771,"activeCount":102},[],{"trials":8773,"activeCount":102},[],{"intervention":3560,"totalTrials":375,"cells":8775},{"EARLY_PHASE1":8776,"PHASE1":8778,"PHASE2":8784,"PHASE3":8794,"PHASE4":8796,"NA":8798},{"trials":8777,"activeCount":102},[],{"trials":8779,"activeCount":102},[8780],{"nctId":2053,"briefTitle":2054,"status":108,"phases":8781,"primaryCompletion":2056,"completion":2057,"start":2058,"enrollment":999,"conditions":8782,"interventions":8783},[90],[2060,2061,2062,2063],[2065,2036],{"trials":8785,"activeCount":102},[8786,8790],{"nctId":3545,"briefTitle":3546,"status":200,"phases":8787,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":3067,"conditions":8788,"interventions":8789},[91],[3552,3553,3554,3555,3556,3557,3558],[3560,166],{"nctId":3590,"briefTitle":3591,"status":248,"phases":8791,"primaryCompletion":3593,"completion":3593,"start":3594,"enrollment":375,"conditions":8792,"interventions":8793},[91],[1280,3596,678,3597],[3560,166],{"trials":8795,"activeCount":102},[],{"trials":8797,"activeCount":102},[],{"trials":8799,"activeCount":102},[],{"intervention":453,"totalTrials":375,"cells":8801},{"EARLY_PHASE1":8802,"PHASE1":8804,"PHASE2":8810,"PHASE3":8827,"PHASE4":8829,"NA":8831},{"trials":8803,"activeCount":102},[],{"trials":8805,"activeCount":102},[8806],{"nctId":443,"briefTitle":444,"status":248,"phases":8807,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":8808,"interventions":8809},[90],[450],[452,141,440,439,418,441,453],{"trials":8811,"activeCount":102},[8812,8816],{"nctId":484,"briefTitle":485,"status":248,"phases":8813,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":8814,"interventions":8815},[90,91],[491],[493,141,440,494,418,441,453],{"nctId":8817,"briefTitle":8818,"status":248,"phases":8819,"primaryCompletion":1492,"completion":8820,"start":8821,"enrollment":156,"conditions":8822,"interventions":8824},"NCT00089284","Phase I\u002FII Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL",[90,91],"2008-08-20","2003-10-28",[8823],"Non-Hodgkin's Lymphoma (NHL)",[453,8825,8826],"motexafin gadolinium","111Indium-Zevalin and 90Yttrium-Zevalin",{"trials":8828,"activeCount":102},[],{"trials":8830,"activeCount":102},[],{"trials":8832,"activeCount":102},[],{"intervention":182,"totalTrials":273,"cells":8834},{"EARLY_PHASE1":8835,"PHASE1":8837,"PHASE2":8839,"PHASE3":8849,"PHASE4":8851,"NA":8853},{"trials":8836,"activeCount":102},[],{"trials":8838,"activeCount":102},[],{"trials":8840,"activeCount":102},[8841,8845],{"nctId":3645,"briefTitle":3646,"status":108,"phases":8842,"primaryCompletion":110,"completion":110,"start":3648,"conditions":8843,"interventions":8844},[90,91],[24],[1994,1851,182],{"nctId":168,"briefTitle":169,"status":108,"phases":8846,"primaryCompletion":171,"completion":171,"start":111,"conditions":8847,"interventions":8848},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"trials":8850,"activeCount":102},[],{"trials":8852,"activeCount":102},[],{"trials":8854,"activeCount":102},[],{"intervention":6897,"totalTrials":273,"cells":8856},{"EARLY_PHASE1":8857,"PHASE1":8863,"PHASE2":8865,"PHASE3":8871,"PHASE4":8873,"NA":8875},{"trials":8858,"activeCount":102},[8859],{"nctId":6892,"briefTitle":6893,"status":261,"phases":8860,"start":1885,"enrollment":102,"conditions":8861,"interventions":8862},[89],[1495,24,4843],[143,212,215,6897,6898,6899],{"trials":8864,"activeCount":102},[],{"trials":8866,"activeCount":102},[8867],{"nctId":8817,"briefTitle":8818,"status":248,"phases":8868,"primaryCompletion":1492,"completion":8820,"start":8821,"enrollment":156,"conditions":8869,"interventions":8870},[90,91],[8823],[453,8825,8826],{"trials":8872,"activeCount":102},[],{"trials":8874,"activeCount":102},[],{"trials":8876,"activeCount":102},[],{"intervention":1638,"totalTrials":273,"cells":8878},{"EARLY_PHASE1":8879,"PHASE1":8881,"PHASE2":8883,"PHASE3":8893,"PHASE4":8895,"NA":8897},{"trials":8880,"activeCount":102},[],{"trials":8882,"activeCount":102},[],{"trials":8884,"activeCount":102},[8885,8889],{"nctId":1628,"briefTitle":1629,"status":261,"phases":8886,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":102,"conditions":8887,"interventions":8888},[91],[1634,1635,1636],[1638,632],{"nctId":1668,"briefTitle":1669,"status":248,"phases":8890,"primaryCompletion":1671,"completion":1671,"start":1672,"enrollment":273,"conditions":8891,"interventions":8892},[91],[1634,1635,1636],[1675,632],{"trials":8894,"activeCount":102},[],{"trials":8896,"activeCount":102},[],{"trials":8898,"activeCount":102},[],{"intervention":8900,"totalTrials":273,"cells":8901},"Allogeneic Stem Cell Transplantation",{"EARLY_PHASE1":8902,"PHASE1":8904,"PHASE2":8912,"PHASE3":8924,"PHASE4":8926,"NA":8928},{"trials":8903,"activeCount":102},[],{"trials":8905,"activeCount":102},[8906],{"nctId":8907,"briefTitle":8908,"status":261,"phases":8909,"primaryCompletion":1644,"completion":1644,"start":6338,"enrollment":102,"conditions":8910,"interventions":8911},"NCT00278590","Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus",[90],[8325],[8900],{"trials":8913,"activeCount":102},[8914],{"nctId":8915,"briefTitle":8916,"status":248,"phases":8917,"primaryCompletion":1654,"completion":1654,"start":8918,"enrollment":273,"conditions":8919,"interventions":8921},"NCT00282438","Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis",[90,91],"2003-12",[8920],"Sarcoidosis",[8922,8923],"Autologous hematopoietic stem cell transplantation","Allogeneic stem cell transplantation",{"trials":8925,"activeCount":102},[],{"trials":8927,"activeCount":102},[],{"trials":8929,"activeCount":102},[],{"intervention":8931,"totalTrials":273,"cells":8932},"Telapristone Acetate",{"EARLY_PHASE1":8933,"PHASE1":8935,"PHASE2":8937,"PHASE3":8960,"PHASE4":8962,"NA":8964},{"trials":8934,"activeCount":102},[],{"trials":8936,"activeCount":102},[],{"trials":8938,"activeCount":102},[8939,8952],{"nctId":8940,"briefTitle":8941,"status":108,"phases":8942,"primaryCompletion":8943,"completion":1383,"start":4621,"enrollment":5157,"conditions":8944,"interventions":8951},"NCT02314156","Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy",[91],"2018-01",[8945,8946,2267,8947,8948,2008,2009,8949,8950],"BRCA1 Mutation Carrier","BRCA2 Mutation Carrier","Lobular Breast Carcinoma In Situ","Stage 0 Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer",[8931,8931],{"nctId":8953,"briefTitle":8954,"status":200,"phases":8955,"primaryCompletion":2001,"completion":8956,"start":626,"enrollment":311,"conditions":8957,"interventions":8958},"NCT01800422","Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer",[91],"2022-03",[2008,2009,2010],[8959],"telapristone acetate",{"trials":8961,"activeCount":102},[],{"trials":8963,"activeCount":102},[],{"trials":8965,"activeCount":102},[],{"intervention":2281,"totalTrials":273,"cells":8967},{"EARLY_PHASE1":8968,"PHASE1":8970,"PHASE2":8972,"PHASE3":8982,"PHASE4":8984,"NA":8986},{"trials":8969,"activeCount":102},[],{"trials":8971,"activeCount":102},[],{"trials":8973,"activeCount":102},[8974,8978],{"nctId":2271,"briefTitle":2272,"status":108,"phases":8975,"primaryCompletion":1491,"start":2274,"enrollment":28,"conditions":8976,"interventions":8977},[91],[2276,2277],[2279,2280,2281],{"nctId":2283,"briefTitle":2284,"status":108,"phases":8979,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":238,"conditions":8980,"interventions":8981},[91],[2267,1279],[2249,2291],{"trials":8983,"activeCount":102},[],{"trials":8985,"activeCount":102},[],{"trials":8987,"activeCount":102},[],{"intervention":175,"totalTrials":273,"cells":8989},{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":8994,"PHASE3":9004,"PHASE4":9006,"NA":9008},{"trials":8991,"activeCount":102},[],{"trials":8993,"activeCount":102},[],{"trials":8995,"activeCount":102},[8996,9000],{"nctId":168,"briefTitle":169,"status":108,"phases":8997,"primaryCompletion":171,"completion":171,"start":111,"conditions":8998,"interventions":8999},[91],[24],[174,120,175,176,177,178,179,180,181,123,182,183],{"nctId":2156,"briefTitle":2157,"status":248,"phases":9001,"primaryCompletion":2159,"completion":1846,"start":111,"conditions":9002,"interventions":9003},[91],[2161],[175,2073,2135,2163,180],{"trials":9005,"activeCount":102},[],{"trials":9007,"activeCount":102},[],{"trials":9009,"activeCount":102},[],{"intervention":8270,"totalTrials":273,"cells":9011},{"EARLY_PHASE1":9012,"PHASE1":9014,"PHASE2":9020,"PHASE3":9026,"PHASE4":9028,"NA":9030},{"trials":9013,"activeCount":102},[],{"trials":9015,"activeCount":102},[9016],{"nctId":8247,"briefTitle":8248,"status":248,"phases":9017,"primaryCompletion":8250,"completion":8250,"start":8251,"enrollment":273,"conditions":9018,"interventions":9019},[90],[8253,8254,8255,8256,8257,8258,8259,8260,8261,8262,8263,8264,8265,8266,8267,3914,8268],[8270,178],{"trials":9021,"activeCount":102},[9022],{"nctId":3575,"briefTitle":3576,"status":200,"phases":9023,"primaryCompletion":3578,"completion":3579,"start":3580,"enrollment":1371,"conditions":9024,"interventions":9025},[91],[3582,3583,3584,3585,3586],[3588,166],{"trials":9027,"activeCount":102},[],{"trials":9029,"activeCount":102},[],{"trials":9031,"activeCount":102},[],{"intervention":8922,"totalTrials":273,"cells":9033},{"EARLY_PHASE1":9034,"PHASE1":9036,"PHASE2":9038,"PHASE3":9054,"PHASE4":9056,"NA":9058},{"trials":9035,"activeCount":102},[],{"trials":9037,"activeCount":102},[],{"trials":9039,"activeCount":102},[9040,9044],{"nctId":8915,"briefTitle":8916,"status":248,"phases":9041,"primaryCompletion":1654,"completion":1654,"start":8918,"enrollment":273,"conditions":9042,"interventions":9043},[90,91],[8920],[8922,8923],{"nctId":9045,"briefTitle":9046,"status":261,"phases":9047,"primaryCompletion":1654,"completion":1654,"start":9048,"enrollment":102,"conditions":9049,"interventions":9051},"NCT01285934","Hematopoietic Stem Cell Support Versus Insulin in T1D",[90,91],"2009-01",[9050],"Diabetes Mellitus, Type 1",[9052,9053],"Autologous Hematopoietic Stem Cell Transplantation","intensive insulin therapy",{"trials":9055,"activeCount":102},[],{"trials":9057,"activeCount":102},[],{"trials":9059,"activeCount":102},[],{"intervention":3375,"totalTrials":273,"cells":9061},{"EARLY_PHASE1":9062,"PHASE1":9064,"PHASE2":9066,"PHASE3":9091,"PHASE4":9093,"NA":9095},{"trials":9063,"activeCount":102},[],{"trials":9065,"activeCount":102},[],{"trials":9067,"activeCount":102},[9068,9072],{"nctId":3362,"briefTitle":3363,"status":108,"phases":9069,"primaryCompletion":3365,"completion":3366,"start":3367,"enrollment":25,"conditions":9070,"interventions":9071},[90,91],[3369,3370,3371,3372,3373],[3358,3375],{"nctId":9073,"briefTitle":9074,"status":108,"phases":9075,"primaryCompletion":9076,"completion":9077,"start":9078,"enrollment":9079,"conditions":9080,"interventions":9088},"NCT02357810","Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas",[91],"2018-04-27","2021-10-12","2015-03-21",178,[9081,9082,9083,9084,9085,9086,9087],"Adult Liposarcoma","Metastatic Liposarcoma","Metastatic Osteosarcoma","Recurrent Adult Soft Tissue Sarcoma","Recurrent Liposarcoma","Recurrent Osteosarcoma","Stage IV Adult Soft Tissue Sarcoma",[9089,9090],"Pazopanib Hydrochloride","Oral Topotecan Hydrochloride",{"trials":9092,"activeCount":102},[],{"trials":9094,"activeCount":102},[],{"trials":9096,"activeCount":102},[],{"intervention":9098,"totalTrials":273,"cells":9099},"Tivozanib",{"EARLY_PHASE1":9100,"PHASE1":9102,"PHASE2":9104,"PHASE3":9127,"PHASE4":9129,"NA":9131},{"trials":9101,"activeCount":102},[],{"trials":9103,"activeCount":102},[],{"trials":9105,"activeCount":102},[9106,9116],{"nctId":9107,"briefTitle":9108,"status":108,"phases":9109,"primaryCompletion":9110,"completion":3281,"start":1923,"enrollment":1548,"conditions":9111,"interventions":9115},"NCT01853644","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[91],"2018-10-02",[9112,9113,9114],"Recurrent Epithelial Ovarian Cancer","Recurrent Fallopian Tube Cancer","Recurrent Primary Peritoneal Cancer",[9098],{"nctId":9117,"briefTitle":9118,"status":108,"phases":9119,"primaryCompletion":9120,"completion":9121,"start":9122,"enrollment":6637,"conditions":9123,"interventions":9125},"NCT01782313","A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas",[91],"2015-05-27","2016-12-28","2013-03-06",[9084,9124,9087],"Stage III Adult Soft Tissue Sarcoma",[9126],"tivozanib",{"trials":9128,"activeCount":102},[],{"trials":9130,"activeCount":102},[],{"trials":9132,"activeCount":102},[],{"intervention":1995,"totalTrials":273,"cells":9134},{"EARLY_PHASE1":9135,"PHASE1":9137,"PHASE2":9143,"PHASE3":9149,"PHASE4":9151,"NA":9153},{"trials":9136,"activeCount":102},[],{"trials":9138,"activeCount":102},[9139],{"nctId":3612,"briefTitle":3613,"status":108,"phases":9140,"primaryCompletion":3295,"completion":3295,"start":111,"enrollment":156,"conditions":9141,"interventions":9142},[90],[21],[120,177,1851,1995],{"trials":9144,"activeCount":102},[9145],{"nctId":1988,"briefTitle":1989,"status":108,"phases":9146,"primaryCompletion":1991,"completion":1991,"start":111,"conditions":9147,"interventions":9148},[91],[21],[120,1540,177,1994,1995],{"trials":9150,"activeCount":102},[],{"trials":9152,"activeCount":102},[],{"trials":9154,"activeCount":102},[],{"intervention":9156,"totalTrials":273,"cells":9157},"Alendronate",{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9162,"PHASE3":9183,"PHASE4":9185,"NA":9187},{"trials":9159,"activeCount":102},[],{"trials":9161,"activeCount":102},[],{"trials":9163,"activeCount":102},[9164,9176],{"nctId":9165,"briefTitle":9166,"status":108,"phases":9167,"primaryCompletion":9168,"completion":9168,"start":9169,"enrollment":131,"conditions":9170,"interventions":9174},"NCT04708886","Romosozumab in Women With Chronic SCI",[91],"2024-06-10","2021-03-01",[7480,7479,9171,9172,9173],"Osteopenia, Osteoporosis","Spinal Cord Injuries","Chronic Spinal Paralysis",[9175,9156],"Romosozumab",{"nctId":9177,"briefTitle":9178,"status":108,"phases":9179,"primaryCompletion":9180,"completion":9180,"start":984,"enrollment":1371,"conditions":9181,"interventions":9182},"NCT02195895","Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide",[91],"2016-08-05",[7477,7479,7480],[9156],{"trials":9184,"activeCount":102},[],{"trials":9186,"activeCount":102},[],{"trials":9188,"activeCount":102},[],{"intervention":9190,"totalTrials":273,"cells":9191},"Durvalumab",{"EARLY_PHASE1":9192,"PHASE1":9194,"PHASE2":9204,"PHASE3":9217,"PHASE4":9219,"NA":9221},{"trials":9193,"activeCount":102},[],{"trials":9195,"activeCount":102},[9196],{"nctId":9197,"briefTitle":9198,"status":261,"phases":9199,"primaryCompletion":1653,"start":1653,"enrollment":102,"conditions":9200,"interventions":9203},"NCT02871323","Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis",[90],[9201,9202],"Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","Primary Myelofibrosis",[9190],{"trials":9205,"activeCount":102},[9206],{"nctId":9207,"briefTitle":9208,"status":108,"phases":9209,"primaryCompletion":9210,"completion":9211,"start":9212,"enrollment":1974,"conditions":9213,"interventions":9215},"NCT02794883","Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma",[91],"2018-05-09","2020-06-17","2016-11-01",[9214,2516],"Malignant Glioma",[9190,9216],"Tremelimumab",{"trials":9218,"activeCount":102},[],{"trials":9220,"activeCount":102},[],{"trials":9222,"activeCount":102},[],{"intervention":9216,"totalTrials":273,"cells":9224},{"EARLY_PHASE1":9225,"PHASE1":9227,"PHASE2":9229,"PHASE3":9245,"PHASE4":9247,"NA":9249},{"trials":9226,"activeCount":102},[],{"trials":9228,"activeCount":102},[],{"trials":9230,"activeCount":102},[9231,9235],{"nctId":9207,"briefTitle":9208,"status":108,"phases":9232,"primaryCompletion":9210,"completion":9211,"start":9212,"enrollment":1974,"conditions":9233,"interventions":9234},[91],[9214,2516],[9190,9216],{"nctId":9236,"briefTitle":9237,"status":108,"phases":9238,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":156,"conditions":9242,"interventions":9243},"NCT02536794","MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer",[91],"2020-02-06","2021-01-22","2016-01-14",[1278,1279,1280,1282,678],[9244,9216],"Anti-B7H1 Monoclonal Antibody MEDI4736",{"trials":9246,"activeCount":102},[],{"trials":9248,"activeCount":102},[],{"trials":9250,"activeCount":102},[],{"intervention":7124,"totalTrials":273,"cells":9252},{"EARLY_PHASE1":9253,"PHASE1":9255,"PHASE2":9261,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9254,"activeCount":102},[],{"trials":9256,"activeCount":102},[9257],{"nctId":7116,"briefTitle":7117,"status":248,"phases":9258,"primaryCompletion":7119,"completion":7119,"start":6744,"enrollment":375,"conditions":9259,"interventions":9260},[90],[24,7121],[7123,120,7124,7125,7126],{"trials":9262,"activeCount":102},[9263],{"nctId":7146,"briefTitle":7147,"status":108,"phases":9264,"primaryCompletion":7149,"completion":7149,"start":6785,"conditions":9265,"interventions":9266},[90,91],[21,115,24,116,6848],[120,7124,7152,7125],{"trials":9268,"activeCount":102},[],{"trials":9270,"activeCount":102},[],{"trials":9272,"activeCount":102},[],{"intervention":7125,"totalTrials":273,"cells":9274},{"EARLY_PHASE1":9275,"PHASE1":9277,"PHASE2":9283,"PHASE3":9289,"PHASE4":9291,"NA":9293},{"trials":9276,"activeCount":102},[],{"trials":9278,"activeCount":102},[9279],{"nctId":7116,"briefTitle":7117,"status":248,"phases":9280,"primaryCompletion":7119,"completion":7119,"start":6744,"enrollment":375,"conditions":9281,"interventions":9282},[90],[24,7121],[7123,120,7124,7125,7126],{"trials":9284,"activeCount":102},[9285],{"nctId":7146,"briefTitle":7147,"status":108,"phases":9286,"primaryCompletion":7149,"completion":7149,"start":6785,"conditions":9287,"interventions":9288},[90,91],[21,115,24,116,6848],[120,7124,7152,7125],{"trials":9290,"activeCount":102},[],{"trials":9292,"activeCount":102},[],{"trials":9294,"activeCount":102},[],{"intervention":7123,"totalTrials":273,"cells":9296},{"EARLY_PHASE1":9297,"PHASE1":9299,"PHASE2":9305,"PHASE3":9315,"PHASE4":9317,"NA":9319},{"trials":9298,"activeCount":102},[],{"trials":9300,"activeCount":102},[9301],{"nctId":7116,"briefTitle":7117,"status":248,"phases":9302,"primaryCompletion":7119,"completion":7119,"start":6744,"enrollment":375,"conditions":9303,"interventions":9304},[90],[24,7121],[7123,120,7124,7125,7126],{"trials":9306,"activeCount":102},[9307],{"nctId":9308,"briefTitle":9309,"status":108,"phases":9310,"primaryCompletion":9311,"completion":9311,"start":2146,"conditions":9312,"interventions":9314},"NCT00004914","Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue",[91],"2001-12",[9313,2394,1500],"Anemia",[7123],{"trials":9316,"activeCount":102},[],{"trials":9318,"activeCount":102},[],{"trials":9320,"activeCount":102},[],{"intervention":9322,"totalTrials":273,"cells":9323},"trastuzumab",{"EARLY_PHASE1":9324,"PHASE1":9326,"PHASE2":9328,"PHASE3":9350,"PHASE4":9352,"NA":9354},{"trials":9325,"activeCount":102},[],{"trials":9327,"activeCount":102},[],{"trials":9329,"activeCount":102},[9330,9337],{"nctId":9331,"briefTitle":9332,"status":261,"phases":9333,"primaryCompletion":6825,"completion":6825,"start":8511,"enrollment":102,"conditions":9334,"interventions":9335},"NCT00057993","Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer",[91],[21],[9322,9336],"exemestane",{"nctId":9338,"briefTitle":9339,"status":248,"phases":9340,"primaryCompletion":9341,"completion":9342,"start":9343,"enrollment":131,"conditions":9344,"interventions":9347},"NCT02774681","Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis",[91],"2019-02-13","2020-02-16","2016-08-31",[9345,1278,1280,9346,1281,1282,678],"Breast Carcinoma Metastatic in the Brain","HER2\u002FNeu Positive",[9348,9349],"Palbociclib","Trastuzumab",{"trials":9351,"activeCount":102},[],{"trials":9353,"activeCount":102},[],{"trials":9355,"activeCount":102},[],{"intervention":1391,"totalTrials":273,"cells":9357},{"EARLY_PHASE1":9358,"PHASE1":9360,"PHASE2":9372,"PHASE3":9378,"PHASE4":9380,"NA":9382},{"trials":9359,"activeCount":102},[],{"trials":9361,"activeCount":102},[9362],{"nctId":9363,"briefTitle":9364,"status":108,"phases":9365,"primaryCompletion":9366,"completion":9367,"start":9368,"enrollment":3314,"conditions":9369,"interventions":9370},"NCT00858429","Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases",[90],"2014-03-19","2014-07-08","2009-04-01",[902,1497],[9371],"capecitabine",{"trials":9373,"activeCount":102},[9374],{"nctId":1379,"briefTitle":1380,"status":200,"phases":9375,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":156,"conditions":9376,"interventions":9377},[91],[1278,1280,1281,1282,1386,1387,1388,1389,678,1283],[1391,1228],{"trials":9379,"activeCount":102},[],{"trials":9381,"activeCount":102},[],{"trials":9383,"activeCount":102},[],{"intervention":8583,"totalTrials":229,"cells":9385},{"EARLY_PHASE1":9386,"PHASE1":9388,"PHASE2":9390,"PHASE3":9396,"PHASE4":9398,"NA":9400},{"trials":9387,"activeCount":102},[],{"trials":9389,"activeCount":102},[],{"trials":9391,"activeCount":102},[9392],{"nctId":8574,"briefTitle":8575,"status":108,"phases":9393,"primaryCompletion":1509,"completion":8577,"start":8578,"enrollment":205,"conditions":9394,"interventions":9395},[90,91],[8580,8581],[1840,8583,8584],{"trials":9397,"activeCount":102},[],{"trials":9399,"activeCount":102},[],{"trials":9401,"activeCount":102},[],{"intervention":8584,"totalTrials":229,"cells":9403},{"EARLY_PHASE1":9404,"PHASE1":9406,"PHASE2":9408,"PHASE3":9414,"PHASE4":9416,"NA":9418},{"trials":9405,"activeCount":102},[],{"trials":9407,"activeCount":102},[],{"trials":9409,"activeCount":102},[9410],{"nctId":8574,"briefTitle":8575,"status":108,"phases":9411,"primaryCompletion":1509,"completion":8577,"start":8578,"enrollment":205,"conditions":9412,"interventions":9413},[90,91],[8580,8581],[1840,8583,8584],{"trials":9415,"activeCount":102},[],{"trials":9417,"activeCount":102},[],{"trials":9419,"activeCount":102},[],{"intervention":9421,"totalTrials":229,"cells":9422},"Choline Chloride",{"EARLY_PHASE1":9423,"PHASE1":9425,"PHASE2":9427,"PHASE3":9436,"PHASE4":9438,"NA":9440},{"trials":9424,"activeCount":102},[],{"trials":9426,"activeCount":102},[],{"trials":9428,"activeCount":102},[9429],{"nctId":9430,"briefTitle":9431,"status":248,"phases":9432,"completion":447,"start":9433,"enrollment":4122,"conditions":9434,"interventions":9435},"NCT00031135","Total Parenteral Nutrition-Associated Liver Disease",[91],"2001-09",[7979],[9421],{"trials":9437,"activeCount":102},[],{"trials":9439,"activeCount":102},[],{"trials":9441,"activeCount":102},[],{"intervention":9443,"totalTrials":229,"cells":9444},"Fluorine F 18 DCFPyL",{"EARLY_PHASE1":9445,"PHASE1":9447,"PHASE2":9449,"PHASE3":9463,"PHASE4":9465,"NA":9467},{"trials":9446,"activeCount":102},[],{"trials":9448,"activeCount":102},[],{"trials":9450,"activeCount":102},[9451],{"nctId":9452,"briefTitle":9453,"status":261,"phases":9454,"primaryCompletion":9455,"completion":9456,"start":9457,"enrollment":102,"conditions":9458,"interventions":9460},"NCT04910425","PSMA-Targeted 18F-DCFPyL PET\u002FMRI for the Detection of Prostate Cancer",[91],"2026-06-17","2028-07","2023-06-17",[9459],"Prostate Carcinoma",[9443,9461,9462],"Gadobenate Dimeglumine","Gadobutrol",{"trials":9464,"activeCount":102},[],{"trials":9466,"activeCount":102},[],{"trials":9468,"activeCount":102},[],{"intervention":9461,"totalTrials":229,"cells":9470},{"EARLY_PHASE1":9471,"PHASE1":9473,"PHASE2":9475,"PHASE3":9481,"PHASE4":9483,"NA":9485},{"trials":9472,"activeCount":102},[],{"trials":9474,"activeCount":102},[],{"trials":9476,"activeCount":102},[9477],{"nctId":9452,"briefTitle":9453,"status":261,"phases":9478,"primaryCompletion":9455,"completion":9456,"start":9457,"enrollment":102,"conditions":9479,"interventions":9480},[91],[9459],[9443,9461,9462],{"trials":9482,"activeCount":102},[],{"trials":9484,"activeCount":102},[],{"trials":9486,"activeCount":102},[],{"intervention":9462,"totalTrials":229,"cells":9488},{"EARLY_PHASE1":9489,"PHASE1":9491,"PHASE2":9493,"PHASE3":9499,"PHASE4":9501,"NA":9503},{"trials":9490,"activeCount":102},[],{"trials":9492,"activeCount":102},[],{"trials":9494,"activeCount":102},[9495],{"nctId":9452,"briefTitle":9453,"status":261,"phases":9496,"primaryCompletion":9455,"completion":9456,"start":9457,"enrollment":102,"conditions":9497,"interventions":9498},[91],[9459],[9443,9461,9462],{"trials":9500,"activeCount":102},[],{"trials":9502,"activeCount":102},[],{"trials":9504,"activeCount":102},[],{"intervention":9506,"totalTrials":229,"cells":9507},"Conjugated Estrogens\u002FBazedoxifene",{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9512,"PHASE3":9522,"PHASE4":9524,"NA":9526},{"trials":9509,"activeCount":102},[],{"trials":9511,"activeCount":102},[],{"trials":9513,"activeCount":102},[9514],{"nctId":9515,"briefTitle":9516,"status":108,"phases":9517,"primaryCompletion":9518,"completion":9518,"start":6516,"enrollment":4639,"conditions":9519,"interventions":9521},"NCT02694809","The PROMISE Study: Duavee in Women With DCIS",[91],"2024-06-19",[2267,9520],"Postmenopausal",[9506],{"trials":9523,"activeCount":102},[],{"trials":9525,"activeCount":102},[],{"trials":9527,"activeCount":102},[],{"intervention":1829,"totalTrials":229,"cells":9529},{"EARLY_PHASE1":9530,"PHASE1":9532,"PHASE2":9534,"PHASE3":9540,"PHASE4":9542,"NA":9544},{"trials":9531,"activeCount":102},[],{"trials":9533,"activeCount":102},[],{"trials":9535,"activeCount":102},[9536],{"nctId":1814,"briefTitle":1815,"status":108,"phases":9537,"primaryCompletion":1817,"completion":1818,"start":1819,"enrollment":375,"conditions":9538,"interventions":9539},[91],[1821,1822,1823,1318,1319,1320,1824,1825,1826],[1828,1829],{"trials":9541,"activeCount":102},[],{"trials":9543,"activeCount":102},[],{"trials":9545,"activeCount":102},[],{"intervention":9547,"totalTrials":229,"cells":9548},"Regimen A",{"EARLY_PHASE1":9549,"PHASE1":9551,"PHASE2":9553,"PHASE3":9565,"PHASE4":9567,"NA":9569},{"trials":9550,"activeCount":102},[],{"trials":9552,"activeCount":102},[],{"trials":9554,"activeCount":102},[9555],{"nctId":9556,"briefTitle":9557,"status":108,"phases":9558,"primaryCompletion":9559,"completion":9560,"start":9561,"enrollment":3067,"conditions":9562,"interventions":9563},"NCT00392990","Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma",[91],"2011-12-03","2013-05-28","2007-02-06",[24],[9547,9564],"Regimen B",{"trials":9566,"activeCount":102},[],{"trials":9568,"activeCount":102},[],{"trials":9570,"activeCount":102},[],{"intervention":9564,"totalTrials":229,"cells":9572},{"EARLY_PHASE1":9573,"PHASE1":9575,"PHASE2":9577,"PHASE3":9583,"PHASE4":9585,"NA":9587},{"trials":9574,"activeCount":102},[],{"trials":9576,"activeCount":102},[],{"trials":9578,"activeCount":102},[9579],{"nctId":9556,"briefTitle":9557,"status":108,"phases":9580,"primaryCompletion":9559,"completion":9560,"start":9561,"enrollment":3067,"conditions":9581,"interventions":9582},[91],[24],[9547,9564],{"trials":9584,"activeCount":102},[],{"trials":9586,"activeCount":102},[],{"trials":9588,"activeCount":102},[],{"intervention":9590,"totalTrials":229,"cells":9591},"Methylphenidate",{"EARLY_PHASE1":9592,"PHASE1":9594,"PHASE2":9596,"PHASE3":9606,"PHASE4":9608,"NA":9610},{"trials":9593,"activeCount":102},[],{"trials":9595,"activeCount":102},[],{"trials":9597,"activeCount":102},[9598],{"nctId":9599,"briefTitle":9600,"status":108,"phases":9601,"primaryCompletion":9602,"completion":9602,"start":9603,"enrollment":402,"conditions":9604,"interventions":9605},"NCT05669924","Neural Correlates of Acute Pain Dynamics",[91],"2024-04-26","2022-09-19",[15],[9590],{"trials":9607,"activeCount":102},[],{"trials":9609,"activeCount":102},[],{"trials":9611,"activeCount":102},[],{"intervention":482,"totalTrials":229,"cells":9613},{"EARLY_PHASE1":9614,"PHASE1":9616,"PHASE2":9618,"PHASE3":9624,"PHASE4":9626,"NA":9628},{"trials":9615,"activeCount":102},[],{"trials":9617,"activeCount":102},[],{"trials":9619,"activeCount":102},[9620],{"nctId":469,"briefTitle":470,"status":108,"phases":9621,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":9622,"interventions":9623},[91],[477,478,479,480],[418,482],{"trials":9625,"activeCount":102},[],{"trials":9627,"activeCount":102},[],{"trials":9629,"activeCount":102},[],{"intervention":9631,"totalTrials":229,"cells":9632},"MMFS-202-302",{"EARLY_PHASE1":9633,"PHASE1":9635,"PHASE2":9637,"PHASE3":9646,"PHASE4":9648,"NA":9650},{"trials":9634,"activeCount":102},[],{"trials":9636,"activeCount":102},[],{"trials":9638,"activeCount":102},[9639],{"nctId":9640,"briefTitle":9641,"status":108,"phases":9642,"primaryCompletion":9643,"completion":9643,"start":779,"enrollment":341,"conditions":9644,"interventions":9645},"NCT02237235","Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia",[91],"2017-08",[5240,5241],[9631],{"trials":9647,"activeCount":102},[],{"trials":9649,"activeCount":102},[],{"trials":9651,"activeCount":102},[],{"intervention":4743,"totalTrials":229,"cells":9653},{"EARLY_PHASE1":9654,"PHASE1":9656,"PHASE2":9658,"PHASE3":9664,"PHASE4":9666,"NA":9668},{"trials":9655,"activeCount":102},[],{"trials":9657,"activeCount":102},[],{"trials":9659,"activeCount":102},[9660],{"nctId":4736,"briefTitle":4737,"status":261,"phases":9661,"primaryCompletion":4612,"completion":4612,"start":4739,"enrollment":102,"conditions":9662,"interventions":9663},[91],[4741],[4727,4743,4743],{"trials":9665,"activeCount":102},[],{"trials":9667,"activeCount":102},[],{"trials":9669,"activeCount":102},[],{"intervention":9671,"totalTrials":229,"cells":9672},"Denosumab",{"EARLY_PHASE1":9673,"PHASE1":9675,"PHASE2":9677,"PHASE3":9691,"PHASE4":9693,"NA":9695},{"trials":9674,"activeCount":102},[],{"trials":9676,"activeCount":102},[],{"trials":9678,"activeCount":102},[9679],{"nctId":9680,"briefTitle":9681,"status":248,"phases":9682,"primaryCompletion":9683,"completion":9684,"start":9685,"enrollment":229,"conditions":9686,"interventions":9690},"NCT03070002","Denosumab in Treating Patients With ER and\u002For PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",[91],"2018-03-06","2018-04-24","2017-10-19",[9687,9688,1279,1280,9689,678],"Breast Carcinoma Metastatic in the Bone","Circulating Tumor Cell Count","Progesterone Receptor Positive",[9671],{"trials":9692,"activeCount":102},[],{"trials":9694,"activeCount":102},[],{"trials":9696,"activeCount":102},[],{"intervention":7422,"totalTrials":229,"cells":9698},{"EARLY_PHASE1":9699,"PHASE1":9701,"PHASE2":9703,"PHASE3":9709,"PHASE4":9711,"NA":9713},{"trials":9700,"activeCount":102},[],{"trials":9702,"activeCount":102},[],{"trials":9704,"activeCount":102},[9705],{"nctId":7416,"briefTitle":7417,"status":108,"phases":9706,"primaryCompletion":7419,"completion":7419,"start":6818,"conditions":9707,"interventions":9708},[90,91],[1500],[7422,6870],{"trials":9710,"activeCount":102},[],{"trials":9712,"activeCount":102},[],{"trials":9714,"activeCount":102},[],{"intervention":8399,"totalTrials":229,"cells":9716},{"EARLY_PHASE1":9717,"PHASE1":9719,"PHASE2":9721,"PHASE3":9727,"PHASE4":9729,"NA":9731},{"trials":9718,"activeCount":102},[],{"trials":9720,"activeCount":102},[],{"trials":9722,"activeCount":102},[9723],{"nctId":8391,"briefTitle":8392,"status":261,"phases":9724,"primaryCompletion":8394,"completion":8395,"start":3470,"enrollment":102,"conditions":9725,"interventions":9726},[91],[4124],[8398,8399,8400],{"trials":9728,"activeCount":102},[],{"trials":9730,"activeCount":102},[],{"trials":9732,"activeCount":102},[],{"intervention":8400,"totalTrials":229,"cells":9734},{"EARLY_PHASE1":9735,"PHASE1":9737,"PHASE2":9739,"PHASE3":9745,"PHASE4":9747,"NA":9749},{"trials":9736,"activeCount":102},[],{"trials":9738,"activeCount":102},[],{"trials":9740,"activeCount":102},[9741],{"nctId":8391,"briefTitle":8392,"status":261,"phases":9742,"primaryCompletion":8394,"completion":8395,"start":3470,"enrollment":102,"conditions":9743,"interventions":9744},[91],[4124],[8398,8399,8400],{"trials":9746,"activeCount":102},[],{"trials":9748,"activeCount":102},[],{"trials":9750,"activeCount":102},[],{"intervention":9752,"totalTrials":229,"cells":9753},"henna paste",{"EARLY_PHASE1":9754,"PHASE1":9756,"PHASE2":9758,"PHASE3":9768,"PHASE4":9770,"NA":9772},{"trials":9755,"activeCount":102},[],{"trials":9757,"activeCount":102},[],{"trials":9759,"activeCount":102},[9760],{"nctId":9761,"briefTitle":9762,"status":261,"phases":9763,"primaryCompletion":7730,"completion":7730,"start":9764,"enrollment":102,"conditions":9765,"interventions":9767},"NCT01097850","Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome",[91],"2010-03",[9766],"Hand Foot Skin Syndrome",[9752],{"trials":9769,"activeCount":102},[],{"trials":9771,"activeCount":102},[],{"trials":9773,"activeCount":102},[],{"intervention":1748,"totalTrials":229,"cells":9775},{"EARLY_PHASE1":9776,"PHASE1":9778,"PHASE2":9780,"PHASE3":9786,"PHASE4":9788,"NA":9790},{"trials":9777,"activeCount":102},[],{"trials":9779,"activeCount":102},[],{"trials":9781,"activeCount":102},[9782],{"nctId":1741,"briefTitle":1742,"status":261,"phases":9783,"primaryCompletion":573,"completion":1744,"start":549,"enrollment":102,"conditions":9784,"interventions":9785},[91],[1746],[517,141,440,1732,441,1748,1749],{"trials":9787,"activeCount":102},[],{"trials":9789,"activeCount":102},[],{"trials":9791,"activeCount":102},[],{"intervention":9793,"totalTrials":229,"cells":9794},"Immune ablation and hematopoietic stem cell support.",{"EARLY_PHASE1":9795,"PHASE1":9797,"PHASE2":9799,"PHASE3":9807,"PHASE4":9809,"NA":9811},{"trials":9796,"activeCount":102},[],{"trials":9798,"activeCount":102},[],{"trials":9800,"activeCount":102},[9801],{"nctId":9802,"briefTitle":9803,"status":108,"phases":9804,"primaryCompletion":1846,"completion":5609,"start":921,"enrollment":1788,"conditions":9805,"interventions":9806},"NCT00271934","Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study",[91],[8325],[9793],{"trials":9808,"activeCount":102},[],{"trials":9810,"activeCount":102},[],{"trials":9812,"activeCount":102},[],{"intervention":1648,"totalTrials":229,"cells":9814},{"EARLY_PHASE1":9815,"PHASE1":9817,"PHASE2":9819,"PHASE3":9825,"PHASE4":9827,"NA":9829},{"trials":9816,"activeCount":102},[],{"trials":9818,"activeCount":102},[],{"trials":9820,"activeCount":102},[9821],{"nctId":1640,"briefTitle":1641,"status":108,"phases":9822,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":9823,"interventions":9824},[91],[1635,1634],[1648,632],{"trials":9826,"activeCount":102},[],{"trials":9828,"activeCount":102},[],{"trials":9830,"activeCount":102},[],{"intervention":9832,"totalTrials":229,"cells":9833},"regorafenib",{"EARLY_PHASE1":9834,"PHASE1":9836,"PHASE2":9838,"PHASE3":9849,"PHASE4":9851,"NA":9853},{"trials":9835,"activeCount":102},[],{"trials":9837,"activeCount":102},[],{"trials":9839,"activeCount":102},[9840],{"nctId":9841,"briefTitle":9842,"status":108,"phases":9843,"primaryCompletion":9844,"completion":9077,"start":9845,"enrollment":1548,"conditions":9846,"interventions":9848},"NCT02048722","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",[91],"2019-10-14","2014-06-13",[9847,9084,9124,9087],"Adult Angiosarcoma",[9832],{"trials":9850,"activeCount":102},[],{"trials":9852,"activeCount":102},[],{"trials":9854,"activeCount":102},[],{"intervention":904,"totalTrials":229,"cells":9856},{"EARLY_PHASE1":9857,"PHASE1":9859,"PHASE2":9861,"PHASE3":9867,"PHASE4":9869,"NA":9871},{"trials":9858,"activeCount":102},[],{"trials":9860,"activeCount":102},[],{"trials":9862,"activeCount":102},[9863],{"nctId":896,"briefTitle":897,"status":108,"phases":9864,"primaryCompletion":899,"completion":899,"start":110,"enrollment":900,"conditions":9865,"interventions":9866},[90,91],[902],[886,904],{"trials":9868,"activeCount":102},[],{"trials":9870,"activeCount":102},[],{"trials":9872,"activeCount":102},[],{"intervention":9874,"totalTrials":229,"cells":9875},"Autologous Stem Cell Transplantation",{"EARLY_PHASE1":9876,"PHASE1":9878,"PHASE2":9880,"PHASE3":9889,"PHASE4":9891,"NA":9893},{"trials":9877,"activeCount":102},[],{"trials":9879,"activeCount":102},[],{"trials":9881,"activeCount":102},[9882],{"nctId":9883,"briefTitle":9884,"status":248,"phases":9885,"primaryCompletion":5609,"completion":9886,"start":1797,"enrollment":229,"conditions":9887,"interventions":9888},"NCT00271947","Crohn's Disease Stem Cell Transplantation",[91],"2013-04",[1746],[9874],{"trials":9890,"activeCount":102},[],{"trials":9892,"activeCount":102},[],{"trials":9894,"activeCount":102},[],{"intervention":9896,"totalTrials":229,"cells":9897},"TM5614",{"EARLY_PHASE1":9898,"PHASE1":9900,"PHASE2":9902,"PHASE3":9913,"PHASE4":9915,"NA":9917},{"trials":9899,"activeCount":102},[],{"trials":9901,"activeCount":102},[],{"trials":9903,"activeCount":102},[9904],{"nctId":9905,"briefTitle":9906,"status":151,"phases":9907,"primaryCompletion":9908,"completion":9909,"start":6223,"enrollment":253,"conditions":9910,"interventions":9912},"NCT04634799","Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19",[90,91],"2025-04-23","2025-05-30",[9911],"Covid19",[9896],{"trials":9914,"activeCount":102},[],{"trials":9916,"activeCount":102},[],{"trials":9918,"activeCount":102},[],{"intervention":2279,"totalTrials":229,"cells":9920},{"EARLY_PHASE1":9921,"PHASE1":9923,"PHASE2":9925,"PHASE3":9931,"PHASE4":9933,"NA":9935},{"trials":9922,"activeCount":102},[],{"trials":9924,"activeCount":102},[],{"trials":9926,"activeCount":102},[9927],{"nctId":2271,"briefTitle":2272,"status":108,"phases":9928,"primaryCompletion":1491,"start":2274,"enrollment":28,"conditions":9929,"interventions":9930},[91],[2276,2277],[2279,2280,2281],{"trials":9932,"activeCount":102},[],{"trials":9934,"activeCount":102},[],{"trials":9936,"activeCount":102},[],{"intervention":9938,"totalTrials":229,"cells":9939},"becatecarin",{"EARLY_PHASE1":9940,"PHASE1":9942,"PHASE2":9944,"PHASE3":9952,"PHASE4":9954,"NA":9956},{"trials":9941,"activeCount":102},[],{"trials":9943,"activeCount":102},[],{"trials":9945,"activeCount":102},[9946],{"nctId":9947,"briefTitle":9948,"status":248,"phases":9949,"primaryCompletion":9433,"completion":9433,"start":458,"conditions":9950,"interventions":9951},"NCT00006262","Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer",[91],[7800],[9938],{"trials":9953,"activeCount":102},[],{"trials":9955,"activeCount":102},[],{"trials":9957,"activeCount":102},[],{"intervention":9959,"totalTrials":229,"cells":9960},"Recombinant EphB4-HSA Fusion Protein",{"EARLY_PHASE1":9961,"PHASE1":9963,"PHASE2":9965,"PHASE3":9985,"PHASE4":9987,"NA":9989},{"trials":9962,"activeCount":102},[],{"trials":9964,"activeCount":102},[],{"trials":9966,"activeCount":102},[9967],{"nctId":9968,"briefTitle":9969,"status":200,"phases":9970,"primaryCompletion":9971,"completion":9972,"start":9973,"enrollment":1511,"conditions":9974,"interventions":9984},"NCT04033432","sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",[91],"2021-02-05","2022-06-30","2019-09-20",[9975,9976,9977,9978,9979,9980,9981,9982,3133,9983],"Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents","Metastatic Prostate Adenocarcinoma","Progressive Disease","Prostate Carcinoma Metastatic in the Bone","Prostate Carcinoma Metastatic in the Soft Tissue","PSA Progression","Testosterone Less Than 50 ng\u002FdL",[9959],{"trials":9986,"activeCount":102},[],{"trials":9988,"activeCount":102},[],{"trials":9990,"activeCount":102},[],{"intervention":9992,"totalTrials":229,"cells":9993},"esterified estrogens",{"EARLY_PHASE1":9994,"PHASE1":9996,"PHASE2":9998,"PHASE3":10007,"PHASE4":10009,"NA":10011},{"trials":9995,"activeCount":102},[],{"trials":9997,"activeCount":102},[],{"trials":9999,"activeCount":102},[10000],{"nctId":10001,"briefTitle":10002,"status":248,"phases":10003,"primaryCompletion":7419,"completion":7419,"start":10004,"enrollment":229,"conditions":10005,"interventions":10006},"NCT00131924","High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy",[91],"2004-03",[21],[9992],{"trials":10008,"activeCount":102},[],{"trials":10010,"activeCount":102},[],{"trials":10012,"activeCount":102},[],{"intervention":10014,"totalTrials":229,"cells":10015},"standard of care",{"EARLY_PHASE1":10016,"PHASE1":10018,"PHASE2":10020,"PHASE3":10029,"PHASE4":10031,"NA":10033},{"trials":10017,"activeCount":102},[],{"trials":10019,"activeCount":102},[],{"trials":10021,"activeCount":102},[10022],{"nctId":10023,"briefTitle":10024,"status":108,"phases":10025,"primaryCompletion":1491,"completion":4923,"start":447,"enrollment":36,"conditions":10026,"interventions":10028},"NCT00278525","Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma",[91],[10027],"SYSTEMIC SCLERODERMA",[10014],{"trials":10030,"activeCount":102},[],{"trials":10032,"activeCount":102},[],{"trials":10034,"activeCount":102},[],{"intervention":3543,"totalTrials":229,"cells":10036},{"EARLY_PHASE1":10037,"PHASE1":10039,"PHASE2":10041,"PHASE3":10047,"PHASE4":10049,"NA":10051},{"trials":10038,"activeCount":102},[],{"trials":10040,"activeCount":102},[],{"trials":10042,"activeCount":102},[10043],{"nctId":3530,"briefTitle":3531,"status":261,"phases":10044,"primaryCompletion":3533,"completion":3534,"start":3535,"enrollment":102,"conditions":10045,"interventions":10046},[91],[3537,3538,3539,3540,3541],[166,143,3543],{"trials":10048,"activeCount":102},[],{"trials":10050,"activeCount":102},[],{"trials":10052,"activeCount":102},[],{"intervention":1850,"totalTrials":229,"cells":10054},{"EARLY_PHASE1":10055,"PHASE1":10057,"PHASE2":10059,"PHASE3":10065,"PHASE4":10067,"NA":10069},{"trials":10056,"activeCount":102},[],{"trials":10058,"activeCount":102},[],{"trials":10060,"activeCount":102},[10061],{"nctId":1842,"briefTitle":1843,"status":248,"phases":10062,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1329,"conditions":10063,"interventions":10064},[91],[912],[1539,1540,1850,1851],{"trials":10066,"activeCount":102},[],{"trials":10068,"activeCount":102},[],{"trials":10070,"activeCount":102},[],{"intervention":10072,"totalTrials":229,"cells":10073},"maraviroc",{"EARLY_PHASE1":10074,"PHASE1":10076,"PHASE2":10078,"PHASE3":10089,"PHASE4":10091,"NA":10093},{"trials":10075,"activeCount":102},[],{"trials":10077,"activeCount":102},[],{"trials":10079,"activeCount":102},[10080],{"nctId":10081,"briefTitle":10082,"status":108,"phases":10083,"primaryCompletion":9886,"completion":9886,"start":1714,"enrollment":3067,"conditions":10084,"interventions":10086},"NCT00993148","Maraviroc Plus Darunavir\u002FRitonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1",[91],[10085,7453],"HIV-1 Infection",[10072,10087,10088],"darunavir","ritonavir",{"trials":10090,"activeCount":102},[],{"trials":10092,"activeCount":102},[],{"trials":10094,"activeCount":102},[],{"intervention":10087,"totalTrials":229,"cells":10096},{"EARLY_PHASE1":10097,"PHASE1":10099,"PHASE2":10101,"PHASE3":10107,"PHASE4":10109,"NA":10111},{"trials":10098,"activeCount":102},[],{"trials":10100,"activeCount":102},[],{"trials":10102,"activeCount":102},[10103],{"nctId":10081,"briefTitle":10082,"status":108,"phases":10104,"primaryCompletion":9886,"completion":9886,"start":1714,"enrollment":3067,"conditions":10105,"interventions":10106},[91],[10085,7453],[10072,10087,10088],{"trials":10108,"activeCount":102},[],{"trials":10110,"activeCount":102},[],{"trials":10112,"activeCount":102},[],{"intervention":10088,"totalTrials":229,"cells":10114},{"EARLY_PHASE1":10115,"PHASE1":10117,"PHASE2":10119,"PHASE3":10125,"PHASE4":10127,"NA":10129},{"trials":10116,"activeCount":102},[],{"trials":10118,"activeCount":102},[],{"trials":10120,"activeCount":102},[10121],{"nctId":10081,"briefTitle":10082,"status":108,"phases":10122,"primaryCompletion":9886,"completion":9886,"start":1714,"enrollment":3067,"conditions":10123,"interventions":10124},[91],[10085,7453],[10072,10087,10088],{"trials":10126,"activeCount":102},[],{"trials":10128,"activeCount":102},[],{"trials":10130,"activeCount":102},[],{"intervention":10132,"totalTrials":229,"cells":10133},"Lovastatin",{"EARLY_PHASE1":10134,"PHASE1":10136,"PHASE2":10138,"PHASE3":10150,"PHASE4":10152,"NA":10154},{"trials":10135,"activeCount":102},[],{"trials":10137,"activeCount":102},[],{"trials":10139,"activeCount":102},[10140],{"nctId":10141,"briefTitle":10142,"status":261,"phases":10143,"start":998,"enrollment":102,"conditions":10144,"interventions":10149},"NCT01110642","Novel Treatment for Syndromic Ichthyoses",[91],[10145,10146,10147,10148],"Syndromic Ichthyoses","CHILD Syndrome","Smith Lemli Opitz Syndrome","Conradi Syndrome",[10132],{"trials":10151,"activeCount":102},[],{"trials":10153,"activeCount":102},[],{"trials":10155,"activeCount":102},[],{"intervention":10157,"totalTrials":229,"cells":10158},"vatalanib",{"EARLY_PHASE1":10159,"PHASE1":10161,"PHASE2":10163,"PHASE3":10172,"PHASE4":10174,"NA":10176},{"trials":10160,"activeCount":102},[],{"trials":10162,"activeCount":102},[],{"trials":10164,"activeCount":102},[10165],{"nctId":10166,"briefTitle":10167,"status":108,"phases":10168,"primaryCompletion":4638,"completion":10169,"start":1847,"enrollment":3067,"conditions":10170,"interventions":10171},"NCT00348790","Vatalanib in Treating Patients With Recurrent or Progressive Meningioma",[91],"2013-07",[1495,1927],[10157],{"trials":10173,"activeCount":102},[],{"trials":10175,"activeCount":102},[],{"trials":10177,"activeCount":102},[],{"intervention":1978,"totalTrials":229,"cells":10179},{"EARLY_PHASE1":10180,"PHASE1":10182,"PHASE2":10184,"PHASE3":10190,"PHASE4":10192,"NA":10194},{"trials":10181,"activeCount":102},[],{"trials":10183,"activeCount":102},[],{"trials":10185,"activeCount":102},[10186],{"nctId":1969,"briefTitle":1970,"status":248,"phases":10187,"primaryCompletion":434,"completion":1972,"start":1973,"enrollment":1974,"conditions":10188,"interventions":10189},[90,91],[912],[1540,1514,1851,1977,1978,1979],{"trials":10191,"activeCount":102},[],{"trials":10193,"activeCount":102},[],{"trials":10195,"activeCount":102},[],{"intervention":1979,"totalTrials":229,"cells":10197},{"EARLY_PHASE1":10198,"PHASE1":10200,"PHASE2":10202,"PHASE3":10208,"PHASE4":10210,"NA":10212},{"trials":10199,"activeCount":102},[],{"trials":10201,"activeCount":102},[],{"trials":10203,"activeCount":102},[10204],{"nctId":1969,"briefTitle":1970,"status":248,"phases":10205,"primaryCompletion":434,"completion":1972,"start":1973,"enrollment":1974,"conditions":10206,"interventions":10207},[90,91],[912],[1540,1514,1851,1977,1978,1979],{"trials":10209,"activeCount":102},[],{"trials":10211,"activeCount":102},[],{"trials":10213,"activeCount":102},[],{"intervention":10215,"totalTrials":229,"cells":10216},"urea 40% cream",{"EARLY_PHASE1":10217,"PHASE1":10219,"PHASE2":10221,"PHASE3":10235,"PHASE4":10237,"NA":10239},{"trials":10218,"activeCount":102},[],{"trials":10220,"activeCount":102},[],{"trials":10222,"activeCount":102},[10223],{"nctId":10224,"briefTitle":10225,"status":248,"phases":10226,"primaryCompletion":10227,"completion":10227,"start":7909,"enrollment":475,"conditions":10228,"interventions":10231},"NCT00667589","Sorafenib-induced Hand- Foot Skin Reaction Treatment",[91],"2010-12",[10229,10230],"Hand-foot Skin Reaction","Rash",[10215,10232,10233,10234],"fluocinonide 0.05% cream","tazarotene 0.1% cream","bland emollient cream",{"trials":10236,"activeCount":102},[],{"trials":10238,"activeCount":102},[],{"trials":10240,"activeCount":102},[],{"intervention":10232,"totalTrials":229,"cells":10242},{"EARLY_PHASE1":10243,"PHASE1":10245,"PHASE2":10247,"PHASE3":10253,"PHASE4":10255,"NA":10257},{"trials":10244,"activeCount":102},[],{"trials":10246,"activeCount":102},[],{"trials":10248,"activeCount":102},[10249],{"nctId":10224,"briefTitle":10225,"status":248,"phases":10250,"primaryCompletion":10227,"completion":10227,"start":7909,"enrollment":475,"conditions":10251,"interventions":10252},[91],[10229,10230],[10215,10232,10233,10234],{"trials":10254,"activeCount":102},[],{"trials":10256,"activeCount":102},[],{"trials":10258,"activeCount":102},[],{"intervention":10233,"totalTrials":229,"cells":10260},{"EARLY_PHASE1":10261,"PHASE1":10263,"PHASE2":10265,"PHASE3":10271,"PHASE4":10273,"NA":10275},{"trials":10262,"activeCount":102},[],{"trials":10264,"activeCount":102},[],{"trials":10266,"activeCount":102},[10267],{"nctId":10224,"briefTitle":10225,"status":248,"phases":10268,"primaryCompletion":10227,"completion":10227,"start":7909,"enrollment":475,"conditions":10269,"interventions":10270},[91],[10229,10230],[10215,10232,10233,10234],{"trials":10272,"activeCount":102},[],{"trials":10274,"activeCount":102},[],{"trials":10276,"activeCount":102},[],{"intervention":10234,"totalTrials":229,"cells":10278},{"EARLY_PHASE1":10279,"PHASE1":10281,"PHASE2":10283,"PHASE3":10289,"PHASE4":10291,"NA":10293},{"trials":10280,"activeCount":102},[],{"trials":10282,"activeCount":102},[],{"trials":10284,"activeCount":102},[10285],{"nctId":10224,"briefTitle":10225,"status":248,"phases":10286,"primaryCompletion":10227,"completion":10227,"start":7909,"enrollment":475,"conditions":10287,"interventions":10288},[91],[10229,10230],[10215,10232,10233,10234],{"trials":10290,"activeCount":102},[],{"trials":10292,"activeCount":102},[],{"trials":10294,"activeCount":102},[],{"intervention":10296,"totalTrials":229,"cells":10297},"Carvedilol",{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10302,"PHASE3":10312,"PHASE4":10314,"NA":10316},{"trials":10299,"activeCount":102},[],{"trials":10301,"activeCount":102},[],{"trials":10303,"activeCount":102},[10304],{"nctId":10305,"briefTitle":10306,"status":200,"phases":10307,"primaryCompletion":778,"completion":778,"start":1684,"enrollment":5521,"conditions":10308,"interventions":10311},"NCT02993198","A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging",[91],[10309,10310],"HER2 Positive Breast Cancer","Cardiovascular Abnormalities",[10296],{"trials":10313,"activeCount":102},[],{"trials":10315,"activeCount":102},[],{"trials":10317,"activeCount":102},[],{"intervention":1986,"totalTrials":229,"cells":10319},{"EARLY_PHASE1":10320,"PHASE1":10322,"PHASE2":10324,"PHASE3":10330,"PHASE4":10332,"NA":10334},{"trials":10321,"activeCount":102},[],{"trials":10323,"activeCount":102},[],{"trials":10325,"activeCount":102},[10326],{"nctId":1981,"briefTitle":1982,"status":108,"phases":10327,"primaryCompletion":1972,"completion":1972,"start":1973,"conditions":10328,"interventions":10329},[90,91],[912],[1540,1986],{"trials":10331,"activeCount":102},[],{"trials":10333,"activeCount":102},[],{"trials":10335,"activeCount":102},[],{"intervention":493,"totalTrials":229,"cells":10337},{"EARLY_PHASE1":10338,"PHASE1":10340,"PHASE2":10342,"PHASE3":10348,"PHASE4":10350,"NA":10352},{"trials":10339,"activeCount":102},[],{"trials":10341,"activeCount":102},[],{"trials":10343,"activeCount":102},[10344],{"nctId":484,"briefTitle":485,"status":248,"phases":10345,"primaryCompletion":487,"completion":488,"start":489,"enrollment":31,"conditions":10346,"interventions":10347},[90,91],[491],[493,141,440,494,418,441,453],{"trials":10349,"activeCount":102},[],{"trials":10351,"activeCount":102},[],{"trials":10353,"activeCount":102},[],{"intervention":1322,"totalTrials":229,"cells":10355},{"EARLY_PHASE1":10356,"PHASE1":10358,"PHASE2":10360,"PHASE3":10366,"PHASE4":10368,"NA":10370},{"trials":10357,"activeCount":102},[],{"trials":10359,"activeCount":102},[],{"trials":10361,"activeCount":102},[10362],{"nctId":1310,"briefTitle":1311,"status":108,"phases":10363,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":10364,"interventions":10365},[91],[1318,1319,1320],[1322,1228],{"trials":10367,"activeCount":102},[],{"trials":10369,"activeCount":102},[],{"trials":10371,"activeCount":102},[],{"intervention":10373,"totalTrials":229,"cells":10374},"Standard treatment with a conventional drug",{"EARLY_PHASE1":10375,"PHASE1":10377,"PHASE2":10379,"PHASE3":10388,"PHASE4":10390,"NA":10392},{"trials":10376,"activeCount":102},[],{"trials":10378,"activeCount":102},[],{"trials":10380,"activeCount":102},[10381],{"nctId":10382,"briefTitle":10383,"status":108,"phases":10384,"primaryCompletion":534,"completion":488,"start":10385,"enrollment":4720,"conditions":10386,"interventions":10387},"NCT00273364","Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study",[91],"2005-11-16",[831],[10373],{"trials":10389,"activeCount":102},[],{"trials":10391,"activeCount":102},[],{"trials":10393,"activeCount":102},[],{"intervention":10395,"totalTrials":229,"cells":10396},"Cohort 1:Nilotinib Oral",{"EARLY_PHASE1":10397,"PHASE1":10399,"PHASE2":10401,"PHASE3":10414,"PHASE4":10416,"NA":10418},{"trials":10398,"activeCount":102},[],{"trials":10400,"activeCount":102},[],{"trials":10402,"activeCount":102},[10403],{"nctId":10404,"briefTitle":10405,"status":108,"phases":10406,"primaryCompletion":10407,"completion":10408,"start":414,"enrollment":10409,"conditions":10410,"interventions":10412},"NCT03205488","Nilotinib in Parkinson's Disease",[91],"2019-08-26","2019-09-28",76,[10411],"Parkinson Disease",[10395,10413],"Cohort 2: Nilotinib Oral",{"trials":10415,"activeCount":102},[],{"trials":10417,"activeCount":102},[],{"trials":10419,"activeCount":102},[],{"intervention":10413,"totalTrials":229,"cells":10421},{"EARLY_PHASE1":10422,"PHASE1":10424,"PHASE2":10426,"PHASE3":10432,"PHASE4":10434,"NA":10436},{"trials":10423,"activeCount":102},[],{"trials":10425,"activeCount":102},[],{"trials":10427,"activeCount":102},[10428],{"nctId":10404,"briefTitle":10405,"status":108,"phases":10429,"primaryCompletion":10407,"completion":10408,"start":414,"enrollment":10409,"conditions":10430,"interventions":10431},[91],[10411],[10395,10413],{"trials":10433,"activeCount":102},[],{"trials":10435,"activeCount":102},[],{"trials":10437,"activeCount":102},[],{"intervention":10439,"totalTrials":229,"cells":10440},"Alwextin cream",{"EARLY_PHASE1":10441,"PHASE1":10443,"PHASE2":10445,"PHASE3":10454,"PHASE4":10456,"NA":10458},{"trials":10442,"activeCount":102},[],{"trials":10444,"activeCount":102},[],{"trials":10446,"activeCount":102},[10447],{"nctId":10448,"briefTitle":10449,"status":108,"phases":10450,"primaryCompletion":4638,"completion":4638,"start":10451,"enrollment":900,"conditions":10452,"interventions":10453},"NCT00825565","Study of Alwextin® Cream in Treating Epidermolysis Bullosa",[91],"2009-02",[3964],[10439],{"trials":10455,"activeCount":102},[],{"trials":10457,"activeCount":102},[],{"trials":10459,"activeCount":102},[],{"intervention":10461,"totalTrials":229,"cells":10462},"Allogeneic Stem Cell Therapy",{"EARLY_PHASE1":10463,"PHASE1":10465,"PHASE2":10467,"PHASE3":10475,"PHASE4":10477,"NA":10479},{"trials":10464,"activeCount":102},[],{"trials":10466,"activeCount":102},[],{"trials":10468,"activeCount":102},[10469],{"nctId":10470,"briefTitle":10471,"status":248,"phases":10472,"primaryCompletion":433,"completion":433,"start":1490,"enrollment":253,"conditions":10473,"interventions":10474},"NCT01288053","Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease",[90,91],[1746],[10461],{"trials":10476,"activeCount":102},[],{"trials":10478,"activeCount":102},[],{"trials":10480,"activeCount":102},[],{"intervention":10482,"totalTrials":229,"cells":10483},"VM202",{"EARLY_PHASE1":10484,"PHASE1":10486,"PHASE2":10488,"PHASE3":10499,"PHASE4":10501,"NA":10503},{"trials":10485,"activeCount":102},[],{"trials":10487,"activeCount":102},[],{"trials":10489,"activeCount":102},[10490],{"nctId":10491,"briefTitle":10492,"status":108,"phases":10493,"primaryCompletion":10494,"completion":10495,"start":10496,"enrollment":2601,"conditions":10497,"interventions":10498},"NCT03363165","Hepatocyte Growth Factor to Improve Functioning in PAD",[91],"2023-02-10","2023-09-05","2018-01-01",[1022],[10482],{"trials":10500,"activeCount":102},[],{"trials":10502,"activeCount":102},[],{"trials":10504,"activeCount":102},[],{"intervention":10506,"totalTrials":229,"cells":10507},"tretinoin",{"EARLY_PHASE1":10508,"PHASE1":10510,"PHASE2":10512,"PHASE3":10521,"PHASE4":10523,"NA":10525},{"trials":10509,"activeCount":102},[],{"trials":10511,"activeCount":102},[],{"trials":10513,"activeCount":102},[10514],{"nctId":10515,"briefTitle":10516,"status":108,"phases":10517,"primaryCompletion":2070,"completion":2070,"start":10518,"conditions":10519,"interventions":10520},"NCT00002479","Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome",[91],"1991-10",[24],[10506],{"trials":10522,"activeCount":102},[],{"trials":10524,"activeCount":102},[],{"trials":10526,"activeCount":102},[],{"intervention":6937,"totalTrials":229,"cells":10528},{"EARLY_PHASE1":10529,"PHASE1":10531,"PHASE2":10533,"PHASE3":10539,"PHASE4":10541,"NA":10543},{"trials":10530,"activeCount":102},[],{"trials":10532,"activeCount":102},[],{"trials":10534,"activeCount":102},[10535],{"nctId":6929,"briefTitle":6930,"status":248,"phases":10536,"primaryCompletion":6932,"completion":6933,"start":6934,"enrollment":3314,"conditions":10537,"interventions":10538},[90,91],[24],[6915,2085,6937],{"trials":10540,"activeCount":102},[],{"trials":10542,"activeCount":102},[],{"trials":10544,"activeCount":102},[],{"intervention":1658,"totalTrials":229,"cells":10546},{"EARLY_PHASE1":10547,"PHASE1":10549,"PHASE2":10551,"PHASE3":10557,"PHASE4":10559,"NA":10561},{"trials":10548,"activeCount":102},[],{"trials":10550,"activeCount":102},[],{"trials":10552,"activeCount":102},[10553],{"nctId":1650,"briefTitle":1651,"status":108,"phases":10554,"primaryCompletion":1653,"completion":603,"start":1654,"enrollment":1655,"conditions":10555,"interventions":10556},[91],[21],[632,1658],{"trials":10558,"activeCount":102},[],{"trials":10560,"activeCount":102},[],{"trials":10562,"activeCount":102},[],{"intervention":10564,"totalTrials":229,"cells":10565},"Docetaxel and Prednisone",{"EARLY_PHASE1":10566,"PHASE1":10568,"PHASE2":10570,"PHASE3":10580,"PHASE4":10582,"NA":10584},{"trials":10567,"activeCount":102},[],{"trials":10569,"activeCount":102},[],{"trials":10571,"activeCount":102},[10572],{"nctId":10573,"briefTitle":10574,"status":261,"phases":10575,"primaryCompletion":998,"completion":998,"start":5672,"enrollment":102,"conditions":10576,"interventions":10578},"NCT01087580","Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer",[91],[10577],"PROSTATE CANCER",[10564,10564,10579],"Radiation Therapy",{"trials":10581,"activeCount":102},[],{"trials":10583,"activeCount":102},[],{"trials":10585,"activeCount":102},[],{"intervention":10579,"totalTrials":229,"cells":10587},{"EARLY_PHASE1":10588,"PHASE1":10590,"PHASE2":10592,"PHASE3":10598,"PHASE4":10600,"NA":10602},{"trials":10589,"activeCount":102},[],{"trials":10591,"activeCount":102},[],{"trials":10593,"activeCount":102},[10594],{"nctId":10573,"briefTitle":10574,"status":261,"phases":10595,"primaryCompletion":998,"completion":998,"start":5672,"enrollment":102,"conditions":10596,"interventions":10597},[91],[10577],[10564,10564,10579],{"trials":10599,"activeCount":102},[],{"trials":10601,"activeCount":102},[],{"trials":10603,"activeCount":102},[],{"intervention":9175,"totalTrials":229,"cells":10605},{"EARLY_PHASE1":10606,"PHASE1":10608,"PHASE2":10610,"PHASE3":10616,"PHASE4":10618,"NA":10620},{"trials":10607,"activeCount":102},[],{"trials":10609,"activeCount":102},[],{"trials":10611,"activeCount":102},[10612],{"nctId":9165,"briefTitle":9166,"status":108,"phases":10613,"primaryCompletion":9168,"completion":9168,"start":9169,"enrollment":131,"conditions":10614,"interventions":10615},[91],[7480,7479,9171,9172,9173],[9175,9156],{"trials":10617,"activeCount":102},[],{"trials":10619,"activeCount":102},[],{"trials":10621,"activeCount":102},[],{"intervention":1348,"totalTrials":229,"cells":10623},{"EARLY_PHASE1":10624,"PHASE1":10626,"PHASE2":10628,"PHASE3":10634,"PHASE4":10636,"NA":10638},{"trials":10625,"activeCount":102},[],{"trials":10627,"activeCount":102},[],{"trials":10629,"activeCount":102},[10630],{"nctId":1334,"briefTitle":1335,"status":200,"phases":10631,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":156,"conditions":10632,"interventions":10633},[91],[1341,1342,1343,1344,1345],[1347,142,1228,1348],{"trials":10635,"activeCount":102},[],{"trials":10637,"activeCount":102},[],{"trials":10639,"activeCount":102},[],{"intervention":10641,"totalTrials":229,"cells":10642},"AZ compound",{"EARLY_PHASE1":10643,"PHASE1":10645,"PHASE2":10647,"PHASE3":10659,"PHASE4":10661,"NA":10663},{"trials":10644,"activeCount":102},[],{"trials":10646,"activeCount":102},[],{"trials":10648,"activeCount":102},[10649],{"nctId":10650,"briefTitle":10651,"status":108,"phases":10652,"primaryCompletion":10653,"completion":10654,"start":10655,"enrollment":19,"conditions":10656,"interventions":10657},"NCT02874144","Anti-Inflammatory Agent in Sinusitis",[91],"2020-01-07","2020-08-10","2016-06-20",[268],[10641,10658],"Intranasal corticosteroid",{"trials":10660,"activeCount":102},[],{"trials":10662,"activeCount":102},[],{"trials":10664,"activeCount":102},[],{"intervention":10658,"totalTrials":229,"cells":10666},{"EARLY_PHASE1":10667,"PHASE1":10669,"PHASE2":10671,"PHASE3":10677,"PHASE4":10679,"NA":10681},{"trials":10668,"activeCount":102},[],{"trials":10670,"activeCount":102},[],{"trials":10672,"activeCount":102},[10673],{"nctId":10650,"briefTitle":10651,"status":108,"phases":10674,"primaryCompletion":10653,"completion":10654,"start":10655,"enrollment":19,"conditions":10675,"interventions":10676},[91],[268],[10641,10658],{"trials":10678,"activeCount":102},[],{"trials":10680,"activeCount":102},[],{"trials":10682,"activeCount":102},[],{"intervention":10684,"totalTrials":229,"cells":10685},"octreotide acetate",{"EARLY_PHASE1":10686,"PHASE1":10688,"PHASE2":10690,"PHASE3":10703,"PHASE4":10705,"NA":10707},{"trials":10687,"activeCount":102},[],{"trials":10689,"activeCount":102},[],{"trials":10691,"activeCount":102},[10692],{"nctId":10693,"briefTitle":10694,"status":108,"phases":10695,"primaryCompletion":110,"completion":110,"start":111,"conditions":10696,"interventions":10702},"NCT00004895","Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery",[91],[2049,10697,10698,2173,10699,10700,7800,1874,10701,460],"Constipation, Impaction, and Bowel Obstruction","Extrahepatic Bile Duct Cancer","Gastrointestinal Stromal Tumor","Nausea and Vomiting","Peritoneal Cavity Cancer",[10684],{"trials":10704,"activeCount":102},[],{"trials":10706,"activeCount":102},[],{"trials":10708,"activeCount":102},[],{"intervention":10710,"totalTrials":229,"cells":10711},"Ibuprofen",{"EARLY_PHASE1":10712,"PHASE1":10714,"PHASE2":10716,"PHASE3":10728,"PHASE4":10730,"NA":10732},{"trials":10713,"activeCount":102},[],{"trials":10715,"activeCount":102},[],{"trials":10717,"activeCount":102},[10718],{"nctId":10719,"briefTitle":10720,"status":261,"phases":10721,"primaryCompletion":10722,"completion":10722,"start":10723,"enrollment":102,"conditions":10724,"interventions":10726},"NCT02443142","Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury",[91],"2016-07-01","2015-05-01",[10725],"Brain Concussion",[10710,10727],"Acetaminophen",{"trials":10729,"activeCount":102},[],{"trials":10731,"activeCount":102},[],{"trials":10733,"activeCount":102},[],{"intervention":10727,"totalTrials":229,"cells":10735},{"EARLY_PHASE1":10736,"PHASE1":10738,"PHASE2":10740,"PHASE3":10746,"PHASE4":10748,"NA":10750},{"trials":10737,"activeCount":102},[],{"trials":10739,"activeCount":102},[],{"trials":10741,"activeCount":102},[10742],{"nctId":10719,"briefTitle":10720,"status":261,"phases":10743,"primaryCompletion":10722,"completion":10722,"start":10723,"enrollment":102,"conditions":10744,"interventions":10745},[91],[10725],[10710,10727],{"trials":10747,"activeCount":102},[],{"trials":10749,"activeCount":102},[],{"trials":10751,"activeCount":102},[],{"intervention":10753,"totalTrials":229,"cells":10754},"Ghrelin",{"EARLY_PHASE1":10755,"PHASE1":10757,"PHASE2":10759,"PHASE3":10768,"PHASE4":10770,"NA":10772},{"trials":10756,"activeCount":102},[],{"trials":10758,"activeCount":102},[],{"trials":10760,"activeCount":102},[10761],{"nctId":10762,"briefTitle":10763,"status":108,"phases":10764,"primaryCompletion":2854,"completion":2854,"start":10765,"enrollment":3067,"conditions":10766,"interventions":10767},"NCT04377126","Unacylated Ghrelin to Improve Functioning in PAD",[91],"2020-07-08",[1022],[10753],{"trials":10769,"activeCount":102},[],{"trials":10771,"activeCount":102},[],{"trials":10773,"activeCount":102},[],{"intervention":10775,"totalTrials":229,"cells":10776},"Milnacipran",{"EARLY_PHASE1":10777,"PHASE1":10779,"PHASE2":10781,"PHASE3":10790,"PHASE4":10792,"NA":10794},{"trials":10778,"activeCount":102},[],{"trials":10780,"activeCount":102},[],{"trials":10782,"activeCount":102},[10783],{"nctId":10784,"briefTitle":10785,"status":108,"phases":10786,"primaryCompletion":7730,"completion":5609,"start":10787,"enrollment":402,"conditions":10788,"interventions":10789},"NCT01225068","Effect of Milnacipran in Chronic Neuropathic Low Back Pain",[91],"2010-10",[4834],[10775],{"trials":10791,"activeCount":102},[],{"trials":10793,"activeCount":102},[],{"trials":10795,"activeCount":102},[],{"intervention":2013,"totalTrials":229,"cells":10797},{"EARLY_PHASE1":10798,"PHASE1":10800,"PHASE2":10802,"PHASE3":10808,"PHASE4":10810,"NA":10812},{"trials":10799,"activeCount":102},[],{"trials":10801,"activeCount":102},[],{"trials":10803,"activeCount":102},[10804],{"nctId":1997,"briefTitle":1998,"status":200,"phases":10805,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":156,"conditions":10806,"interventions":10807},[91],[2004,2005,2006,2007,2008,2009,2010,1387,1388,1389,2011],[2013,1540],{"trials":10809,"activeCount":102},[],{"trials":10811,"activeCount":102},[],{"trials":10813,"activeCount":102},[],{"intervention":8826,"totalTrials":229,"cells":10815},{"EARLY_PHASE1":10816,"PHASE1":10818,"PHASE2":10820,"PHASE3":10826,"PHASE4":10828,"NA":10830},{"trials":10817,"activeCount":102},[],{"trials":10819,"activeCount":102},[],{"trials":10821,"activeCount":102},[10822],{"nctId":8817,"briefTitle":8818,"status":248,"phases":10823,"primaryCompletion":1492,"completion":8820,"start":8821,"enrollment":156,"conditions":10824,"interventions":10825},[90,91],[8823],[453,8825,8826],{"trials":10827,"activeCount":102},[],{"trials":10829,"activeCount":102},[],{"trials":10831,"activeCount":102},[],{"intervention":10833,"totalTrials":229,"cells":10834},"Pidilizumab",{"EARLY_PHASE1":10835,"PHASE1":10837,"PHASE2":10839,"PHASE3":10850,"PHASE4":10852,"NA":10854},{"trials":10836,"activeCount":102},[],{"trials":10838,"activeCount":102},[],{"trials":10840,"activeCount":102},[10841],{"nctId":10842,"briefTitle":10843,"status":248,"phases":10844,"primaryCompletion":6516,"completion":6516,"start":10845,"enrollment":582,"conditions":10846,"interventions":10849},"NCT02530125","Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission",[91],"2015-09",[10847,10848],"Stage III Diffuse Large B-Cell Lymphoma","Stage IV Diffuse Large B-Cell Lymphoma",[10833],{"trials":10851,"activeCount":102},[],{"trials":10853,"activeCount":102},[],{"trials":10855,"activeCount":102},[],{"intervention":10857,"totalTrials":229,"cells":10858},"efalizumab",{"EARLY_PHASE1":10859,"PHASE1":10861,"PHASE2":10863,"PHASE3":10873,"PHASE4":10875,"NA":10877},{"trials":10860,"activeCount":102},[],{"trials":10862,"activeCount":102},[],{"trials":10864,"activeCount":102},[10865],{"nctId":10866,"briefTitle":10867,"status":261,"phases":10868,"primaryCompletion":10869,"completion":10869,"start":6362,"enrollment":102,"conditions":10870,"interventions":10872},"NCT00746980","Efalizumab in the Treatment of Alopecia, Phase II",[91],"2009-07",[10871],"Alopecia Totalis",[10857],{"trials":10874,"activeCount":102},[],{"trials":10876,"activeCount":102},[],{"trials":10878,"activeCount":102},[],{"intervention":214,"totalTrials":229,"cells":10880},{"EARLY_PHASE1":10881,"PHASE1":10883,"PHASE2":10885,"PHASE3":10891,"PHASE4":10893,"NA":10895},{"trials":10882,"activeCount":102},[],{"trials":10884,"activeCount":102},[],{"trials":10886,"activeCount":102},[10887],{"nctId":198,"briefTitle":199,"status":200,"phases":10888,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":10889,"interventions":10890},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"trials":10892,"activeCount":102},[],{"trials":10894,"activeCount":102},[],{"trials":10896,"activeCount":102},[],{"intervention":216,"totalTrials":229,"cells":10898},{"EARLY_PHASE1":10899,"PHASE1":10901,"PHASE2":10903,"PHASE3":10909,"PHASE4":10911,"NA":10913},{"trials":10900,"activeCount":102},[],{"trials":10902,"activeCount":102},[],{"trials":10904,"activeCount":102},[10905],{"nctId":198,"briefTitle":199,"status":200,"phases":10906,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":10907,"interventions":10908},[90,91],[207,208,133,209,210],[141,212,142,213,214,215,97,143,216,145],{"trials":10910,"activeCount":102},[],{"trials":10912,"activeCount":102},[],{"trials":10914,"activeCount":102},[],{"intervention":10916,"totalTrials":229,"cells":10917},"Regadenoson",{"EARLY_PHASE1":10918,"PHASE1":10920,"PHASE2":10922,"PHASE3":10932,"PHASE4":10934,"NA":10936},{"trials":10919,"activeCount":102},[],{"trials":10921,"activeCount":102},[],{"trials":10923,"activeCount":102},[10924],{"nctId":10925,"briefTitle":10926,"status":108,"phases":10927,"primaryCompletion":5608,"completion":5608,"start":4922,"enrollment":224,"conditions":10928,"interventions":10930},"NCT01655043","Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI",[91],[10929],"Myocardial Ischemia",[10916,10931],"gadofoveset trisodium",{"trials":10933,"activeCount":102},[],{"trials":10935,"activeCount":102},[],{"trials":10937,"activeCount":102},[],{"intervention":10931,"totalTrials":229,"cells":10939},{"EARLY_PHASE1":10940,"PHASE1":10942,"PHASE2":10944,"PHASE3":10950,"PHASE4":10952,"NA":10954},{"trials":10941,"activeCount":102},[],{"trials":10943,"activeCount":102},[],{"trials":10945,"activeCount":102},[10946],{"nctId":10925,"briefTitle":10926,"status":108,"phases":10947,"primaryCompletion":5608,"completion":5608,"start":4922,"enrollment":224,"conditions":10948,"interventions":10949},[91],[10929],[10916,10931],{"trials":10951,"activeCount":102},[],{"trials":10953,"activeCount":102},[],{"trials":10955,"activeCount":102},[],{"intervention":8482,"totalTrials":229,"cells":10957},{"EARLY_PHASE1":10958,"PHASE1":10960,"PHASE2":10962,"PHASE3":10968,"PHASE4":10970,"NA":10972},{"trials":10959,"activeCount":102},[],{"trials":10961,"activeCount":102},[],{"trials":10963,"activeCount":102},[10964],{"nctId":8476,"briefTitle":8477,"status":248,"phases":10965,"primaryCompletion":6784,"completion":6784,"start":8479,"conditions":10966,"interventions":10967},[91],[21],[180,8482],{"trials":10969,"activeCount":102},[],{"trials":10971,"activeCount":102},[],{"trials":10973,"activeCount":102},[],{"intervention":7152,"totalTrials":229,"cells":10975},{"EARLY_PHASE1":10976,"PHASE1":10978,"PHASE2":10980,"PHASE3":10986,"PHASE4":10988,"NA":10990},{"trials":10977,"activeCount":102},[],{"trials":10979,"activeCount":102},[],{"trials":10981,"activeCount":102},[10982],{"nctId":7146,"briefTitle":7147,"status":108,"phases":10983,"primaryCompletion":7149,"completion":7149,"start":6785,"conditions":10984,"interventions":10985},[90,91],[21,115,24,116,6848],[120,7124,7152,7125],{"trials":10987,"activeCount":102},[],{"trials":10989,"activeCount":102},[],{"trials":10991,"activeCount":102},[],{"intervention":10993,"totalTrials":229,"cells":10994},"Alpha lipoic acid",{"EARLY_PHASE1":10995,"PHASE1":10997,"PHASE2":10999,"PHASE3":11008,"PHASE4":11010,"NA":11012},{"trials":10996,"activeCount":102},[],{"trials":10998,"activeCount":102},[],{"trials":11000,"activeCount":102},[11001],{"nctId":11002,"briefTitle":11003,"status":108,"phases":11004,"primaryCompletion":5751,"completion":1713,"start":8746,"enrollment":253,"conditions":11005,"interventions":11007},"NCT01313117","Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy",[90,91],[11006],"Peripheral Neuropathy",[10993],{"trials":11009,"activeCount":102},[],{"trials":11011,"activeCount":102},[],{"trials":11013,"activeCount":102},[],{"intervention":11015,"totalTrials":229,"cells":11016},"DDAVP",{"EARLY_PHASE1":11017,"PHASE1":11019,"PHASE2":11021,"PHASE3":11030,"PHASE4":11032,"NA":11034},{"trials":11018,"activeCount":102},[],{"trials":11020,"activeCount":102},[],{"trials":11022,"activeCount":102},[11023],{"nctId":11024,"briefTitle":11025,"status":108,"phases":11026,"primaryCompletion":4599,"completion":4599,"start":10227,"enrollment":1511,"conditions":11027,"interventions":11029},"NCT00961532","Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept",[91],[11028],"Intracerebral Hemorrhage",[11015],{"trials":11031,"activeCount":102},[],{"trials":11033,"activeCount":102},[],{"trials":11035,"activeCount":102},[],{"intervention":11037,"totalTrials":229,"cells":11038},"Secukinumab",{"EARLY_PHASE1":11039,"PHASE1":11041,"PHASE2":11043,"PHASE3":11057,"PHASE4":11059,"NA":11061},{"trials":11040,"activeCount":102},[],{"trials":11042,"activeCount":102},[],{"trials":11044,"activeCount":102},[11045],{"nctId":11046,"briefTitle":11047,"status":108,"phases":11048,"primaryCompletion":11049,"completion":11049,"start":5019,"enrollment":224,"conditions":11050,"interventions":11056},"NCT03041038","The Efficacy and Safety of Secukinumab in Patients With Ichthyoses",[91],"2020-08-31",[11051,11052,11053,11054,2357,11055],"Ichthyosis","Autosomal Recessive Congenital Ichthyosis","Lamellar Ichthyosis","Congenital Ichthyosiform Erythroderma","Netherton Syndrome",[11037],{"trials":11058,"activeCount":102},[],{"trials":11060,"activeCount":102},[],{"trials":11062,"activeCount":102},[],{"intervention":3667,"totalTrials":229,"cells":11064},{"EARLY_PHASE1":11065,"PHASE1":11067,"PHASE2":11069,"PHASE3":11075,"PHASE4":11077,"NA":11079},{"trials":11066,"activeCount":102},[],{"trials":11068,"activeCount":102},[],{"trials":11070,"activeCount":102},[11071],{"nctId":3660,"briefTitle":3661,"status":200,"phases":11072,"primaryCompletion":3663,"completion":1546,"start":3664,"enrollment":935,"conditions":11073,"interventions":11074},[91],[21],[1851,3667],{"trials":11076,"activeCount":102},[],{"trials":11078,"activeCount":102},[],{"trials":11080,"activeCount":102},[],{"intervention":11082,"totalTrials":229,"cells":11083},"ibrutinib",{"EARLY_PHASE1":11084,"PHASE1":11086,"PHASE2":11088,"PHASE3":11098,"PHASE4":11100,"NA":11102},{"trials":11085,"activeCount":102},[],{"trials":11087,"activeCount":102},[],{"trials":11089,"activeCount":102},[11090],{"nctId":11091,"briefTitle":11092,"status":200,"phases":11093,"primaryCompletion":11094,"completion":547,"start":11095,"enrollment":1645,"conditions":11096,"interventions":11097},"NCT02242097","Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma",[91],"2023-01-05","2015-01-12",[6976,6993,7029,7043,7056],[11082],{"trials":11099,"activeCount":102},[],{"trials":11101,"activeCount":102},[],{"trials":11103,"activeCount":102},[],{"intervention":11105,"totalTrials":229,"cells":11106},"gancyclovir gel",{"EARLY_PHASE1":11107,"PHASE1":11109,"PHASE2":11111,"PHASE3":11123,"PHASE4":11125,"NA":11127},{"trials":11108,"activeCount":102},[],{"trials":11110,"activeCount":102},[],{"trials":11112,"activeCount":102},[11113],{"nctId":11114,"briefTitle":11115,"status":248,"phases":11116,"primaryCompletion":11117,"completion":11117,"start":11118,"enrollment":900,"conditions":11119,"interventions":11121},"NCT02382588","Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis",[91],"2020-05-11","2013-12-10",[11120],"Herpes Zoster Keratitis",[11105,11122],"Hypromellose gel",{"trials":11124,"activeCount":102},[],{"trials":11126,"activeCount":102},[],{"trials":11128,"activeCount":102},[],{"intervention":11122,"totalTrials":229,"cells":11130},{"EARLY_PHASE1":11131,"PHASE1":11133,"PHASE2":11135,"PHASE3":11141,"PHASE4":11143,"NA":11145},{"trials":11132,"activeCount":102},[],{"trials":11134,"activeCount":102},[],{"trials":11136,"activeCount":102},[11137],{"nctId":11114,"briefTitle":11115,"status":248,"phases":11138,"primaryCompletion":11117,"completion":11117,"start":11118,"enrollment":900,"conditions":11139,"interventions":11140},[91],[11120],[11105,11122],{"trials":11142,"activeCount":102},[],{"trials":11144,"activeCount":102},[],{"trials":11146,"activeCount":102},[],{"intervention":9090,"totalTrials":229,"cells":11148},{"EARLY_PHASE1":11149,"PHASE1":11151,"PHASE2":11153,"PHASE3":11159,"PHASE4":11161,"NA":11163},{"trials":11150,"activeCount":102},[],{"trials":11152,"activeCount":102},[],{"trials":11154,"activeCount":102},[11155],{"nctId":9073,"briefTitle":9074,"status":108,"phases":11156,"primaryCompletion":9076,"completion":9077,"start":9078,"enrollment":9079,"conditions":11157,"interventions":11158},[91],[9081,9082,9083,9084,9085,9086,9087],[9089,9090],{"trials":11160,"activeCount":102},[],{"trials":11162,"activeCount":102},[],{"trials":11164,"activeCount":102},[],{"intervention":11166,"totalTrials":229,"cells":11167},"Dynacirc CR",{"EARLY_PHASE1":11168,"PHASE1":11170,"PHASE2":11172,"PHASE3":11180,"PHASE4":11182,"NA":11184},{"trials":11169,"activeCount":102},[],{"trials":11171,"activeCount":102},[],{"trials":11173,"activeCount":102},[11174],{"nctId":11175,"briefTitle":11176,"status":108,"phases":11177,"primaryCompletion":7774,"completion":1221,"start":5455,"enrollment":1548,"conditions":11178,"interventions":11179},"NCT00753636","Parkinson's Disease Isradipine Safety Study",[91],[8002],[11166],{"trials":11181,"activeCount":102},[],{"trials":11183,"activeCount":102},[],{"trials":11185,"activeCount":102},[],{"intervention":9336,"totalTrials":229,"cells":11187},{"EARLY_PHASE1":11188,"PHASE1":11190,"PHASE2":11192,"PHASE3":11198,"PHASE4":11200,"NA":11202},{"trials":11189,"activeCount":102},[],{"trials":11191,"activeCount":102},[],{"trials":11193,"activeCount":102},[11194],{"nctId":9331,"briefTitle":9332,"status":261,"phases":11195,"primaryCompletion":6825,"completion":6825,"start":8511,"enrollment":102,"conditions":11196,"interventions":11197},[91],[21],[9322,9336],{"trials":11199,"activeCount":102},[],{"trials":11201,"activeCount":102},[],{"trials":11203,"activeCount":102},[],{"intervention":9053,"totalTrials":229,"cells":11205},{"EARLY_PHASE1":11206,"PHASE1":11208,"PHASE2":11210,"PHASE3":11216,"PHASE4":11218,"NA":11220},{"trials":11207,"activeCount":102},[],{"trials":11209,"activeCount":102},[],{"trials":11211,"activeCount":102},[11212],{"nctId":9045,"briefTitle":9046,"status":261,"phases":11213,"primaryCompletion":1654,"completion":1654,"start":9048,"enrollment":102,"conditions":11214,"interventions":11215},[90,91],[9050],[9052,9053],{"trials":11217,"activeCount":102},[],{"trials":11219,"activeCount":102},[],{"trials":11221,"activeCount":102},[],{"intervention":8448,"totalTrials":229,"cells":11223},{"EARLY_PHASE1":11224,"PHASE1":11226,"PHASE2":11228,"PHASE3":11234,"PHASE4":11236,"NA":11238},{"trials":11225,"activeCount":102},[],{"trials":11227,"activeCount":102},[],{"trials":11229,"activeCount":102},[11230],{"nctId":8442,"briefTitle":8443,"status":108,"phases":11231,"primaryCompletion":4612,"completion":4612,"start":8445,"enrollment":6729,"conditions":11232,"interventions":11233},[91],[2049],[8448,1840,915],{"trials":11235,"activeCount":102},[],{"trials":11237,"activeCount":102},[],{"trials":11239,"activeCount":102},[],{"intervention":1377,"totalTrials":229,"cells":11241},{"EARLY_PHASE1":11242,"PHASE1":11244,"PHASE2":11246,"PHASE3":11252,"PHASE4":11254,"NA":11256},{"trials":11243,"activeCount":102},[],{"trials":11245,"activeCount":102},[],{"trials":11247,"activeCount":102},[11248],{"nctId":1366,"briefTitle":1367,"status":248,"phases":11249,"primaryCompletion":804,"completion":1369,"start":1370,"enrollment":1371,"conditions":11250,"interventions":11251},[91],[1373,1374,1375],[1228,1377],{"trials":11253,"activeCount":102},[],{"trials":11255,"activeCount":102},[],{"trials":11257,"activeCount":102},[],{"intervention":11259,"totalTrials":229,"cells":11260},"allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes",{"EARLY_PHASE1":11261,"PHASE1":11263,"PHASE2":11265,"PHASE3":11275,"PHASE4":11277,"NA":11279},{"trials":11262,"activeCount":102},[],{"trials":11264,"activeCount":102},[],{"trials":11266,"activeCount":102},[11267],{"nctId":11268,"briefTitle":11269,"status":108,"phases":11270,"primaryCompletion":11271,"completion":11271,"start":8479,"conditions":11272,"interventions":11273},"NCT00005606","Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation",[91],"2003-09",[115,24,116],[11259,11274],"autologous Epstein-Barr virus-specific cytotoxic T lymphocytes",{"trials":11276,"activeCount":102},[],{"trials":11278,"activeCount":102},[],{"trials":11280,"activeCount":102},[],{"intervention":11274,"totalTrials":229,"cells":11282},{"EARLY_PHASE1":11283,"PHASE1":11285,"PHASE2":11287,"PHASE3":11293,"PHASE4":11295,"NA":11297},{"trials":11284,"activeCount":102},[],{"trials":11286,"activeCount":102},[],{"trials":11288,"activeCount":102},[11289],{"nctId":11268,"briefTitle":11269,"status":108,"phases":11290,"primaryCompletion":11271,"completion":11271,"start":8479,"conditions":11291,"interventions":11292},[91],[115,24,116],[11259,11274],{"trials":11294,"activeCount":102},[],{"trials":11296,"activeCount":102},[],{"trials":11298,"activeCount":102},[],{"intervention":9348,"totalTrials":229,"cells":11300},{"EARLY_PHASE1":11301,"PHASE1":11303,"PHASE2":11305,"PHASE3":11311,"PHASE4":11313,"NA":11315},{"trials":11302,"activeCount":102},[],{"trials":11304,"activeCount":102},[],{"trials":11306,"activeCount":102},[11307],{"nctId":9338,"briefTitle":9339,"status":248,"phases":11308,"primaryCompletion":9341,"completion":9342,"start":9343,"enrollment":131,"conditions":11309,"interventions":11310},[91],[9345,1278,1280,9346,1281,1282,678],[9348,9349],{"trials":11312,"activeCount":102},[],{"trials":11314,"activeCount":102},[],{"trials":11316,"activeCount":102},[],{"intervention":11318,"totalTrials":229,"cells":11319},"Teriparatide",{"EARLY_PHASE1":11320,"PHASE1":11322,"PHASE2":11324,"PHASE3":11334,"PHASE4":11336,"NA":11338},{"trials":11321,"activeCount":102},[],{"trials":11323,"activeCount":102},[],{"trials":11325,"activeCount":102},[11326],{"nctId":11327,"briefTitle":11328,"status":108,"phases":11329,"primaryCompletion":11330,"completion":11330,"start":11331,"enrollment":3067,"conditions":11332,"interventions":11333},"NCT02025179","12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)",[91],"2015-08-14","2013-01",[7477,7479,7480],[11318],{"trials":11335,"activeCount":102},[],{"trials":11337,"activeCount":102},[],{"trials":11339,"activeCount":102},[],{"intervention":11341,"totalTrials":229,"cells":11342},"Induction Therapy - Capecitabine",{"EARLY_PHASE1":11343,"PHASE1":11345,"PHASE2":11347,"PHASE3":11361,"PHASE4":11363,"NA":11365},{"trials":11344,"activeCount":102},[],{"trials":11346,"activeCount":102},[],{"trials":11348,"activeCount":102},[11349],{"nctId":11350,"briefTitle":11351,"status":108,"phases":11352,"primaryCompletion":11353,"completion":11354,"start":11355,"enrollment":537,"conditions":11356,"interventions":11357},"NCT00711412","Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer",[91],"2009-05-29","2013-01-30","2006-05-31",[2161],[11341,11358,11359,11360],"Induction Therapy - Oxaliplatin","Combination Therapy - Capecitabine","Combination Therapy - Oxaliplatin",{"trials":11362,"activeCount":102},[],{"trials":11364,"activeCount":102},[],{"trials":11366,"activeCount":102},[],{"intervention":11358,"totalTrials":229,"cells":11368},{"EARLY_PHASE1":11369,"PHASE1":11371,"PHASE2":11373,"PHASE3":11379,"PHASE4":11381,"NA":11383},{"trials":11370,"activeCount":102},[],{"trials":11372,"activeCount":102},[],{"trials":11374,"activeCount":102},[11375],{"nctId":11350,"briefTitle":11351,"status":108,"phases":11376,"primaryCompletion":11353,"completion":11354,"start":11355,"enrollment":537,"conditions":11377,"interventions":11378},[91],[2161],[11341,11358,11359,11360],{"trials":11380,"activeCount":102},[],{"trials":11382,"activeCount":102},[],{"trials":11384,"activeCount":102},[],{"intervention":11359,"totalTrials":229,"cells":11386},{"EARLY_PHASE1":11387,"PHASE1":11389,"PHASE2":11391,"PHASE3":11397,"PHASE4":11399,"NA":11401},{"trials":11388,"activeCount":102},[],{"trials":11390,"activeCount":102},[],{"trials":11392,"activeCount":102},[11393],{"nctId":11350,"briefTitle":11351,"status":108,"phases":11394,"primaryCompletion":11353,"completion":11354,"start":11355,"enrollment":537,"conditions":11395,"interventions":11396},[91],[2161],[11341,11358,11359,11360],{"trials":11398,"activeCount":102},[],{"trials":11400,"activeCount":102},[],{"trials":11402,"activeCount":102},[],{"intervention":11360,"totalTrials":229,"cells":11404},{"EARLY_PHASE1":11405,"PHASE1":11407,"PHASE2":11409,"PHASE3":11415,"PHASE4":11417,"NA":11419},{"trials":11406,"activeCount":102},[],{"trials":11408,"activeCount":102},[],{"trials":11410,"activeCount":102},[11411],{"nctId":11350,"briefTitle":11351,"status":108,"phases":11412,"primaryCompletion":11353,"completion":11354,"start":11355,"enrollment":537,"conditions":11413,"interventions":11414},[91],[2161],[11341,11358,11359,11360],{"trials":11416,"activeCount":102},[],{"trials":11418,"activeCount":102},[],{"trials":11420,"activeCount":102},[],{"intervention":11422,"totalTrials":229,"cells":11423},"GLYX-13",{"EARLY_PHASE1":11424,"PHASE1":11426,"PHASE2":11428,"PHASE3":11438,"PHASE4":11440,"NA":11442},{"trials":11425,"activeCount":102},[],{"trials":11427,"activeCount":102},[],{"trials":11429,"activeCount":102},[11430],{"nctId":11431,"briefTitle":11432,"status":248,"phases":11433,"primaryCompletion":250,"completion":250,"start":11434,"enrollment":537,"conditions":11435,"interventions":11437},"NCT01844726","Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness",[91],"2013-05",[11436,5478],"Psychiatric Illness",[11422],{"trials":11439,"activeCount":102},[],{"trials":11441,"activeCount":102},[],{"trials":11443,"activeCount":102},[],{"intervention":4755,"totalTrials":229,"cells":11445},{"EARLY_PHASE1":11446,"PHASE1":11448,"PHASE2":11450,"PHASE3":11456,"PHASE4":11458,"NA":11460},{"trials":11447,"activeCount":102},[],{"trials":11449,"activeCount":102},[],{"trials":11451,"activeCount":102},[11452],{"nctId":4745,"briefTitle":4746,"status":261,"phases":11453,"primaryCompletion":4748,"completion":4749,"start":4750,"enrollment":102,"conditions":11454,"interventions":11455},[91],[4741,4752,4753],[4755,4727],{"trials":11457,"activeCount":102},[],{"trials":11459,"activeCount":102},[],{"trials":11461,"activeCount":102},[],{"intervention":11463,"totalTrials":229,"cells":11464},"raloxifene",{"EARLY_PHASE1":11465,"PHASE1":11467,"PHASE2":11469,"PHASE3":11478,"PHASE4":11480,"NA":11482},{"trials":11466,"activeCount":102},[],{"trials":11468,"activeCount":102},[],{"trials":11470,"activeCount":102},[11471],{"nctId":11472,"briefTitle":11473,"status":108,"phases":11474,"primaryCompletion":8479,"completion":8479,"start":6840,"conditions":11475,"interventions":11477},"NCT00004915","Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer",[91],[11476],"Endometrial Cancer",[11463],{"trials":11479,"activeCount":102},[],{"trials":11481,"activeCount":102},[],{"trials":11483,"activeCount":102},[],{"intervention":2333,"totalTrials":229,"cells":11485},{"EARLY_PHASE1":11486,"PHASE1":11488,"PHASE2":11490,"PHASE3":11496,"PHASE4":11498,"NA":11500},{"trials":11487,"activeCount":102},[],{"trials":11489,"activeCount":102},[],{"trials":11491,"activeCount":102},[11492],{"nctId":2315,"briefTitle":2316,"status":108,"phases":11493,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":11494,"interventions":11495},[91],[2322,2323,2324,2325,2326,2327,2328],[2330,179,2331,2332,2333,2334,2335],{"trials":11497,"activeCount":102},[],{"trials":11499,"activeCount":102},[],{"trials":11501,"activeCount":102},[],{"intervention":2334,"totalTrials":229,"cells":11503},{"EARLY_PHASE1":11504,"PHASE1":11506,"PHASE2":11508,"PHASE3":11514,"PHASE4":11516,"NA":11518},{"trials":11505,"activeCount":102},[],{"trials":11507,"activeCount":102},[],{"trials":11509,"activeCount":102},[11510],{"nctId":2315,"briefTitle":2316,"status":108,"phases":11511,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":11512,"interventions":11513},[91],[2322,2323,2324,2325,2326,2327,2328],[2330,179,2331,2332,2333,2334,2335],{"trials":11515,"activeCount":102},[],{"trials":11517,"activeCount":102},[],{"trials":11519,"activeCount":102},[],{"intervention":2335,"totalTrials":229,"cells":11521},{"EARLY_PHASE1":11522,"PHASE1":11524,"PHASE2":11526,"PHASE3":11532,"PHASE4":11534,"NA":11536},{"trials":11523,"activeCount":102},[],{"trials":11525,"activeCount":102},[],{"trials":11527,"activeCount":102},[11528],{"nctId":2315,"briefTitle":2316,"status":108,"phases":11529,"primaryCompletion":2318,"completion":2319,"start":1723,"enrollment":2320,"conditions":11530,"interventions":11531},[91],[2322,2323,2324,2325,2326,2327,2328],[2330,179,2331,2332,2333,2334,2335],{"trials":11533,"activeCount":102},[],{"trials":11535,"activeCount":102},[],{"trials":11537,"activeCount":102},[],{"intervention":11539,"totalTrials":229,"cells":11540},"unacelyated ghrelin",{"EARLY_PHASE1":11541,"PHASE1":11543,"PHASE2":11545,"PHASE3":11556,"PHASE4":11558,"NA":11560},{"trials":11542,"activeCount":102},[],{"trials":11544,"activeCount":102},[],{"trials":11546,"activeCount":102},[11547],{"nctId":11548,"briefTitle":11549,"status":108,"phases":11550,"primaryCompletion":11551,"completion":11551,"start":11552,"enrollment":253,"conditions":11553,"interventions":11555},"NCT03358355","Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial",[90,91],"2017-08-30","2016-06-07",[1022,11554,3201],"PAD",[11539],{"trials":11557,"activeCount":102},[],{"trials":11559,"activeCount":102},[],{"trials":11561,"activeCount":102},[],{"intervention":11563,"totalTrials":229,"cells":11564},"Mirtazapine",{"EARLY_PHASE1":11565,"PHASE1":11567,"PHASE2":11569,"PHASE3":11581,"PHASE4":11583,"NA":11585},{"trials":11566,"activeCount":102},[],{"trials":11568,"activeCount":102},[],{"trials":11570,"activeCount":102},[11571],{"nctId":11572,"briefTitle":11573,"status":261,"phases":11574,"primaryCompletion":11575,"completion":11575,"start":11576,"enrollment":102,"conditions":11577,"interventions":11580},"NCT05452174","Endeavor to Stop Nausea\u002FVomiting Associated With Pregnancy (E-SNAP)",[90,91],"2023-10-29","2022-06-13",[30,11578,11579],"Severe Nausea and Vomiting","Hyperemesis Gravidarum",[11563],{"trials":11582,"activeCount":102},[],{"trials":11584,"activeCount":102},[],{"trials":11586,"activeCount":102},[],{"intervention":11588,"totalTrials":229,"cells":11589},"Isradipine CR 5mg",{"EARLY_PHASE1":11590,"PHASE1":11592,"PHASE2":11594,"PHASE3":11605,"PHASE4":11607,"NA":11609},{"trials":11591,"activeCount":102},[],{"trials":11593,"activeCount":102},[],{"trials":11595,"activeCount":102},[11596],{"nctId":11597,"briefTitle":11598,"status":108,"phases":11599,"primaryCompletion":997,"completion":8746,"start":10869,"enrollment":11600,"conditions":11601,"interventions":11602},"NCT00909545","Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease",[91],99,[10411],[11588,11603,11604],"Isradipine CR 10mg","Isradipine CR 20mg",{"trials":11606,"activeCount":102},[],{"trials":11608,"activeCount":102},[],{"trials":11610,"activeCount":102},[],{"intervention":11603,"totalTrials":229,"cells":11612},{"EARLY_PHASE1":11613,"PHASE1":11615,"PHASE2":11617,"PHASE3":11623,"PHASE4":11625,"NA":11627},{"trials":11614,"activeCount":102},[],{"trials":11616,"activeCount":102},[],{"trials":11618,"activeCount":102},[11619],{"nctId":11597,"briefTitle":11598,"status":108,"phases":11620,"primaryCompletion":997,"completion":8746,"start":10869,"enrollment":11600,"conditions":11621,"interventions":11622},[91],[10411],[11588,11603,11604],{"trials":11624,"activeCount":102},[],{"trials":11626,"activeCount":102},[],{"trials":11628,"activeCount":102},[],{"intervention":11604,"totalTrials":229,"cells":11630},{"EARLY_PHASE1":11631,"PHASE1":11633,"PHASE2":11635,"PHASE3":11641,"PHASE4":11643,"NA":11645},{"trials":11632,"activeCount":102},[],{"trials":11634,"activeCount":102},[],{"trials":11636,"activeCount":102},[11637],{"nctId":11597,"briefTitle":11598,"status":108,"phases":11638,"primaryCompletion":997,"completion":8746,"start":10869,"enrollment":11600,"conditions":11639,"interventions":11640},[91],[10411],[11588,11603,11604],{"trials":11642,"activeCount":102},[],{"trials":11644,"activeCount":102},[],{"trials":11646,"activeCount":102},[],{"intervention":11648,"totalTrials":229,"cells":11649},"tocladesine",{"EARLY_PHASE1":11650,"PHASE1":11652,"PHASE2":11654,"PHASE3":11663,"PHASE4":11665,"NA":11667},{"trials":11651,"activeCount":102},[],{"trials":11653,"activeCount":102},[],{"trials":11655,"activeCount":102},[11656],{"nctId":11657,"briefTitle":11658,"status":108,"phases":11659,"primaryCompletion":6785,"completion":6785,"start":11660,"conditions":11661,"interventions":11662},"NCT00004902","Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma",[91],"1998-01",[116],[11648],{"trials":11664,"activeCount":102},[],{"trials":11666,"activeCount":102},[],{"trials":11668,"activeCount":102},[],{"intervention":2175,"totalTrials":229,"cells":11670},{"EARLY_PHASE1":11671,"PHASE1":11673,"PHASE2":11675,"PHASE3":11681,"PHASE4":11683,"NA":11685},{"trials":11672,"activeCount":102},[],{"trials":11674,"activeCount":102},[],{"trials":11676,"activeCount":102},[11677],{"nctId":2165,"briefTitle":2166,"status":108,"phases":11678,"primaryCompletion":2168,"completion":2169,"start":2170,"enrollment":2171,"conditions":11679,"interventions":11680},[90,91],[2173,1500],[914,2135,2175],{"trials":11682,"activeCount":102},[],{"trials":11684,"activeCount":102},[],{"trials":11686,"activeCount":102},[],{"intervention":9244,"totalTrials":229,"cells":11688},{"EARLY_PHASE1":11689,"PHASE1":11691,"PHASE2":11693,"PHASE3":11699,"PHASE4":11701,"NA":11703},{"trials":11690,"activeCount":102},[],{"trials":11692,"activeCount":102},[],{"trials":11694,"activeCount":102},[11695],{"nctId":9236,"briefTitle":9237,"status":108,"phases":11696,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":156,"conditions":11697,"interventions":11698},[91],[1278,1279,1280,1282,678],[9244,9216],{"trials":11700,"activeCount":102},[],{"trials":11702,"activeCount":102},[],{"trials":11704,"activeCount":102},[],{"intervention":439,"totalTrials":375,"cells":11706},{"EARLY_PHASE1":11707,"PHASE1":11709,"PHASE2":11723,"PHASE3":11725,"PHASE4":11727,"NA":11729},{"trials":11708,"activeCount":102},[],{"trials":11710,"activeCount":102},[11711,11715,11719],{"nctId":430,"briefTitle":431,"status":248,"phases":11712,"primaryCompletion":433,"completion":433,"start":434,"enrollment":253,"conditions":11713,"interventions":11714},[90],[436],[438,141,439,440,418,441],{"nctId":443,"briefTitle":444,"status":248,"phases":11716,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":11717,"interventions":11718},[90],[450],[452,141,440,439,418,441,453],{"nctId":4788,"briefTitle":4789,"status":248,"phases":11720,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":11721,"interventions":11722},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"trials":11724,"activeCount":102},[],{"trials":11726,"activeCount":102},[],{"trials":11728,"activeCount":102},[],{"trials":11730,"activeCount":102},[],{"intervention":11732,"totalTrials":273,"cells":11733},"lapatinib ditosylate",{"EARLY_PHASE1":11734,"PHASE1":11746,"PHASE2":11755,"PHASE3":11757,"PHASE4":11759,"NA":11761},{"trials":11735,"activeCount":102},[11736],{"nctId":11737,"briefTitle":11738,"status":108,"phases":11739,"primaryCompletion":11740,"completion":11741,"start":11742,"enrollment":156,"conditions":11743,"interventions":11744},"NCT00331630","Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",[89],"2006-11-10","2010-08-05","2006-05-04",[21],[11732,11745],"paclitaxel albumin-stabilized nanoparticle formulation",{"trials":11747,"activeCount":102},[11748],{"nctId":11749,"briefTitle":11750,"status":108,"phases":11751,"primaryCompletion":2002,"completion":2002,"start":1847,"enrollment":31,"conditions":11752,"interventions":11753},"NCT00316875","Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer",[90],[21],[11732,11754],"Doxil",{"trials":11756,"activeCount":102},[],{"trials":11758,"activeCount":102},[],{"trials":11760,"activeCount":102},[],{"trials":11762,"activeCount":102},[],{"intervention":7104,"totalTrials":273,"cells":11764},{"EARLY_PHASE1":11765,"PHASE1":11767,"PHASE2":11777,"PHASE3":11779,"PHASE4":11781,"NA":11783},{"trials":11766,"activeCount":102},[],{"trials":11768,"activeCount":102},[11769,11773],{"nctId":7089,"briefTitle":7090,"status":248,"phases":11770,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":273,"conditions":11771,"interventions":11772},[90],[7096,7097,7098,3915,7099,7100,7101,7102],[212,542,517,7104,7105,7106],{"nctId":6740,"briefTitle":6741,"status":261,"phases":11774,"primaryCompletion":6743,"completion":6743,"start":6744,"enrollment":102,"conditions":11775,"interventions":11776},[90],[21,2050,912,6746,6747],[176,177,464,6749],{"trials":11778,"activeCount":102},[],{"trials":11780,"activeCount":102},[],{"trials":11782,"activeCount":102},[],{"trials":11784,"activeCount":102},[],{"intervention":3440,"totalTrials":273,"cells":11786},{"EARLY_PHASE1":11787,"PHASE1":11789,"PHASE2":11802,"PHASE3":11804,"PHASE4":11806,"NA":11808},{"trials":11788,"activeCount":102},[],{"trials":11790,"activeCount":102},[11791,11798],{"nctId":11792,"briefTitle":11793,"status":108,"phases":11794,"primaryCompletion":11434,"completion":11434,"start":1221,"enrollment":1511,"conditions":11795,"interventions":11796},"NCT00983424","Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer",[90],[2909],[3440,11797],"nab-paclitaxel",{"nctId":3432,"briefTitle":3433,"status":248,"phases":11799,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":11800,"interventions":11801},[90],[3436],[438,517,141,3438,3439,3440,3348],{"trials":11803,"activeCount":102},[],{"trials":11805,"activeCount":102},[],{"trials":11807,"activeCount":102},[],{"trials":11809,"activeCount":102},[],{"intervention":11811,"totalTrials":229,"cells":11812},"Expanded Tregs",{"EARLY_PHASE1":11813,"PHASE1":11815,"PHASE2":11825,"PHASE3":11827,"PHASE4":11829,"NA":11831},{"trials":11814,"activeCount":102},[],{"trials":11816,"activeCount":102},[11817],{"nctId":11818,"briefTitle":11819,"status":108,"phases":11820,"primaryCompletion":11821,"completion":11821,"start":984,"enrollment":98,"conditions":11822,"interventions":11824},"NCT02145325","Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients",[90],"2016-06-16",[11823],"End Stage Renal Disease",[11811],{"trials":11826,"activeCount":102},[],{"trials":11828,"activeCount":102},[],{"trials":11830,"activeCount":102},[],{"trials":11832,"activeCount":102},[],{"intervention":11754,"totalTrials":229,"cells":11834},{"EARLY_PHASE1":11835,"PHASE1":11837,"PHASE2":11843,"PHASE3":11845,"PHASE4":11847,"NA":11849},{"trials":11836,"activeCount":102},[],{"trials":11838,"activeCount":102},[11839],{"nctId":11749,"briefTitle":11750,"status":108,"phases":11840,"primaryCompletion":2002,"completion":2002,"start":1847,"enrollment":31,"conditions":11841,"interventions":11842},[90],[21],[11732,11754],{"trials":11844,"activeCount":102},[],{"trials":11846,"activeCount":102},[],{"trials":11848,"activeCount":102},[],{"trials":11850,"activeCount":102},[],{"intervention":121,"totalTrials":229,"cells":11852},{"EARLY_PHASE1":11853,"PHASE1":11855,"PHASE2":11861,"PHASE3":11863,"PHASE4":11865,"NA":11867},{"trials":11854,"activeCount":102},[],{"trials":11856,"activeCount":102},[11857],{"nctId":106,"briefTitle":107,"status":108,"phases":11858,"primaryCompletion":110,"completion":110,"start":111,"conditions":11859,"interventions":11860},[90],[113,114,115,24,116,117,118],[120,121,122,123],{"trials":11862,"activeCount":102},[],{"trials":11864,"activeCount":102},[],{"trials":11866,"activeCount":102},[],{"trials":11868,"activeCount":102},[],{"intervention":3507,"totalTrials":229,"cells":11870},{"EARLY_PHASE1":11871,"PHASE1":11873,"PHASE2":11879,"PHASE3":11881,"PHASE4":11883,"NA":11885},{"trials":11872,"activeCount":102},[],{"trials":11874,"activeCount":102},[11875],{"nctId":3494,"briefTitle":3495,"status":108,"phases":11876,"primaryCompletion":3497,"completion":3498,"start":3499,"enrollment":1493,"conditions":11877,"interventions":11878},[90],[3501,158,3502,3503,3504,3505],[166,3507],{"trials":11880,"activeCount":102},[],{"trials":11882,"activeCount":102},[],{"trials":11884,"activeCount":102},[],{"trials":11886,"activeCount":102},[],{"intervention":11888,"totalTrials":229,"cells":11889},"Yttrium-90",{"EARLY_PHASE1":11890,"PHASE1":11892,"PHASE2":11902,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11891,"activeCount":102},[],{"trials":11893,"activeCount":102},[11894],{"nctId":11895,"briefTitle":11896,"status":108,"phases":11897,"primaryCompletion":1644,"completion":11898,"start":10451,"enrollment":2646,"conditions":11899,"interventions":11900},"NCT00846131","Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma",[90],"2016-09",[2468],[11901,11888],"Sorafenib",{"trials":11903,"activeCount":102},[],{"trials":11905,"activeCount":102},[],{"trials":11907,"activeCount":102},[],{"trials":11909,"activeCount":102},[],{"intervention":11911,"totalTrials":229,"cells":11912},"Clofarabine",{"EARLY_PHASE1":11913,"PHASE1":11915,"PHASE2":11923,"PHASE3":11925,"PHASE4":11927,"NA":11929},{"trials":11914,"activeCount":102},[],{"trials":11916,"activeCount":102},[11917],{"nctId":11918,"briefTitle":11919,"status":261,"phases":11920,"start":1753,"enrollment":102,"conditions":11921,"interventions":11922},"NCT01065545","The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia",[90],[3819],[11911],{"trials":11924,"activeCount":102},[],{"trials":11926,"activeCount":102},[],{"trials":11928,"activeCount":102},[],{"trials":11930,"activeCount":102},[],{"intervention":11932,"totalTrials":229,"cells":11933},"carfilzomib",{"EARLY_PHASE1":11934,"PHASE1":11936,"PHASE2":11946,"PHASE3":11948,"PHASE4":11950,"NA":11952},{"trials":11935,"activeCount":102},[],{"trials":11937,"activeCount":102},[11938],{"nctId":11939,"briefTitle":11940,"status":248,"phases":11941,"primaryCompletion":11942,"completion":11942,"start":11943,"enrollment":448,"conditions":11944,"interventions":11945},"NCT01738594","Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma",[90],"2016-10-11","2013-03-22",[7007,7013,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230],[11932,2232],{"trials":11947,"activeCount":102},[],{"trials":11949,"activeCount":102},[],{"trials":11951,"activeCount":102},[],{"trials":11953,"activeCount":102},[],{"intervention":1245,"totalTrials":229,"cells":11955},{"EARLY_PHASE1":11956,"PHASE1":11958,"PHASE2":11964,"PHASE3":11966,"PHASE4":11968,"NA":11970},{"trials":11957,"activeCount":102},[],{"trials":11959,"activeCount":102},[11960],{"nctId":1235,"briefTitle":1236,"status":261,"phases":11961,"primaryCompletion":1238,"completion":1238,"start":1238,"enrollment":102,"conditions":11962,"interventions":11963},[90],[1240,1241,1242,1243],[47,1228,1245],{"trials":11965,"activeCount":102},[],{"trials":11967,"activeCount":102},[],{"trials":11969,"activeCount":102},[],{"trials":11971,"activeCount":102},[],{"intervention":11973,"totalTrials":229,"cells":11974},"Neural stem cells loaded with an oncolytic adenovirus",{"EARLY_PHASE1":11975,"PHASE1":11977,"PHASE2":11995,"PHASE3":11997,"PHASE4":11999,"NA":12001},{"trials":11976,"activeCount":102},[],{"trials":11978,"activeCount":102},[11979],{"nctId":11980,"briefTitle":11981,"status":108,"phases":11982,"primaryCompletion":11983,"completion":11984,"start":11985,"enrollment":131,"conditions":11986,"interventions":11994},"NCT03072134","Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma",[90],"2020-04-06","2021-07-01","2017-04-24",[11987,11988,11989,11990,2514,11991,11992,11993],"Glioma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma","Astrocytoma, Grade III","Astrocytoma, Grade IV","Brain Cancer",[11973],{"trials":11996,"activeCount":102},[],{"trials":11998,"activeCount":102},[],{"trials":12000,"activeCount":102},[],{"trials":12002,"activeCount":102},[],{"intervention":7105,"totalTrials":229,"cells":12004},{"EARLY_PHASE1":12005,"PHASE1":12007,"PHASE2":12013,"PHASE3":12015,"PHASE4":12017,"NA":12019},{"trials":12006,"activeCount":102},[],{"trials":12008,"activeCount":102},[12009],{"nctId":7089,"briefTitle":7090,"status":248,"phases":12010,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":273,"conditions":12011,"interventions":12012},[90],[7096,7097,7098,3915,7099,7100,7101,7102],[212,542,517,7104,7105,7106],{"trials":12014,"activeCount":102},[],{"trials":12016,"activeCount":102},[],{"trials":12018,"activeCount":102},[],{"trials":12020,"activeCount":102},[],{"intervention":7106,"totalTrials":229,"cells":12022},{"EARLY_PHASE1":12023,"PHASE1":12025,"PHASE2":12031,"PHASE3":12033,"PHASE4":12035,"NA":12037},{"trials":12024,"activeCount":102},[],{"trials":12026,"activeCount":102},[12027],{"nctId":7089,"briefTitle":7090,"status":248,"phases":12028,"primaryCompletion":7092,"completion":7093,"start":7094,"enrollment":273,"conditions":12029,"interventions":12030},[90],[7096,7097,7098,3915,7099,7100,7101,7102],[212,542,517,7104,7105,7106],{"trials":12032,"activeCount":102},[],{"trials":12034,"activeCount":102},[],{"trials":12036,"activeCount":102},[],{"trials":12038,"activeCount":102},[],{"intervention":3522,"totalTrials":229,"cells":12040},{"EARLY_PHASE1":12041,"PHASE1":12043,"PHASE2":12049,"PHASE3":12051,"PHASE4":12053,"NA":12055},{"trials":12042,"activeCount":102},[],{"trials":12044,"activeCount":102},[12045],{"nctId":3509,"briefTitle":3510,"status":248,"phases":12046,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":229,"conditions":12047,"interventions":12048},[90],[3516,3517,3518,3519,3520],[3522,166],{"trials":12050,"activeCount":102},[],{"trials":12052,"activeCount":102},[],{"trials":12054,"activeCount":102},[],{"trials":12056,"activeCount":102},[],{"intervention":144,"totalTrials":229,"cells":12058},{"EARLY_PHASE1":12059,"PHASE1":12061,"PHASE2":12067,"PHASE3":12069,"PHASE4":12071,"NA":12073},{"trials":12060,"activeCount":102},[],{"trials":12062,"activeCount":102},[12063],{"nctId":125,"briefTitle":126,"status":108,"phases":12064,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":12065,"interventions":12066},[90],[133,134,135,136,137,138,139],[141,142,97,143,144,145],{"trials":12068,"activeCount":102},[],{"trials":12070,"activeCount":102},[],{"trials":12072,"activeCount":102},[],{"trials":12074,"activeCount":102},[],{"intervention":12076,"totalTrials":229,"cells":12077},"Stem Cell Transplantation",{"EARLY_PHASE1":12078,"PHASE1":12080,"PHASE2":12088,"PHASE3":12090,"PHASE4":12092,"NA":12094},{"trials":12079,"activeCount":102},[],{"trials":12081,"activeCount":102},[12082],{"nctId":12083,"briefTitle":12084,"status":108,"phases":12085,"primaryCompletion":2046,"completion":7774,"start":8023,"enrollment":98,"conditions":12086,"interventions":12087},"NCT00278603","Stem Cell Injection for Peripheral Vascular Disease",[90],[1184],[12076],{"trials":12089,"activeCount":102},[],{"trials":12091,"activeCount":102},[],{"trials":12093,"activeCount":102},[],{"trials":12095,"activeCount":102},[],{"intervention":8544,"totalTrials":229,"cells":12097},{"EARLY_PHASE1":12098,"PHASE1":12100,"PHASE2":12106,"PHASE3":12108,"PHASE4":12110,"NA":12112},{"trials":12099,"activeCount":102},[],{"trials":12101,"activeCount":102},[12102],{"nctId":8539,"briefTitle":8540,"status":248,"phases":12103,"primaryCompletion":2046,"completion":2046,"start":7976,"enrollment":36,"conditions":12104,"interventions":12105},[90],[1874],[1514,8544],{"trials":12107,"activeCount":102},[],{"trials":12109,"activeCount":102},[],{"trials":12111,"activeCount":102},[],{"trials":12113,"activeCount":102},[],{"intervention":8750,"totalTrials":229,"cells":12115},{"EARLY_PHASE1":12116,"PHASE1":12118,"PHASE2":12124,"PHASE3":12126,"PHASE4":12128,"NA":12130},{"trials":12117,"activeCount":102},[],{"trials":12119,"activeCount":102},[12120],{"nctId":8743,"briefTitle":8744,"status":248,"phases":12121,"primaryCompletion":8746,"completion":4851,"start":1221,"enrollment":900,"conditions":12122,"interventions":12123},[90],[8748,2909],[8750,8736],{"trials":12125,"activeCount":102},[],{"trials":12127,"activeCount":102},[],{"trials":12129,"activeCount":102},[],{"trials":12131,"activeCount":102},[],{"intervention":11797,"totalTrials":229,"cells":12133},{"EARLY_PHASE1":12134,"PHASE1":12136,"PHASE2":12142,"PHASE3":12144,"PHASE4":12146,"NA":12148},{"trials":12135,"activeCount":102},[],{"trials":12137,"activeCount":102},[12138],{"nctId":11792,"briefTitle":11793,"status":108,"phases":12139,"primaryCompletion":11434,"completion":11434,"start":1221,"enrollment":1511,"conditions":12140,"interventions":12141},[90],[2909],[3440,11797],{"trials":12143,"activeCount":102},[],{"trials":12145,"activeCount":102},[],{"trials":12147,"activeCount":102},[],{"trials":12149,"activeCount":102},[],{"intervention":12151,"totalTrials":229,"cells":12152},"oltipraz",{"EARLY_PHASE1":12153,"PHASE1":12155,"PHASE2":12165,"PHASE3":12167,"PHASE4":12169,"NA":12171},{"trials":12154,"activeCount":102},[],{"trials":12156,"activeCount":102},[12157],{"nctId":12158,"briefTitle":12159,"status":108,"phases":12160,"primaryCompletion":12161,"completion":12161,"start":12162,"conditions":12163,"interventions":12164},"NCT00006457","Oltipraz in the Prevention of Lung Cancer in People Who Smoke",[90],"2004-04","2000-08",[912],[12151],{"trials":12166,"activeCount":102},[],{"trials":12168,"activeCount":102},[],{"trials":12170,"activeCount":102},[],{"trials":12172,"activeCount":102},[],{"intervention":4794,"totalTrials":229,"cells":12174},{"EARLY_PHASE1":12175,"PHASE1":12177,"PHASE2":12183,"PHASE3":12185,"PHASE4":12187,"NA":12189},{"trials":12176,"activeCount":102},[],{"trials":12178,"activeCount":102},[12179],{"nctId":4788,"briefTitle":4789,"status":248,"phases":12180,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":12181,"interventions":12182},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"trials":12184,"activeCount":102},[],{"trials":12186,"activeCount":102},[],{"trials":12188,"activeCount":102},[],{"trials":12190,"activeCount":102},[],{"intervention":4795,"totalTrials":229,"cells":12192},{"EARLY_PHASE1":12193,"PHASE1":12195,"PHASE2":12201,"PHASE3":12203,"PHASE4":12205,"NA":12207},{"trials":12194,"activeCount":102},[],{"trials":12196,"activeCount":102},[12197],{"nctId":4788,"briefTitle":4789,"status":248,"phases":12198,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":12199,"interventions":12200},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"trials":12202,"activeCount":102},[],{"trials":12204,"activeCount":102},[],{"trials":12206,"activeCount":102},[],{"trials":12208,"activeCount":102},[],{"intervention":4796,"totalTrials":229,"cells":12210},{"EARLY_PHASE1":12211,"PHASE1":12213,"PHASE2":12219,"PHASE3":12221,"PHASE4":12223,"NA":12225},{"trials":12212,"activeCount":102},[],{"trials":12214,"activeCount":102},[12215],{"nctId":4788,"briefTitle":4789,"status":248,"phases":12216,"primaryCompletion":433,"completion":433,"start":4791,"enrollment":448,"conditions":12217,"interventions":12218},[90],[480],[4794,4795,141,439,441,4796,517,1749,440],{"trials":12220,"activeCount":102},[],{"trials":12222,"activeCount":102},[],{"trials":12224,"activeCount":102},[],{"trials":12226,"activeCount":102},[],{"intervention":462,"totalTrials":229,"cells":12228},{"EARLY_PHASE1":12229,"PHASE1":12231,"PHASE2":12237,"PHASE3":12239,"PHASE4":12241,"NA":12243},{"trials":12230,"activeCount":102},[],{"trials":12232,"activeCount":102},[12233],{"nctId":455,"briefTitle":456,"status":108,"phases":12234,"primaryCompletion":458,"completion":458,"start":111,"conditions":12235,"interventions":12236},[90],[113,114,115,24,116,117,118,460],[462,120,463,177,464,122,465],{"trials":12238,"activeCount":102},[],{"trials":12240,"activeCount":102},[],{"trials":12242,"activeCount":102},[],{"trials":12244,"activeCount":102},[],{"intervention":463,"totalTrials":229,"cells":12246},{"EARLY_PHASE1":12247,"PHASE1":12249,"PHASE2":12255,"PHASE3":12257,"PHASE4":12259,"NA":12261},{"trials":12248,"activeCount":102},[],{"trials":12250,"activeCount":102},[12251],{"nctId":455,"briefTitle":456,"status":108,"phases":12252,"primaryCompletion":458,"completion":458,"start":111,"conditions":12253,"interventions":12254},[90],[113,114,115,24,116,117,118,460],[462,120,463,177,464,122,465],{"trials":12256,"activeCount":102},[],{"trials":12258,"activeCount":102},[],{"trials":12260,"activeCount":102},[],{"trials":12262,"activeCount":102},[],{"intervention":12264,"totalTrials":229,"cells":12265},"Nicotinamide",{"EARLY_PHASE1":12266,"PHASE1":12268,"PHASE2":12281,"PHASE3":12283,"PHASE4":12285,"NA":12287},{"trials":12267,"activeCount":102},[],{"trials":12269,"activeCount":102},[12270],{"nctId":12271,"briefTitle":12272,"status":108,"phases":12273,"primaryCompletion":12274,"completion":12274,"start":12275,"enrollment":2601,"conditions":12276,"interventions":12277},"NCT03136705","Healthy Combine Study",[90],"2017-12-01","2016-02-03",[5478],[12264,12278,12279,12280],"Lanthanum Carbonate","Lanthanum Carbonate Placebo","Nicotinamide Placebo",{"trials":12282,"activeCount":102},[],{"trials":12284,"activeCount":102},[],{"trials":12286,"activeCount":102},[],{"trials":12288,"activeCount":102},[],{"intervention":12278,"totalTrials":229,"cells":12290},{"EARLY_PHASE1":12291,"PHASE1":12293,"PHASE2":12299,"PHASE3":12301,"PHASE4":12303,"NA":12305},{"trials":12292,"activeCount":102},[],{"trials":12294,"activeCount":102},[12295],{"nctId":12271,"briefTitle":12272,"status":108,"phases":12296,"primaryCompletion":12274,"completion":12274,"start":12275,"enrollment":2601,"conditions":12297,"interventions":12298},[90],[5478],[12264,12278,12279,12280],{"trials":12300,"activeCount":102},[],{"trials":12302,"activeCount":102},[],{"trials":12304,"activeCount":102},[],{"trials":12306,"activeCount":102},[],{"intervention":12279,"totalTrials":229,"cells":12308},{"EARLY_PHASE1":12309,"PHASE1":12311,"PHASE2":12317,"PHASE3":12319,"PHASE4":12321,"NA":12323},{"trials":12310,"activeCount":102},[],{"trials":12312,"activeCount":102},[12313],{"nctId":12271,"briefTitle":12272,"status":108,"phases":12314,"primaryCompletion":12274,"completion":12274,"start":12275,"enrollment":2601,"conditions":12315,"interventions":12316},[90],[5478],[12264,12278,12279,12280],{"trials":12318,"activeCount":102},[],{"trials":12320,"activeCount":102},[],{"trials":12322,"activeCount":102},[],{"trials":12324,"activeCount":102},[],{"intervention":12280,"totalTrials":229,"cells":12326},{"EARLY_PHASE1":12327,"PHASE1":12329,"PHASE2":12335,"PHASE3":12337,"PHASE4":12339,"NA":12341},{"trials":12328,"activeCount":102},[],{"trials":12330,"activeCount":102},[12331],{"nctId":12271,"briefTitle":12272,"status":108,"phases":12332,"primaryCompletion":12274,"completion":12274,"start":12275,"enrollment":2601,"conditions":12333,"interventions":12334},[90],[5478],[12264,12278,12279,12280],{"trials":12336,"activeCount":102},[],{"trials":12338,"activeCount":102},[],{"trials":12340,"activeCount":102},[],{"trials":12342,"activeCount":102},[],{"intervention":12344,"totalTrials":229,"cells":12345},"Nicardipine",{"EARLY_PHASE1":12346,"PHASE1":12348,"PHASE2":12358,"PHASE3":12360,"PHASE4":12362,"NA":12364},{"trials":12347,"activeCount":102},[],{"trials":12349,"activeCount":102},[12350],{"nctId":12351,"briefTitle":12352,"status":108,"phases":12353,"primaryCompletion":4739,"completion":4739,"start":4851,"enrollment":402,"conditions":12354,"interventions":12356},"NCT01951950","Nicardipine vs Esmolol Craniotomy Emergence",[90],[12355],"Brain Tumors",[12344,12357],"Esmolol",{"trials":12359,"activeCount":102},[],{"trials":12361,"activeCount":102},[],{"trials":12363,"activeCount":102},[],{"trials":12365,"activeCount":102},[],{"intervention":12357,"totalTrials":229,"cells":12367},{"EARLY_PHASE1":12368,"PHASE1":12370,"PHASE2":12376,"PHASE3":12378,"PHASE4":12380,"NA":12382},{"trials":12369,"activeCount":102},[],{"trials":12371,"activeCount":102},[12372],{"nctId":12351,"briefTitle":12352,"status":108,"phases":12373,"primaryCompletion":4739,"completion":4739,"start":4851,"enrollment":402,"conditions":12374,"interventions":12375},[90],[12355],[12344,12357],{"trials":12377,"activeCount":102},[],{"trials":12379,"activeCount":102},[],{"trials":12381,"activeCount":102},[],{"trials":12383,"activeCount":102},[],{"intervention":8761,"totalTrials":229,"cells":12385},{"EARLY_PHASE1":12386,"PHASE1":12388,"PHASE2":12394,"PHASE3":12396,"PHASE4":12398,"NA":12400},{"trials":12387,"activeCount":102},[],{"trials":12389,"activeCount":102},[12390],{"nctId":8752,"briefTitle":8753,"status":261,"phases":12391,"primaryCompletion":8755,"completion":8755,"start":6577,"enrollment":102,"conditions":12392,"interventions":12393},[90],[8757,8758,8759],[8761,8736],{"trials":12395,"activeCount":102},[],{"trials":12397,"activeCount":102},[],{"trials":12399,"activeCount":102},[],{"trials":12401,"activeCount":102},[],{"intervention":12403,"totalTrials":229,"cells":12404},"sodium stibogluconate",{"EARLY_PHASE1":12405,"PHASE1":12407,"PHASE2":12415,"PHASE3":12417,"PHASE4":12419,"NA":12421},{"trials":12406,"activeCount":102},[],{"trials":12408,"activeCount":102},[12409],{"nctId":12410,"briefTitle":12411,"status":248,"phases":12412,"primaryCompletion":985,"completion":11434,"start":10869,"enrollment":229,"conditions":12413,"interventions":12414},"NCT01009502","Phase I\u002FII Trial of Sodium Stibogluconate in Myelodysplastic Syndrome",[90],[117],[12403],{"trials":12416,"activeCount":102},[],{"trials":12418,"activeCount":102},[],{"trials":12420,"activeCount":102},[],{"trials":12422,"activeCount":102},[],{"intervention":8503,"totalTrials":229,"cells":12424},{"EARLY_PHASE1":12425,"PHASE1":12427,"PHASE2":12433,"PHASE3":12435,"PHASE4":12437,"NA":12439},{"trials":12426,"activeCount":102},[],{"trials":12428,"activeCount":102},[12429],{"nctId":8496,"briefTitle":8497,"status":248,"phases":12430,"primaryCompletion":8499,"completion":8499,"start":3353,"enrollment":582,"conditions":12431,"interventions":12432},[90],[8501],[8503,8504],{"trials":12434,"activeCount":102},[],{"trials":12436,"activeCount":102},[],{"trials":12438,"activeCount":102},[],{"trials":12440,"activeCount":102},[],{"intervention":7126,"totalTrials":229,"cells":12442},{"EARLY_PHASE1":12443,"PHASE1":12445,"PHASE2":12451,"PHASE3":12453,"PHASE4":12455,"NA":12457},{"trials":12444,"activeCount":102},[],{"trials":12446,"activeCount":102},[12447],{"nctId":7116,"briefTitle":7117,"status":248,"phases":12448,"primaryCompletion":7119,"completion":7119,"start":6744,"enrollment":375,"conditions":12449,"interventions":12450},[90],[24,7121],[7123,120,7124,7125,7126],{"trials":12452,"activeCount":102},[],{"trials":12454,"activeCount":102},[],{"trials":12456,"activeCount":102},[],{"trials":12458,"activeCount":102},[],{"intervention":12460,"totalTrials":229,"cells":12461},"Alefacept",{"EARLY_PHASE1":12462,"PHASE1":12464,"PHASE2":12474,"PHASE3":12476,"PHASE4":12478,"NA":12480},{"trials":12463,"activeCount":102},[],{"trials":12465,"activeCount":102},[12466],{"nctId":12467,"briefTitle":12468,"status":248,"phases":12469,"primaryCompletion":1491,"completion":252,"start":12470,"enrollment":253,"conditions":12471,"interventions":12473},"NCT01163799","A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients",[90],"2010-07",[12472],"Transplant; Failure, Kidney",[12460],{"trials":12475,"activeCount":102},[],{"trials":12477,"activeCount":102},[],{"trials":12479,"activeCount":102},[],{"trials":12481,"activeCount":102},[],{"intervention":12483,"totalTrials":229,"cells":12484},"PI3K inhibitor BYL719",{"EARLY_PHASE1":12485,"PHASE1":12487,"PHASE2":12500,"PHASE3":12502,"PHASE4":12504,"NA":12506},{"trials":12486,"activeCount":102},[],{"trials":12488,"activeCount":102},[12489],{"nctId":12490,"briefTitle":12491,"status":108,"phases":12492,"primaryCompletion":12493,"completion":12494,"start":12495,"enrollment":1371,"conditions":12496,"interventions":12498},"NCT02038010","BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx",[90],"2015-04-15","2017-05-20","2014-05-21",[12497,677,1387,1388,1389,678],"HER2-positive Breast Cancer",[12483,12499],"ado-trastuzumab emtansine",{"trials":12501,"activeCount":102},[],{"trials":12503,"activeCount":102},[],{"trials":12505,"activeCount":102},[],{"trials":12507,"activeCount":102},[],{"intervention":12499,"totalTrials":229,"cells":12509},{"EARLY_PHASE1":12510,"PHASE1":12512,"PHASE2":12518,"PHASE3":12520,"PHASE4":12522,"NA":12524},{"trials":12511,"activeCount":102},[],{"trials":12513,"activeCount":102},[12514],{"nctId":12490,"briefTitle":12491,"status":108,"phases":12515,"primaryCompletion":12493,"completion":12494,"start":12495,"enrollment":1371,"conditions":12516,"interventions":12517},[90],[12497,677,1387,1388,1389,678],[12483,12499],{"trials":12519,"activeCount":102},[],{"trials":12521,"activeCount":102},[],{"trials":12523,"activeCount":102},[],{"trials":12525,"activeCount":102},[],{"intervention":3357,"totalTrials":229,"cells":12527},{"EARLY_PHASE1":12528,"PHASE1":12530,"PHASE2":12536,"PHASE3":12538,"PHASE4":12540,"NA":12542},{"trials":12529,"activeCount":102},[],{"trials":12531,"activeCount":102},[12532],{"nctId":3350,"briefTitle":3351,"status":248,"phases":12533,"primaryCompletion":3353,"completion":3353,"start":3354,"enrollment":1511,"conditions":12534,"interventions":12535},[90],[1495],[3357,3358],{"trials":12537,"activeCount":102},[],{"trials":12539,"activeCount":102},[],{"trials":12541,"activeCount":102},[],{"trials":12543,"activeCount":102},[],{"intervention":12545,"totalTrials":229,"cells":12546},"substance P",{"EARLY_PHASE1":12547,"PHASE1":12549,"PHASE2":12560,"PHASE3":12562,"PHASE4":12564,"NA":12566},{"trials":12548,"activeCount":102},[],{"trials":12550,"activeCount":102},[12551],{"nctId":12552,"briefTitle":12553,"status":108,"phases":12554,"primaryCompletion":12555,"completion":12555,"start":5752,"enrollment":402,"conditions":12556,"interventions":12558},"NCT01280149","Reduction of IgE Antibody in Human Allergic Subjects",[90],"2017-06-20",[12557],"Seasonal Allergic Rhinitis",[12545,12559],"substance P injections",{"trials":12561,"activeCount":102},[],{"trials":12563,"activeCount":102},[],{"trials":12565,"activeCount":102},[],{"trials":12567,"activeCount":102},[],{"intervention":12559,"totalTrials":229,"cells":12569},{"EARLY_PHASE1":12570,"PHASE1":12572,"PHASE2":12578,"PHASE3":12580,"PHASE4":12582,"NA":12584},{"trials":12571,"activeCount":102},[],{"trials":12573,"activeCount":102},[12574],{"nctId":12552,"briefTitle":12553,"status":108,"phases":12575,"primaryCompletion":12555,"completion":12555,"start":5752,"enrollment":402,"conditions":12576,"interventions":12577},[90],[12557],[12545,12559],{"trials":12579,"activeCount":102},[],{"trials":12581,"activeCount":102},[],{"trials":12583,"activeCount":102},[],{"trials":12585,"activeCount":102},[],{"intervention":3438,"totalTrials":229,"cells":12587},{"EARLY_PHASE1":12588,"PHASE1":12590,"PHASE2":12596,"PHASE3":12598,"PHASE4":12600,"NA":12602},{"trials":12589,"activeCount":102},[],{"trials":12591,"activeCount":102},[12592],{"nctId":3432,"briefTitle":3433,"status":248,"phases":12593,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":12594,"interventions":12595},[90],[3436],[438,517,141,3438,3439,3440,3348],{"trials":12597,"activeCount":102},[],{"trials":12599,"activeCount":102},[],{"trials":12601,"activeCount":102},[],{"trials":12603,"activeCount":102},[],{"intervention":3439,"totalTrials":229,"cells":12605},{"EARLY_PHASE1":12606,"PHASE1":12608,"PHASE2":12614,"PHASE3":12616,"PHASE4":12618,"NA":12620},{"trials":12607,"activeCount":102},[],{"trials":12609,"activeCount":102},[12610],{"nctId":3432,"briefTitle":3433,"status":248,"phases":12611,"primaryCompletion":433,"completion":433,"start":921,"enrollment":582,"conditions":12612,"interventions":12613},[90],[3436],[438,517,141,3438,3439,3440,3348],{"trials":12615,"activeCount":102},[],{"trials":12617,"activeCount":102},[],{"trials":12619,"activeCount":102},[],{"trials":12621,"activeCount":102},[],{"intervention":1270,"totalTrials":229,"cells":12623},{"EARLY_PHASE1":12624,"PHASE1":12626,"PHASE2":12632,"PHASE3":12634,"PHASE4":12636,"NA":12638},{"trials":12625,"activeCount":102},[],{"trials":12627,"activeCount":102},[12628],{"nctId":1258,"briefTitle":1259,"status":108,"phases":12629,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":253,"conditions":12630,"interventions":12631},[90],[1265,1266,1267,1268],[1270,1228],{"trials":12633,"activeCount":102},[],{"trials":12635,"activeCount":102},[],{"trials":12637,"activeCount":102},[],{"trials":12639,"activeCount":102},[],{"intervention":12641,"totalTrials":229,"cells":12642},"Vincristine Sulfate Liposome",{"EARLY_PHASE1":12643,"PHASE1":12645,"PHASE2":12655,"PHASE3":12657,"PHASE4":12659,"NA":12661},{"trials":12644,"activeCount":102},[],{"trials":12646,"activeCount":102},[12647],{"nctId":12648,"briefTitle":12649,"status":261,"phases":12650,"primaryCompletion":12651,"start":251,"enrollment":102,"conditions":12652,"interventions":12653},"NCT02861040","Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",[90],"2018-07",[3517,3519],[12641,12654],"Volasertib",{"trials":12656,"activeCount":102},[],{"trials":12658,"activeCount":102},[],{"trials":12660,"activeCount":102},[],{"trials":12662,"activeCount":102},[],{"intervention":12654,"totalTrials":229,"cells":12664},{"EARLY_PHASE1":12665,"PHASE1":12667,"PHASE2":12673,"PHASE3":12675,"PHASE4":12677,"NA":12679},{"trials":12666,"activeCount":102},[],{"trials":12668,"activeCount":102},[12669],{"nctId":12648,"briefTitle":12649,"status":261,"phases":12670,"primaryCompletion":12651,"start":251,"enrollment":102,"conditions":12671,"interventions":12672},[90],[3517,3519],[12641,12654],{"trials":12674,"activeCount":102},[],{"trials":12676,"activeCount":102},[],{"trials":12678,"activeCount":102},[],{"trials":12680,"activeCount":102},[],{"intervention":6916,"totalTrials":229,"cells":12682},{"EARLY_PHASE1":12683,"PHASE1":12685,"PHASE2":12691,"PHASE3":12693,"PHASE4":12695,"NA":12697},{"trials":12684,"activeCount":102},[],{"trials":12686,"activeCount":102},[12687],{"nctId":6907,"briefTitle":6908,"status":108,"phases":12688,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":537,"conditions":12689,"interventions":12690},[90],[24],[120,6915,6916,178,464,6917],{"trials":12692,"activeCount":102},[],{"trials":12694,"activeCount":102},[],{"trials":12696,"activeCount":102},[],{"trials":12698,"activeCount":102},[],{"intervention":12700,"totalTrials":229,"cells":12701},"Fibroblast Treatment",{"EARLY_PHASE1":12702,"PHASE1":12704,"PHASE2":12713,"PHASE3":12715,"PHASE4":12717,"NA":12719},{"trials":12703,"activeCount":102},[],{"trials":12705,"activeCount":102},[12706],{"nctId":12707,"briefTitle":12708,"status":248,"phases":12709,"primaryCompletion":626,"completion":626,"start":9886,"enrollment":582,"conditions":12710,"interventions":12712},"NCT01704209","Collagen Injections for the Treatment of Acne Scars and Wrinkles",[90],[12711,4009],"Acne Scars",[12700],{"trials":12714,"activeCount":102},[],{"trials":12716,"activeCount":102},[],{"trials":12718,"activeCount":102},[],{"trials":12720,"activeCount":102},[],{"intervention":6898,"totalTrials":229,"cells":12722},{"EARLY_PHASE1":12723,"PHASE1":12729,"PHASE2":12731,"PHASE3":12733,"PHASE4":12735,"NA":12737},{"trials":12724,"activeCount":102},[12725],{"nctId":6892,"briefTitle":6893,"status":261,"phases":12726,"start":1885,"enrollment":102,"conditions":12727,"interventions":12728},[89],[1495,24,4843],[143,212,215,6897,6898,6899],{"trials":12730,"activeCount":102},[],{"trials":12732,"activeCount":102},[],{"trials":12734,"activeCount":102},[],{"trials":12736,"activeCount":102},[],{"trials":12738,"activeCount":102},[],{"intervention":12740,"totalTrials":229,"cells":12741},"Targeted Molecular Therapy",{"EARLY_PHASE1":12742,"PHASE1":12752,"PHASE2":12754,"PHASE3":12756,"PHASE4":12758,"NA":12760},{"trials":12743,"activeCount":102},[12744],{"nctId":12745,"briefTitle":12746,"status":108,"phases":12747,"primaryCompletion":12748,"completion":12749,"start":1384,"enrollment":900,"conditions":12750,"interventions":12751},"NCT03020017","NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery",[89],"2018-09-06","2020-08-19",[2512,2516],[12740],{"trials":12753,"activeCount":102},[],{"trials":12755,"activeCount":102},[],{"trials":12757,"activeCount":102},[],{"trials":12759,"activeCount":102},[],{"trials":12761,"activeCount":102},[],{"intervention":12763,"totalTrials":229,"cells":12764},"High-dose interleukin-2",{"EARLY_PHASE1":12765,"PHASE1":12773,"PHASE2":12775,"PHASE3":12777,"PHASE4":12779,"NA":12781},{"trials":12766,"activeCount":102},[12767],{"nctId":12768,"briefTitle":12769,"status":108,"phases":12770,"primaryCompletion":2159,"completion":1713,"start":1547,"enrollment":1493,"conditions":12771,"interventions":12772},"NCT00276835","Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer",[89],[2050,6746],[12763],{"trials":12774,"activeCount":102},[],{"trials":12776,"activeCount":102},[],{"trials":12778,"activeCount":102},[],{"trials":12780,"activeCount":102},[],{"trials":12782,"activeCount":102},[],{"intervention":12784,"totalTrials":229,"cells":12785},"Carboprost Tromethamine",{"EARLY_PHASE1":12786,"PHASE1":12798,"PHASE2":12800,"PHASE3":12802,"PHASE4":12804,"NA":12806},{"trials":12787,"activeCount":102},[12788],{"nctId":12789,"briefTitle":12790,"status":108,"phases":12791,"primaryCompletion":12792,"completion":12792,"start":4681,"enrollment":36,"conditions":12793,"interventions":12797},"NCT05518812","Carboprost (Hemabate) for Fibroid Resection",[89],"2024-05-06",[12794,12795,12796],"Fibroid Uterus","Gynecologic Disease","Leiomyoma, Uterine",[12784],{"trials":12799,"activeCount":102},[],{"trials":12801,"activeCount":102},[],{"trials":12803,"activeCount":102},[],{"trials":12805,"activeCount":102},[],{"trials":12807,"activeCount":102},[],{"intervention":11745,"totalTrials":229,"cells":12809},{"EARLY_PHASE1":12810,"PHASE1":12816,"PHASE2":12818,"PHASE3":12820,"PHASE4":12822,"NA":12824},{"trials":12811,"activeCount":102},[12812],{"nctId":11737,"briefTitle":11738,"status":108,"phases":12813,"primaryCompletion":11740,"completion":11741,"start":11742,"enrollment":156,"conditions":12814,"interventions":12815},[89],[21],[11732,11745],{"trials":12817,"activeCount":102},[],{"trials":12819,"activeCount":102},[],{"trials":12821,"activeCount":102},[],{"trials":12823,"activeCount":102},[],{"trials":12825,"activeCount":102},[],{"intervention":4661,"totalTrials":229,"cells":12827},{"EARLY_PHASE1":12828,"PHASE1":12834,"PHASE2":12836,"PHASE3":12838,"PHASE4":12840,"NA":12842},{"trials":12829,"activeCount":102},[12830],{"nctId":4651,"briefTitle":4652,"status":108,"phases":12831,"primaryCompletion":4654,"completion":4654,"start":1653,"enrollment":4655,"conditions":12832,"interventions":12833},[89],[4657,4658],[4660,4661],{"trials":12835,"activeCount":102},[],{"trials":12837,"activeCount":102},[],{"trials":12839,"activeCount":102},[],{"trials":12841,"activeCount":102},[],{"trials":12843,"activeCount":102},[],{"intervention":12845,"totalTrials":229,"cells":12846},"Sildenafil",{"EARLY_PHASE1":12847,"PHASE1":12858,"PHASE2":12860,"PHASE3":12862,"PHASE4":12864,"NA":12866},{"trials":12848,"activeCount":102},[12849],{"nctId":12850,"briefTitle":12851,"status":108,"phases":12852,"primaryCompletion":12853,"completion":12853,"start":12854,"enrollment":273,"conditions":12855,"interventions":12857},"NCT03229512","Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction",[89],"2020-06-04","2017-04-11",[12856],"Hand Foot Skin Reaction",[12845],{"trials":12859,"activeCount":102},[],{"trials":12861,"activeCount":102},[],{"trials":12863,"activeCount":102},[],{"trials":12865,"activeCount":102},[],{"trials":12867,"activeCount":102},[],{"intervention":12869,"totalTrials":229,"cells":12870},"Cholate testing",{"EARLY_PHASE1":12871,"PHASE1":12882,"PHASE2":12884,"PHASE3":12886,"PHASE4":12888,"NA":12890},{"trials":12872,"activeCount":102},[12873],{"nctId":12874,"briefTitle":12875,"status":108,"phases":12876,"primaryCompletion":12877,"completion":12877,"start":12878,"enrollment":1511,"conditions":12879,"interventions":12881},"NCT02506335","Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease",[89],"2018-05-01","2015-09-01",[12880,5569],"Liver Disease",[12869],{"trials":12883,"activeCount":102},[],{"trials":12885,"activeCount":102},[],{"trials":12887,"activeCount":102},[],{"trials":12889,"activeCount":102},[],{"trials":12891,"activeCount":102},[],{"intervention":12893,"totalTrials":229,"cells":12894},"Pulmozyme",{"EARLY_PHASE1":12895,"PHASE1":12903,"PHASE2":12905,"PHASE3":12907,"PHASE4":12909,"NA":12911},{"trials":12896,"activeCount":102},[12897],{"nctId":12898,"briefTitle":12899,"status":200,"phases":12900,"primaryCompletion":489,"completion":5019,"start":473,"enrollment":1974,"conditions":12901,"interventions":12902},"NCT00536952","Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy",[89],[923],[12893],{"trials":12904,"activeCount":102},[],{"trials":12906,"activeCount":102},[],{"trials":12908,"activeCount":102},[],{"trials":12910,"activeCount":102},[],{"trials":12912,"activeCount":102},[],{"intervention":3689,"totalTrials":229,"cells":12914},{"EARLY_PHASE1":12915,"PHASE1":12921,"PHASE2":12923,"PHASE3":12925,"PHASE4":12927,"NA":12929},{"trials":12916,"activeCount":102},[12917],{"nctId":3680,"briefTitle":3681,"status":108,"phases":12918,"primaryCompletion":3683,"completion":3684,"start":3685,"enrollment":28,"conditions":12919,"interventions":12920},[89],[3687],[3689,3675],{"trials":12922,"activeCount":102},[],{"trials":12924,"activeCount":102},[],{"trials":12926,"activeCount":102},[],{"trials":12928,"activeCount":102},[],{"trials":12930,"activeCount":102},[],{"intervention":8687,"totalTrials":229,"cells":12932},{"EARLY_PHASE1":12933,"PHASE1":12939,"PHASE2":12941,"PHASE3":12943,"PHASE4":12945,"NA":12947},{"trials":12934,"activeCount":102},[12935],{"nctId":8682,"briefTitle":8683,"status":108,"phases":12936,"primaryCompletion":7774,"completion":5863,"start":1797,"enrollment":224,"conditions":12937,"interventions":12938},[89],[2050],[174,8687],{"trials":12940,"activeCount":102},[],{"trials":12942,"activeCount":102},[],{"trials":12944,"activeCount":102},[],{"trials":12946,"activeCount":102},[],{"trials":12948,"activeCount":102},[],{"intervention":12950,"totalTrials":229,"cells":12951},"topical calcipotriene 0.005% ointment",{"EARLY_PHASE1":12952,"PHASE1":12963,"PHASE2":12965,"PHASE3":12967,"PHASE4":12969,"NA":12971},{"trials":12953,"activeCount":102},[12954],{"nctId":12955,"briefTitle":12956,"status":248,"phases":12957,"primaryCompletion":973,"completion":973,"start":12958,"enrollment":273,"conditions":12959,"interventions":12962},"NCT02411643","Molecular Effects of Topical Calcipotriene on Morphea",[89],"2015-03",[12960,12961],"Morphea","Localized Scleroderma",[12950],{"trials":12964,"activeCount":102},[],{"trials":12966,"activeCount":102},[],{"trials":12968,"activeCount":102},[],{"trials":12970,"activeCount":102},[],{"trials":12972,"activeCount":102},[],{"intervention":12974,"totalTrials":229,"cells":12975},"Cromolyn Sodium",{"EARLY_PHASE1":12976,"PHASE1":12986,"PHASE2":12988,"PHASE3":12990,"PHASE4":12992,"NA":12994},{"trials":12977,"activeCount":102},[12978],{"nctId":12979,"briefTitle":12980,"status":108,"phases":12981,"primaryCompletion":12982,"completion":9972,"start":5520,"enrollment":224,"conditions":12983,"interventions":12984},"NCT03167216","Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction",[89],"2022-04-01",[4853],[12974,12985],"Cetirizine Hydrochloride",{"trials":12987,"activeCount":102},[],{"trials":12989,"activeCount":102},[],{"trials":12991,"activeCount":102},[],{"trials":12993,"activeCount":102},[],{"trials":12995,"activeCount":102},[],{"intervention":12985,"totalTrials":229,"cells":12997},{"EARLY_PHASE1":12998,"PHASE1":13004,"PHASE2":13006,"PHASE3":13008,"PHASE4":13010,"NA":13012},{"trials":12999,"activeCount":102},[13000],{"nctId":12979,"briefTitle":12980,"status":108,"phases":13001,"primaryCompletion":12982,"completion":9972,"start":5520,"enrollment":224,"conditions":13002,"interventions":13003},[89],[4853],[12974,12985],{"trials":13005,"activeCount":102},[],{"trials":13007,"activeCount":102},[],{"trials":13009,"activeCount":102},[],{"trials":13011,"activeCount":102},[],{"trials":13013,"activeCount":102},[],{"intervention":13015,"totalTrials":229,"cells":13016},"ICG",{"EARLY_PHASE1":13017,"PHASE1":13032,"PHASE2":13034,"PHASE3":13036,"PHASE4":13038,"NA":13040},{"trials":13018,"activeCount":102},[13019],{"nctId":13020,"briefTitle":13021,"status":108,"phases":13022,"primaryCompletion":13023,"completion":13023,"start":13024,"enrollment":1935,"conditions":13025,"interventions":13031},"NCT03927651","ICG to Assess Ovarian Perfusion",[89],"2022-11-15","2019-06-01",[12794,5022,13026,13027,13028,13029,13030],"Uterus Myoma","Uterine Fibroid","Uterine Adenomyosis","Endometrial Cyst","Uterine Cyst",[13015],{"trials":13033,"activeCount":102},[],{"trials":13035,"activeCount":102},[],{"trials":13037,"activeCount":102},[],{"trials":13039,"activeCount":102},[],{"trials":13041,"activeCount":102},[],{"intervention":13043,"totalTrials":229,"cells":13044},"Siltuximab",{"EARLY_PHASE1":13045,"PHASE1":13057,"PHASE2":13059,"PHASE3":13061,"PHASE4":13063,"NA":13065},{"trials":13046,"activeCount":102},[13047],{"nctId":13048,"briefTitle":13049,"status":261,"phases":13050,"primaryCompletion":13051,"start":433,"enrollment":102,"conditions":13052,"interventions":13056},"NCT02805868","Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis",[89],"2019-02",[13053,13054,9202,13055],"Myelofibrosis","Polycythemia Vera","Thrombocytopenia",[13043],{"trials":13058,"activeCount":102},[],{"trials":13060,"activeCount":102},[],{"trials":13062,"activeCount":102},[],{"trials":13064,"activeCount":102},[],{"trials":13066,"activeCount":102},[],{"intervention":13068,"totalTrials":229,"cells":13069},"Ustekinumab",{"EARLY_PHASE1":13070,"PHASE1":13081,"PHASE2":13083,"PHASE3":13085,"PHASE4":13087,"NA":13089},{"trials":13071,"activeCount":102},[13072],{"nctId":13073,"briefTitle":13074,"status":108,"phases":13075,"primaryCompletion":13076,"completion":13077,"start":13078,"enrollment":419,"conditions":13079,"interventions":13080},"NCT04549792","An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses",[89],"2024-01-12","2024-06-26","2021-04-01",[11051],[13068],{"trials":13082,"activeCount":102},[],{"trials":13084,"activeCount":102},[],{"trials":13086,"activeCount":102},[],{"trials":13088,"activeCount":102},[],{"trials":13090,"activeCount":102},[],{"intervention":13092,"totalTrials":229,"cells":13093},"Diclofenac epolamine patch",{"EARLY_PHASE1":13094,"PHASE1":13103,"PHASE2":13105,"PHASE3":13107,"PHASE4":13109,"NA":13111},{"trials":13095,"activeCount":102},[13096],{"nctId":13097,"briefTitle":13098,"status":108,"phases":13099,"primaryCompletion":13100,"completion":13100,"start":1753,"enrollment":156,"conditions":13101,"interventions":13102},"NCT01380353","Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine",[89],"2012-11-12",[21],[13092],{"trials":13104,"activeCount":102},[],{"trials":13106,"activeCount":102},[],{"trials":13108,"activeCount":102},[],{"trials":13110,"activeCount":102},[],{"trials":13112,"activeCount":102},[],{"intervention":13114,"totalTrials":229,"cells":13115},"dexlansoprazole",{"EARLY_PHASE1":13116,"PHASE1":13128,"PHASE2":13130,"PHASE3":13132,"PHASE4":13134,"NA":13136},{"trials":13117,"activeCount":102},[13118],{"nctId":13119,"briefTitle":13120,"status":108,"phases":13121,"primaryCompletion":13122,"completion":13122,"start":13123,"enrollment":13124,"conditions":13125,"interventions":13127},"NCT03202537","Effectiveness of Physiologic Testing in PPI Non-Responders",[89],"2022-07-31","2017-07-01",240,[13126],"Gastro Esophageal Reflux",[13114],{"trials":13129,"activeCount":102},[],{"trials":13131,"activeCount":102},[],{"trials":13133,"activeCount":102},[],{"trials":13135,"activeCount":102},[],{"trials":13137,"activeCount":102},[],{"intervention":13139,"totalTrials":229,"cells":13140},"Ingenol mebutate",{"EARLY_PHASE1":13141,"PHASE1":13150,"PHASE2":13152,"PHASE3":13154,"PHASE4":13156,"NA":13158},{"trials":13142,"activeCount":102},[13143],{"nctId":13144,"briefTitle":13145,"status":261,"phases":13146,"primaryCompletion":947,"completion":947,"start":3381,"enrollment":102,"conditions":13147,"interventions":13149},"NCT01735942","Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions",[89],[13148],"Actinic Keratosis",[13139],{"trials":13151,"activeCount":102},[],{"trials":13153,"activeCount":102},[],{"trials":13155,"activeCount":102},[],{"trials":13157,"activeCount":102},[],{"trials":13159,"activeCount":102},[],{"intervention":13161,"totalTrials":448,"cells":13162},"Lidocaine",{"EARLY_PHASE1":13163,"PHASE1":13165,"PHASE2":13167,"PHASE3":13169,"PHASE4":13171,"NA":13187},{"trials":13164,"activeCount":102},[],{"trials":13166,"activeCount":102},[],{"trials":13168,"activeCount":102},[],{"trials":13170,"activeCount":102},[],{"trials":13172,"activeCount":102},[13173,13180],{"nctId":13174,"briefTitle":13175,"status":108,"phases":13176,"primaryCompletion":7731,"completion":7731,"start":7149,"enrollment":205,"conditions":13177,"interventions":13178},"NCT01515540","Brain Imaging of Lidoderm for Chronic Back Pain",[93],[4834],[13179],"lidocaine",{"nctId":13181,"briefTitle":13182,"status":248,"phases":13183,"primaryCompletion":996,"completion":996,"start":1886,"enrollment":13184,"conditions":13185,"interventions":13186},"NCT00913003","Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery",[93],22,[15],[13161],{"trials":13188,"activeCount":102},[13189,13196,13202,13208,13215],{"nctId":13190,"briefTitle":13191,"status":108,"phases":13192,"primaryCompletion":5431,"completion":5431,"start":12470,"enrollment":311,"conditions":13193,"interventions":13195},"NCT01207401","Paracervical Block Before Intrauterine Device (IUD) Insertion",[94],[13194],"Pain Control for Intrauterine Device Insertions",[13161],{"nctId":13197,"briefTitle":13198,"status":108,"phases":13199,"primaryCompletion":1491,"completion":996,"start":4638,"enrollment":189,"conditions":13200,"interventions":13201},"NCT01250002","Lidocaine and Outpatient Gynecologic Laparoscopy",[94],[15],[13161],{"nctId":13203,"briefTitle":13204,"status":108,"phases":13205,"primaryCompletion":3381,"completion":5631,"start":7731,"enrollment":9,"conditions":13206,"interventions":13207},"NCT01180660","IV Lidocaine on Postoperative Pain and QOR on Morbid Obese Patients Undergoing Bypass Surgery",[94],[15,27],[13161,620],{"nctId":13209,"briefTitle":13210,"status":200,"phases":13211,"primaryCompletion":547,"completion":547,"start":433,"enrollment":7977,"conditions":13212,"interventions":13213},"NCT02823002","Pain Perception: Lidocaine Rate\u002FTemp\u002FBuffer",[94],[15],[13161,13214],"Buffer",{"nctId":13216,"briefTitle":13217,"status":261,"phases":13218,"primaryCompletion":13219,"completion":13219,"start":13220,"enrollment":102,"conditions":13221,"interventions":13222},"NCT02257346","Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery",[94],"2015-02-15","2014-11-01",[30],[13161,620],{"intervention":620,"totalTrials":475,"cells":13224},{"EARLY_PHASE1":13225,"PHASE1":13227,"PHASE2":13229,"PHASE3":13235,"PHASE4":13237,"NA":13247},{"trials":13226,"activeCount":102},[],{"trials":13228,"activeCount":102},[],{"trials":13230,"activeCount":102},[13231],{"nctId":4677,"briefTitle":4678,"status":261,"phases":13232,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":102,"conditions":13233,"interventions":13234},[91],[21,4683],[4646,4685],{"trials":13236,"activeCount":102},[],{"trials":13238,"activeCount":102},[13239,13243],{"nctId":612,"briefTitle":613,"status":261,"phases":13240,"primaryCompletion":615,"completion":615,"start":616,"enrollment":102,"conditions":13241,"interventions":13242},[93],[618],[610,581,620,609],{"nctId":5748,"briefTitle":5749,"status":108,"phases":13244,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":1724,"conditions":13245,"interventions":13246},[93],[5754],[5735,620],{"trials":13248,"activeCount":102},[13249,13253,13262],{"nctId":13203,"briefTitle":13204,"status":108,"phases":13250,"primaryCompletion":3381,"completion":5631,"start":7731,"enrollment":9,"conditions":13251,"interventions":13252},[94],[15,27],[13161,620],{"nctId":13254,"briefTitle":13255,"status":248,"phases":13256,"primaryCompletion":5631,"completion":13257,"start":13258,"enrollment":224,"conditions":13259,"interventions":13260},"NCT02430389","Effect of Remifentanil on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy",[94],"2014-12","2012-07",[1687],[13261,620],"Remifentanil",{"nctId":13216,"briefTitle":13217,"status":261,"phases":13263,"primaryCompletion":13219,"completion":13219,"start":13220,"enrollment":102,"conditions":13264,"interventions":13265},[94],[30],[13161,620],{"intervention":1689,"totalTrials":887,"cells":13267},{"EARLY_PHASE1":13268,"PHASE1":13270,"PHASE2":13272,"PHASE3":13274,"PHASE4":13276,"NA":13291},{"trials":13269,"activeCount":102},[],{"trials":13271,"activeCount":102},[],{"trials":13273,"activeCount":102},[],{"trials":13275,"activeCount":102},[],{"trials":13277,"activeCount":102},[13278,13282],{"nctId":1681,"briefTitle":1682,"status":261,"phases":13279,"primaryCompletion":1684,"completion":1684,"start":1684,"enrollment":102,"conditions":13280,"interventions":13281},[93],[1686,15,1687],[632,1689],{"nctId":13283,"briefTitle":13284,"status":108,"phases":13285,"primaryCompletion":13286,"completion":13287,"start":604,"enrollment":628,"conditions":13288,"interventions":13290},"NCT01997515","Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study",[93],"2019-07-26","2019-08-22",[15,27,13289],"Hypoxia",[1689],{"trials":13292,"activeCount":102},[13293,13300,13307],{"nctId":13294,"briefTitle":13295,"status":261,"phases":13296,"primaryCompletion":4622,"completion":4622,"enrollment":102,"conditions":13297,"interventions":13299},"NCT01825083","The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl",[94],[13298],"Hypercarbia",[1689],{"nctId":13301,"briefTitle":13302,"status":108,"phases":13303,"primaryCompletion":11434,"completion":11434,"start":2002,"enrollment":1935,"conditions":13304,"interventions":13306},"NCT01535976","Ketamine Infusion and Hypoventilation",[94],[13305],"Hypoventilation",[1689],{"nctId":13308,"briefTitle":13309,"status":108,"phases":13310,"primaryCompletion":2046,"completion":2046,"start":13311,"enrollment":13312,"conditions":13313,"interventions":13317},"NCT00486902","Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?",[94],"2006-07",188,[13314,13315,13316],"Ketamine Adverse Reaction","Effects of; Anesthesia, Spinal and Epidural, in Pregnancy","Complication of Labor and\u002For Delivery",[1689],{"intervention":610,"totalTrials":582,"cells":13319},{"EARLY_PHASE1":13320,"PHASE1":13322,"PHASE2":13324,"PHASE3":13337,"PHASE4":13339,"NA":13349},{"trials":13321,"activeCount":102},[],{"trials":13323,"activeCount":102},[],{"trials":13325,"activeCount":102},[13326],{"nctId":13327,"briefTitle":13328,"status":248,"phases":13329,"primaryCompletion":13330,"completion":13331,"start":13332,"enrollment":1511,"conditions":13333,"interventions":13336},"NCT03115567","A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption",[91],"2020-04-24","2022-09-02","2017-02-16",[13334,13335],"Acneiform Rash","Papulopustular Eruption",[610],{"trials":13338,"activeCount":102},[],{"trials":13340,"activeCount":102},[13341,13345],{"nctId":599,"briefTitle":600,"status":108,"phases":13342,"primaryCompletion":602,"completion":603,"start":604,"enrollment":341,"conditions":13343,"interventions":13344},[93],[606,607],[609,610,581],{"nctId":612,"briefTitle":613,"status":261,"phases":13346,"primaryCompletion":615,"completion":615,"start":616,"enrollment":102,"conditions":13347,"interventions":13348},[93],[618],[610,581,620,609],{"trials":13350,"activeCount":102},[13351],{"nctId":13352,"briefTitle":13353,"status":108,"phases":13354,"primaryCompletion":13355,"completion":13355,"start":5608,"enrollment":628,"conditions":13356,"interventions":13358},"NCT02577991","Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF)",[94],"2017-06",[13357],"Cervical Spine",[13359,610],"Decadron",{"intervention":13361,"totalTrials":375,"cells":13362},"Insulin",{"EARLY_PHASE1":13363,"PHASE1":13373,"PHASE2":13375,"PHASE3":13377,"PHASE4":13379,"NA":13390},{"trials":13364,"activeCount":102},[13365],{"nctId":13366,"briefTitle":13367,"status":108,"phases":13368,"primaryCompletion":252,"completion":252,"start":3353,"enrollment":5564,"conditions":13369,"interventions":13372},"NCT00993057","Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia",[89],[13370,13371],"Brain Neoplasms","Intracranial Aneurysm",[13361],{"trials":13374,"activeCount":102},[],{"trials":13376,"activeCount":102},[],{"trials":13378,"activeCount":102},[],{"trials":13380,"activeCount":102},[13381],{"nctId":13382,"briefTitle":13383,"status":108,"phases":13384,"primaryCompletion":616,"completion":947,"start":1786,"enrollment":13385,"conditions":13386,"interventions":13389},"NCT01211730","Study of Glycemic Control on Liver Transplantation Outcomes",[93],164,[13387,6340,13388],"Evidence of Liver Transplantation","Rejection",[13361],{"trials":13391,"activeCount":102},[13392],{"nctId":13393,"briefTitle":13394,"status":261,"phases":13395,"primaryCompletion":1490,"completion":1490,"start":9048,"enrollment":102,"conditions":13396,"interventions":13397},"NCT00615381","Supraphysiologic Insulin to Improve Outcomes After Surgical Treatment of Unruptured Cerebral Aneurysms",[94],[13371],[13361],{"intervention":2232,"totalTrials":375,"cells":13399},{"EARLY_PHASE1":13400,"PHASE1":13402,"PHASE2":13408,"PHASE3":13414,"PHASE4":13416,"NA":13418},{"trials":13401,"activeCount":102},[],{"trials":13403,"activeCount":102},[13404],{"nctId":11939,"briefTitle":11940,"status":248,"phases":13405,"primaryCompletion":11942,"completion":11942,"start":11943,"enrollment":448,"conditions":13406,"interventions":13407},[90],[7007,7013,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230],[11932,2232],{"trials":13409,"activeCount":102},[13410],{"nctId":2207,"briefTitle":2208,"status":200,"phases":13411,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":156,"conditions":13412,"interventions":13413},[91],[2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230],[2232,2183],{"trials":13415,"activeCount":102},[],{"trials":13417,"activeCount":102},[],{"trials":13419,"activeCount":102},[13420],{"nctId":13421,"briefTitle":13422,"status":108,"phases":13423,"primaryCompletion":1644,"completion":1654,"start":4612,"enrollment":1655,"conditions":13424,"interventions":13426},"NCT02296398","Long-term Use of Romidepsin in Patients With CTCL",[],[13425],"Cutaneous T-cell Lymphoma",[13427],"Romidepsin",{"intervention":1801,"totalTrials":375,"cells":13429},{"EARLY_PHASE1":13430,"PHASE1":13432,"PHASE2":13434,"PHASE3":13436,"PHASE4":13438,"NA":13454},{"trials":13431,"activeCount":102},[],{"trials":13433,"activeCount":102},[],{"trials":13435,"activeCount":102},[],{"trials":13437,"activeCount":102},[],{"trials":13439,"activeCount":102},[13440,13444],{"nctId":1793,"briefTitle":1794,"status":248,"phases":13441,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":402,"conditions":13442,"interventions":13443},[93],[1799],[1749,1801,1732,1802],{"nctId":13445,"briefTitle":13446,"status":108,"phases":13447,"primaryCompletion":13448,"completion":13449,"start":3664,"enrollment":13450,"conditions":13451,"interventions":13453},"NCT00866879","Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients",[93],"2017-12","2019-03",275,[13452],"Renal Transplant Rejection",[1801],{"trials":13455,"activeCount":102},[13456],{"nctId":13457,"briefTitle":13458,"status":108,"phases":13459,"primaryCompletion":13460,"completion":13460,"start":13461,"enrollment":999,"conditions":13462,"interventions":13465},"NCT02062944","SRL (Sirolimus) Withdrawal",[94],"2020-07","2013-03",[13463,13464],"Acute Rejection of Liver Transplant","Effects of Immunosuppressant Therapy",[1801],{"intervention":1717,"totalTrials":273,"cells":13467},{"EARLY_PHASE1":13468,"PHASE1":13470,"PHASE2":13480,"PHASE3":13482,"PHASE4":13484,"NA":13486},{"trials":13469,"activeCount":102},[],{"trials":13471,"activeCount":102},[13472],{"nctId":13473,"briefTitle":13474,"status":261,"phases":13475,"primaryCompletion":4612,"completion":4612,"start":4622,"enrollment":102,"conditions":13476,"interventions":13479},"NCT01677650","Pharmacogenomics of Methadone in Spine Fusion Surgery",[90],[13477,13478],"Scoliosis","Kyphosis",[1717],{"trials":13481,"activeCount":102},[],{"trials":13483,"activeCount":102},[],{"trials":13485,"activeCount":102},[],{"trials":13487,"activeCount":102},[13488],{"nctId":1710,"briefTitle":1711,"status":261,"phases":13489,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":102,"conditions":13490,"interventions":13491},[94],[1697],[1717,632],{"intervention":7537,"totalTrials":273,"cells":13493},{"EARLY_PHASE1":13494,"PHASE1":13496,"PHASE2":13498,"PHASE3":13500,"PHASE4":13506,"NA":13508},{"trials":13495,"activeCount":102},[],{"trials":13497,"activeCount":102},[],{"trials":13499,"activeCount":102},[],{"trials":13501,"activeCount":102},[13502],{"nctId":7531,"briefTitle":7532,"status":108,"phases":13503,"primaryCompletion":56,"completion":56,"start":7534,"enrollment":755,"conditions":13504,"interventions":13505},[92],[1022],[7520,7537],{"trials":13507,"activeCount":102},[],{"trials":13509,"activeCount":102},[13510],{"nctId":13511,"briefTitle":13512,"status":108,"phases":13513,"primaryCompletion":446,"completion":11898,"start":4612,"enrollment":526,"conditions":13514,"interventions":13515},"NCT02246660","RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)",[94],[3201],[7537],{"intervention":13517,"totalTrials":273,"cells":13518},"0.9% normal saline",{"EARLY_PHASE1":13519,"PHASE1":13521,"PHASE2":13523,"PHASE3":13525,"PHASE4":13527,"NA":13533},{"trials":13520,"activeCount":102},[],{"trials":13522,"activeCount":102},[],{"trials":13524,"activeCount":102},[],{"trials":13526,"activeCount":102},[],{"trials":13528,"activeCount":102},[13529],{"nctId":6513,"briefTitle":6514,"status":108,"phases":13530,"primaryCompletion":6516,"completion":6516,"start":1490,"enrollment":5564,"conditions":13531,"interventions":13532},[93],[1697,30,27],[6519,6500,6520,6521],{"trials":13534,"activeCount":102},[13535],{"nctId":13536,"briefTitle":13537,"status":261,"phases":13538,"primaryCompletion":13539,"completion":13539,"start":4621,"enrollment":102,"conditions":13540,"interventions":13542},"NCT02383992","Postoperative Care of Sutured Wounds",[94],"2019-10-01",[13541],"Wound Healing",[13543,13517],"3% H2O2 solution",{"intervention":11901,"totalTrials":273,"cells":13545},{"EARLY_PHASE1":13546,"PHASE1":13548,"PHASE2":13554,"PHASE3":13556,"PHASE4":13558,"NA":13560},{"trials":13547,"activeCount":102},[],{"trials":13549,"activeCount":102},[13550],{"nctId":11895,"briefTitle":11896,"status":108,"phases":13551,"primaryCompletion":1644,"completion":11898,"start":10451,"enrollment":2646,"conditions":13552,"interventions":13553},[90],[2468],[11901,11888],{"trials":13555,"activeCount":102},[],{"trials":13557,"activeCount":102},[],{"trials":13559,"activeCount":102},[],{"trials":13561,"activeCount":102},[13562],{"nctId":13563,"briefTitle":13564,"status":248,"phases":13565,"primaryCompletion":996,"completion":4851,"start":264,"enrollment":253,"conditions":13566,"interventions":13568},"NCT00727532","Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",[94],[13567,2050],"Hereditary Clear Cell Renal Cell Carcinoma",[11901],{"intervention":13570,"totalTrials":273,"cells":13571},"Misoprostol",{"EARLY_PHASE1":13572,"PHASE1":13574,"PHASE2":13576,"PHASE3":13578,"PHASE4":13580,"NA":13589},{"trials":13573,"activeCount":102},[],{"trials":13575,"activeCount":102},[],{"trials":13577,"activeCount":102},[],{"trials":13579,"activeCount":102},[],{"trials":13581,"activeCount":102},[13582],{"nctId":13583,"briefTitle":13584,"status":248,"phases":13585,"primaryCompletion":572,"completion":572,"start":489,"enrollment":1655,"conditions":13586,"interventions":13588},"NCT02209545","Misoprostol for Reduction of Blood Loss During Fibroid Surgery",[93],[13587],"Fibroids",[13570],{"trials":13590,"activeCount":102},[13591],{"nctId":13592,"briefTitle":13593,"status":108,"phases":13594,"primaryCompletion":13595,"completion":13595,"start":13596,"enrollment":13597,"conditions":13598,"interventions":13600},"NCT03039036","Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction",[94],"2022-12-01","2017-09-12",69,[13599],"Labor Induction",[13570],{"intervention":13602,"totalTrials":273,"cells":13603},"Botulinum toxin type A",{"EARLY_PHASE1":13604,"PHASE1":13606,"PHASE2":13608,"PHASE3":13610,"PHASE4":13612,"NA":13614},{"trials":13605,"activeCount":102},[],{"trials":13607,"activeCount":102},[],{"trials":13609,"activeCount":102},[],{"trials":13611,"activeCount":102},[],{"trials":13613,"activeCount":102},[],{"trials":13615,"activeCount":102},[13616,13623],{"nctId":13617,"briefTitle":13618,"status":261,"phases":13619,"primaryCompletion":1382,"completion":1382,"start":1382,"enrollment":102,"conditions":13620,"interventions":13622},"NCT03284047","Botox for Gummy Smile",[94],[13621],"Gingival Exposure",[13602],{"nctId":13624,"briefTitle":13625,"status":108,"phases":13626,"primaryCompletion":997,"completion":997,"start":10227,"enrollment":224,"conditions":13627,"interventions":13629},"NCT01274611","Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)",[94],[13628],"Axillary Hyperhidrosis",[13630],"Botulinum Toxin Type A",{"intervention":13632,"totalTrials":273,"cells":13633},"Ketamine group",{"EARLY_PHASE1":13634,"PHASE1":13636,"PHASE2":13638,"PHASE3":13640,"PHASE4":13642,"NA":13648},{"trials":13635,"activeCount":102},[],{"trials":13637,"activeCount":102},[],{"trials":13639,"activeCount":102},[],{"trials":13641,"activeCount":102},[],{"trials":13643,"activeCount":102},[13644],{"nctId":6167,"briefTitle":6168,"status":261,"phases":13645,"primaryCompletion":6170,"completion":6170,"start":6171,"enrollment":102,"conditions":13646,"interventions":13647},[93],[6173],[6175,6154],{"trials":13649,"activeCount":102},[13650],{"nctId":13651,"briefTitle":13652,"status":248,"phases":13653,"primaryCompletion":5236,"completion":5236,"start":13654,"enrollment":3067,"conditions":13655,"interventions":13656},"NCT01250418","SNAP VS BIS(OAA\u002FS) Scale During a Sedation Regimen With and Without Ketamine",[94],"2010-08",[15],[13632],{"intervention":13658,"totalTrials":273,"cells":13659},"Oxytocin",{"EARLY_PHASE1":13660,"PHASE1":13662,"PHASE2":13664,"PHASE3":13666,"PHASE4":13668,"NA":13680},{"trials":13661,"activeCount":102},[],{"trials":13663,"activeCount":102},[],{"trials":13665,"activeCount":102},[],{"trials":13667,"activeCount":102},[],{"trials":13669,"activeCount":102},[13670],{"nctId":13671,"briefTitle":13672,"status":108,"phases":13673,"primaryCompletion":4951,"completion":13674,"start":13675,"enrollment":13676,"conditions":13677,"interventions":13679},"NCT02487797","Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation",[93],"2020-09-28","2015-09-28",1003,[13678],"Dystocia",[13658],{"trials":13681,"activeCount":102},[13682],{"nctId":13683,"briefTitle":13684,"status":261,"phases":13685,"primaryCompletion":13686,"completion":13687,"start":13688,"enrollment":102,"conditions":13689,"interventions":13692},"NCT03172858","Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices",[94],"2020-05","2020-09","2018-11-01",[13690,13691],"Premature Rupture of Membrane","Unfavorable Cervix",[13658],{"intervention":13694,"totalTrials":229,"cells":13695},"salmeterol-fluticasone",{"EARLY_PHASE1":13696,"PHASE1":13698,"PHASE2":13700,"PHASE3":13702,"PHASE4":13704,"NA":13706},{"trials":13697,"activeCount":102},[],{"trials":13699,"activeCount":102},[],{"trials":13701,"activeCount":102},[],{"trials":13703,"activeCount":102},[],{"trials":13705,"activeCount":102},[],{"trials":13707,"activeCount":102},[13708],{"nctId":13709,"briefTitle":13710,"status":261,"phases":13711,"primaryCompletion":5863,"completion":8746,"start":6362,"enrollment":102,"conditions":13712,"interventions":13715},"NCT00741767","The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD",[94],[13713,13714],"Chronic Obstructive Pulmonary Disease","Sleep Disorders",[13694],{"intervention":13717,"totalTrials":229,"cells":13718},"Buccal Swab",{"EARLY_PHASE1":13719,"PHASE1":13721,"PHASE2":13723,"PHASE3":13725,"PHASE4":13727,"NA":13729},{"trials":13720,"activeCount":102},[],{"trials":13722,"activeCount":102},[],{"trials":13724,"activeCount":102},[],{"trials":13726,"activeCount":102},[],{"trials":13728,"activeCount":102},[],{"trials":13730,"activeCount":102},[13731],{"nctId":13732,"briefTitle":13733,"status":108,"phases":13734,"primaryCompletion":10787,"completion":1491,"start":7731,"enrollment":22,"conditions":13735,"interventions":13737},"NCT01016106","Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population",[94],[404,13736],"Ichthyosis Vulgaris",[13717],{"intervention":13739,"totalTrials":229,"cells":13740},"Drug .5% Ropivacaine",{"EARLY_PHASE1":13741,"PHASE1":13743,"PHASE2":13745,"PHASE3":13747,"PHASE4":13749,"NA":13751},{"trials":13742,"activeCount":102},[],{"trials":13744,"activeCount":102},[],{"trials":13746,"activeCount":102},[],{"trials":13748,"activeCount":102},[],{"trials":13750,"activeCount":102},[],{"trials":13752,"activeCount":102},[13753],{"nctId":13754,"briefTitle":13755,"status":108,"phases":13756,"primaryCompletion":10787,"completion":10787,"start":9764,"enrollment":3696,"conditions":13757,"interventions":13758},"NCT01074229","Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy",[94],[1697],[13739,13759],"20 cc of 0.25% ropivacaine",{"intervention":13759,"totalTrials":229,"cells":13761},{"EARLY_PHASE1":13762,"PHASE1":13764,"PHASE2":13766,"PHASE3":13768,"PHASE4":13770,"NA":13772},{"trials":13763,"activeCount":102},[],{"trials":13765,"activeCount":102},[],{"trials":13767,"activeCount":102},[],{"trials":13769,"activeCount":102},[],{"trials":13771,"activeCount":102},[],{"trials":13773,"activeCount":102},[13774],{"nctId":13754,"briefTitle":13755,"status":108,"phases":13775,"primaryCompletion":10787,"completion":10787,"start":9764,"enrollment":3696,"conditions":13776,"interventions":13777},[94],[1697],[13739,13759],{"intervention":13779,"totalTrials":229,"cells":13780},"flutamide",{"EARLY_PHASE1":13781,"PHASE1":13783,"PHASE2":13785,"PHASE3":13787,"PHASE4":13789,"NA":13791},{"trials":13782,"activeCount":102},[],{"trials":13784,"activeCount":102},[],{"trials":13786,"activeCount":102},[],{"trials":13788,"activeCount":102},[],{"trials":13790,"activeCount":102},[],{"trials":13792,"activeCount":102},[13793],{"nctId":13794,"briefTitle":13795,"status":108,"phases":13796,"primaryCompletion":5631,"completion":5631,"start":13311,"enrollment":13797,"conditions":13798,"interventions":13801},"NCT00442689","Metabolic Syndrome in PCOS: Precursors and Interventions",[94],97,[13799,13800],"Polycystic Ovary Syndrome","Metabolic Syndrome",[13779,13802],"ethinyl estradiol 35 mcg and drospirenone 3 mg",{"intervention":13802,"totalTrials":229,"cells":13804},{"EARLY_PHASE1":13805,"PHASE1":13807,"PHASE2":13809,"PHASE3":13811,"PHASE4":13813,"NA":13815},{"trials":13806,"activeCount":102},[],{"trials":13808,"activeCount":102},[],{"trials":13810,"activeCount":102},[],{"trials":13812,"activeCount":102},[],{"trials":13814,"activeCount":102},[],{"trials":13816,"activeCount":102},[13817],{"nctId":13794,"briefTitle":13795,"status":108,"phases":13818,"primaryCompletion":5631,"completion":5631,"start":13311,"enrollment":13797,"conditions":13819,"interventions":13820},[94],[13799,13800],[13779,13802],{"intervention":13822,"totalTrials":229,"cells":13823},"Ulipristal Acetate",{"EARLY_PHASE1":13824,"PHASE1":13826,"PHASE2":13828,"PHASE3":13830,"PHASE4":13832,"NA":13834},{"trials":13825,"activeCount":102},[],{"trials":13827,"activeCount":102},[],{"trials":13829,"activeCount":102},[],{"trials":13831,"activeCount":102},[],{"trials":13833,"activeCount":102},[],{"trials":13835,"activeCount":102},[13836],{"nctId":13837,"briefTitle":13838,"status":108,"phases":13839,"primaryCompletion":1205,"completion":13840,"start":222,"enrollment":3696,"conditions":13841,"interventions":13844},"NCT05285605","Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy",[],"2024-01-22",[5090,13842,13843],"Contraceptive Usage","Reproductive Issues",[13822],{"intervention":13846,"totalTrials":229,"cells":13847},"Magnesium Sulfate",{"EARLY_PHASE1":13848,"PHASE1":13850,"PHASE2":13852,"PHASE3":13854,"PHASE4":13856,"NA":13858},{"trials":13849,"activeCount":102},[],{"trials":13851,"activeCount":102},[],{"trials":13853,"activeCount":102},[],{"trials":13855,"activeCount":102},[],{"trials":13857,"activeCount":102},[],{"trials":13859,"activeCount":102},[13860],{"nctId":13861,"briefTitle":13862,"status":108,"phases":13863,"primaryCompletion":13864,"completion":5820,"start":8000,"enrollment":6314,"conditions":13865,"interventions":13867},"NCT02454322","The Effect of Magnesium on Maternal Mood, Cognitive Function, and Birth Experience",[],"2020-11",[13866],"Depression, Postpartum",[13846],{"intervention":13869,"totalTrials":229,"cells":13870},"Neosporin",{"EARLY_PHASE1":13871,"PHASE1":13873,"PHASE2":13875,"PHASE3":13877,"PHASE4":13879,"NA":13881},{"trials":13872,"activeCount":102},[],{"trials":13874,"activeCount":102},[],{"trials":13876,"activeCount":102},[],{"trials":13878,"activeCount":102},[],{"trials":13880,"activeCount":102},[],{"trials":13882,"activeCount":102},[13883],{"nctId":13884,"briefTitle":13885,"status":108,"phases":13886,"primaryCompletion":4638,"completion":4638,"start":7975,"enrollment":13887,"conditions":13888,"interventions":13890},"NCT00997139","Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment",[94],216,[13889],"Nasal Carriers of Staphylococcus Aureus",[13869],{"intervention":13892,"totalTrials":229,"cells":13893},"Systemic lidocaine",{"EARLY_PHASE1":13894,"PHASE1":13896,"PHASE2":13898,"PHASE3":13900,"PHASE4":13902,"NA":13904},{"trials":13895,"activeCount":102},[],{"trials":13897,"activeCount":102},[],{"trials":13899,"activeCount":102},[],{"trials":13901,"activeCount":102},[],{"trials":13903,"activeCount":102},[],{"trials":13905,"activeCount":102},[13906],{"nctId":13907,"briefTitle":13908,"status":261,"phases":13909,"primaryCompletion":13910,"completion":13910,"start":13911,"enrollment":102,"conditions":13912,"interventions":13913},"NCT02053558","(TAP) Block vs. Systemic Lidocaine: Effects on Recovery",[94],"2017-02","2014-11-03",[15,1687],[13892,13914],"TAP BLOCK with ropivacaine",{"intervention":13914,"totalTrials":229,"cells":13916},{"EARLY_PHASE1":13917,"PHASE1":13919,"PHASE2":13921,"PHASE3":13923,"PHASE4":13925,"NA":13927},{"trials":13918,"activeCount":102},[],{"trials":13920,"activeCount":102},[],{"trials":13922,"activeCount":102},[],{"trials":13924,"activeCount":102},[],{"trials":13926,"activeCount":102},[],{"trials":13928,"activeCount":102},[13929],{"nctId":13907,"briefTitle":13908,"status":261,"phases":13930,"primaryCompletion":13910,"completion":13910,"start":13911,"enrollment":102,"conditions":13931,"interventions":13932},[94],[15,1687],[13892,13914],{"intervention":13359,"totalTrials":229,"cells":13934},{"EARLY_PHASE1":13935,"PHASE1":13937,"PHASE2":13939,"PHASE3":13941,"PHASE4":13943,"NA":13945},{"trials":13936,"activeCount":102},[],{"trials":13938,"activeCount":102},[],{"trials":13940,"activeCount":102},[],{"trials":13942,"activeCount":102},[],{"trials":13944,"activeCount":102},[],{"trials":13946,"activeCount":102},[13947],{"nctId":13352,"briefTitle":13353,"status":108,"phases":13948,"primaryCompletion":13355,"completion":13355,"start":5608,"enrollment":628,"conditions":13949,"interventions":13950},[94],[13357],[13359,610],{"intervention":13952,"totalTrials":229,"cells":13953},"Active Comparator",{"EARLY_PHASE1":13954,"PHASE1":13956,"PHASE2":13958,"PHASE3":13960,"PHASE4":13962,"NA":13964},{"trials":13955,"activeCount":102},[],{"trials":13957,"activeCount":102},[],{"trials":13959,"activeCount":102},[],{"trials":13961,"activeCount":102},[],{"trials":13963,"activeCount":102},[],{"trials":13965,"activeCount":102},[13966],{"nctId":13967,"briefTitle":13968,"status":248,"phases":13969,"primaryCompletion":5609,"completion":5609,"start":10787,"enrollment":900,"conditions":13970,"interventions":13971},"NCT01337739","Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery",[94],[15],[13952],{"intervention":13543,"totalTrials":229,"cells":13973},{"EARLY_PHASE1":13974,"PHASE1":13976,"PHASE2":13978,"PHASE3":13980,"PHASE4":13982,"NA":13984},{"trials":13975,"activeCount":102},[],{"trials":13977,"activeCount":102},[],{"trials":13979,"activeCount":102},[],{"trials":13981,"activeCount":102},[],{"trials":13983,"activeCount":102},[],{"trials":13985,"activeCount":102},[13986],{"nctId":13536,"briefTitle":13537,"status":261,"phases":13987,"primaryCompletion":13539,"completion":13539,"start":4621,"enrollment":102,"conditions":13988,"interventions":13989},[94],[13541],[13543,13517],{"intervention":13991,"totalTrials":229,"cells":13992},"Pregabalin administration",{"EARLY_PHASE1":13993,"PHASE1":13995,"PHASE2":13997,"PHASE3":13999,"PHASE4":14001,"NA":14003},{"trials":13994,"activeCount":102},[],{"trials":13996,"activeCount":102},[],{"trials":13998,"activeCount":102},[],{"trials":14000,"activeCount":102},[],{"trials":14002,"activeCount":102},[],{"trials":14004,"activeCount":102},[14005],{"nctId":14006,"briefTitle":14007,"status":261,"phases":14008,"start":5752,"enrollment":102,"conditions":14009,"interventions":14010},"NCT01466101","Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy",[94],[15],[13991],{"intervention":14012,"totalTrials":229,"cells":14013},"Tacrolimus Withdrawal and Everolimus Monotherapy",{"EARLY_PHASE1":14014,"PHASE1":14016,"PHASE2":14018,"PHASE3":14020,"PHASE4":14022,"NA":14024},{"trials":14015,"activeCount":102},[],{"trials":14017,"activeCount":102},[],{"trials":14019,"activeCount":102},[],{"trials":14021,"activeCount":102},[],{"trials":14023,"activeCount":102},[],{"trials":14025,"activeCount":102},[14026],{"nctId":14027,"briefTitle":14028,"status":108,"phases":14029,"primaryCompletion":14030,"completion":14030,"start":602,"enrollment":6729,"conditions":14031,"interventions":14033},"NCT02736227","Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation",[94],"2021-03",[14032],"Liver Transplantation",[14012],{"intervention":14035,"totalTrials":229,"cells":14036},"Petrolatum United States Pharmacopeia",{"EARLY_PHASE1":14037,"PHASE1":14039,"PHASE2":14041,"PHASE3":14043,"PHASE4":14045,"NA":14047},{"trials":14038,"activeCount":102},[],{"trials":14040,"activeCount":102},[],{"trials":14042,"activeCount":102},[],{"trials":14044,"activeCount":102},[],{"trials":14046,"activeCount":102},[],{"trials":14048,"activeCount":102},[14049],{"nctId":14050,"briefTitle":14051,"status":108,"phases":14052,"primaryCompletion":171,"completion":171,"start":13311,"enrollment":780,"conditions":14053,"interventions":14055},"NCT00363038","Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising",[94],[14054],"Ecchymosis",[14035,14056,14057,14058],"Vitamin K and retinol ointment","Arnica ointment","Vitamin K ointment",{"intervention":14056,"totalTrials":229,"cells":14060},{"EARLY_PHASE1":14061,"PHASE1":14063,"PHASE2":14065,"PHASE3":14067,"PHASE4":14069,"NA":14071},{"trials":14062,"activeCount":102},[],{"trials":14064,"activeCount":102},[],{"trials":14066,"activeCount":102},[],{"trials":14068,"activeCount":102},[],{"trials":14070,"activeCount":102},[],{"trials":14072,"activeCount":102},[14073],{"nctId":14050,"briefTitle":14051,"status":108,"phases":14074,"primaryCompletion":171,"completion":171,"start":13311,"enrollment":780,"conditions":14075,"interventions":14076},[94],[14054],[14035,14056,14057,14058],{"intervention":14057,"totalTrials":229,"cells":14078},{"EARLY_PHASE1":14079,"PHASE1":14081,"PHASE2":14083,"PHASE3":14085,"PHASE4":14087,"NA":14089},{"trials":14080,"activeCount":102},[],{"trials":14082,"activeCount":102},[],{"trials":14084,"activeCount":102},[],{"trials":14086,"activeCount":102},[],{"trials":14088,"activeCount":102},[],{"trials":14090,"activeCount":102},[14091],{"nctId":14050,"briefTitle":14051,"status":108,"phases":14092,"primaryCompletion":171,"completion":171,"start":13311,"enrollment":780,"conditions":14093,"interventions":14094},[94],[14054],[14035,14056,14057,14058],{"intervention":14058,"totalTrials":229,"cells":14096},{"EARLY_PHASE1":14097,"PHASE1":14099,"PHASE2":14101,"PHASE3":14103,"PHASE4":14105,"NA":14107},{"trials":14098,"activeCount":102},[],{"trials":14100,"activeCount":102},[],{"trials":14102,"activeCount":102},[],{"trials":14104,"activeCount":102},[],{"trials":14106,"activeCount":102},[],{"trials":14108,"activeCount":102},[14109],{"nctId":14050,"briefTitle":14051,"status":108,"phases":14110,"primaryCompletion":171,"completion":171,"start":13311,"enrollment":780,"conditions":14111,"interventions":14112},[94],[14054],[14035,14056,14057,14058],{"intervention":14114,"totalTrials":229,"cells":14115},"Carbidopa-Levodopa",{"EARLY_PHASE1":14116,"PHASE1":14118,"PHASE2":14120,"PHASE3":14122,"PHASE4":14124,"NA":14126},{"trials":14117,"activeCount":102},[],{"trials":14119,"activeCount":102},[],{"trials":14121,"activeCount":102},[],{"trials":14123,"activeCount":102},[],{"trials":14125,"activeCount":102},[],{"trials":14127,"activeCount":102},[14128],{"nctId":14129,"briefTitle":14130,"status":108,"phases":14131,"primaryCompletion":13258,"completion":13258,"start":1753,"enrollment":3314,"conditions":14132,"interventions":14133},"NCT01528592","PharmacoMRI of Parkinson Disease",[94],[8002],[14114],{"intervention":14135,"totalTrials":229,"cells":14136},"Rozerem",{"EARLY_PHASE1":14137,"PHASE1":14139,"PHASE2":14141,"PHASE3":14143,"PHASE4":14145,"NA":14147},{"trials":14138,"activeCount":102},[],{"trials":14140,"activeCount":102},[],{"trials":14142,"activeCount":102},[],{"trials":14144,"activeCount":102},[],{"trials":14146,"activeCount":102},[],{"trials":14148,"activeCount":102},[14149],{"nctId":14150,"briefTitle":14151,"status":248,"phases":14152,"primaryCompletion":2274,"completion":2274,"start":7909,"enrollment":375,"conditions":14153,"interventions":14156},"NCT00745030","Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism",[94],[14154,14155],"REM Behavior Disorder","Parkinsonism",[14135],{"intervention":14158,"totalTrials":229,"cells":14159},"lamotrigine",{"EARLY_PHASE1":14160,"PHASE1":14162,"PHASE2":14164,"PHASE3":14166,"PHASE4":14168,"NA":14170},{"trials":14161,"activeCount":102},[],{"trials":14163,"activeCount":102},[],{"trials":14165,"activeCount":102},[],{"trials":14167,"activeCount":102},[],{"trials":14169,"activeCount":102},[],{"trials":14171,"activeCount":102},[14172],{"nctId":14173,"briefTitle":14174,"status":108,"phases":14175,"primaryCompletion":14176,"completion":3663,"start":4851,"enrollment":156,"conditions":14177,"interventions":14178},"NCT01996293","Pregnant Women Taking Lamictal for Bipolar Disorder",[],"2020-08",[7824],[14158],{"intervention":14180,"totalTrials":229,"cells":14181},"Telmisartan",{"EARLY_PHASE1":14182,"PHASE1":14184,"PHASE2":14186,"PHASE3":14188,"PHASE4":14190,"NA":14192},{"trials":14183,"activeCount":102},[],{"trials":14185,"activeCount":102},[],{"trials":14187,"activeCount":102},[],{"trials":14189,"activeCount":102},[],{"trials":14191,"activeCount":102},[],{"trials":14193,"activeCount":102},[14194],{"nctId":14195,"briefTitle":14196,"status":108,"phases":14197,"primaryCompletion":14198,"completion":4717,"start":14199,"enrollment":14200,"conditions":14201,"interventions":14202},"NCT02593110","Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease",[94],"2022-05-06","2016-01-04",114,[1022],[14180],{"intervention":3299,"totalTrials":229,"cells":14204},{"EARLY_PHASE1":14205,"PHASE1":14207,"PHASE2":14209,"PHASE3":14211,"PHASE4":14213,"NA":14215},{"trials":14206,"activeCount":102},[],{"trials":14208,"activeCount":102},[],{"trials":14210,"activeCount":102},[],{"trials":14212,"activeCount":102},[],{"trials":14214,"activeCount":102},[],{"trials":14216,"activeCount":102},[14217],{"nctId":3292,"briefTitle":3293,"status":248,"phases":14218,"primaryCompletion":1714,"completion":1714,"start":3295,"enrollment":375,"conditions":14219,"interventions":14220},[94],[3297],[3299,3268,3300,3301],{"intervention":3300,"totalTrials":229,"cells":14222},{"EARLY_PHASE1":14223,"PHASE1":14225,"PHASE2":14227,"PHASE3":14229,"PHASE4":14231,"NA":14233},{"trials":14224,"activeCount":102},[],{"trials":14226,"activeCount":102},[],{"trials":14228,"activeCount":102},[],{"trials":14230,"activeCount":102},[],{"trials":14232,"activeCount":102},[],{"trials":14234,"activeCount":102},[14235],{"nctId":3292,"briefTitle":3293,"status":248,"phases":14236,"primaryCompletion":1714,"completion":1714,"start":3295,"enrollment":375,"conditions":14237,"interventions":14238},[94],[3297],[3299,3268,3300,3301],{"intervention":3301,"totalTrials":229,"cells":14240},{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14245,"PHASE3":14247,"PHASE4":14249,"NA":14251},{"trials":14242,"activeCount":102},[],{"trials":14244,"activeCount":102},[],{"trials":14246,"activeCount":102},[],{"trials":14248,"activeCount":102},[],{"trials":14250,"activeCount":102},[],{"trials":14252,"activeCount":102},[14253],{"nctId":3292,"briefTitle":3293,"status":248,"phases":14254,"primaryCompletion":1714,"completion":1714,"start":3295,"enrollment":375,"conditions":14255,"interventions":14256},[94],[3297],[3299,3268,3300,3301],{"intervention":14258,"totalTrials":229,"cells":14259},"Single injection posterior tibial nerve block",{"EARLY_PHASE1":14260,"PHASE1":14262,"PHASE2":14264,"PHASE3":14266,"PHASE4":14268,"NA":14270},{"trials":14261,"activeCount":102},[],{"trials":14263,"activeCount":102},[],{"trials":14265,"activeCount":102},[],{"trials":14267,"activeCount":102},[],{"trials":14269,"activeCount":102},[],{"trials":14271,"activeCount":102},[14272],{"nctId":14273,"briefTitle":14274,"status":261,"phases":14275,"primaryCompletion":13257,"completion":13257,"start":996,"enrollment":102,"conditions":14276,"interventions":14278},"NCT01555216","Continuous Tibial Nerve Block Versus Single Shot Tibial Nerve Block",[94],[14277],"Hallux Valgus",[14258,14279],"Posterior tibial nerve catheter",{"intervention":14279,"totalTrials":229,"cells":14281},{"EARLY_PHASE1":14282,"PHASE1":14284,"PHASE2":14286,"PHASE3":14288,"PHASE4":14290,"NA":14292},{"trials":14283,"activeCount":102},[],{"trials":14285,"activeCount":102},[],{"trials":14287,"activeCount":102},[],{"trials":14289,"activeCount":102},[],{"trials":14291,"activeCount":102},[],{"trials":14293,"activeCount":102},[14294],{"nctId":14273,"briefTitle":14274,"status":261,"phases":14295,"primaryCompletion":13257,"completion":13257,"start":996,"enrollment":102,"conditions":14296,"interventions":14297},[94],[14277],[14258,14279],{"intervention":14299,"totalTrials":229,"cells":14300},"Ephedrine",{"EARLY_PHASE1":14301,"PHASE1":14303,"PHASE2":14305,"PHASE3":14307,"PHASE4":14309,"NA":14311},{"trials":14302,"activeCount":102},[],{"trials":14304,"activeCount":102},[],{"trials":14306,"activeCount":102},[],{"trials":14308,"activeCount":102},[],{"trials":14310,"activeCount":102},[],{"trials":14312,"activeCount":102},[14313],{"nctId":14314,"briefTitle":14315,"status":108,"phases":14316,"primaryCompletion":5019,"completion":5019,"start":13311,"enrollment":4720,"conditions":14317,"interventions":14320},"NCT00458003","Phenylephrine in Spinal Anesthesia in Preeclamptic Patients",[94],[14318,14319],"Preeclampsia","Hypotension",[14299,14321],"Phenylephrine",{"intervention":14321,"totalTrials":229,"cells":14323},{"EARLY_PHASE1":14324,"PHASE1":14326,"PHASE2":14328,"PHASE3":14330,"PHASE4":14332,"NA":14334},{"trials":14325,"activeCount":102},[],{"trials":14327,"activeCount":102},[],{"trials":14329,"activeCount":102},[],{"trials":14331,"activeCount":102},[],{"trials":14333,"activeCount":102},[],{"trials":14335,"activeCount":102},[14336],{"nctId":14314,"briefTitle":14315,"status":108,"phases":14337,"primaryCompletion":5019,"completion":5019,"start":13311,"enrollment":4720,"conditions":14338,"interventions":14339},[94],[14318,14319],[14299,14321],{"intervention":14341,"totalTrials":229,"cells":14342},".9 normal saline",{"EARLY_PHASE1":14343,"PHASE1":14345,"PHASE2":14347,"PHASE3":14349,"PHASE4":14351,"NA":14353},{"trials":14344,"activeCount":102},[],{"trials":14346,"activeCount":102},[],{"trials":14348,"activeCount":102},[],{"trials":14350,"activeCount":102},[],{"trials":14352,"activeCount":102},[],{"trials":14354,"activeCount":102},[14355],{"nctId":14356,"briefTitle":14357,"status":108,"phases":14358,"primaryCompletion":4922,"completion":4922,"start":1491,"enrollment":755,"conditions":14359,"interventions":14360},"NCT01451762","A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery",[94],[1687,15],[14341,14361,14362],"25 mg diphenhydramine IV","50 mg diphenhydramine IV",{"intervention":14361,"totalTrials":229,"cells":14364},{"EARLY_PHASE1":14365,"PHASE1":14367,"PHASE2":14369,"PHASE3":14371,"PHASE4":14373,"NA":14375},{"trials":14366,"activeCount":102},[],{"trials":14368,"activeCount":102},[],{"trials":14370,"activeCount":102},[],{"trials":14372,"activeCount":102},[],{"trials":14374,"activeCount":102},[],{"trials":14376,"activeCount":102},[14377],{"nctId":14356,"briefTitle":14357,"status":108,"phases":14378,"primaryCompletion":4922,"completion":4922,"start":1491,"enrollment":755,"conditions":14379,"interventions":14380},[94],[1687,15],[14341,14361,14362],{"intervention":14362,"totalTrials":229,"cells":14382},{"EARLY_PHASE1":14383,"PHASE1":14385,"PHASE2":14387,"PHASE3":14389,"PHASE4":14391,"NA":14393},{"trials":14384,"activeCount":102},[],{"trials":14386,"activeCount":102},[],{"trials":14388,"activeCount":102},[],{"trials":14390,"activeCount":102},[],{"trials":14392,"activeCount":102},[],{"trials":14394,"activeCount":102},[14395],{"nctId":14356,"briefTitle":14357,"status":108,"phases":14396,"primaryCompletion":4922,"completion":4922,"start":1491,"enrollment":755,"conditions":14397,"interventions":14398},[94],[1687,15],[14341,14361,14362],{"intervention":14400,"totalTrials":229,"cells":14401},"Formulation A",{"EARLY_PHASE1":14402,"PHASE1":14404,"PHASE2":14406,"PHASE3":14408,"PHASE4":14410,"NA":14412},{"trials":14403,"activeCount":102},[],{"trials":14405,"activeCount":102},[],{"trials":14407,"activeCount":102},[],{"trials":14409,"activeCount":102},[],{"trials":14411,"activeCount":102},[],{"trials":14413,"activeCount":102},[14414],{"nctId":14415,"briefTitle":14416,"status":108,"phases":14417,"primaryCompletion":6362,"completion":6362,"start":473,"enrollment":98,"conditions":14418,"interventions":14420},"NCT00848744","Comparison of Two Salicylic Acid Formulations",[94],[14419],"Acne Vulgaris",[14400,14421],"Formulation B",{"intervention":14421,"totalTrials":229,"cells":14423},{"EARLY_PHASE1":14424,"PHASE1":14426,"PHASE2":14428,"PHASE3":14430,"PHASE4":14432,"NA":14434},{"trials":14425,"activeCount":102},[],{"trials":14427,"activeCount":102},[],{"trials":14429,"activeCount":102},[],{"trials":14431,"activeCount":102},[],{"trials":14433,"activeCount":102},[],{"trials":14435,"activeCount":102},[14436],{"nctId":14415,"briefTitle":14416,"status":108,"phases":14437,"primaryCompletion":6362,"completion":6362,"start":473,"enrollment":98,"conditions":14438,"interventions":14439},[94],[14419],[14400,14421],{"intervention":14441,"totalTrials":229,"cells":14442},"ATX-101",{"EARLY_PHASE1":14443,"PHASE1":14445,"PHASE2":14447,"PHASE3":14449,"PHASE4":14451,"NA":14453},{"trials":14444,"activeCount":102},[],{"trials":14446,"activeCount":102},[],{"trials":14448,"activeCount":102},[],{"trials":14450,"activeCount":102},[],{"trials":14452,"activeCount":102},[],{"trials":14454,"activeCount":102},[14455],{"nctId":14456,"briefTitle":14457,"status":248,"phases":14458,"primaryCompletion":14459,"completion":14459,"start":14460,"enrollment":900,"conditions":14461,"interventions":14463},"NCT03284034","Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat",[94],"2020-06-08","2017-11-27",[14462],"Upper Back Fat",[14441],{"intervention":14465,"totalTrials":229,"cells":14466},"Metreleptin",{"EARLY_PHASE1":14467,"PHASE1":14469,"PHASE2":14471,"PHASE3":14473,"PHASE4":14475,"NA":14477},{"trials":14468,"activeCount":102},[],{"trials":14470,"activeCount":102},[],{"trials":14472,"activeCount":102},[],{"trials":14474,"activeCount":102},[],{"trials":14476,"activeCount":102},[],{"trials":14478,"activeCount":102},[14479],{"nctId":14480,"briefTitle":14481,"status":108,"phases":14482,"primaryCompletion":14483,"completion":14483,"start":14484,"enrollment":273,"conditions":14485,"interventions":14487},"NCT04063488","The Effects of Metreleptin in Congenital Leptin Deficiency",[],"2021-08-13","2019-06-20",[14486],"Congenital Leptin Deficiency (Disorder)",[14465],{"intervention":14489,"totalTrials":229,"cells":14490},"Group 1",{"EARLY_PHASE1":14491,"PHASE1":14493,"PHASE2":14495,"PHASE3":14497,"PHASE4":14499,"NA":14501},{"trials":14492,"activeCount":102},[],{"trials":14494,"activeCount":102},[],{"trials":14496,"activeCount":102},[],{"trials":14498,"activeCount":102},[],{"trials":14500,"activeCount":102},[],{"trials":14502,"activeCount":102},[14503],{"nctId":14504,"briefTitle":14505,"status":108,"phases":14506,"primaryCompletion":5019,"completion":5019,"start":1490,"enrollment":14507,"conditions":14508,"interventions":14510},"NCT01074190","The Effect of Neuraxial Analgesia on Maternal Breastfeeding",[94],345,[15,14509],"Breastfeeding",[14489,14511,14512],"Group 2","Group 3",{"intervention":14511,"totalTrials":229,"cells":14514},{"EARLY_PHASE1":14515,"PHASE1":14517,"PHASE2":14519,"PHASE3":14521,"PHASE4":14523,"NA":14525},{"trials":14516,"activeCount":102},[],{"trials":14518,"activeCount":102},[],{"trials":14520,"activeCount":102},[],{"trials":14522,"activeCount":102},[],{"trials":14524,"activeCount":102},[],{"trials":14526,"activeCount":102},[14527],{"nctId":14504,"briefTitle":14505,"status":108,"phases":14528,"primaryCompletion":5019,"completion":5019,"start":1490,"enrollment":14507,"conditions":14529,"interventions":14530},[94],[15,14509],[14489,14511,14512],{"intervention":14512,"totalTrials":229,"cells":14532},{"EARLY_PHASE1":14533,"PHASE1":14535,"PHASE2":14537,"PHASE3":14539,"PHASE4":14541,"NA":14543},{"trials":14534,"activeCount":102},[],{"trials":14536,"activeCount":102},[],{"trials":14538,"activeCount":102},[],{"trials":14540,"activeCount":102},[],{"trials":14542,"activeCount":102},[],{"trials":14544,"activeCount":102},[14545],{"nctId":14504,"briefTitle":14505,"status":108,"phases":14546,"primaryCompletion":5019,"completion":5019,"start":1490,"enrollment":14507,"conditions":14547,"interventions":14548},[94],[15,14509],[14489,14511,14512],{"intervention":14550,"totalTrials":229,"cells":14551},"Bimatoprost 0.01%",{"EARLY_PHASE1":14552,"PHASE1":14554,"PHASE2":14556,"PHASE3":14558,"PHASE4":14560,"NA":14562},{"trials":14553,"activeCount":102},[],{"trials":14555,"activeCount":102},[],{"trials":14557,"activeCount":102},[],{"trials":14559,"activeCount":102},[],{"trials":14561,"activeCount":102},[],{"trials":14563,"activeCount":102},[14564],{"nctId":14565,"briefTitle":14566,"status":108,"phases":14567,"primaryCompletion":14568,"completion":14568,"start":14569,"enrollment":1316,"conditions":14570,"interventions":14573},"NCT02448043","Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure",[94],"2016-05-06","2015-06-04",[14571,14572],"Nail Growth Cessation","Intraocular Pressure",[14550],{"intervention":14575,"totalTrials":229,"cells":14576},"blood pressure maintenance based on cerebral blood flow autoregulation measurement",{"EARLY_PHASE1":14577,"PHASE1":14579,"PHASE2":14581,"PHASE3":14583,"PHASE4":14585,"NA":14587},{"trials":14578,"activeCount":102},[],{"trials":14580,"activeCount":102},[],{"trials":14582,"activeCount":102},[],{"trials":14584,"activeCount":102},[],{"trials":14586,"activeCount":102},[],{"trials":14588,"activeCount":102},[14589],{"nctId":14590,"briefTitle":14591,"status":108,"phases":14592,"primaryCompletion":14593,"completion":14594,"start":14595,"enrollment":14596,"conditions":14597,"interventions":14600},"NCT00981474","Cerebral Autoregulation Monitoring During Cardiac Surgery",[94],"2020-02-04","2020-02-28","2009-09-01",460,[14598,14599],"Thoracic Surgery","Cardiopulmonary Bypass",[14575],{"intervention":14602,"totalTrials":229,"cells":14603},"Quetiapine",{"EARLY_PHASE1":14604,"PHASE1":14606,"PHASE2":14608,"PHASE3":14610,"PHASE4":14612,"NA":14614},{"trials":14605,"activeCount":102},[],{"trials":14607,"activeCount":102},[],{"trials":14609,"activeCount":102},[],{"trials":14611,"activeCount":102},[],{"trials":14613,"activeCount":102},[],{"trials":14615,"activeCount":102},[14616],{"nctId":14617,"briefTitle":14618,"status":108,"phases":14619,"primaryCompletion":14176,"completion":3663,"start":602,"enrollment":582,"conditions":14620,"interventions":14621},"NCT02978534","Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum",[],[7824],[14602],{"intervention":14623,"totalTrials":229,"cells":14624},"2% Chlorhexidine cloth",{"EARLY_PHASE1":14625,"PHASE1":14627,"PHASE2":14629,"PHASE3":14631,"PHASE4":14633,"NA":14635},{"trials":14626,"activeCount":102},[],{"trials":14628,"activeCount":102},[],{"trials":14630,"activeCount":102},[],{"trials":14632,"activeCount":102},[],{"trials":14634,"activeCount":102},[],{"trials":14636,"activeCount":102},[14637],{"nctId":14638,"briefTitle":14639,"status":108,"phases":14640,"primaryCompletion":13654,"completion":10787,"start":1490,"enrollment":238,"conditions":14641,"interventions":14643},"NCT01090479","Pre-operative Preparation Using 2% Chlorhexidine Cloth For Shoulder Surgery",[94],[14642],"Post-operative Surgical Site Infections",[14623],{"intervention":14645,"totalTrials":229,"cells":14646},"Tacrolimus with MMF",{"EARLY_PHASE1":14647,"PHASE1":14649,"PHASE2":14651,"PHASE3":14653,"PHASE4":14655,"NA":14657},{"trials":14648,"activeCount":102},[],{"trials":14650,"activeCount":102},[],{"trials":14652,"activeCount":102},[],{"trials":14654,"activeCount":102},[],{"trials":14656,"activeCount":102},[],{"trials":14658,"activeCount":102},[14659],{"nctId":14660,"briefTitle":14661,"status":108,"phases":14662,"primaryCompletion":13686,"completion":13686,"start":625,"enrollment":14663,"conditions":14664,"interventions":14666},"NCT01653847","Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens",[94],88,[14665],"End Stage Renal Failure With Renal Transplant",[14645,14667],"Group 2: Tacrolimus with Everolimus.",{"intervention":14667,"totalTrials":229,"cells":14669},{"EARLY_PHASE1":14670,"PHASE1":14672,"PHASE2":14674,"PHASE3":14676,"PHASE4":14678,"NA":14680},{"trials":14671,"activeCount":102},[],{"trials":14673,"activeCount":102},[],{"trials":14675,"activeCount":102},[],{"trials":14677,"activeCount":102},[],{"trials":14679,"activeCount":102},[],{"trials":14681,"activeCount":102},[14682],{"nctId":14660,"briefTitle":14661,"status":108,"phases":14683,"primaryCompletion":13686,"completion":13686,"start":625,"enrollment":14663,"conditions":14684,"interventions":14685},[94],[14665],[14645,14667],{"intervention":14687,"totalTrials":229,"cells":14688},"levetiracetam",{"EARLY_PHASE1":14689,"PHASE1":14691,"PHASE2":14693,"PHASE3":14695,"PHASE4":14697,"NA":14699},{"trials":14690,"activeCount":102},[],{"trials":14692,"activeCount":102},[],{"trials":14694,"activeCount":102},[],{"trials":14696,"activeCount":102},[],{"trials":14698,"activeCount":102},[],{"trials":14700,"activeCount":102},[14701],{"nctId":14702,"briefTitle":14703,"status":261,"phases":14704,"primaryCompletion":2159,"completion":2159,"start":899,"enrollment":102,"conditions":14705,"interventions":14707},"NCT00415376","Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases",[94],[1495,14706,1500],"Seizure",[14687],{"intervention":14709,"totalTrials":229,"cells":14710},"Group A Intravenous bolus of 1000 ml lactated ringers solution",{"EARLY_PHASE1":14711,"PHASE1":14713,"PHASE2":14715,"PHASE3":14717,"PHASE4":14719,"NA":14721},{"trials":14712,"activeCount":102},[],{"trials":14714,"activeCount":102},[],{"trials":14716,"activeCount":102},[],{"trials":14718,"activeCount":102},[],{"trials":14720,"activeCount":102},[],{"trials":14722,"activeCount":102},[14723],{"nctId":14724,"briefTitle":14725,"status":248,"phases":14726,"primaryCompletion":13258,"completion":13258,"start":14727,"enrollment":14728,"conditions":14729,"interventions":14730},"NCT00787176","The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes",[94],"2007-09",251,[30,5780],[14709,14731,14732,14733],"Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1\u002F2 current rate","Group C 125 mL\u002Fhr of lactated ringers","Group D 125 mL\u002Fhr lactated ringers oxytocin decreased to 1\u002F2 current rate",{"intervention":14731,"totalTrials":229,"cells":14735},{"EARLY_PHASE1":14736,"PHASE1":14738,"PHASE2":14740,"PHASE3":14742,"PHASE4":14744,"NA":14746},{"trials":14737,"activeCount":102},[],{"trials":14739,"activeCount":102},[],{"trials":14741,"activeCount":102},[],{"trials":14743,"activeCount":102},[],{"trials":14745,"activeCount":102},[],{"trials":14747,"activeCount":102},[14748],{"nctId":14724,"briefTitle":14725,"status":248,"phases":14749,"primaryCompletion":13258,"completion":13258,"start":14727,"enrollment":14728,"conditions":14750,"interventions":14751},[94],[30,5780],[14709,14731,14732,14733],{"intervention":14732,"totalTrials":229,"cells":14753},{"EARLY_PHASE1":14754,"PHASE1":14756,"PHASE2":14758,"PHASE3":14760,"PHASE4":14762,"NA":14764},{"trials":14755,"activeCount":102},[],{"trials":14757,"activeCount":102},[],{"trials":14759,"activeCount":102},[],{"trials":14761,"activeCount":102},[],{"trials":14763,"activeCount":102},[],{"trials":14765,"activeCount":102},[14766],{"nctId":14724,"briefTitle":14725,"status":248,"phases":14767,"primaryCompletion":13258,"completion":13258,"start":14727,"enrollment":14728,"conditions":14768,"interventions":14769},[94],[30,5780],[14709,14731,14732,14733],{"intervention":14733,"totalTrials":229,"cells":14771},{"EARLY_PHASE1":14772,"PHASE1":14774,"PHASE2":14776,"PHASE3":14778,"PHASE4":14780,"NA":14782},{"trials":14773,"activeCount":102},[],{"trials":14775,"activeCount":102},[],{"trials":14777,"activeCount":102},[],{"trials":14779,"activeCount":102},[],{"trials":14781,"activeCount":102},[],{"trials":14783,"activeCount":102},[14784],{"nctId":14724,"briefTitle":14725,"status":248,"phases":14785,"primaryCompletion":13258,"completion":13258,"start":14727,"enrollment":14728,"conditions":14786,"interventions":14787},[94],[30,5780],[14709,14731,14732,14733],{"intervention":14789,"totalTrials":229,"cells":14790},"Nucleoside analogue switch",{"EARLY_PHASE1":14791,"PHASE1":14793,"PHASE2":14795,"PHASE3":14797,"PHASE4":14799,"NA":14801},{"trials":14792,"activeCount":102},[],{"trials":14794,"activeCount":102},[],{"trials":14796,"activeCount":102},[],{"trials":14798,"activeCount":102},[],{"trials":14800,"activeCount":102},[],{"trials":14802,"activeCount":102},[14803],{"nctId":14804,"briefTitle":14805,"status":108,"phases":14806,"primaryCompletion":920,"completion":14807,"start":14808,"enrollment":131,"conditions":14809,"interventions":14810},"NCT00225082","SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function",[],"2007-10","2004-11",[7911],[14789],{"intervention":14812,"totalTrials":229,"cells":14813},"ziprasidone vs. aripiprazole",{"EARLY_PHASE1":14814,"PHASE1":14816,"PHASE2":14818,"PHASE3":14820,"PHASE4":14822,"NA":14824},{"trials":14815,"activeCount":102},[],{"trials":14817,"activeCount":102},[],{"trials":14819,"activeCount":102},[],{"trials":14821,"activeCount":102},[],{"trials":14823,"activeCount":102},[],{"trials":14825,"activeCount":102},[14826],{"nctId":14827,"briefTitle":14828,"status":108,"phases":14829,"primaryCompletion":7822,"completion":7822,"start":7419,"enrollment":2320,"conditions":14830,"interventions":14831},"NCT00288366","Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome",[94],[5240,5241,7824],[14812,14832],"aripiprazole vs. ziprasidone",{"intervention":14832,"totalTrials":229,"cells":14834},{"EARLY_PHASE1":14835,"PHASE1":14837,"PHASE2":14839,"PHASE3":14841,"PHASE4":14843,"NA":14845},{"trials":14836,"activeCount":102},[],{"trials":14838,"activeCount":102},[],{"trials":14840,"activeCount":102},[],{"trials":14842,"activeCount":102},[],{"trials":14844,"activeCount":102},[],{"trials":14846,"activeCount":102},[14847],{"nctId":14827,"briefTitle":14828,"status":108,"phases":14848,"primaryCompletion":7822,"completion":7822,"start":7419,"enrollment":2320,"conditions":14849,"interventions":14850},[94],[5240,5241,7824],[14812,14832],{"intervention":14852,"totalTrials":229,"cells":14853},"Iron Sucrose",{"EARLY_PHASE1":14854,"PHASE1":14856,"PHASE2":14858,"PHASE3":14860,"PHASE4":14862,"NA":14864},{"trials":14855,"activeCount":102},[],{"trials":14857,"activeCount":102},[],{"trials":14859,"activeCount":102},[],{"trials":14861,"activeCount":102},[],{"trials":14863,"activeCount":102},[],{"trials":14865,"activeCount":102},[14866],{"nctId":14867,"briefTitle":14868,"status":108,"phases":14869,"primaryCompletion":6473,"completion":6473,"start":14870,"enrollment":14871,"conditions":14872,"interventions":14875},"NCT03106298","Iron Deficiency and FGF23 Regulation in CKD and HF",[],"2015-12-18",77,[2994,14873,14874],"Chronic Heart Failure","Iron Deficiency Anemia",[14852],{"intervention":14877,"totalTrials":229,"cells":14878},"4-hydroxytamoxifen",{"EARLY_PHASE1":14879,"PHASE1":14881,"PHASE2":14883,"PHASE3":14885,"PHASE4":14887,"NA":14889},{"trials":14880,"activeCount":102},[],{"trials":14882,"activeCount":102},[],{"trials":14884,"activeCount":102},[],{"trials":14886,"activeCount":102},[],{"trials":14888,"activeCount":102},[],{"trials":14890,"activeCount":102},[14891],{"nctId":14892,"briefTitle":14893,"status":108,"phases":14894,"primaryCompletion":6338,"completion":6338,"start":14895,"conditions":14896,"interventions":14897},"NCT00084344","Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women",[94],"2003-04",[21],[14877],{"intervention":14899,"totalTrials":229,"cells":14900},"doxycycline",{"EARLY_PHASE1":14901,"PHASE1":14903,"PHASE2":14905,"PHASE3":14907,"PHASE4":14909,"NA":14911},{"trials":14902,"activeCount":102},[],{"trials":14904,"activeCount":102},[],{"trials":14906,"activeCount":102},[],{"trials":14908,"activeCount":102},[],{"trials":14910,"activeCount":102},[],{"trials":14912,"activeCount":102},[14913],{"nctId":14914,"briefTitle":14915,"status":261,"phases":14916,"primaryCompletion":2274,"start":2046,"enrollment":102,"conditions":14917,"interventions":14919},"NCT00803842","Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash",[94],[14918],"Non Small Cell Lung Cancer",[14899],{"intervention":14921,"totalTrials":229,"cells":14922},"hydromorphone",{"EARLY_PHASE1":14923,"PHASE1":14925,"PHASE2":14927,"PHASE3":14929,"PHASE4":14931,"NA":14933},{"trials":14924,"activeCount":102},[],{"trials":14926,"activeCount":102},[],{"trials":14928,"activeCount":102},[],{"trials":14930,"activeCount":102},[],{"trials":14932,"activeCount":102},[],{"trials":14934,"activeCount":102},[14935],{"nctId":14936,"briefTitle":14937,"status":261,"phases":14938,"primaryCompletion":4612,"completion":4612,"start":4612,"enrollment":102,"conditions":14939,"interventions":14941},"NCT01123486","Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint",[94],[15,14940],"Ventilatory Depression",[14921],{"intervention":14943,"totalTrials":229,"cells":14944},"CeraVe Baby Diaper Rash Cream",{"EARLY_PHASE1":14945,"PHASE1":14947,"PHASE2":14949,"PHASE3":14951,"PHASE4":14953,"NA":14955},{"trials":14946,"activeCount":102},[],{"trials":14948,"activeCount":102},[],{"trials":14950,"activeCount":102},[],{"trials":14952,"activeCount":102},[],{"trials":14954,"activeCount":102},[],{"trials":14956,"activeCount":102},[14957],{"nctId":14958,"briefTitle":14959,"status":248,"phases":14960,"primaryCompletion":446,"completion":446,"start":13257,"enrollment":582,"conditions":14961,"interventions":14963},"NCT02299206","CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants",[94],[14962],"Diaper Rash",[14943,14964],"Desitin Maximum Strength Original Paste",{"intervention":14964,"totalTrials":229,"cells":14966},{"EARLY_PHASE1":14967,"PHASE1":14969,"PHASE2":14971,"PHASE3":14973,"PHASE4":14975,"NA":14977},{"trials":14968,"activeCount":102},[],{"trials":14970,"activeCount":102},[],{"trials":14972,"activeCount":102},[],{"trials":14974,"activeCount":102},[],{"trials":14976,"activeCount":102},[],{"trials":14978,"activeCount":102},[14979],{"nctId":14958,"briefTitle":14959,"status":248,"phases":14980,"primaryCompletion":446,"completion":446,"start":13257,"enrollment":582,"conditions":14981,"interventions":14982},[94],[14962],[14943,14964],{"intervention":14984,"totalTrials":229,"cells":14985},"administration of magnesium sulfate",{"EARLY_PHASE1":14986,"PHASE1":14988,"PHASE2":14990,"PHASE3":14992,"PHASE4":14994,"NA":14996},{"trials":14987,"activeCount":102},[],{"trials":14989,"activeCount":102},[],{"trials":14991,"activeCount":102},[],{"trials":14993,"activeCount":102},[],{"trials":14995,"activeCount":102},[],{"trials":14997,"activeCount":102},[14998],{"nctId":14999,"briefTitle":15000,"status":108,"phases":15001,"primaryCompletion":9886,"completion":9886,"start":5431,"enrollment":311,"conditions":15002,"interventions":15004},"NCT01433081","The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients",[94],[15,15003],"Opioid Use, Unspecified, Uncomplicated",[14984],{"intervention":15006,"totalTrials":229,"cells":15007},"Indomethacin and antibiotics",{"EARLY_PHASE1":15008,"PHASE1":15010,"PHASE2":15012,"PHASE3":15014,"PHASE4":15016,"NA":15018},{"trials":15009,"activeCount":102},[],{"trials":15011,"activeCount":102},[],{"trials":15013,"activeCount":102},[],{"trials":15015,"activeCount":102},[],{"trials":15017,"activeCount":102},[],{"trials":15019,"activeCount":102},[15020],{"nctId":15021,"briefTitle":15022,"status":108,"phases":15023,"primaryCompletion":13461,"completion":4622,"start":9764,"enrollment":1426,"conditions":15024,"interventions":15026},"NCT01114516","Multifactorial Approach to Emergent Cerclage",[94],[15025],"Cervical Insufficiency",[15006],{"intervention":15028,"totalTrials":229,"cells":15029},"Intracutaneous injections",{"EARLY_PHASE1":15030,"PHASE1":15032,"PHASE2":15034,"PHASE3":15036,"PHASE4":15038,"NA":15040},{"trials":15031,"activeCount":102},[],{"trials":15033,"activeCount":102},[],{"trials":15035,"activeCount":102},[],{"trials":15037,"activeCount":102},[],{"trials":15039,"activeCount":102},[],{"trials":15041,"activeCount":102},[15042],{"nctId":15043,"briefTitle":15044,"status":248,"phases":15045,"primaryCompletion":4599,"completion":4599,"start":997,"enrollment":900,"conditions":15046,"interventions":15047},"NCT01513447","Intracutaneous Sterile Water Injections",[94],[5780],[15028],{"intervention":13261,"totalTrials":229,"cells":15049},{"EARLY_PHASE1":15050,"PHASE1":15052,"PHASE2":15054,"PHASE3":15056,"PHASE4":15058,"NA":15060},{"trials":15051,"activeCount":102},[],{"trials":15053,"activeCount":102},[],{"trials":15055,"activeCount":102},[],{"trials":15057,"activeCount":102},[],{"trials":15059,"activeCount":102},[],{"trials":15061,"activeCount":102},[15062],{"nctId":13254,"briefTitle":13255,"status":248,"phases":15063,"primaryCompletion":5631,"completion":13257,"start":13258,"enrollment":224,"conditions":15064,"interventions":15065},[94],[1687],[13261,620],{"intervention":15067,"totalTrials":229,"cells":15068},"Benzoyl Peroxide",{"EARLY_PHASE1":15069,"PHASE1":15071,"PHASE2":15073,"PHASE3":15075,"PHASE4":15077,"NA":15079},{"trials":15070,"activeCount":102},[],{"trials":15072,"activeCount":102},[],{"trials":15074,"activeCount":102},[],{"trials":15076,"activeCount":102},[],{"trials":15078,"activeCount":102},[],{"trials":15080,"activeCount":102},[15081],{"nctId":15082,"briefTitle":15083,"status":108,"phases":15084,"primaryCompletion":15085,"completion":15085,"start":14807,"enrollment":1610,"conditions":15086,"interventions":15087},"NCT00558831","Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris",[94],"2008-01",[14419],[15067,15088],"Moisturizing Lotion",{"intervention":15088,"totalTrials":229,"cells":15090},{"EARLY_PHASE1":15091,"PHASE1":15093,"PHASE2":15095,"PHASE3":15097,"PHASE4":15099,"NA":15101},{"trials":15092,"activeCount":102},[],{"trials":15094,"activeCount":102},[],{"trials":15096,"activeCount":102},[],{"trials":15098,"activeCount":102},[],{"trials":15100,"activeCount":102},[],{"trials":15102,"activeCount":102},[15103],{"nctId":15082,"briefTitle":15083,"status":108,"phases":15104,"primaryCompletion":15085,"completion":15085,"start":14807,"enrollment":1610,"conditions":15105,"interventions":15106},[94],[14419],[15067,15088],{"intervention":15108,"totalTrials":229,"cells":15109},"Crisaborole",{"EARLY_PHASE1":15110,"PHASE1":15112,"PHASE2":15114,"PHASE3":15116,"PHASE4":15118,"NA":15120},{"trials":15111,"activeCount":102},[],{"trials":15113,"activeCount":102},[],{"trials":15115,"activeCount":102},[],{"trials":15117,"activeCount":102},[],{"trials":15119,"activeCount":102},[],{"trials":15121,"activeCount":102},[15122],{"nctId":15123,"briefTitle":15124,"status":108,"phases":15125,"primaryCompletion":15126,"completion":367,"start":15127,"enrollment":31,"conditions":15128,"interventions":15129},"NCT03770858","Wearable Skin Sensors to Assess Nocturnal Scratch Behavior",[],"2021-08-30","2019-04-18",[404],[15108],{"intervention":15131,"totalTrials":229,"cells":15132},"Alisertib",{"EARLY_PHASE1":15133,"PHASE1":15135,"PHASE2":15137,"PHASE3":15139,"PHASE4":15141,"NA":15143},{"trials":15134,"activeCount":102},[],{"trials":15136,"activeCount":102},[],{"trials":15138,"activeCount":102},[],{"trials":15140,"activeCount":102},[],{"trials":15142,"activeCount":102},[],{"trials":15144,"activeCount":102},[15145],{"nctId":15146,"briefTitle":15147,"status":200,"phases":15148,"primaryCompletion":15149,"completion":15150,"start":15151,"enrollment":7977,"conditions":15152,"interventions":15154},"NCT02530619","Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia",[94],"2018-05-21","2022-05","2015-10-09",[15153,13053,9202],"Acute Megakaryoblastic Leukemia",[15131],{"intervention":13214,"totalTrials":229,"cells":15156},{"EARLY_PHASE1":15157,"PHASE1":15159,"PHASE2":15161,"PHASE3":15163,"PHASE4":15165,"NA":15167},{"trials":15158,"activeCount":102},[],{"trials":15160,"activeCount":102},[],{"trials":15162,"activeCount":102},[],{"trials":15164,"activeCount":102},[],{"trials":15166,"activeCount":102},[],{"trials":15168,"activeCount":102},[15169],{"nctId":13209,"briefTitle":13210,"status":200,"phases":15170,"primaryCompletion":547,"completion":547,"start":433,"enrollment":7977,"conditions":15171,"interventions":15172},[94],[15],[13161,13214],{"intervention":15174,"totalTrials":229,"cells":15175},"Esmolol administered at a rate of 0.5 mg\u002Fkg followed by an infusion of 5-15 mcg\u002Fkg\u002Fmin",{"EARLY_PHASE1":15176,"PHASE1":15178,"PHASE2":15180,"PHASE3":15182,"PHASE4":15184,"NA":15186},{"trials":15177,"activeCount":102},[],{"trials":15179,"activeCount":102},[],{"trials":15181,"activeCount":102},[],{"trials":15183,"activeCount":102},[],{"trials":15185,"activeCount":102},[],{"trials":15187,"activeCount":102},[15188],{"nctId":15189,"briefTitle":15190,"status":108,"phases":15191,"primaryCompletion":13257,"completion":13257,"start":11331,"enrollment":189,"conditions":15192,"interventions":15193},"NCT01782898","The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery",[94],[15],[15174],{"intervention":15195,"totalTrials":229,"cells":15196},"enoxaparin",{"EARLY_PHASE1":15197,"PHASE1":15199,"PHASE2":15201,"PHASE3":15203,"PHASE4":15205,"NA":15207},{"trials":15198,"activeCount":102},[],{"trials":15200,"activeCount":102},[],{"trials":15202,"activeCount":102},[],{"trials":15204,"activeCount":102},[],{"trials":15206,"activeCount":102},[],{"trials":15208,"activeCount":102},[15209],{"nctId":15210,"briefTitle":15211,"status":108,"phases":15212,"primaryCompletion":15213,"completion":15213,"start":15214,"enrollment":475,"conditions":15215,"interventions":15217},"NCT00004875","Heparin or Enoxaparin in Patients With Cancer",[],"1999-03","1996-07",[24,15216,1500],"Thromboembolism",[15195,15218],"heparin",{"intervention":15218,"totalTrials":229,"cells":15220},{"EARLY_PHASE1":15221,"PHASE1":15223,"PHASE2":15225,"PHASE3":15227,"PHASE4":15229,"NA":15231},{"trials":15222,"activeCount":102},[],{"trials":15224,"activeCount":102},[],{"trials":15226,"activeCount":102},[],{"trials":15228,"activeCount":102},[],{"trials":15230,"activeCount":102},[],{"trials":15232,"activeCount":102},[15233],{"nctId":15210,"briefTitle":15211,"status":108,"phases":15234,"primaryCompletion":15213,"completion":15213,"start":15214,"enrollment":475,"conditions":15235,"interventions":15236},[],[24,15216,1500],[15195,15218],{"intervention":1730,"totalTrials":229,"cells":15238},{"EARLY_PHASE1":15239,"PHASE1":15241,"PHASE2":15243,"PHASE3":15245,"PHASE4":15247,"NA":15249},{"trials":15240,"activeCount":102},[],{"trials":15242,"activeCount":102},[],{"trials":15244,"activeCount":102},[],{"trials":15246,"activeCount":102},[],{"trials":15248,"activeCount":102},[],{"trials":15250,"activeCount":102},[15251],{"nctId":1719,"briefTitle":1720,"status":108,"phases":15252,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":15253,"interventions":15254},[94],[1726,1727,1728],[1730,632],{"intervention":15256,"totalTrials":229,"cells":15257},"Lidocaine Administration",{"EARLY_PHASE1":15258,"PHASE1":15260,"PHASE2":15262,"PHASE3":15264,"PHASE4":15266,"NA":15268},{"trials":15259,"activeCount":102},[],{"trials":15261,"activeCount":102},[],{"trials":15263,"activeCount":102},[],{"trials":15265,"activeCount":102},[],{"trials":15267,"activeCount":102},[],{"trials":15269,"activeCount":102},[15270],{"nctId":15271,"briefTitle":15272,"status":248,"phases":15273,"primaryCompletion":251,"completion":251,"start":4621,"enrollment":273,"conditions":15274,"interventions":15275},"NCT02574832","Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery",[94],[30,1687,15],[15256],{"intervention":15277,"totalTrials":229,"cells":15278},".9 normal saline placebo",{"EARLY_PHASE1":15279,"PHASE1":15281,"PHASE2":15283,"PHASE3":15285,"PHASE4":15287,"NA":15289},{"trials":15280,"activeCount":102},[],{"trials":15282,"activeCount":102},[],{"trials":15284,"activeCount":102},[],{"trials":15286,"activeCount":102},[],{"trials":15288,"activeCount":102},[],{"trials":15290,"activeCount":102},[15291],{"nctId":15292,"briefTitle":15293,"status":108,"phases":15294,"primaryCompletion":15295,"completion":4612,"start":627,"enrollment":15296,"conditions":15297,"interventions":15298},"NCT01619852","Lidocaine and Prevention of Chronic Pain",[94],"2014-07",148,[1687],[15277,15299],"Group L",{"intervention":15299,"totalTrials":229,"cells":15301},{"EARLY_PHASE1":15302,"PHASE1":15304,"PHASE2":15306,"PHASE3":15308,"PHASE4":15310,"NA":15312},{"trials":15303,"activeCount":102},[],{"trials":15305,"activeCount":102},[],{"trials":15307,"activeCount":102},[],{"trials":15309,"activeCount":102},[],{"trials":15311,"activeCount":102},[],{"trials":15313,"activeCount":102},[15314],{"nctId":15292,"briefTitle":15293,"status":108,"phases":15315,"primaryCompletion":15295,"completion":4612,"start":627,"enrollment":15296,"conditions":15316,"interventions":15317},[94],[1687],[15277,15299],{"intervention":15319,"totalTrials":229,"cells":15320},"Routine oxytocin",{"EARLY_PHASE1":15321,"PHASE1":15323,"PHASE2":15325,"PHASE3":15327,"PHASE4":15329,"NA":15331},{"trials":15322,"activeCount":102},[],{"trials":15324,"activeCount":102},[],{"trials":15326,"activeCount":102},[],{"trials":15328,"activeCount":102},[],{"trials":15330,"activeCount":102},[],{"trials":15332,"activeCount":102},[15333],{"nctId":15334,"briefTitle":15335,"status":248,"phases":15336,"primaryCompletion":15337,"completion":15337,"start":984,"enrollment":15338,"conditions":15339,"interventions":15340},"NCT02121184","Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes",[94],"2021-09-21",172,[30,5780],[15319,15341],"Half-dose oxytocin",{"intervention":15341,"totalTrials":229,"cells":15343},{"EARLY_PHASE1":15344,"PHASE1":15346,"PHASE2":15348,"PHASE3":15350,"PHASE4":15352,"NA":15354},{"trials":15345,"activeCount":102},[],{"trials":15347,"activeCount":102},[],{"trials":15349,"activeCount":102},[],{"trials":15351,"activeCount":102},[],{"trials":15353,"activeCount":102},[],{"trials":15355,"activeCount":102},[15356],{"nctId":15334,"briefTitle":15335,"status":248,"phases":15357,"primaryCompletion":15337,"completion":15337,"start":984,"enrollment":15338,"conditions":15358,"interventions":15359},[94],[30,5780],[15319,15341],{"intervention":15361,"totalTrials":229,"cells":15362},"(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.",{"EARLY_PHASE1":15363,"PHASE1":15365,"PHASE2":15367,"PHASE3":15369,"PHASE4":15371,"NA":15373},{"trials":15364,"activeCount":102},[],{"trials":15366,"activeCount":102},[],{"trials":15368,"activeCount":102},[],{"trials":15370,"activeCount":102},[],{"trials":15372,"activeCount":102},[],{"trials":15374,"activeCount":102},[15375],{"nctId":15376,"briefTitle":15377,"status":108,"phases":15378,"primaryCompletion":13258,"completion":252,"start":9764,"enrollment":36,"conditions":15379,"interventions":15380},"NCT01075087","The Effect of Pre-Operative Transversus Abdominis Plane (TAP) Block in the Post Operative Opioid Consumption in Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery: A Prospective,Randomized, Blinded Study",[94],[15,27,1687],[15361],{"intervention":15382,"totalTrials":229,"cells":15383},"Influenza vaccine",{"EARLY_PHASE1":15384,"PHASE1":15386,"PHASE2":15388,"PHASE3":15390,"PHASE4":15392,"NA":15394},{"trials":15385,"activeCount":102},[],{"trials":15387,"activeCount":102},[],{"trials":15389,"activeCount":102},[],{"trials":15391,"activeCount":102},[],{"trials":15393,"activeCount":102},[],{"trials":15395,"activeCount":102},[15396],{"nctId":15397,"briefTitle":15398,"status":108,"phases":15399,"primaryCompletion":15400,"completion":4693,"start":4621,"enrollment":36,"conditions":15401,"interventions":15403},"NCT02623075","Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney\u002FStem Cell Transplant Recipients",[],"2016-12-05",[15402],"Influenza",[15382],{"intervention":15405,"totalTrials":229,"cells":15406},"granulocyte macrophage colony stimulating factor",{"EARLY_PHASE1":15407,"PHASE1":15409,"PHASE2":15411,"PHASE3":15413,"PHASE4":15415,"NA":15417},{"trials":15408,"activeCount":102},[],{"trials":15410,"activeCount":102},[],{"trials":15412,"activeCount":102},[],{"trials":15414,"activeCount":102},[],{"trials":15416,"activeCount":102},[],{"trials":15418,"activeCount":102},[15419],{"nctId":15420,"briefTitle":15421,"status":108,"phases":15422,"primaryCompletion":15423,"completion":15423,"start":1491,"enrollment":15424,"conditions":15425,"interventions":15426},"NCT01408901","Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)",[94],"2017-08-15",210,[3201],[15405],{"intervention":15428,"totalTrials":229,"cells":15429},"polymerase chain reaction",{"EARLY_PHASE1":15430,"PHASE1":15432,"PHASE2":15434,"PHASE3":15436,"PHASE4":15438,"NA":15440},{"trials":15431,"activeCount":102},[],{"trials":15433,"activeCount":102},[],{"trials":15435,"activeCount":102},[],{"trials":15437,"activeCount":102},[],{"trials":15439,"activeCount":102},[],{"trials":15441,"activeCount":102},[15442],{"nctId":15443,"briefTitle":15444,"status":108,"phases":15445,"primaryCompletion":8168,"completion":8168,"start":8479,"enrollment":780,"conditions":15446,"interventions":15447},"NCT00005619","Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia",[],[115],[15428],{"intervention":15449,"totalTrials":229,"cells":15450},"Desflurane",{"EARLY_PHASE1":15451,"PHASE1":15453,"PHASE2":15455,"PHASE3":15457,"PHASE4":15459,"NA":15461},{"trials":15452,"activeCount":102},[],{"trials":15454,"activeCount":102},[],{"trials":15456,"activeCount":102},[],{"trials":15458,"activeCount":102},[],{"trials":15460,"activeCount":102},[],{"trials":15462,"activeCount":102},[15463],{"nctId":15464,"briefTitle":15465,"status":108,"phases":15466,"primaryCompletion":985,"completion":985,"start":1221,"enrollment":6363,"conditions":15467,"interventions":15468},"NCT01202162","A Comparison of Desflurane vs. Sevoflurane and the Time to Awakening and the Incidence and Severity of Cough",[94],[1687,1686],[15449,15469],"Administration of Sevoflurane",{"intervention":15469,"totalTrials":229,"cells":15471},{"EARLY_PHASE1":15472,"PHASE1":15474,"PHASE2":15476,"PHASE3":15478,"PHASE4":15480,"NA":15482},{"trials":15473,"activeCount":102},[],{"trials":15475,"activeCount":102},[],{"trials":15477,"activeCount":102},[],{"trials":15479,"activeCount":102},[],{"trials":15481,"activeCount":102},[],{"trials":15483,"activeCount":102},[15484],{"nctId":15464,"briefTitle":15465,"status":108,"phases":15485,"primaryCompletion":985,"completion":985,"start":1221,"enrollment":6363,"conditions":15486,"interventions":15487},[94],[1687,1686],[15449,15469],{"intervention":15489,"totalTrials":229,"cells":15490},"IV acetaminophen",{"EARLY_PHASE1":15491,"PHASE1":15493,"PHASE2":15495,"PHASE3":15497,"PHASE4":15499,"NA":15501},{"trials":15492,"activeCount":102},[],{"trials":15494,"activeCount":102},[],{"trials":15496,"activeCount":102},[],{"trials":15498,"activeCount":102},[],{"trials":15500,"activeCount":102},[],{"trials":15502,"activeCount":102},[15503],{"nctId":15504,"briefTitle":15505,"status":108,"phases":15506,"primaryCompletion":13257,"completion":13257,"start":604,"enrollment":189,"conditions":15507,"interventions":15508},"NCT01852955","Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery",[94],[15],[15489],{"intervention":15510,"totalTrials":229,"cells":15511},"Topical benzoyl peroxide 10.0% cream - Formulation 1",{"EARLY_PHASE1":15512,"PHASE1":15514,"PHASE2":15516,"PHASE3":15518,"PHASE4":15520,"NA":15522},{"trials":15513,"activeCount":102},[],{"trials":15515,"activeCount":102},[],{"trials":15517,"activeCount":102},[],{"trials":15519,"activeCount":102},[],{"trials":15521,"activeCount":102},[],{"trials":15523,"activeCount":102},[15524],{"nctId":15525,"briefTitle":15526,"status":108,"phases":15527,"primaryCompletion":9048,"completion":9048,"start":3295,"enrollment":98,"conditions":15528,"interventions":15529},"NCT00787943","Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris",[94],[14419],[15510,15530],"Topical benzoyl peroxide 10.0% cream - Formulation 2",{"intervention":15530,"totalTrials":229,"cells":15532},{"EARLY_PHASE1":15533,"PHASE1":15535,"PHASE2":15537,"PHASE3":15539,"PHASE4":15541,"NA":15543},{"trials":15534,"activeCount":102},[],{"trials":15536,"activeCount":102},[],{"trials":15538,"activeCount":102},[],{"trials":15540,"activeCount":102},[],{"trials":15542,"activeCount":102},[],{"trials":15544,"activeCount":102},[15545],{"nctId":15525,"briefTitle":15526,"status":108,"phases":15546,"primaryCompletion":9048,"completion":9048,"start":3295,"enrollment":98,"conditions":15547,"interventions":15548},[94],[14419],[15510,15530],{"intervention":15550,"totalTrials":229,"cells":15551},"Morphine-CP-saline",{"EARLY_PHASE1":15552,"PHASE1":15554,"PHASE2":15556,"PHASE3":15558,"PHASE4":15560,"NA":15562},{"trials":15553,"activeCount":102},[],{"trials":15555,"activeCount":102},[],{"trials":15557,"activeCount":102},[],{"trials":15559,"activeCount":102},[],{"trials":15561,"activeCount":102},[],{"trials":15563,"activeCount":102},[15564],{"nctId":15565,"briefTitle":15566,"status":108,"phases":15567,"primaryCompletion":15568,"completion":15568,"start":6825,"enrollment":15569,"conditions":15570,"interventions":15573},"NCT00487084","Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia",[94],"2008-09",136,[15571,15572],"Labor","Analgesia, Epidural",[15550,15574,15575],"saline-2CP-morphine","saline-lidocaine-morphine",{"intervention":15574,"totalTrials":229,"cells":15577},{"EARLY_PHASE1":15578,"PHASE1":15580,"PHASE2":15582,"PHASE3":15584,"PHASE4":15586,"NA":15588},{"trials":15579,"activeCount":102},[],{"trials":15581,"activeCount":102},[],{"trials":15583,"activeCount":102},[],{"trials":15585,"activeCount":102},[],{"trials":15587,"activeCount":102},[],{"trials":15589,"activeCount":102},[15590],{"nctId":15565,"briefTitle":15566,"status":108,"phases":15591,"primaryCompletion":15568,"completion":15568,"start":6825,"enrollment":15569,"conditions":15592,"interventions":15593},[94],[15571,15572],[15550,15574,15575],{"intervention":15575,"totalTrials":229,"cells":15595},{"EARLY_PHASE1":15596,"PHASE1":15598,"PHASE2":15600,"PHASE3":15602,"PHASE4":15604,"NA":15606},{"trials":15597,"activeCount":102},[],{"trials":15599,"activeCount":102},[],{"trials":15601,"activeCount":102},[],{"trials":15603,"activeCount":102},[],{"trials":15605,"activeCount":102},[],{"trials":15607,"activeCount":102},[15608],{"nctId":15565,"briefTitle":15566,"status":108,"phases":15609,"primaryCompletion":15568,"completion":15568,"start":6825,"enrollment":15569,"conditions":15610,"interventions":15611},[94],[15571,15572],[15550,15574,15575],{"intervention":15613,"totalTrials":229,"cells":15614},"Pegylated interferon α-2b",{"EARLY_PHASE1":15615,"PHASE1":15617,"PHASE2":15619,"PHASE3":15621,"PHASE4":15623,"NA":15625},{"trials":15616,"activeCount":102},[],{"trials":15618,"activeCount":102},[],{"trials":15620,"activeCount":102},[],{"trials":15622,"activeCount":102},[],{"trials":15624,"activeCount":102},[],{"trials":15626,"activeCount":102},[15627],{"nctId":15628,"briefTitle":15629,"status":248,"phases":15630,"primaryCompletion":1753,"completion":997,"start":15568,"enrollment":448,"conditions":15631,"interventions":15632},"NCT00724061","Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL",[94],[24],[15613],{"intervention":15634,"totalTrials":229,"cells":15635},"Group A: Saline Group",{"EARLY_PHASE1":15636,"PHASE1":15638,"PHASE2":15640,"PHASE3":15642,"PHASE4":15644,"NA":15646},{"trials":15637,"activeCount":102},[],{"trials":15639,"activeCount":102},[],{"trials":15641,"activeCount":102},[],{"trials":15643,"activeCount":102},[],{"trials":15645,"activeCount":102},[],{"trials":15647,"activeCount":102},[15648],{"nctId":15649,"briefTitle":15650,"status":248,"phases":15651,"primaryCompletion":13461,"completion":13461,"start":9764,"enrollment":13184,"conditions":15652,"interventions":15653},"NCT01106846","Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery",[94],[15],[15634,15654],"Group B: 1% Ketamine group",{"intervention":15654,"totalTrials":229,"cells":15656},{"EARLY_PHASE1":15657,"PHASE1":15659,"PHASE2":15661,"PHASE3":15663,"PHASE4":15665,"NA":15667},{"trials":15658,"activeCount":102},[],{"trials":15660,"activeCount":102},[],{"trials":15662,"activeCount":102},[],{"trials":15664,"activeCount":102},[],{"trials":15666,"activeCount":102},[],{"trials":15668,"activeCount":102},[15669],{"nctId":15649,"briefTitle":15650,"status":248,"phases":15670,"primaryCompletion":13461,"completion":13461,"start":9764,"enrollment":13184,"conditions":15671,"interventions":15672},[94],[15],[15634,15654],{"intervention":15674,"totalTrials":229,"cells":15675},"Infusion of Donor Hematopoietic Stem Cells and Campath-1H",{"EARLY_PHASE1":15676,"PHASE1":15678,"PHASE2":15680,"PHASE3":15682,"PHASE4":15684,"NA":15686},{"trials":15677,"activeCount":102},[],{"trials":15679,"activeCount":102},[],{"trials":15681,"activeCount":102},[],{"trials":15683,"activeCount":102},[],{"trials":15685,"activeCount":102},[],{"trials":15687,"activeCount":102},[15688],{"nctId":15689,"briefTitle":15690,"status":108,"phases":15691,"primaryCompletion":572,"completion":15692,"start":15085,"enrollment":14663,"conditions":15693,"interventions":15697},"NCT00619528","HLA-Identical Sibling Renal Transplant Tolerance",[94],"2023-09",[15694,15695,15696],"Immunosuppression","Kidney Transplantation","Graft Rejection",[15674],{"intervention":15699,"totalTrials":229,"cells":15700},"Pharmacotherapy",{"EARLY_PHASE1":15701,"PHASE1":15703,"PHASE2":15705,"PHASE3":15707,"PHASE4":15709,"NA":15711},{"trials":15702,"activeCount":102},[],{"trials":15704,"activeCount":102},[],{"trials":15706,"activeCount":102},[],{"trials":15708,"activeCount":102},[],{"trials":15710,"activeCount":102},[],{"trials":15712,"activeCount":102},[15713],{"nctId":15714,"briefTitle":15715,"status":248,"phases":15716,"primaryCompletion":15717,"completion":15717,"start":250,"enrollment":6729,"conditions":15718,"interventions":15720},"NCT02505022","Role Functioning Changes NOS",[],"2021-01",[5240,15719,7824],"Psychotic Disorders",[15699],{"intervention":15722,"totalTrials":229,"cells":15723},"Soy isoflavones",{"EARLY_PHASE1":15724,"PHASE1":15726,"PHASE2":15728,"PHASE3":15730,"PHASE4":15732,"NA":15734},{"trials":15725,"activeCount":102},[],{"trials":15727,"activeCount":102},[],{"trials":15729,"activeCount":102},[],{"trials":15731,"activeCount":102},[],{"trials":15733,"activeCount":102},[],{"trials":15735,"activeCount":102},[15736],{"nctId":15737,"briefTitle":15738,"status":108,"phases":15739,"primaryCompletion":15740,"completion":15740,"start":7419,"enrollment":419,"conditions":15741,"interventions":15742},"NCT00277446","Dietary Supplementation With Soy Isoflavones in Asthma",[94],"2007-04",[7777],[15722],{"intervention":15744,"totalTrials":229,"cells":15745},"Tadalafil",{"EARLY_PHASE1":15746,"PHASE1":15748,"PHASE2":15750,"PHASE3":15752,"PHASE4":15754,"NA":15756},{"trials":15747,"activeCount":102},[],{"trials":15749,"activeCount":102},[],{"trials":15751,"activeCount":102},[],{"trials":15753,"activeCount":102},[],{"trials":15755,"activeCount":102},[],{"trials":15757,"activeCount":102},[15758],{"nctId":15759,"briefTitle":15760,"status":108,"phases":15761,"primaryCompletion":1221,"completion":1796,"start":15568,"enrollment":98,"conditions":15762,"interventions":15764},"NCT00822354","Tadalafil for the Treatment of Raynaud's",[94],[15763],"Raynaud",[15744],{"intervention":15766,"totalTrials":229,"cells":15767},"Intranasal Oxytocin",{"EARLY_PHASE1":15768,"PHASE1":15770,"PHASE2":15772,"PHASE3":15774,"PHASE4":15776,"NA":15778},{"trials":15769,"activeCount":102},[],{"trials":15771,"activeCount":102},[],{"trials":15773,"activeCount":102},[],{"trials":15775,"activeCount":102},[],{"trials":15777,"activeCount":102},[],{"trials":15779,"activeCount":102},[15780],{"nctId":15781,"briefTitle":15782,"status":261,"phases":15783,"primaryCompletion":1644,"completion":1644,"start":1684,"enrollment":102,"conditions":15784,"interventions":15785},"NCT01988649","Oxytocin and Pain Sensitivity and Threshold",[94],[15],[15766],{"intervention":15787,"totalTrials":229,"cells":15788},"Group 2.5",{"EARLY_PHASE1":15789,"PHASE1":15791,"PHASE2":15793,"PHASE3":15795,"PHASE4":15797,"NA":15799},{"trials":15790,"activeCount":102},[],{"trials":15792,"activeCount":102},[],{"trials":15794,"activeCount":102},[],{"trials":15796,"activeCount":102},[],{"trials":15798,"activeCount":102},[],{"trials":15800,"activeCount":102},[15801],{"nctId":15802,"briefTitle":15803,"status":108,"phases":15804,"primaryCompletion":15805,"completion":6516,"start":8499,"enrollment":13124,"conditions":15806,"interventions":15807},"NCT01991743","A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version",[94],"2016-10",[30,15],[15787,15808,15809,15810],"Group 5","Group 7.5","Group 10",{"intervention":15808,"totalTrials":229,"cells":15812},{"EARLY_PHASE1":15813,"PHASE1":15815,"PHASE2":15817,"PHASE3":15819,"PHASE4":15821,"NA":15823},{"trials":15814,"activeCount":102},[],{"trials":15816,"activeCount":102},[],{"trials":15818,"activeCount":102},[],{"trials":15820,"activeCount":102},[],{"trials":15822,"activeCount":102},[],{"trials":15824,"activeCount":102},[15825],{"nctId":15802,"briefTitle":15803,"status":108,"phases":15826,"primaryCompletion":15805,"completion":6516,"start":8499,"enrollment":13124,"conditions":15827,"interventions":15828},[94],[30,15],[15787,15808,15809,15810],{"intervention":15809,"totalTrials":229,"cells":15830},{"EARLY_PHASE1":15831,"PHASE1":15833,"PHASE2":15835,"PHASE3":15837,"PHASE4":15839,"NA":15841},{"trials":15832,"activeCount":102},[],{"trials":15834,"activeCount":102},[],{"trials":15836,"activeCount":102},[],{"trials":15838,"activeCount":102},[],{"trials":15840,"activeCount":102},[],{"trials":15842,"activeCount":102},[15843],{"nctId":15802,"briefTitle":15803,"status":108,"phases":15844,"primaryCompletion":15805,"completion":6516,"start":8499,"enrollment":13124,"conditions":15845,"interventions":15846},[94],[30,15],[15787,15808,15809,15810],{"intervention":15810,"totalTrials":229,"cells":15848},{"EARLY_PHASE1":15849,"PHASE1":15851,"PHASE2":15853,"PHASE3":15855,"PHASE4":15857,"NA":15859},{"trials":15850,"activeCount":102},[],{"trials":15852,"activeCount":102},[],{"trials":15854,"activeCount":102},[],{"trials":15856,"activeCount":102},[],{"trials":15858,"activeCount":102},[],{"trials":15860,"activeCount":102},[15861],{"nctId":15802,"briefTitle":15803,"status":108,"phases":15862,"primaryCompletion":15805,"completion":6516,"start":8499,"enrollment":13124,"conditions":15863,"interventions":15864},[94],[30,15],[15787,15808,15809,15810],{"intervention":15866,"totalTrials":229,"cells":15867},"Lithium",{"EARLY_PHASE1":15868,"PHASE1":15870,"PHASE2":15872,"PHASE3":15874,"PHASE4":15876,"NA":15878},{"trials":15869,"activeCount":102},[],{"trials":15871,"activeCount":102},[],{"trials":15873,"activeCount":102},[],{"trials":15875,"activeCount":102},[],{"trials":15877,"activeCount":102},[],{"trials":15879,"activeCount":102},[15880],{"nctId":15881,"briefTitle":15882,"status":108,"phases":15883,"primaryCompletion":15884,"completion":2000,"start":1684,"enrollment":253,"conditions":15885,"interventions":15886},"NCT02490241","Lithium Therapy: Understanding Mothers, Metabolism and Mood",[],"2019-12",[7824],[15866],{"intervention":15888,"totalTrials":229,"cells":15889},"Drysol",{"EARLY_PHASE1":15890,"PHASE1":15892,"PHASE2":15894,"PHASE3":15896,"PHASE4":15898,"NA":15900},{"trials":15891,"activeCount":102},[],{"trials":15893,"activeCount":102},[],{"trials":15895,"activeCount":102},[],{"trials":15897,"activeCount":102},[],{"trials":15899,"activeCount":102},[],{"trials":15901,"activeCount":102},[15902],{"nctId":15903,"briefTitle":15904,"status":108,"phases":15905,"primaryCompletion":3354,"completion":3354,"start":3664,"enrollment":2646,"conditions":15906,"interventions":15909},"NCT00509886","Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating",[94],[15907,15908],"Hyperhidrosis","Excess Sweating",[15888,15910],"Drioff",{"intervention":15910,"totalTrials":229,"cells":15912},{"EARLY_PHASE1":15913,"PHASE1":15915,"PHASE2":15917,"PHASE3":15919,"PHASE4":15921,"NA":15923},{"trials":15914,"activeCount":102},[],{"trials":15916,"activeCount":102},[],{"trials":15918,"activeCount":102},[],{"trials":15920,"activeCount":102},[],{"trials":15922,"activeCount":102},[],{"trials":15924,"activeCount":102},[15925],{"nctId":15903,"briefTitle":15904,"status":108,"phases":15926,"primaryCompletion":3354,"completion":3354,"start":3664,"enrollment":2646,"conditions":15927,"interventions":15928},[94],[15907,15908],[15888,15910],{"intervention":15930,"totalTrials":229,"cells":15931},"Cocoa",{"EARLY_PHASE1":15932,"PHASE1":15934,"PHASE2":15936,"PHASE3":15938,"PHASE4":15940,"NA":15942},{"trials":15933,"activeCount":102},[],{"trials":15935,"activeCount":102},[],{"trials":15937,"activeCount":102},[],{"trials":15939,"activeCount":102},[],{"trials":15941,"activeCount":102},[],{"trials":15943,"activeCount":102},[15944],{"nctId":15945,"briefTitle":15946,"status":108,"phases":15947,"primaryCompletion":15948,"completion":15948,"start":6516,"enrollment":537,"conditions":15949,"interventions":15950},"NCT02876887","Cocoa to Improve Walking Performance in Peripheral Artery Disease",[94],"2019-10-15",[1022],[15930]]